<SEC-DOCUMENT>0001193125-25-122087.txt : 20250519
<SEC-HEADER>0001193125-25-122087.hdr.sgml : 20250519
<ACCEPTANCE-DATETIME>20250519065017
ACCESSION NUMBER:		0001193125-25-122087
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20250519
DATE AS OF CHANGE:		20250519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284770
		FILM NUMBER:		25961458

	BUSINESS ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020
		BUSINESS PHONE:		972 (3) 914-8213

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		124 DVORA HANEVI'A ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6944020

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands IV B.V.
		CENTRAL INDEX KEY:			0001679174
		ORGANIZATION NAME:           	
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284770-01
		FILM NUMBER:		25961460

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31 (0)20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands III B.V.
		CENTRAL INDEX KEY:			0001679183
		ORGANIZATION NAME:           	
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284770-02
		FILM NUMBER:		25961459

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31 (0)20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Teva Pharmaceutical Finance Netherlands II B.V.
		CENTRAL INDEX KEY:			0001628587
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-284770-03
		FILM NUMBER:		25961461

	BUSINESS ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
		BUSINESS PHONE:		31(0) 20-2193000

	MAIL ADDRESS:	
		STREET 1:		PIET HEINKADE 107
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1019 GM
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d830217d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR> Registration No. 333-284770 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P><DIV STYLE="position:relative; overflow:visible; width:651pt; height:30pt; transform-origin:bottom left; transform: rotate(-90deg) translate(-100%, 100%) translateX(30pt);">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>INFORMATION IN THIS PRELIMINARY PROSPECTUS SUPPLEMENT IS NOT COMPLETE AND MAY BE CHANGED. THE DEFINITIVE TERMS OF THE TRANSACTIONS
DESCRIBED HEREIN WILL BE DESCRIBED IN THE FINAL VERSION OF THIS DOCUMENT. THIS PRELIMINARY PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS ARE NOT AN OFFER TO SELL THESE SECURITIES AND ARE NOT SOLICITING AN OFFER TO BUY THESE SECURITIES IN ANY
JURISDICTION WHERE THE OFFER OR SALE IS NOT PERMITTED. </B></FONT></P></DIV><DIV STYLE="position:relative; overflow:visible; margin-left:48pt; margin-right:48pt; transform: translateY(-30pt);">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to Completion </B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Preliminary Prospectus Supplement, dated May&nbsp;19, 2025 </B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus dated
February&nbsp;7, 2025) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$2,000,000,000 (equivalent) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830217g10j07.jpg" ALT="LOGO" STYLE="width:1.72199in;height:0.614254in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&#8195;&#8195;&#8195;&#8195;% Senior Notes due 2031 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;&#8195;&#8195;% Senior Notes due 2032 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands IV B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;&#8195;&#8195;% Senior Notes due 2030 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Payment of principal and interest unconditionally guaranteed by Teva Pharmaceutical Industries Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands II B.V. (&#147;Teva Finance II&#148;) is offering: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> of its <B></B><B></B><B>&#8195;</B>% Senior Notes
due 2031 (the &#147;Euro notes&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands III B.V. (&#147;Teva Finance III&#148;)
is offering: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> of its <B>&#8195;</B>% Senior Notes due 2032 (the
&#147;2032 USD notes&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Finance Netherlands IV B.V. (&#147;Teva Finance IV&#148;) is offering:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$&#8195;&#8195;&#8195;&#8195;of its&#8195;% Senior Notes due 2030 (the &#147;2030 USD notes&#148; and, together
with the 2032 USD notes, the &#147;USD notes&#148; and, together with the Euro notes, the &#147;notes&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro
notes will mature on&#8195;&#8195;&#8195;&#8195;, 2031. The 2032 USD notes will mature on&#8195;&#8195;&#8195;&#8195;, 2032 and the 2030 USD notes will mature on&#8195;&#8195;&#8195;&#8195;, 2030. Interest on the Euro notes will be payable annually
in arrears on &#8195;&#8195;&#8195;&#8195; of each year, beginning &#8195;&#8195;&#8195;&#8195;, 2026. Interest on the USD notes will be payable semi-annually in arrears on&#8195;&#8195;&#8195;&#8195;and&#8195;&#8195;&#8195;&#8195;of each year,
beginning&#8195;&#8195;&#8195;&#8195;, 2025. Payment of all principal and interest payable on the notes is unconditionally guaranteed by Teva Pharmaceutical Industries Limited (&#147;Teva&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II, Teva Finance III and Teva Finance IV may redeem each series of the notes in whole or in part, at any time at a redemption
price equal to the greater of the principal amount of the notes of the relevant series, and the applicable &#147;make-whole&#148; amount plus, in each case, accrued and unpaid interest thereon, if any, to, but not including, the redemption date;
provided that if Teva Finance II, Teva Finance III or Teva Finance IV redeems the notes on or after the applicable Par Call Date (as defined herein for such series), the redemption price shall be equal to 100% of the principal amount of such series
then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date. See &#147;Description of the Euro Notes and the Guarantee&#151;Optional Redemption by the Issuer&#148; and
&#147;Description of the USD Notes and the Guarantee&#151; Optional Redemption by the Issuer.&#148; Each series of the notes may also be redeemed, in whole but not in part, at 100% of the aggregate principal amount of such notes, plus accrued and
unpaid interest, if any, at any time at Teva Finance II&#146;s, Teva Finance III&#146;s or Teva Finance IV&#146;s option, as applicable, or Teva&#146;s option, </P></DIV>
<p STYLE="clear:both; font-size:1pt; height:0">&nbsp;</p>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
solely upon the imposition of certain withholding taxes. See &#147;Description of the Euro Notes and the Guarantees&#151;Tax Redemption&#148; and &#147;Description of the USD Notes and the
Guarantees&#151;Tax Redemption.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes will be unsecured senior obligations of Teva Finance II, which is an indirect
subsidiary of Teva, and the guarantee will be an unsecured senior obligation of Teva. The 2032 USD notes will be unsecured senior obligations of Teva Finance III, which is an indirect subsidiary of Teva, and the guarantee will be an unsecured senior
obligation of Teva. The 2030 USD notes will be unsecured senior obligations of Teva Finance&nbsp;IV, which is an indirect subsidiary of Teva, and the guarantee will be an unsecured senior obligation of Teva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in the notes involves risks. See &#147;<A HREF="#supprom830217_4">Risk Factors</A>&#148; beginning on page <FONT
STYLE="white-space:nowrap">S-14</FONT> of this prospectus supplement and page 4 of the accompanying prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the
contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Euro&nbsp;Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;2032<BR>USD&nbsp;Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;2030<BR>USD&nbsp;Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to issuer (before expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Plus accrued interest, if any, from&#8195;&#8195;&#8195;&#8195;, 2025, if settlement occurs after such date.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s principal executive offices are located at 124 Dvora HaNevi&#146;a Street, Tel Aviv, 6944020, Israel, and
our telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-914-8213.</FONT></FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the USD notes to investors through the book-entry facilities of The Depository Trust Company
(&#147;DTC&#148;) and its direct participants, including Euroclear Bank S.A./N.V. (&#147;Euroclear&#148;), as operator of the Euroclear System, and Clearstream Banking, <I>soci&eacute;t&eacute; anonyme </I>(&#147;Clearstream&#148;), and the Euro
notes will be delivered to investors through the book-entry facilities of Euroclear and Clearstream, on or about&#8195;&#8195;&#8195;&#8195;, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Active Joint Book-Running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="top"><B>BNP&nbsp;PARIBAS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>BofA&nbsp;Securities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>HSBC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IMI-Intesa&nbsp;Sanpaolo</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>J.P.&nbsp;Morgan</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Passive Joint Book-Running Managers </I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:13pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:13pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Goldman Sachs&nbsp;Bank Europe SE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Mizuho</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>MUFG</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>PNC&nbsp;Capital Markets&nbsp;LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is &#8195;&#8195;&#8195;&#8195;, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>We have not, and the underwriters have not, authorized anyone to provide any information
or to make any representations other than those contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus supplement and the accompanying prospectus is an offer to sell only the notes offered hereby, but only under circumstances
and in jurisdictions where it is lawful to do so. The information contained in this prospectus supplement and the accompanying prospectus is current only as of the respective dates of such documents. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_1">STABILIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-vi</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_2">CURRENCY AND EXCHANGE RATE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-vii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_3">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_7">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_8">DESCRIPTION OF THE EURO NOTES AND THE GUARANTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_9">DESCRIPTION OF THE USD NOTES AND THE GUARANTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-41</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_10">UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-58</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_11">DUTCH TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-64</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_12">ISRAELI TAX CONSIDERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-67</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_13">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-69</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_14">LISTING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-77</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_15">CERTAIN INSOLVENCY LAW CONSIDERATIONS; LIMITATIONS ON VALIDITY AND ENFORCEABILITY
 OF THE NOTES AND THE INDENTURES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_16">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-84</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_17">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-84</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_18">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-84</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom830217_19">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-84</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_2">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_3">FINANCE SUBSIDIARIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_7">DESCRIPTION OF ORDINARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_8">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_9">DESCRIPTION OF DEBT SECURITIES AND GUARANTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_10">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_12">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_16">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_17">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice to European Economic Area Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prohibition of Sales to EEA Retail Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus have been prepared on the basis that all offers of the notes will be made pursuant
to an exemption under Regulation (EU) 2017/1129 (as supplemented, amended or superseded, the &#147;Prospectus Regulation&#148;), as implemented in member states of the European Economic Area (the &#147;EEA&#148;), from the requirement to produce a
prospectus which is compliant with the Prospectus Regulation for offers of the notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, any person making or intending to make
any offer of the notes within the EEA should only do so in circumstances in which no obligation arises for us or any of the underwriters to produce a prospectus for such offer that is compliant with the Prospectus Regulation. Neither we nor the
underwriters have authorized, nor do we or they authorize, the making of any offer of notes through any financial intermediary, other than offers made by the underwriters, which constitute the final placement of the notes contemplated in this
prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes described in this prospectus supplement and the accompanying prospectus
are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA. For these purposes, a retail investor means a person who is one (or more) of:
(i)&nbsp;a retail client as defined in point (11)&nbsp;of Article 4(1) of Directive 2014/65/EU (as amended, &#147;MiFID II&#148;); (ii) a customer within the meaning of Directive 2016/97/EU (as amended, the &#147;Insurance Distribution
Directive&#148;), where that customer would not qualify as a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Article 2 of the Prospectus Regulation. Consequently, no
key information document required by Regulation (EU) No 1286/2014 (as amended, the &#147;PRIIPs Regulation&#148;) for offering or selling the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore
offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MiFID
II Product Governance / Professional Investors and ECPs-only Target Market </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product
approval process, the target market assessment in respect of the notes has led to the conclusion that: (i)&nbsp;the target market for the notes is eligible counterparties (&#147;ECPs&#148;) and professional clients only, each as defined in MiFID II;
and (ii)&nbsp;all channels for distribution of the notes to eligible counterparties and professional clients are appropriate. Any person subsequently offering, selling or recommending the notes (a &#147;distributor&#148;) should take into
consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the notes (by either adopting or refining the
manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a member state of the EEA
who receives any communication in respect of, or who acquires any notes under, the offers to the public contemplated in this prospectus supplement and accompanying prospectus will be deemed to have represented, warranted and agreed to and with each
underwriter and Teva Finance II that: (a)&nbsp;it is a qualified investor within the meaning of point (e)&nbsp;of Article 2 of the Prospectus Regulation and any relevant implementing measure in each member state of the EEA; (b)&nbsp;it is not a
&#147;retail investor&#148; as defined above; and (c)&nbsp;in the case of any notes acquired by it as a financial intermediary, as that term is used in the Prospectus Regulation, (i)&nbsp;the notes acquired by it in the offer have not been acquired
on behalf of, nor have they been acquired with a view to their offer or resale to, persons in any member state of the EEA other than qualified investors, as that term is defined in the Prospectus Regulation, or in circumstances in which the prior
consent of the underwriters has been given to the offer or resale; or (ii)&nbsp;where notes have been acquired by it on behalf of persons in any member state of the EEA other than qualified investors, the offer of those notes to it is not treated
under the Prospectus Regulation as having been made to such persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice to UK Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Prohibition of Sales to UK Retail Investors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to the United Kingdom (the &#147;UK&#148;), each underwriter has represented and agreed, severally and not jointly, that it has not
offered, sold or otherwise made available and will not offer, sell or otherwise make available any notes to any retail investor in the UK. For these purposes, the expression &#147;retail investor&#148; means a person who is one (or more) of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client, as defined in point (8)&nbsp;of Article 2 of Regulation (EU) No 2017/565 as it forms part of
domestic law in the UK by virtue of the European Union (Withdrawal) Act 2018 (&#147;EUWA&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of the provisions of the UK Financial Services and Markets Act 2000, as amended
(the &#147;FSMA&#148;) and any rules or regulations made under the FSMA to implement the Insurance Distribution Directive, where that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article 2(1) of Regulation
(EU) No 600/2014 as it forms part of domestic law in the UK by virtue of the EUWA; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not a qualified investor as defined in Article 2 of the Prospectus Regulation as it forms part of domestic law
in the UK by virtue of the EUWA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, no key information document required by the PRIIPS Regulation as it
forms part of UK domestic law by virtue of the EUWA (the &#147;UK PRIIPs Regulation&#148;) for offering or selling the notes or otherwise making them available to retail investors in the UK has been prepared and therefore offering or selling the
notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
supplement has been prepared on the basis that any offer of the notes in the UK will be made pursuant to an exemption under the Prospectus Regulation as it forms part of UK domestic law by virtue of the EUWA (the &#147;UK Prospectus
Regulation&#148;) from the requirement to publish a prospectus for offers of the notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>UK MiFIR Product Governance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Professional investors and eligible counterparties only target market: Solely for the purposes of the manufacturers&#146; product approval
process, the target market assessment in respect of the debt securities has led to the conclusion that: (i)&nbsp;the target market for the debt securities is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook
(&#147;COBS&#148;), and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA (&#147;UK MiFIR&#148;); and (ii)&nbsp;all channels for distribution of the debt securities to eligible
counterparties and professional clients are appropriate. A distributor should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to the FCA Handbook Product Intervention and Product Governance
Sourcebook (the &#147;UK MiFIR Product Governance Rules&#148;) is responsible for undertaking its own target market assessment in respect of the debt securities (by either adopting or refining the manufacturers&#146; target market assessment) and
determining appropriate distribution channels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This issue and distribution of this prospectus supplement and the accompanying prospectus
is restricted by law. This offering memorandum is not being distributed by, nor has it been approved for the purposes of section&nbsp;21 of the Financial Services and Markets Act 2000 by, a person authorized under the Financial Services and Markets
Act 2000. This prospectus supplement and the accompanying prospectus are only being distributed to and are only directed at (i)&nbsp;persons who are outside the UK or (ii)&nbsp;investment professionals falling within Article&nbsp;19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;), (iii) high net worth entities, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of
the Order or (iv)&nbsp;persons to whom an invitation or inducement to engage in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any notes may otherwise lawfully be communicated or
caused to be communicated (all such persons together being referred to as &#147;relevant persons&#148;). Accordingly, by accepting delivery of this prospectus supplement or the accompanying prospectus, the recipient warrants and acknowledges that it
is such a relevant person. The notes are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire the notes will be engaged in only with, relevant persons. Any person who is not a relevant person should
not act or rely on this prospectus supplement or the accompanying prospectus. No part of this prospectus supplement or the accompanying prospectus should be published, reproduced, distributed or otherwise made available in whole or in part to any
other person without our prior written consent. The notes are not being offered or sold to any person in the United Kingdom, except in circumstances which will not result in an offer of securities to the public in the United Kingdom within the
meaning of Part VI of the Financial Services and Markets Act 2000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notice to Dutch Investors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus is directed only at qualified investors as defined in the Prospectus Regulation.
The notes have not, may not and will not be offered, sold or delivered in the Netherlands, other than to qualified investors (as defined in the Prospectus Regulation). This prospectus supplement and the accompanying prospectus must not be acted on
or relied on by persons who are not qualified investors. Any investment or investment activity to which this prospectus supplement and the accompanying prospectus relates is available only to qualified investors and will be engaged in only with
qualified investors. Recipients of this prospectus supplement and the accompanying prospectus are not permitted to transmit it to any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-v </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_1"></A>STABILIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>In connection with the issue of the notes, certain of the joint book-running managers (or persons acting on behalf of any of the joint
book-running managers) may over-allot notes or effect transactions with a view to supporting the market price of the notes at a level higher than that which might otherwise prevail. However, there is no assurance that the joint book-running managers
(or persons acting on behalf of a joint book-running manager) will undertake stabilization action. Such stabilizing, if commenced, may be discontinued at any time and, if begun, must be brought to an end after a limited period. Any stabilization
action or overallotment must be conducted by the relevant joint book-running managers (or persons acting on behalf of any joint book-running manager) in accordance with all applicable laws and rules and in the case of the Euro notes may begin on or
after the date on which adequate public disclosure of the terms of the offering of the notes is made and, if begun, may be ended at any time, but it must end no later than 30 days after the issue date, or no later than 60 days after the date of the
allotment of the notes, whichever is earlier. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-vi </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_2"></A>CURRENCY AND EXCHANGE RATE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the average, high, low and end of period nominal noon exchange rates published by
the Bloomberg&#146;s London Composite figure. Such rates are set forth as U.S. dollars per &#128;1.00. The exchange rates provided below are provided solely for convenience. We do not make any representation that euros could have been converted into
U.S. dollars at the rates shown or at any other rate. You should note that the rates set forth below may differ from the actual rates used in our accounting processes and in the preparation of our consolidated financial statements, which are
incorporated by reference herein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the year ended<BR>December&nbsp;31,<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;three&nbsp;months<BR>ended</B><br><B>March&nbsp;31, 2025</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>U.S. dollars (USD)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Period end rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">High rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Low rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The average of the exchange rates for all days during the applicable year. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-vii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_3"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere or incorporated by reference in this prospectus supplement and the accompanying
prospectus. This is not intended to be a complete description of the matters covered in this prospectus supplement and the accompanying prospectus and is subject to, and qualified in its entirety by reference to, the more detailed information and
financial statements (including the notes thereto) included or incorporated by reference in this prospectus supplement and the accompanying prospectus. Unless otherwise indicated, all references to the &#147;Company,&#148; &#147;we,&#148;
&#147;us,&#148; &#147;our&#148; or &#147;Teva&#148; refer to Teva Pharmaceutical Industries Limited and its subsidiaries. All references to &#147;Teva Finance II&#148; refer to Teva Pharmaceutical Finance Netherlands II B.V., an indirect subsidiary
of Teva, all references to &#147;Teva Finance III&#148; refer to Teva Pharmaceutical Finance Netherlands III B.V., an indirect subsidiary of Teva, and all references to &#147;Teva Finance IV&#148; refer to Teva Pharmaceutical Finance Netherlands IV
B.V., an indirect subsidiary of Teva. Together, Teva Finance II, Teva Finance III and Teva Finance IV are referred to herein as the &#147;Issuers.&#148; All references to the &#147;accompanying prospectus&#148; are to the prospectus dated
February&nbsp;7, 2025. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Business Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global pharmaceutical company, harnessing our generics expertise and stepping up innovation to continue the momentum behind the
discovery, delivery and expanded development of modern medicine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate worldwide, with headquarters in Israel and a significant
presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities enables our approximately 37,000 employees across 57 markets to push the boundaries of scientific innovation and deliver quality
medicines to help improve health outcomes for millions of patients every day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva was incorporated in Israel on February&nbsp;13, 1944,
and is the successor to a number of Israeli corporations, the oldest of which was established in 1901. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Our Business Segments
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate our business through three segments: United States (previously referred to as the North America segment), Europe and
International Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">biosimilars&nbsp;and&nbsp;over-the-counter&nbsp;(&#147;OTC&#148;)&nbsp;products,</FONT></FONT> as well as innovative medicines. This structure enables strong alignment and integration
between operations, commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these three segments, we have other activities, primarily the sale of active pharmaceutical ingredients (&#147;API&#148;) to
third parties, certain contract manufacturing services <FONT STYLE="white-space:nowrap">and&nbsp;an&nbsp;out-licensing&nbsp;platform</FONT> offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>The Issuers </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva
Finance II, Teva Finance III and Teva Finance IV are Dutch private limited liability companies that were formed on October&nbsp;16, 2013, September&nbsp;21, 2015 and April&nbsp;22, 2016, respectively. Their address is Busweg 1, 2031 DA Haarlem,
Netherlands, telephone number +31 <FONT STYLE="white-space:nowrap">(0)23-5147147.</FONT> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Recent Developments </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tender Offer </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with this
offering, we commenced a tender offer (collectively, the &#147;Tender Offer&#148;, and each tender offer, an &#147;Offer&#148;) to purchase, for cash, notes of the series listed below (collectively, the &#147;Tender Offer Notes&#148;), for a maximum
combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the &#147;Total Maximum Amount&#148;) comprised of (i)&nbsp;up to $1,550,000,000 aggregate purchase price (the &#147;Pool 1 Tender
Cap&#148;) in respect of Teva Pharmaceutical Finance Netherlands III B.V.&#146;s 3.150% Senior Notes due 2026 (the &#147;Pool 1 Notes&#148;), (ii) up to $250,000,000 (equivalent) aggregate purchase price (the &#147;Pool 2 Tender Cap&#148;) in
respect of Teva Pharmaceutical Finance Netherlands III B.V.&#146;s 4.750% Sustainability-Linked Senior Notes due 2027 and Teva Pharmaceutical Finance Netherlands II B.V.&#146;s 3.750% Sustainability-Linked Senior Notes due 2027 (collectively, the
&#147;Pool 2 Notes&#148;), and (iii)&nbsp;up to $200,000,000 (equivalent) aggregate purchase price (the &#147;Pool 3 Tender Cap&#148;) in respect of Teva Pharmaceutical Finance Netherlands III B.V.&#146;s 7.875% Sustainability-Linked Senior Notes
due 2029, Teva Pharmaceutical Finance Netherlands II B.V.&#146;s 7.375% Sustainability-Linked Senior Notes due 2029 and Teva Pharmaceutical Finance Netherland III B.V.&#146;s 8.125% Sustainability-Linked Senior Notes due 2031 (collectively, the
&#147;Pool 3 Notes&#148;), in each case in the priorities set forth below, in each case, exclusive of accrued and unpaid interest. The principal amounts outstanding of the Tender Offer Notes below are as of March&nbsp;31, 2025. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars or Euros per $1,000 or &#128;1,000, as<BR>applicable, principal amount</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Capped<BR>Tender<BR>Offers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Title of<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CUSIP / ISIN /<BR>Common Code</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pool Tender<BR>Caps&nbsp;(Purchase<BR>Price&nbsp;(excluding<BR>Accrued<BR>Interest))<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acceptance<BR>Priority<BR>Level<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Authorized<BR>Denominations<BR>(principal<BR>amount)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>First&nbsp;Par<BR>Call&nbsp;Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Reference<BR>Security or<BR>Interpolated<BR><FONT STYLE="white-space:nowrap">Mid-Swap</FONT><BR>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bloomberg<BR>Reference<BR>Page / Screen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fixed<BR>Spread<BR>(basis<BR>points)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tender Offer<BR>Consideration<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Early<BR>Tender<BR>Premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Consideration<SUP STYLE="font-size:75%; vertical-align:top">(3)(6)</SUP></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle">Pool 1 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.150%<BR>Senior Notes<BR>due 2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands III<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAE1 /<BR>US88167AAE10<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$3,377,644,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$1,550,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$2,000 and<BR>integral<BR>multiples of<BR>$1,000&nbsp;in&nbsp;excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$931.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$981.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle" ROWSPAN="2">Pool 2 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">4.750%<BR>Sustainability-<BR>Linked Senior<BR>Notes due<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands III<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAP6 /<BR>US88167AAP66<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$1,000,000,000</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="2">$250,000,000<BR>(equivalent)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and<BR>integral<BR>multiples of<BR>$1,000 in excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">February&nbsp;9,<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$947.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$997.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.750%<BR>Sustainability-<BR>Linked Senior<BR>Notes due<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands II<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">XS2406607098 /<BR>240660709<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&#128;1,100,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;100,000 and<BR>integral<BR>multiples of<BR>&#128;1,000 in excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">February&nbsp;9,<BR>2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;963.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;1,013.50</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle" ROWSPAN="3">Pool 3 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">7.875%<BR>Sustainability-<BR>Linked Senior<BR>Notes due<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands III<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAS0 /<BR>US88167AAS06<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$600,000,000</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="3">$200,000,000<BR>(equivalent)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and<BR>integral<BR>multiples of<BR>$1,000 in excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15,<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.875%&nbsp;U.S.<BR>Treasury&nbsp;due<BR>April&nbsp;30,<BR>2030</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">FIT1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">+135</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See&nbsp;Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">7.375%<BR>Sustainability-<BR>Linked Senior<BR>Notes due<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands II<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">XS2592804434 /<BR>259280443<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&#128;800,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;100,000 and<BR>integral<BR>multiples of<BR>&#128;1,000 in excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15,<BR>2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2029 Euro<BR>Notes<BR>Interpolated<BR><FONT STYLE="white-space:nowrap">Mid-Swap</FONT><BR>Rate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">IRSB<BR>EU&lt;GO&gt;(7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">+150</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See&nbsp;Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">8.125%<BR>Sustainability-<BR>Linked Senior<BR>Notes due<BR>2031</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva<BR>Pharmaceutical<BR>Finance<BR>Netherlands III<BR>B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAR2 /<BR>US88167AAR23<BR>(Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$500,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and<BR>integral<BR>multiples of<BR>$1,000 in excess<BR>thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15,<BR>2031</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.875% U.S.<BR>Treasury due<BR>April&nbsp;30,<BR>2030</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">FIT1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">+155</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
</TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Pool 1 Maximum Amount of $1,550,000,000 represents the maximum aggregate purchase price in respect of Pool
1 Notes that will be purchased in the Pool 1 Tender Offers. The Pool 2 Maximum Amount of $250,000,000 (equivalent) represents the maximum aggregate purchase price in respect of Pool 2 Notes that will be purchased in the Pool 2 Tender Offers. The
Pool 3 Maximum Amount of $200,000,000 (equivalent) represents the maximum aggregate purchase price in respect of Pool 3 Notes that will be purchased in the Pool 3 Tender Offers. The Pool Tender Caps can be increased or decreased at Teva&#146;s sole
discretion, and in each case are exclusive of Accrued Interest. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Total Maximum Amount, the Pool Tender Caps and proration, the principal amount of each series of
Tender Offer Notes that is purchased in each of the Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column. Tender Offer Notes tendered at or prior to the Early
Tender Time will also be accepted for purchase in priority to Tender Offer Notes tendered thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes accrued and unpaid interest, which will also be paid. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tender Offer Consideration in respect of the Notes of each relevant series will equal the applicable Total
Consideration minus the applicable Early Tender Premium. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Total Consideration in respect of the Pool 3 Notes of each relevant series shall be calculated from the
applicable Reference Yield and the applicable Fixed Spread and which, when calculated in such manner, already includes the applicable Early Tender Premium. The applicable Total Consideration will be calculated with reference to the First Par Call
Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such amount already includes the Early Tender Premium. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pricing Source: BGN. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more of the underwriters or their respective affiliates may own Tender Offer Notes and be eligible to participate in the Tender Offer.
As a result, one or more of the underwriters or their respective affiliates may receive a portion of the net proceeds from this offering (in excess of any underwriter discounts, if applicable). See &#147;Underwriting&#151;Conflicts of
Interest.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After deducting the underwriters&#146; discounts and estimated offering expenses, we expect to use the net proceeds of
this offering, together with cash on hand, (i)&nbsp;to fund the Tender Offer for a maximum combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (as it may be amended prior to expiration
thereof), (ii) to pay fees and expenses in connection therewith and (iii)&nbsp;to the extent of any remaining proceeds, for the repayment of outstanding debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested
pending application for their stated purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tender Offer is scheduled to expire at 5:00 p.m., Eastern Time, on June 17, 2025, with
an expected early tender deadline of 5:00 p.m., Eastern Time, on June&nbsp;2, 2025 and early settlement date of June&nbsp;5, 2025. This prospectus supplement is not an offer to purchase or a solicitation of an offer to sell any of the Tender Offer
Notes and the Tender Offer is not an offer to sell or a solicitation of an offer to purchase the notes offered thereby. The Tender Offer is being made solely pursuant to an offer to purchase related thereto. The Tender Offer is conditioned on, among
other things, the consummation of this offering. This offering, however, is not conditioned on the consummation of the Tender Offer or the tender of any specific amount of the Tender Offer Notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Executive Order of the President of the United States </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;12, 2025, the President of the United States issued an executive order that sought to lower the prices of drugs in the United
States to align them with the prices paid for such drugs in other countries. Amongst other things, the executive order directs the Secretary of Health and Human Services, within 30 days of the executive order, to establish a &#147;most favored
nation&#148; pricing mechanism through which the U.S. government will </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
request that pharmaceutical manufacturers provide prescription medications at price targets to be set based on the lowest price paid for such medications in a peer country. As it is unclear how
the current United States Presidential administration will implement the executive order or what price targets will be established, there is uncertainty as to how our business may be impacted. We continue to monitor developments relating to the
executive order. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>United States Tariffs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. government recently announced tariffs on products imported from several jurisdictions in which we operate and source our raw materials
from, and has made announcements regarding the potential imposition of tariffs on other jurisdictions. Certain of the announced tariffs have been delayed and we are currently assessing the potential impact on our supply chain and our global
operations. However, the U.S. government may in the future pause, reimpose or increase tariffs, and countries subject to such tariffs have and in the future may impose reciprocal tariffs or other restrictive trade measures in response. Any of these
actions could impact our costs and our global operations. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Organizational Structure </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following diagram illustrates our simplified corporate structure: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830217g04r34.jpg" ALT="LOGO" STYLE="width:6.25655in;height:2.88559in;">
 </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional shareholders have interests of less than 1% in the aggregate. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuer of 0.250% Convertible Senior Debentures due 2026 and 6.150% Senior Notes due 2036.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Guarantor of the notes offered hereby, 7.375% Sustainability-Linked Senior Notes due 2029, 7.875%
Sustainability-Linked Senior Notes due 2031, 7.875% Sustainability-Linked Senior Notes due 2029, 8.125% Sustainability-Linked Senior Notes due 2031, 0.250% Convertible Senior Debentures due 2026, 6.150% Senior Notes due 2036, 1.875% Senior Notes due
2027, 1.625% Senior Notes due 2028, 3.150% Senior Notes due 2026, 4.100% Senior Notes due 2046, 1.000% Notes due 2025, 6.750% Senior Notes due 2028, 3.750% Sustainability-Linked Senior Notes due 2027, 4.375% Sustainability-Linked Senior Notes due
2030, 4.750% Sustainability-Linked Senior Notes due 2027 and 5.125% Sustainability-Linked Senior Notes due 2029. Borrower under the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, dated as of April&nbsp;29, 2022, as amended on
February&nbsp;6, 2023 and May&nbsp;3, 2024 (the &#147;Sustainability-Linked Revolving Credit Agreement&#148;). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuer of the Euro notes offered hereby, 7.375% Sustainability-Linked Senior Notes due 2029, 7.875%
Sustainability-Linked Senior Notes due 2031, 1.875% Senior Notes due 2027, 1.625% Senior Notes due 2028, 3.750% Sustainability-Linked Senior Notes due 2027 and 4.375% Sustainability-Linked Senior Notes due 2030. Borrower under the
Sustainability-Linked Revolving Credit Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuer of the 2032 USD notes offered hereby, 7.875% Sustainability-Linked Senior Notes due 2029, 8.125%
Sustainability-Linked Senior Notes due 2031, 3.150% Senior Notes due 2026, 4.100% Senior Notes due 2046, 6.750% Senior Notes due 2028, 4.750% Sustainability-Linked Senior Notes due 2027 and 5.125% Sustainability-Linked Senior Notes due 2029.
Borrower under the Sustainability-Linked Revolving Credit Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuer of the 2030 USD notes offered hereby and the 1.000% Senior Notes due 2025. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Borrower under the Sustainability-Linked Revolving Credit Agreement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional shares owned by Teva Pharmaceutical Finance Netherlands B.V. and Teva Pharma B.V., each representing
interests of less than 0.0001%. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional shares owned by Teva Pharmaceuticals Europe B.V., LBC International Corp and Teva Pharma SLU, each
representing interests of approximately 0.01%. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Issuers</B> </P></TD>
<TD>Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V. and Teva Pharmaceutical Finance Netherlands IV B.V., which are indirect, wholly owned subsidiaries of Teva and have no assets or operations other
than in connection with this offering and prior debt offerings. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Securities Offered </B> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#128;&#8195;&#8195;&#8195;&#8195; aggregate principal amount of <B></B><B></B><B></B>&#8195;&#8195;% Senior
Notes due&nbsp;2031; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$&#8195;&#8195;&#8195;&#8195; aggregate principal amount of &#8195;&#8195;% Senior Notes due&nbsp;2032; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$&#8195;&#8195;&#8195;&#8195; aggregate principal amount of <B></B><B></B><B></B>&#8195;&#8195;% Senior Notes
due&nbsp;2030. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Guarantees</B> </P></TD>
<TD>Teva will irrevocably and unconditionally guarantee (i)&nbsp;the punctual payment when due of the principal and interest, whether at maturity, upon redemption, by acceleration or otherwise (including any additional amounts in respect of taxes as
described in &#147;Description of the Euro Notes and the Guarantees&#151;Additional Tax Amounts&#148; and &#147;Description of the USD Notes and the Guarantees&#151;Additional Tax Amounts&#148;) on the notes of each series and (ii)&nbsp;all other
amounts due and payable under the indentures governing the notes. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Ranking</B> </P></TD>
<TD>As indebtedness of Teva, the guarantees will rank: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to the rights of creditors under any debt expressly subordinated to the guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equally with other unsecured debt of Teva from time to time outstanding other than any that is subordinated to
the guarantees </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that
indebtedness; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Maturity Dates</B> </P></TD>
<TD>The Euro notes will mature on&#8195;&#8195;&#8195;&#8195;, 2031. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 2032 USD notes will mature on&#8195;&#8195;&#8195;&#8195;, 2032. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The 2030 USD notes will mature on&#8195;&#8195;&#8195;&#8195;, 2030. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates</B> </P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">In the case of the Euro notes,&#8195;&#8195;&#8195;&#8195; of each year, beginning &#8195;&#8195;&#8195;&#8195;, 2026, and at maturity. In
the case of the USD notes, &#8195;&#8195;&#8195;&#8195; and &#8195;&#8195;&#8195;&#8195;of each year, beginning &#8195;&#8195;&#8195;&#8195;, 2025, and at maturity. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Interest Rates</B> </P></TD>
<TD>&#8195;&#8195;% per year in the case of the Euro notes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#8195;&#8195;% per year in the case of the 2032 USD notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#8195;&#8195;% per year in the case of the 2030 USD notes. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption of the Euro Notes</B> </P></TD>
<TD>Teva Finance II may redeem the Euro notes, in whole or in part, at any time or from time to time, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice. This redemption notice and the redemption may, at Teva Finance
II&#146;s discretion, be subject to one or more conditions precedent. The Euro notes will be redeemable at a redemption price equal to the greater of (1) 100% of the principal amount of the Euro notes to be redeemed and (2)&nbsp;the sum of the
present values of the Remaining Scheduled Payments (as defined in &#147;Description of the Euro Notes and the Guarantees&#151;Optional Redemption by the Issuer&#148;) on the notes being redeemed discounted, on a semi-annual basis (assuming a <FONT
STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at the applicable Reinvestment Rate (as defined in &#147;Description of the Euro Notes and the Guarantees&#151;Optional
Redemption by the Issuer&#148;), plus in each case accrued and unpaid interest thereon, if any, to, but not including, the redemption date. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If we elect to redeem the Euro notes at any time on or after&#8195;&#8195;&#8195;&#8195;, 20<B></B><B></B><B>&#8195;</B><B>&#8195;</B> (three months prior to the maturity date of the Euro notes), we may redeem the Euro
notes, in whole or in part, in each case upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the Euro notes then outstanding to be redeemed plus accrued and unpaid
interest thereon, if any, to, but not including, the redemption date. See &#147;Description of the Euro Notes and the Guarantees&#151;Optional Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption of the USD Notes</B> </P></TD>
<TD>Teva Finance III and Teva Finance IV, as applicable, may redeem the USD notes of any series for which they are the issuer, in whole or in part, at any time or from time to time, upon at least 10 days&#146;, but not more than 60 days&#146;, prior
notice. This redemption notice and the redemption may, at Teva Finance III&#146;s and Teva Finance IV&#146;s discretion, be subject to one or more conditions precedent. The USD notes will be redeemable at a redemption price equal to the greater of
(1) 100% of the principal amount of the USD notes to be redeemed and (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined under &#147;Description of the USD Notes and the Guarantees&#151;Optional Redemption by the
Issuer&#148;) on the USD notes being redeemed discounted, on a semi-annual basis (assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at a rate equal to the sum
of the Treasury Rate (as defined in &#147;Description of the USD Notes and the Guarantees&#151; Optional Redemption by the Issuer&#148;) plus 50 basis points, in the case of the 2032 USD notes and 50 basis points, in the case of the 2030 USD notes,
plus in each case accrued and unpaid interest thereon, if any, to, but not including, the redemption date. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we elect to redeem the 2032 USD notes at any time on or after&#8195;&#8195;&#8195;&#8195;,
20<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> (three months prior to the maturity date </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
of the 2032 USD notes) or the 2030 USD notes at any time on or after&#8195;&#8195;&#8195;&#8195;, 20<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> (three&nbsp;months prior to the
maturity date of the 2030 USD notes), we may redeem the USD notes, in whole or in part, in each case upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the USD
notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date. See &#147;Description of the USD Notes and the Guarantees&#151;Optional Redemption.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Tax Redemption</B> </P></TD>
<TD>Teva Finance II, Teva Finance III or Teva Finance IV, as applicable, and Teva, may redeem all (but not part) of the notes at any time, upon at least 10 days&#146;, but no more than 60 days&#146;, prior notice, at a redemption price equal to 100%
of the aggregate principal amount of such notes, plus accrued and unpaid interest, if any, to, but not including, the redemption date, if Teva Finance II, Teva Finance III or Teva Finance IV, as applicable, or Teva, would become obligated to pay
certain additional amounts in respect of taxes as a result of certain changes in specified tax laws or certain other circumstances. See &#147;Description of the Euro Notes and the Guarantees&#151;Tax Redemption&#148; and &#147;Description of the USD
Notes and the Guarantees&#151;Tax Redemption.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds</B> </P></TD>
<TD>Teva will receive gross proceeds of approximately $2,000,000,000 (equivalent) from this offering before deducting the underwriters&#146; discounts and estimated offering expenses payable by Teva. After deducting the underwriters&#146; discounts
and estimated offering expenses, Teva intends to use the net proceeds of this offering, together with cash on hand, (i)&nbsp;to fund the Tender Offer for a maximum combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to
$2,000,000,000 (equivalent) (as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii)&nbsp;to the extent of any remaining proceeds, for the repayment of outstanding debt upon maturity, tender
offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose. See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Form, Denomination and Registration</B> </P></TD>
<TD> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Euro notes will be issued only in fully registered form without coupons and in minimum denominations of &#128;100,000 principal amount and whole
multiples of &#128;1,000 in excess of &#128;100,000. The USD notes will be issued only in fully registered form without coupons and in minimum denominations of $200,000 principal amount and whole multiples of $1,000 in excess of $200,000. The Euro
notes will be evidenced by one or more global registered notes deposited with and registered in the name of a common depositary for Euroclear and Clearstream or a nominee thereof. Beneficial interests in the Euro notes will be shown on, and
transfers thereof will be effected only through, records maintained in book-entry form by Euroclear and Clearstream and their participants. The USD notes will </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:Times New Roman">
be evidenced by one or more global registered notes deposited with the trustee of the notes, as custodian for DTC. Beneficial interests in the global registered USD notes will be shown on, and
transfers will be effected through, records maintained by DTC and its direct and indirect participants. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Absence of a Public Market for the Notes</B> </P></TD>
<TD>The notes are new securities for which no market currently exists. One or more of the underwriters have advised us that they intend to make markets in the notes as permitted by applicable laws and regulations. The underwriters are not obligated,
however, to make markets in the notes, and they may discontinue this market making at any time in their sole discretion. We cannot assure you that any active or liquid market will develop in the notes. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Listing and Trading</B> </P></TD>
<TD>Application has been made to Euronext Dublin for the Euro notes to be admitted to the Official List and trading on the Global Exchange Market which is the exchange regulated market of Euronext Dublin. The Global Exchange Market is not a
regulated market for the purposes of MiFID II. You should note, however, that there is currently no trading market for the Euro notes, and we cannot assure you that an active or liquid market for the Euro notes will develop. The USD notes will not
be listed on any securities exchange or included in any automated quotation system. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Trustee, Registrar, Transfer Agent and, with<BR> respect to the USD Notes, Paying Agent</B> </P></TD>
<TD>The Bank of New York Mellon. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Principal Paying Agent for the Euro Notes</B> </P></TD>
<TD>The Bank of New York Mellon, London Branch. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk Factors</B> </P></TD>
<TD>Before you invest in the notes, you should carefully consider the risks involved. Accordingly, you should carefully consider the information contained in or incorporated by reference into this prospectus supplement and the accompanying
prospectus, including the discussions under &#147;Risk Factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-13.</FONT> </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Historical Financial Data of Teva </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary operating data of Teva for each of the years in the three-year period ended December&nbsp;31, 2024 and summary balance
sheet data at December&nbsp;31, 2024 and 2023 are derived from Teva&#146;s audited consolidated financial statements and related notes incorporated by reference into this prospectus supplement, which have been prepared in accordance with accounting
principles generally accepted in the United States, or U.S. GAAP. The following summary operating data of Teva for the three months ended March&nbsp;31, 2025 and 2024 and the summary balance sheet data at March&nbsp;31, 2025 are derived from
Teva&#146;s unaudited consolidated financial statements and related notes incorporated by reference into this prospectus supplement, and have been prepared on a basis consistent with Teva&#146;s audited financial statements. In the opinion of
management, the interim financial statements reflect all normal and recurring adjustments necessary for a fair statement of the financial position and results of operations of Teva. You should not rely on these interim results as being indicative of
results Teva may expect for the full year or any other interim period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary operating data of Teva for the last twelve months
(&#147;LTM&#148;) ended March&nbsp;31, 2025, has been derived by adding the audited summary operating data of Teva for the year ended December&nbsp;31, 2024 and the unaudited summary operating data of Teva for the three months ended March&nbsp;31,
2025, and then subtracting the unaudited summary operating data of Teva for the three months ended March&nbsp;31, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information
set forth below is only a summary and is not necessarily indicative of the results of future operations of Teva, and you should read the summary selected historical financial data together with Teva&#146;s audited and unaudited consolidated
financial statements and related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in Teva&#146;s Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;for</FONT> the year ended December&nbsp;31, 2024 (the &#147;Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&#148;)&nbsp;and</FONT> in Teva&#146;s Quarterly Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended March&nbsp;31, 2025 (the &#147;Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q&#148;).</FONT> See the section entitled &#147;Where You Can Find More
Information&#148; for information on where you can obtain copies of the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and the Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three<BR>Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LTM<BR>ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenues</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,846</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling and marketing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">278</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets impairments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other asset impairments, restructuring and other items</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements and loss contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other loss (income)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(107</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three<BR>Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LTM<BR>ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,163</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(523</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share in (profits) losses of associated companies&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#167;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to <FONT STYLE="white-space:nowrap">non-controlling</FONT>
interests</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(56</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) attributable to Teva</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The data presented for the year ended December&nbsp;31, 2022 has been revised to reflect the previously
disclosed revisions in the presentation of these items in our consolidated financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#167;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an amount less than $0.5&nbsp;million. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Identifiable intangible assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,837</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,374</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term debt, including current maturities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,672</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes accounts receivables net of sales reserves and allowances, inventories, prepaid expenses and other
current assets, accounts payables, employee-related obligations, accrued expenses and other current liabilities. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Financial
Data </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three<BR>Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LTM<BR>ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted EBITDA<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have presented <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income, which is defined as
operating income adjusted for goodwill impairment, impairment of long-lived assets and the other items discussed below and Adjusted EBITDA, which is defined as net income (loss) adjusted for financial expenses, income taxes, depreciation and
amortization, legal settlements and loss contingencies, goodwill impairment, impairment of long lived assets, equity compensation and other <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items discussed below. The following are examples of
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
how we utilize <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> measures: (i)&nbsp;our management and Board of Directors use <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and
Adjusted EBITDA to evaluate our operational performance, to compare against work plans and budgets, and ultimately to evaluate the performance of management; (ii)&nbsp;our annual budgets are prepared on a
<FONT STYLE="white-space:nowrap">non-GAAP</FONT> basis; and (iii)&nbsp;senior management&#146;s annual compensation is derived, in part, using these <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> measures. While qualitative factors and judgment
also affect annual bonuses, the principal quantitative element in the determination of such bonuses is performance targets tied to the work plan, and thus is based on the <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and Adjusted
EBITDA. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and Adjusted EBITDA have no standardized meaning and accordingly have limitations in their usefulness to investors. We provide <FONT STYLE="white-space:nowrap">Non-GAAP</FONT>
Operating Income and Adjusted EBITDA because management believes that such data provide useful information to investors. However, investors are cautioned that, unlike financial measures prepared in accordance with U.S. GAAP, <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> measures may not be comparable with the calculation of similar measures for other companies. <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and Adjusted EBITDA are presented solely to
permit investors to more fully understand how management assesses our performance. The limitations of using <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and Adjusted EBITDA as performance measures are that they provide a view of
our results of operations without including all events during a period and may not provide a comparable view of our performance to other companies in the pharmaceutical industry. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below are reconciliations of <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Operating Income and Adjusted EBITDA to operating income (loss)
and net income (loss), respectively, their closest GAAP equivalents. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year<BR>Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LTM<BR>ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GAAP operating income (loss)***</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>GAAP operating margin</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1.8</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5.7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.61</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) for excluded items:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of purchased intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements and loss contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of long-lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to regulatory actions taken in facilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on sale of business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accelerated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating income (loss)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating margin**</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26.38</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items include other exceptional items that we believe
are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other
unusual events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating margin is
<FONT STYLE="white-space:nowrap">Non-GAAP</FONT> operating income as a percentage of revenues. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The data presented for the year ended December&nbsp;31, 2022 has been revised to reflect the previously
disclosed revisions in the presentation of these items in our consolidated financial statements. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three<BR>Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>LTM<BR>ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>U.S. dollars in millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income (loss)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,959</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(615</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,499</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) for excluded items:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(643</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(52</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share in profits (losses) of associated companies- net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#167;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal settlements and loss contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill impairment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of long lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs related to regulatory actions taken in facilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contingent consideration<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (Gain) on sale of business</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items<SUP
STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjusted EBITDA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,041</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Other <FONT STYLE="white-space:nowrap">non-GAAP</FONT> items include other exceptional items that we believe
are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, certain inventory write-offs, material litigation fees and other
unusual events. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The data presented for the year ended December&nbsp;31, 2022 has been revised to reflect previously disclosed
revisions in the presentation of these items in our consolidated financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#167;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents an amount of less than $0.5&nbsp;million. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Before you invest in the notes, you should carefully consider the risks involved. Accordingly, you should carefully consider the
information contained in or incorporated by reference into this prospectus supplement and the accompanying prospectus, including the risk factors listed below, those described in the section entitled &#147;Risk Factors&#148; in Teva&#146;s Annual
Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and the other information contained in this Prospectus Supplement and in the documents incorporated by reference herein, as may be updated from time to time by Teva&#146;s subsequent
reports and other filings under the Exchange Act that are incorporated by reference herein. See &#147;Where You Can Find More Information.&#148; and &#147;Forward-Looking Statements.&#148; </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There may not be liquid
markets for the notes, and you may not be able to sell your notes at attractive prices or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are new issues of
securities for which there are currently no trading markets. Although one or more of the underwriters have advised us that they currently intend to make markets in the notes, they are not obligated to do so and may discontinue their market-making
activities at any time without notice. Although application has been made to Euronext Dublin for the Euro notes to be admitted to the Official List and to trading on the Global Exchange Market, an active market may not develop. We do not intend to
apply for listing of the USD notes on any exchange or any automated quotation system. If active markets for the notes fails to develop or be sustained, the trading prices of the notes could fall, and even if active trading markets were to develop,
the notes could trade at prices that may be lower than their respective initial offering prices. The trading prices of the notes will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevailing interest rates and interest rate volatility; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the markets for similar securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition, results of operations and prospects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the publication of earnings estimates or other research reports and speculation in the press or investment
community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated results of acquisitions and divestitures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our industry and competition; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we cannot assure you that you will be able to sell the notes at attractive prices or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Euro notes may not become, or remain, listed on Euronext Dublin. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Teva Finance II will, pursuant to the indenture governing the Euro notes, agree to make an application to have the Euro notes listed
on Euronext Dublin and admitted to trading on the Global Exchange Market thereof within a reasonable period after the issue date and to maintain such listing as long as the Euro notes are outstanding, Teva Finance II cannot assure you that the Euro
notes will become, or remain, listed. If Teva Finance II cannot maintain the listing on Euronext Dublin and the admission to trading on the Global Exchange Market thereof or it becomes unduly burdensome to make or maintain such listing, Teva Finance
II may cease to make or maintain such listing on Euronext Dublin, provided that it will use reasonable best efforts to obtain and maintain the listing of the Euro notes on another securities exchange, although there can be no assurance that Teva
Finance II will be able to do so. Although no assurance can be made as to the liquidity of the Euro notes as a result of listing on Euronext Dublin or another recognized listing exchange for comparable issuers in accordance with the indenture,
failure to be approved for listing or the delisting of the Euro notes from Euronext Dublin or another listing exchange in accordance with the indenture may have a material adverse effect on a holder&#146;s ability to resell Euro notes in the
secondary market. We do not intend to apply for the Euro notes to be listed on any U.S. securities exchange or to arrange for quotation on any automated dealer quotation system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A downgrade, suspension or withdrawal of the rating assigned by a rating agency to the notes, if any,
could cause the liquidity or market values of the notes to decline significantly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you what ratings will be
assigned to the notes. In addition, we cannot assure you that any rating so assigned will remain for any given period of time or that the rating will not be lowered or withdrawn entirely by the rating agency if in that rating agency&#146;s judgment
future circumstances relating to the basis of the rating, such as adverse changes in our business, so warrant. A downgrade of Teva&#146;s credit rating could negatively affect the liquidity or market values of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to refinance our indebtedness. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may need to refinance all or a portion of our indebtedness, including the notes, before maturity. We cannot assure you that we will be able
to refinance any of our indebtedness on commercially reasonable terms or at all. We cannot assure you that we will be able to obtain sufficient funds to enable us to repay or refinance our debt obligations on commercially reasonable terms or at all.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur additional indebtedness that may adversely affect our ability to meet our financial obligations under the notes. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the notes do not impose any limitation on the ability of Teva, the Issuers or any of Teva&#146;s other subsidiaries to incur
additional unsecured debt. We may incur additional unsecured indebtedness in the future, which could have important consequences to holders of notes, including that we could have insufficient cash to meet our financial obligations, including our
obligations under the notes, and that our ability to obtain additional financing could be impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Holders of the notes will vote jointly together
with holders of the relevant Issuer&#146;s other outstanding Securities under the applicable indenture with respect to amendments that affect all of such Securities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify the applicable indenture and the rights of the holders of Securities (as defined in &#147;Description of the Euro
Notes and Guarantees&#148; and &#147;Description of the USD Notes and the Guarantees,&#148; as applicable) outstanding under such indenture with the consent of the holders of a majority of the aggregate principal amount of Securities outstanding
under that indenture affected by the modification. Accordingly, following consummation of the offering and application of the proceeds therefrom, &#128;<B></B><B></B><B>&#8195;</B><B>&#8195;</B> million of Securities will be outstanding under the
indenture to which Teva Finance II is a party governing the Euro notes and $<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> million of Securities will be outstanding under the indenture to which Teva Finance III is a party governing the
2032 USD notes, and holders of such Securities, including the holders of the Euro notes and the 2032 USD notes offered hereby, respectively, will vote together as a single class with respect to certain matters under the applicable indenture;
provided that certain modifications to certain fundamental items may only be amended with the consent of each affected holder. Similarly, holders of any future Securities issued under the indenture to be executed by Teva Finance IV in connection
with this offering governing the 2030 USD notes will vote together with the holders of the 2030 USD notes with respect to certain matters under such indenture; provided that certain modifications to certain fundamental items may only be amended with
the consent of each affected holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because Teva and the Issuers are foreign entities, you may have difficulties enforcing your rights under the
guarantee and under the notes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is organized under the laws of Israel and certain of Teva&#146;s directors and officers reside
outside of the United States. As a result, service of process on them may be difficult or impossible to effect in the United States. Furthermore, a substantial portion of Teva&#146;s assets are located outside of the United States. Therefore, any
judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a request for enforcement of a foreign judgment shall be submitted in accordance
with the provisions of the Foreign Judgments Enforcement Law, 1958 (the &#147;Foreign Judgments Enforcement Law&#148;) in accordance with which, subject to various time limitations, an Israeli court may declare a judgment rendered by a foreign court
in a civil matter, including judgments awarding monetary or other damages in <FONT STYLE="white-space:nowrap">non-civil</FONT> matters, enforceable if it finds that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was rendered by a court which was, according to the foreign country&#146;s law, competent to
render it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment is no longer appealable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the obligation in the judgment is enforceable according to the rules relating to the enforceability of
judgments in Israel and the substance of the judgment is not contrary to public policy in Israel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment can be executed in the state in which it was given. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign judgment will not be declared enforceable by Israeli courts in accordance the Foreign Judgments Enforcement Law if it was given in a
state, the laws of which do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases), or if its enforcement is likely to prejudice the sovereignty or security of Israel. Pursuant to the Foreign Judgments
Enforcement Law, an Israeli court also will not declare a foreign judgment enforceable if it is proven to the Israeli court that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was obtained by fraud; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there was no due process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was given by a court not competent to render it according to the laws of private international law
in Israel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment conflicts with another judgment that was given in the same matter between the same parties and
which is still valid; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time the action was brought to the foreign court a claim in the same matter and between the same parties
was pending before a court or tribunal in Israel. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Issuers are organized under the laws of The Netherlands, their
managing and supervisory directors reside outside the United States, and all or a significant portion of the assets of such persons are, and substantially all of their assets are, located outside the United States. As a result, it may not be
possible to effect service of process within the United States upon the Issuers or any such person or to enforce against the Issuers or any such person judgments obtained in United States courts predicated upon the civil liability provisions of the
federal securities laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because there is no treaty on the recognition and enforcement of judgments in civil and
commercial matters between the United States and The Netherlands, courts in The Netherlands will not automatically recognize and enforce a final judgment rendered by a United States federal or state court. However, a final judgment obtained in a
United States federal or state court would generally be recognized by a Dutch court of competent jurisdiction, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment results from legal proceedings that comply with the standards of the proper administration of
justice that includes sufficient safeguards (<I>behoorlijke rechtspleging</I>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that judgment has been rendered by a court of competent jurisdiction, in accordance with the principles of due
justice, its contents and enforcement do not conflict with Dutch public policy (<I>openbare orde</I>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the jurisdiction of the relevant federal or state court in the United States has been based on grounds that are
internationally acceptable; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment is not incompatible with a decision rendered between the same parties by a court in the
Netherlands, or with a previous decision rendered between the same parties by a foreign court in a dispute that concerns the same subject and is based on the same cause, provided that the previous decision qualifies for acknowledgement in the
Netherlands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, recognition may be prevented on the ground that the judgment rendered by a United
States federal or state court which is eligible for recognition is not, not yet or no longer formally enforceable under their governing law. Furthermore, enforcement of obligations before the courts of The Netherlands will be subject to the nature
of the remedies available in the courts of The Netherlands, the acceptance by such courts of jurisdiction, the effect of provisions imposing prescription periods and to the availability of defenses such as set off (unless validly waived) and
counter-claim. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, it is noted that the party that has obtained a judgment favorable to it before a United States federal or state
court is not required to bring an action before the courts of The Netherlands seeking an order to what the opposing party was ordered to before a United States federal or state court. That party is free to ask the court for a new substantive
assessment of the dispute. In the latter case, it is up to the court to decide whether, and if so, what evidentiary value is to be attributed to the initial decision. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The guarantees will effectively be subordinated to some of our existing and future indebtedness. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due of the principal of and interest, if any, on the notes. As
indebtedness of Teva, the guarantees will be Teva&#146;s general, unsecured obligations and will rank equally in right of payment with all of Teva&#146;s existing and future unsubordinated, unsecured indebtedness. The guarantees will be effectively
subordinated to any existing and future secured indebtedness Teva may have up to the value of the collateral securing that indebtedness and structurally subordinated to any existing and future liabilities and other indebtedness of our subsidiaries
with respect to the assets of those subsidiaries. These liabilities may include debt securities, credit facilities, trade payables, guarantees, lease obligations, letter of credit obligations and other indebtedness. See &#147;Description of the USD
Notes and the Guarantee&#151;Description of the Guarantees&#148; and &#147;Description of the Euro Notes and the Guarantee&#151;Description of the Guarantees.&#148; The indentures governing the notes do not restrict us or our subsidiaries from
incurring debt in the future, nor do the indentures limit the amount of indebtedness we can issue that is equal in right of payment. As of March&nbsp;31, 2025, after giving effect to this offering, Teva had no secured indebtedness outstanding, and
its subsidiaries, other than finance subsidiaries, had a <I>de minimis</I><B><I> </I></B>amount of indebtedness outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva may be subject to
restrictions on receiving dividends and other payments from its subsidiaries. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva&#146;s income is derived in large part from its
subsidiaries. Accordingly, Teva&#146;s ability to pay its obligations under the guarantees depends in part on the earnings of its subsidiaries and the payment of those earnings to Teva, whether in the form of dividends, loans or advances. Such
payment by Teva&#146;s subsidiaries to Teva may be subject to restrictions. The indenture governing the notes do not restrict Teva, the Issuers or Teva&#146;s other subsidiaries from entering into agreements that contain such restrictions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An investment in the notes by a purchaser whose home currency is not U.S. dollars or euros, as applicable, entails significant risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An investment in the notes by a purchaser whose home currency is not U.S. dollars or euros, as applicable, entails significant risks. These
risks include the possibility of significant changes in rates of exchange between the holder&#146;s home currency and the U.S. dollar or euro, as applicable, and the possibility of the imposition or subsequent modification of foreign exchange
controls. These risks generally depend on factors over which we have no control, such as economic, financial and political events and the supply of and demand for the relevant currencies. In the past, rates of exchange between the U.S. dollar or
euro, as applicable, and certain currencies have been highly volatile, and each holder should be aware that volatility may occur in the future. Fluctuations in any particular exchange rate that have occurred in the past, however, are not necessarily
indicative of fluctuations in the rate that may occur during the terms of the notes. Depreciation of the U.S. dollar or euro, as applicable, against the holder&#146;s home currency would result in a decrease in the effective yield of the notes,
below its coupon rate and, in certain circumstances, could result in a loss to the holder. Investment in the notes by a purchaser whose home currency is not U.S. dollars or euros, as applicable, may also have important tax consequences. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The procedures for book-entry interests to be implemented through Euroclear or Clearstream may not be
adequate to ensure the timely exercise of your rights under the Euro notes. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until Euro notes in definitive registered
form are issued in exchange for global notes, owners of book-entry interests will not be considered owners or holders of the Euro notes except in the limited circumstances provided in the indenture governing the Euro notes. The common depositary for
Euroclear and Clearstream (or its nominee) will be the sole registered holder of the global Euro notes representing the Euro notes. After payment to the common depositary, we will have no responsibility or liability for the payment of interest,
principal or other amounts to the owners of book-entry interests. Accordingly, if you own a book-entry interest, you must rely on the procedures of Euroclear or Clearstream, as applicable, and if you are not a participant in Euroclear or
Clearstream, on the procedures of the participant through which you own your interest, to exercise any rights and obligations of a holder under the indenture governing the Euro notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unlike the holders of the Euro notes themselves, owners of book-entry interests will not have the direct right to act upon our solicitations
for consents, requests for waivers or other actions from holders of the Euro notes. Instead, if you own a book-entry interest, you will be permitted to act only to the extent you have received appropriate proxies to do so from Euroclear or
Clearstream. The procedures implemented for the granting of such proxies may not be sufficient to enable you to vote on any request actions on a timely basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, upon the occurrence of an event of default under the indenture governing the Euro notes, if you own a book-entry interest, you will
be restricted to acting through Euroclear or Clearstream. The procedures to be implemented through Euroclear or Clearstream may not be adequate to ensure the timely exercise of rights under the Euro notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Euro notes and the USD notes have minimum specified denominations of &#128;100,000 and $200,000, respectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes have minimum denominations of &#128;100,000 and multiples of &#128;1,000 in excess thereof. The USD notes have minimum
denominations of $200,000 and multiples of $1,000 in excess thereof. It is therefore possible that notes may be traded in amounts that would cause a holder of notes to hold a principal amount of less than &#128;100,000 or $200,000, as applicable,
following such trade. In such a case, a holder of notes who holds a principal amount of less than &#128;100,000 or $200,000, as applicable, may not receive a definitive certificate in respect of such holding (should definitive certificates be
printed) and would need to purchase a principal amount of notes such that its holding amounts to at least &#128;100,000 or $200,000, as applicable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>In a lawsuit for payment on the Euro notes, an investor may bear currency exchange risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes and the indenture governing the Euro notes will be governed by the laws of the State of New&nbsp;York. Under New York law, a New
York state court rendering a judgment on the Euro notes would be required to render the judgment in euros. The judgment would be converted into U.S. dollars, however, at the exchange rate prevailing on the date of entry of the judgment.
Consequently, in a lawsuit for payment on the Euro notes, investors would bear currency exchange risk until a New York state court judgment is entered. A U.S. federal court sitting in New York with diversity jurisdiction over a dispute arising in
connection with the Euro notes would apply the foregoing New York law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In courts outside of New York, investors may not be able to obtain
a judgment in a currency other than U.S. dollars. For example, a judgment for money in an action based on the Euro notes in many other U.S. federal or state courts ordinarily would be enforced in the United States only in U.S. dollars. The date used
to determine the rate of conversion of euros into U.S. dollars would depend upon various factors, including which court renders the judgment and when the judgment is rendered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_5"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure and analysis in this prospectus supplement, including statements that are predictive in nature, or that depend upon or refer to
future events or conditions, contain or incorporate by reference some forward-looking statements within the meaning of Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act, which are based on management&#146;s current
beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking
statements. You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148; &#147;project,&#148;
&#147;guidance,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could
cause or contribute to such differences include risks relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully compete in the marketplace, including: that we are substantially dependent on our
generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in additional costs
and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product
pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or
through business development, and to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect
our intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional
transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business and operations in general, including: the impact of global economic conditions and other
macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; significant
disruptions of information technology systems, including cybersecurity attacks and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting
business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; our ability to attract, hire, integrate and retain
highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units
and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory
environments; the effects of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage;
increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our
ability to comply with and operate under our deferred prosecution agreement with the U.S. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Department of Justice; potential liability for intellectual property right infringement; product liability claims; failure to comply with complex Medicare, Medicaid and other governmental
programs reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of ESG issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the state of war declared in Israel and the military activity in the region, including the risk of
disruptions to our operations and facilities, such as our manufacturing and R&amp;D facilities, located in Israel, the impact of our employees who are military reservists being called to active military duty, and the impact of the war on the
economic, social and political stability of Israel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as
credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; the
effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; our exposure to changes in international trade policies, including the imposition of tariffs in the
jurisdictions in which we operate, and the effects of such developments on sales of our products and the pricing and availability of our raw materials; and the impact of any future failure to establish and maintain effective internal control over
our financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained or incorporated by reference herein involve a number
of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. You should
understand that many important factors, in addition to those discussed or incorporated by reference in this prospectus, could cause our results to differ materially from those expressed in the forward-looking statements. Potential factors that could
affect our results, include, in addition to others not described in this prospectus supplement, those referenced under &#147;Risk Factors.&#148; These are factors that we think could cause our actual results to differ materially from our expected
results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained in this prospectus supplement, whether as a result of new information, future events or otherwise, except as may be required by law. You are advised, however, to consult any additional
disclosures we make in our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our subsequently filed Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> that are filed with the SEC. See &#147;Risk Factors.&#148; Other factors besides those listed here could also adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the gross proceeds to us from this offering will be approximately $2,000,000,000 (equivalent). After deducting the
underwriters&#146; discounts and estimated offering expenses we expect to use the net proceeds of this offering, together with cash on hand, (i)&nbsp;to fund the Tender Offer for a maximum combined aggregate purchase price (exclusive of accrued and
unpaid interest) of up to $2,000,000,000 (equivalent) (as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith and (iii)&nbsp;to the extent of any remaining proceeds, for the repayment of outstanding
debt upon maturity, tender offer or earlier redemption. Net proceeds may be temporarily invested pending application for their stated purpose. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Tender Offer we will offer to purchase, for cash, Tender Offer Notes, as listed below, for a maximum combined aggregate
purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) comprised of (i)&nbsp;up to $1,550,000,000 aggregate purchase price in respect of the Pool 1 Notes, (ii)&nbsp;up to $250,000,000 (equivalent) aggregate
purchase price in respect of the Pool 2 Notes, and (iii)&nbsp;up to $200,000,000 (equivalent) aggregate purchase price in respect of the Pool 3 Notes, in each case, exclusive of accrued and unpaid interest. Subject to the Total Maximum Amount and
the Tender Caps (which may be increased or decreased by Teva at its sole discretion) specified for the notes listed below, the amount of a series of Tender Offer Notes that is purchased in the Tender Offer on any settlement date will be based on the
Acceptance Priority Levels set out below. The principal amounts outstanding of the Tender Offer Notes below are as of March&nbsp;31, 2025. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollars or Euros per $1,000 or &#128;1,000, as<BR>applicable, principal amount</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:6pt; font-family:Times New Roman; "><B>Capped Tender<BR>Offers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Title of<BR>Notes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Issuer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>CUSIP / ISIN /<BR>Common Code</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal<BR>Amount<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pool Tender<BR>Caps (Purchase<BR>Price (excluding<BR>Accrued<BR>Interest))<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Acceptance<BR>Priority<BR>Level<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Authorized<BR>Denominations<BR>(principal<BR>amount)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>First Par<BR>Call&nbsp;Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Reference<BR>Security or<BR>Interpolated<BR><FONT
STYLE="white-space:nowrap">Mid-Swap</FONT><BR>Rate</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:6pt; font-family:Times New Roman" ALIGN="center"><B>Bloomberg<BR>Reference<BR>Page / Screen</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fixed<BR>Spread<BR>(basis<BR>points)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tender Offer<BR>Consideration<SUP STYLE="font-size:75%; vertical-align:top">(3)(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Early<BR>Tender<BR>Premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Consideration<SUP STYLE="font-size:75%; vertical-align:top">(3)(6)</SUP></B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle">Pool 1 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.150% Senior Notes due 2026</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands III B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAE1 / US88167AAE10 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">3,377,644,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">$1,550,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$2,000 and integral multiples of $1,000&nbsp;in&nbsp;excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$931.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$981.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle" ROWSPAN="2">Pool 2 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">4.750% Sustainability-Linked Senior Notes due 2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands III B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAP6 / US88167AAP66 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">1,000,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="middle">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman"></P></TD>
<TD ROWSPAN="2" VALIGN="middle" ALIGN="right">$250,000,000<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">(equivalent)</P></TD>
<TD ROWSPAN="2" NOWRAP VALIGN="middle">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and integral multiples of $1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">February&nbsp;9, 2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$947.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$997.50</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.750% Sustainability-Linked Senior Notes due 2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands II B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">XS2406607098 / 240660709 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&#128;</TD>
<TD VALIGN="middle" ALIGN="right">1,100,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;100,000 and integral multiples of &#128;1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">February&nbsp;9, 2027</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">N/A</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;963.50</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;1,013.50</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="middle" ROWSPAN="3">Pool 3 Tender Offers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">7.875% Sustainability-Linked Senior Notes due 2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands III B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAS0 / US88167AAS06 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">600,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD ROWSPAN="2" VALIGN="middle">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman"></P></TD>
<TD ROWSPAN="2" VALIGN="middle" ALIGN="right">$200,000,000<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center">(equivalent)</P></TD>
<TD ROWSPAN="2" NOWRAP VALIGN="middle">&nbsp;<BR> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:7pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and integral multiples of $1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15, 2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.875%&nbsp;U.S. Treasury due April&nbsp;30, 2030</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">FIT1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">+135</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See&nbsp;Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See&nbsp;Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">7.375% Sustainability-Linked Senior Notes due 2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands II B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">XS2592804434 / 259280443 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&#128;</TD>
<TD VALIGN="middle" ALIGN="right">800,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;100,000 and integral multiples of &#128;1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15, 2029</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">2029 Euro Notes Interpolated <FONT STYLE="white-space:nowrap">Mid-Swap</FONT> Rate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">IRSB EU&lt;GO&gt;(7)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">+150</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">&#128;50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">8.125% Sustainability-Linked Senior Notes due 2031</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">Teva Pharmaceutical Finance Netherlands III B.V.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">88167AAR2 / US88167AAR23 (Registered)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">$</TD>
<TD VALIGN="middle" ALIGN="right">500,000,000</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="middle"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$200,000 and integral multiples of $1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">June&nbsp;15, 2031</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">3.875% U.S. Treasury due April&nbsp;30, 2030</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">FIT1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right">+155</TD>
<TD NOWRAP VALIGN="middle">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">$50.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center">See Note<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Pool 1 Maximum Amount of $1,550,000,000 represents the maximum aggregate purchase price in respect of Pool
1 Notes that will be purchased in the Pool 1 Tender Offers. The Pool 2 Maximum Amount of $250,000,000 (equivalent) represents the maximum aggregate purchase price in respect of Pool 2 Notes that will be purchased in the Pool 2 Tender Offers. The
Pool 3 Maximum Amount of $200,000,000 (equivalent) represents the maximum aggregate purchase price in respect of Pool 3 Notes that will be purchased in the Pool 3 Tender Offers. The Pool Tender Caps can be increased or decreased at Teva&#146;s sole
discretion, and in each case are exclusive of Accrued Interest. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the Total Maximum Amount, the Pool Tender Caps and proration, the principal amount of each series of
Tender Offer Notes that is purchased in each of the Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column. Tender Offer Notes tendered at or prior to the Early
Tender Time will also be accepted for purchase in priority to Tender Offer Notes tendered thereafter. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Excludes accrued and unpaid interest, which will also be paid. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Tender Offer Consideration in respect of the Notes of each relevant series will equal the applicable Total
Consideration minus the applicable Early Tender Premium. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Total Consideration in respect of the Pool 3 Notes of each relevant series shall be calculated from the
applicable Reference Yield and the applicable Fixed Spread and which, when calculated in such manner, already includes the applicable Early Tender Premium. The applicable Total Consideration will be calculated with reference to the First Par Call
Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Such amount already includes the Early Tender Premium. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pricing Source: BGN. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tender Offer will be made solely pursuant to an offer to purchase related thereto. The Tender Offer is conditioned on, among other things,
the consummation of this offering. This offering, however, is not conditioned on the consummation of the Tender Offer, the tender of any specified amount of the Tender Offer Notes. For more information on the Tender Offer, see
&#147;Summary&#151;Recent Developments&#151;Tender Offer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more of the underwriters or their respective affiliates may own
Tender Offer Notes and be eligible to participate in the Tender Offer. As a result, one or more of the underwriters or their respective affiliates may receive a portion of the net proceeds from this offering (in excess of any underwriters&#146;
discount, if applicable). See &#147;Underwriting&#151;Conflicts of Interest.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth Teva&#146;s capitalization as of March&nbsp;31, 2025: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a historical basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to give effect to the issuance and sale of the notes offered hereby and the application
of the net proceeds from this offering, including in connection with the Tender Offer, as further described below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
illustrative purposes, this table has been prepared based on the assumption that (i) $2,000,000,000 (equivalent) aggregate principal amount of Tender Offer Notes are purchased in the Tender Offer for a combined aggregate principal amount (exclusive
of accrued and unpaid interest) equal to the Total Maximum Amount, (ii)&nbsp;the purchase of Tender Offer Notes will be completed in accordance with the Acceptance Priority Levels and subject to the Tender Caps as further described in
&#147;Summary&#151;Recent Developments&#151;Tender Offer&#148; (see footnote 3 below) and (iii)&nbsp;the pricing contained in the offer to purchase, dated as of the date of this prospectus supplement, applies to the Tender Offer and the purchase of
any Tender Offer Notes in connection therewith. For more information on the Tender Offer, see &#147;Summary&#151;Recent Developments&#151;Tender Offer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table together with our financial statements incorporated by reference in this prospectus supplement, as well as the
information under &#147;Risk Factors&#148; and &#147;Use of Proceeds.&#148; Investors in the notes should not place undue reliance on the as adjusted information included in this prospectus supplement because this offering is not contingent upon any
of the transactions reflected in the adjustments included in the following information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2025*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>U.S.&nbsp;Dollars in<BR>Millions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,680</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">0.25% Convertible debentures due 2026</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current maturities of long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term debt</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.375% EUR Sustainability-linked Senior Notes due 2030</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.750% EUR Sustainability-linked Senior Notes due 2027<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.625% EUR Senior Notes due 2028</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.875% EUR Senior Notes due 2027</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">3.150% USD Senior Notes due 2026<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,824</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.100% USD Senior Notes due 2046</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.750% USD Senior Notes due 2028</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.750% USD Sustainability-linked Senior Notes due 2027<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.125% USD Sustainability-linked Senior Notes due 2029</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">6.150% USD Senior Notes due 2036</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1.000% CHF Senior Notes due 2025</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.375% EUR Sustainability-linked Senior Notes due 2029<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.875% EUR Sustainability-linked Senior Notes due 2031</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">7.875% USD Sustainability-linked Senior Notes due 2029<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">8.125% USD Sustainability-linked Senior Notes due 2031<SUP
STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;&#8199;&#8199;&#8199;&#8201;% EUR Senior Notes due 2031 offered hereby<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;&#8199;&#8199;&#8199;&#8201;% USD Senior Notes due 2032 offered hereby<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#8199;&#8199;&#8199;&#8199;&#8201;% USD Senior Notes due 2030 offered hereby<SUP
STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less current maturities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(398)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less debt issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(68)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term debt<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain amounts in the table may not add up due to rounding. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The &#147;as adjusted&#148; column reflects the use of cash and cash equivalents to consummate the Tender Offer
and this offering and pay fees and expenses in connection therewith. The &#147;as adjusted&#148; column does not reflect the cash cost of accrued interest payable on Tender Offer Notes accepted for tender in the Tender Offer. Any additional cash
from the proceeds of this offering will be used to fund the repayment of outstanding debt upon maturity or earlier redemption. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the impact of changes related to the tender premium, the
<FONT STYLE="white-space:nowrap">write-off</FONT> of deferred financing fees related to the Tender Offer and any gain or loss on the extinguishment of debt. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notes that are subject to the concurrent Tender Offer. Assumes that a principal amount of $1,550&nbsp;million
of 3.150% USD Senior Notes due 2026, $0&nbsp;million of 3.750% EUR Sustainability-linked Senior Notes due 2027, $250&nbsp;million of 4.750% USD Sustainability-linked Senior Notes due 2027, $200&nbsp;million of 7.875% USD Sustainability-linked Senior
Notes due 2029, $0&nbsp;million of 7.375% EUR Sustainability-linked Senior Notes due 2029 and $0&nbsp;million of 8.125% USD Sustainability-linked Senior Notes due 2031 are purchased in the Tender Offer. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents principal amount of each series of notes offered hereby. Does not include debt issuance costs,
underwriting discounts and commissions or other offering expenses. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Total long-term debt consists of Teva&#146;s outstanding senior notes, after deducting current maturities and
debt issuance costs. Does not include other long-term liabilities including deferred income taxes, other taxes and long-term liabilities and operating lease liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_8"></A>DESCRIPTION OF THE EURO NOTES AND THE GUARANTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Teva Finance II will issue &#128;</I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I> aggregate principal
amount of&#8195;&#8195;% Senior Notes due 2031 (for this section, the &#147;Euro notes&#148;) under a senior indenture dated as of March&nbsp;14, 2018, by and among Teva Finance II, Teva, as guarantor, and The Bank of New York Mellon, as trustee
(for this section, the &#147;base indenture&#148;), as supplemented by a fifth supplemental indenture, to be dated on or about </I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I>, 2025, by and among Teva Finance II,
Teva, as guarantor, The Bank of New York Mellon, as trustee, and The Bank of New&nbsp;York Mellon, London Branch, as principal paying agent (for this section, the &#147;fifth supplemental indenture&#148;). The terms of the Euro notes include those
provided in the indenture. Teva will irrevocably and unconditionally guarantee the punctual payment by Teva Finance II of the principal of and interest, if any, on the Euro notes and all other amounts due and payable under the indenture. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description is only a summary of the material provisions of the Euro notes and the related indenture and guarantee. We urge
you to read these documents in their entirety because they, and not this description, define your rights as holders of the Euro notes. You may request copies of these documents at our address set forth in the section titled &#147;Incorporation of
Certain Documents by Reference.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>When we refer to Teva or the guarantor in this section, we refer only to Teva Pharmaceutical
Industries Limited, an Israeli corporation. When we refer to Teva Finance II or the issuer in this section, we refer to Teva Pharmaceutical Finance Netherlands II B.V., an indirect, wholly-owned subsidiary of Teva organized as a Dutch private
limited liability company. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>For this section, we refer to the base indenture, as supplemented by the fifth supplemental indenture,
as &#147;the indenture&#148;. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brief Description of the Euro notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initially be limited to &#128;<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> aggregate principal amount
of the Euro notes, subject to reopening of the Euro notes at the discretion of the issuer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">accrue interest at a rate of <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>% per annum, payable
annually in arrears on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> of each year, beginning on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2026; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">constitute general unsecured obligations of the issuer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be redeemable (in addition to being redeemable as set forth below under &#147;&#151;Tax Redemption&#148;) at the
option of Teva Finance II in whole or in part, at any time and from time to time, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice, at the redemption prices described under &#147;&#151;Optional Redemption by the
Issuer&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mature on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2031, unless earlier redeemed by the issuer.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not contain any financial covenants or restrictions on the amount of additional indebtedness that
Teva, Teva Finance II or any of Teva&#146;s other subsidiaries may incur except as described in &#147;&#151;&nbsp;Certain Covenants&#148; below. The indenture does not protect you in the event of a highly leveraged transaction or change of control
of Teva or Teva Finance II. The indenture does not contain a covenant regulating the offer and/or payment of a consent fee to holders. The Euro notes do not contain any sinking fund provisions. Following consummation of the offering and application
of the proceeds therefrom, &#128;<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> million of Securities (as defined in the base indenture) will be outstanding under the indenture, and holders of such Securities, including the holders of the
Euro notes, will vote together as a single class with respect to certain matters thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II may, without the consent of the holders, issue additional Euro notes under
the indenture with the same terms (except for the issue date, issue price and, in some cases, the first payment of interest or interest accruing prior to the issue date of such additional Euro notes) and with the same ISIN number as the Euro notes
offered hereby in an unlimited aggregate principal amount; provided that if the additional Euro notes are not fungible with the Euro notes offered hereby for United States federal income tax purposes, such additional Euro notes will have a separate
ISIN number. Any additional debt securities having such similar terms, together with the Euro notes, could be considered part of the same series of Euro notes under the indenture; provided that, in the case of any Euro notes represented by global
Euro notes, for so long as may be required by the Securities Act or the procedures of the common depositary, Euroclear or Clearstream (or a successor or clearing system), such additional Euro notes will be represented by one or more separate global
Euro notes in accordance with the terms of the indenture and subject to applicable transfer or other restrictions. We may also from time to time repurchase Euro notes in open market purchases or negotiated transactions without giving prior notice to
holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application has been made to Euronext Dublin to list the Euro notes on the Official List of Euronext Dublin and to admit the
Euro notes to trading on the Global Exchange Market thereof. The application to list the Euro notes on the Official List of Euronext Dublin and to admit the Euro notes to trading on the Global Exchange Market may not be approved and settlement is
not conditioned on obtaining such listing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Guarantees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due, whether at maturity, upon redemption, by acceleration or
otherwise, of the principal of and interest (including any additional amounts in respect of taxes as provided herein), if any, on the Euro notes as well as all other amounts due and payable under the indenture. The respective guarantees will be
enforceable by the trustee, the holders of the applicable Euro notes and their successors, transferees and assigns. Teva will also guarantee the USD notes issued in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each guarantee will be an unsecured senior obligation of Teva. As indebtedness of Teva, after giving effect to the offerings contemplated
hereby, each guarantee will rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to the rights of creditors under indebtedness expressly subordinated to the guarantee (at March&nbsp;31,
2025, Teva had no subordinated indebtedness outstanding); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equally with other unsecured indebtedness of Teva from time to time outstanding other than any that is
subordinated to the guarantee (at March&nbsp;31, 2025 Teva had approximately $16,687&nbsp;million of senior unsecured indebtedness outstanding); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that
indebtedness (at March&nbsp;31, 2025, Teva had no secured indebtedness outstanding); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries (other than the issuer)
(at March&nbsp;31, 2025, Teva&#146;s subsidiaries, other than finance subsidiaries, had a <I>de minimis </I>amount of indebtedness outstanding). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of Interest and Principal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest on the
Euro notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes will bear interest at the rate of &#8195;<B>&#8195;</B><B>&#8195;</B>&#8195;% per year, payable annually
in arrears on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>of each year, beginning <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2026, to the holders of record at the
close of business on the Business Day (as defined below) immediately preceding the related interest payment date. If an interest payment date for the Euro notes falls on a day that is not a Business Day, interest will be payable on the next
succeeding Business Day with the same force and effect as if made on such interest payment date and no interest </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall accrue thereon on account of such delay. Interest on the Euro notes will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve <FONT
STYLE="white-space:nowrap">30-day</FONT> months, and will accrue from <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2025, or from the most recent interest payment date to which interest has been paid to, but not including, the next
interest payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Day&#148; for this section means any day on which commercial banks and foreign exchange markets are
open for business in New York and London; provided that, for purposes of payments on the Euro notes, a &#147;Business Day&#148; must be a day on which the Trans-European Automated Real-Time Gross Settlement Express Transfer System (TARGET) is
operating. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mechanics of Payment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments on the Euro notes represented by global Euro notes will be made through the principal paying agent. Payments on the Euro notes will be
made in euros at the specified office or agency of the principal paying agent; provided that all such payments with respect to the Euro notes represented by one or more global Euro notes deposited with and registered in the name of the common
depositary or its nominee for the accounts of Euroclear and Clearstream, will be by wire transfer of immediately available funds to the account specified in writing by the holder or holders thereof to the common depositary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at our option, if physical Euro notes are issued, we may make payments by wire transfer to the account specified by the holder or
holders thereof as notified to the principal paying agent in writing at least 15 days prior to such payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference to payments
of interest in this section, unless the context otherwise requires, refer to the payment of interest and additional amounts in respect to taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selection and Notice </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If less than all of
the Euro notes are to be redeemed at any time, the trustee or the registrar (as applicable) will select Euro notes for redemption on a pro rata basis (or based on a method that most nearly approximates a pro rata selection as the trustee or the
registrar deems fair and appropriate), unless otherwise required by law or applicable stock exchange or depository requirements. Neither the trustee nor the registrar will be liable for any selections made by it in accordance with this paragraph.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For so long as the Euro notes are listed on Euronext Dublin and the rules of Euronext Dublin so require, the Issuer shall publish a
notice of redemption in a daily newspaper with general circulation in Ireland (which is expected to be the Irish Times) and in addition to such publication, not less than 10 nor more than 60 days prior to the redemption date, mail such notice to
holders of such Euro notes by electronic transmission, first-class mail, postage prepaid, at their respective addresses as they appear on the registration books of the registrar. Such notice of redemption may instead be published on the website of
the Euronext Dublin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any note is to be redeemed in part only, the notice of redemption that relates to that note shall state the
portion of the principal amount thereof to be redeemed, in which case a portion of the original note will be issued in the name of the holder thereof upon cancellation of the original note. In the case of a global note, an appropriate notation will
be made on such note to decrease the principal amount thereof to an amount equal to the unredeemed portion thereof. Subject to the terms of the applicable redemption notice (including any conditions contained therein), Euro notes called for
redemption become due on the date fixed for redemption. On and after the redemption date, interest ceases to accrue on the Euro notes or portions of them called for redemption, unless the redemption price is not paid on the redemption date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption by the Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
issuer may redeem the Euro notes, in whole or in part, at any time or from time to time, on at least 10&nbsp;days&#146;, but not more than 60 days&#146;, prior notice delivered to the registered address of each holder of the Euro
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notes to be redeemed, with a copy of such notice delivered to the trustee and the principal paying agent. The redemption prices will be equal to the greater of (1) 100% of the principal amount of
the Euro notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the Euro notes being redeemed discounted, on a semi- annual basis (assuming a
<FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), at the applicable Reinvestment Rate (as defined below), plus in each case accrued and unpaid interest thereon, if any
(including additional interest, if any), to, but not including, the redemption date; provided that if the issuer redeems the Euro notes on or after the Par Call Date, the redemption price for such Euro notes will be equal to 100% of the aggregate
principal amount of such Euro notes being redeemed, plus accrued and unpaid interest thereon, if any, to, but not including, the redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any redemption of any Euro notes in connection with a corporate transaction (including an equity offering, an incurrence of
indebtedness or a change of control) may, at the issuer&#146;s discretion, be given prior to the completion thereof and any such redemption or notice may, at the issuer&#146;s discretion, be subject to one or more conditions precedent, including,
but not limited to, completion of the related transaction. If such redemption or purchase is so subject to satisfaction of one or more conditions precedent, such notice shall describe each such condition, and such notice may be rescinded or the
redemption date delayed in the event that any or all such conditions shall not have been satisfied by the redemption date. In addition, the issuer may provide in such notice that payment of the redemption price and performance of its obligations
with respect to such redemption may be performed by another person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means a bank appointed by
Teva Finance II which is a primary European government security dealer, and any of its successors, or a market maker in pricing corporate bond issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Par Call Date&#148; means <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>,
20<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> (the date that is three months prior to the maturity date of the Euro notes). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Bund&#148; means the <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>% Federal Government Bond of Bundesrepublik
Deutschland due <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2031, with ISIN <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Dealers&#148; means the Independent Investment Banker and each of the three other banks selected by Teva Finance II which are
primary European government security dealers, and their respective successors, or market makers in pricing corporate bond issues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reinvestment Rate&#148; means 0.50%, plus the greater of (i)&nbsp;the average of the four quotations given by the Reference Dealers of
the <FONT STYLE="white-space:nowrap">mid-market</FONT> semi-annual yield to maturity of the Reference Bund at 11:00 a.m. (Central European time (&#147;CET&#148;)) on the fourth Business Day preceding such redemption date and if the Reference Bund is
no longer outstanding, a Similar Security will be chosen by the Independent Investment Banker at 11:00 a.m. (CET) on the third Business Day in London preceding such redemption date, quoted in writing by the Independent Investment Banker to Teva
Finance II and (ii)&nbsp;zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Remaining Scheduled Payments&#148; means, with respect to each note to be redeemed, the remaining
scheduled payments of principal of and interest on such note as if redeemed on the applicable Par Call Date, determined at the interest rate to be applicable on such redemption date. If the applicable redemption date is not an interest payment date
with respect to such note, the amount of the next succeeding scheduled interest payment on such note will be reduced by the amount of interest accrued on such note to such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Similar Security&#148; means a reference bond or reference bonds issued by the German Federal Government having an actual or
interpolated maturity comparable with the applicable Par Call Date of the Euro notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt
securities of comparable maturity to the applicable Par Call Date of the Euro notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On and after the redemption date, interest will cease to accrue on the Euro notes or any
portion of such Euro notes as is called for redemption (unless we default in the payment of the redemption price and accrued interest). On or prior to the redemption date, we will deposit with the principal paying agent money sufficient to pay the
redemption price of and accrued interest on the Euro notes to be redeemed on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the Euro notes do not prevent Teva,
Teva Finance II or any of Teva&#146;s other subsidiaries from purchasing Euro notes on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Secured Debt</I>. If Teva or any of its subsidiaries creates, incurs or assumes any lien on any of its property (including a
subsidiary&#146;s stock or debt) to secure other Debt, Teva will secure the Euro notes on the same basis for so long as such other Debt is so secured, unless, after giving effect to such lien, the aggregate amount of the secured Debt then
outstanding (not including Debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3)&nbsp;of &#147;&#151;Limitations on Sales and Leasebacks&#148; below would not exceed the greater of
(i) 10% of Teva&#146;s Consolidated Net Worth and (ii)&nbsp;US$2,000,000,000 (or its equivalent in another currency or currencies). The restrictions do not apply to the following liens: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens existing as of the date when Teva Finance II first issues the Euro notes pursuant to the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens on property created, incurred or assumed prior to, at the time of or within one year after the date of
acquisition, completion of construction or completion of improvement of such property to secure all or part of the cost of acquiring, constructing or improving all or any part of such property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">landlord&#146;s, warehousemen&#146;s, material men&#146;s, carriers&#146;, workmen&#146;s, repairmen&#146;s and
other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being contested in good faith in appropriate proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deposits or liens to secure the performance of bids, trade contracts, leases, statutory obligations, surety and
appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) liens existing on any property at the time the property was acquired by Teva or its subsidiaries and
(ii)&nbsp;liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva; provided that, in the case of (i)&nbsp;and (ii), (x) the lien has not been created or assumed in contemplation of the
acquisition of such property or that corporation or other entity becoming a subsidiary of Teva, as applicable; and (y)&nbsp;the lien does not extend to any other property other than the property being acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase money liens upon or in any real property or equipment acquired by Teva or any of its subsidiaries in the
ordinary course of business to secure the purchase price of such property or equipment, or liens existing on such property or equipment at the time of its acquisition (other than any such liens created in contemplation of such acquisition that were
not incurred to finance the acquisition of such property), provided, however, that no such liens shall extend to or cover any properties of any character other than the real property or equipment being acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens securing capital lease obligations in respect of property acquired; provided that no such lien shall extend
to or cover any assets other than the assets subject to such capitalized leases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its
subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws, regulations or statutes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens over any receivable assets subject to a Qualified Securitization Transaction; provided that the aggregate
fair market value of all receivable assets secured in accordance with this subclause shall not </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
exceed US$2,500,000,000 (or its equivalent in another currency or currencies) at any one time outstanding; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not
increased (other than to pay fees and expenses, including premiums, related to such extension, renewal, substitution or replacement) and that such lien is not extended to other property (other than improvements thereon or replacements thereof).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Affiliate&#148; means, with respect to a specified person, another person that directly, or indirectly through
one or more intermediaries, Controls or is Controlled by or is under common Control with the person specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Consolidated Net
Worth&#148; means the stockholders&#146; equity of Teva and its consolidated subsidiaries, as shown on the audited consolidated balance sheet of the guarantor&#146;s latest annual report to stockholders, prepared in accordance with accounting
principles generally accepted in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Control&#148; means the possession, directly or indirectly, of the power to
direct or cause the direction of the management or policies of a person, whether through the ability to exercise voting power, by contract or otherwise. &#147;Controlling&#148; and &#147;Controlled&#148; have meanings correlative thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Debt&#148; means, with respect to any person any liability for borrowed money which, in accordance with GAAP, would be reflected on the
balance sheet of such Person as a liability on the date as of which indebtedness is to be determined, other than accounts payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of business in
connection with the obtaining of materials or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Qualified Securitization Transaction&#148; means any transaction or series
of transactions entered into by Teva or any of its subsidiaries pursuant to which Teva or such subsidiary sells, conveys or otherwise transfers to a Securitization Entity, or grants a security interest in for the benefit of a Securitization Entity,
any Receivable Assets (whether now existing or arising or acquired in the future), or otherwise contributes to the capital of such Securitization Entity, in a transaction in which such Securitization Entity finances its acquisition of or interest in
such Receivable Assets by selling or borrowing against such Receivable Assets; provided that such transaction is <FONT STYLE="white-space:nowrap">non-recourse</FONT> to Teva and its subsidiaries (except for Standard Securitization Undertakings).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Receivable Assets&#148; means ordinary course of business accounts receivable of Teva or any of its subsidiaries, and any assets
related thereto, including, without limitation, all collateral securing such accounts receivable, all contracts and contract rights and all guarantees or other obligations in respect of such accounts receivable, proceeds of such accounts receivable
and other assets (including contract rights) which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization transactions involving accounts receivable and/or receivables
discount without recourse schemes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Securitization Entity&#148; means a corporation or other entity (which may include a special
purpose vehicle and/or a financial institution) to which Teva or any of its subsidiaries transfers Receivable Assets for purposes of a securitization financing, and with respect to which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no portion of the Indebtedness or any other obligations (contingent or otherwise) of such entity (i)&nbsp;is
guaranteed by Teva or any subsidiary of Teva (other than the Securitization Entity) (excluding guarantees of obligations (other than the principal of, and interest on, Indebtedness) pursuant to Standard Securitization Undertakings), (ii) is recourse
to or obligates Teva or any subsidiary of Teva (other than the Securitization Entity) in any way other than pursuant to Standard Securitization Undertakings or (iii)&nbsp;subjects any asset of Teva or any subsidiary of Teva (other than the
Securitization Entity), directly or indirectly, contingently or otherwise, to the satisfaction thereof, other than pursuant to Standard Securitization Undertakings and other than any interest in the Receivable Assets (whether in the form of an
equity interest in such assets or subordinated indebtedness payable primarily from such financed assets) retained or acquired by Teva or any subsidiary of Teva, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither Teva nor any subsidiary of Teva has any material contract, agreement, arrangement or understanding
other than on terms no less favorable to Teva or such subsidiary than those that might be obtained at the time from a corporation or other entities that are not Affiliates of Teva, other than fees payable in the ordinary course of business in
connection with servicing receivables of such entity, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither Teva nor any subsidiary of Teva has any obligation to maintain or preserve such entity&#146;s financial
condition or cause such entity to achieve certain levels of operating results (it being understood that (i)&nbsp;obligations of Teva or other subsidiaries to transfer Receivable Assets to the Securitization Entity, (ii)&nbsp;obligations of Teva or
any other subsidiary to procure such transfers of Receivable Assets to the Securitization Entity, and (iii)&nbsp;Receivable Asset performance measures or credit enhancement measures shall not constitute an obligation to preserve the Securitization
Entity&#146;s financial condition or to cause it to achieve certain levels of operating results). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Standard
Securitization Undertakings&#148; means representations, warranties, covenants and indemnities reasonably customary (as determined by Teva acting in good faith) in accounts receivable securitization transactions and/or receivables discount without
recourse schemes in the applicable jurisdictions, including, to the extent applicable, in a manner consistent with the delivery of a &#147;true sale&#148;/&#147;absolute transfer&#148; opinion with respect to any transfer by Teva or any of its
subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Sales and Leasebacks</I>. Teva will not, and will not permit any subsidiary to, enter into any sale and
leaseback transaction covering any property after the date when Teva Finance II first issues the Euro notes pursuant to the indenture unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale and leaseback transaction: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">involves a lease for a period, including renewals, of not more than five years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">occurs within one year after the date of acquisition, completion of construction or completion of improvement
of such property; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is with Teva or one of its subsidiaries; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or any subsidiary, within one year after the sale and leaseback transaction shall have occurred, applies
or causes to be applied an amount equal to the value of the property so sold and leased back at the time of entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any
subsidiary that is not subordinated to the Euro notes and that has a stated maturity of more than twelve months; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or any subsidiary would be entitled pursuant to the exceptions under &#147;&#151;Limitations on Secured
Debt&#148; above to create, incur, issue or assume indebtedness secured by a lien in the property without equally and ratably securing the Euro notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Other Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture will contain certain other covenants regarding, among other matters, corporate existence and reports to holders of Euro notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Tax Amounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Teva Finance II, as the issuer, nor Teva, as the guarantor, will withhold or deduct from payments made with
respect to the Euro notes on account of any present or future Taxes unless such withholding or deduction is required by law. The term &#147;Taxing Jurisdiction&#148; as used herein means with respect to the Euro notes, The Netherlands, Israel or any
jurisdiction where a successor to Teva Finance II or Teva is incorporated or organized or considered to be a resident, if other than The Netherlands or Israel, respectively, or any jurisdiction through which payments will be made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Taxes&#148; means, with respect to payments on the Euro notes, all taxes,
withholdings, duties, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction or any political subdivision thereof or any authority or agency therein or thereof having power to tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Teva Finance II or Teva is required to withhold or deduct on account of any such Taxes from any payment made under or with
respect to the Euro notes, Teva Finance II or Teva, as the case may be, will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold or deduct such amounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay such additional Tax amounts so that the net amount received by each holder or beneficial owner of the
relevant Euro notes, including those additional Tax amounts, will equal the amount that such holder or beneficial owner would have received if such Taxes had not been required to be withheld or deducted; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay the full amount withheld or deducted to the relevant tax or other authority in accordance with applicable
law, except that no such additional amounts will be payable in respect of any note: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that such Taxes are imposed or levied by reason of such holder (or the beneficial owner) having
some present or former connection with the Taxing Jurisdiction other than the mere holding (or beneficial ownership) of such note or receiving principal or interest payments on the Euro notes (including but not limited to citizenship, nationality,
residence, domicile, or the existence of a business, permanent establishment, a dependent agent, a place of business or a place of management present or deemed present in the Taxing Jurisdiction); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any Taxes that would not have been so withheld or deducted but for the failure by the holder or
the beneficial owner of the Euro notes to make a declaration of <FONT STYLE="white-space:nowrap">non-residence,</FONT> or any other claim or filing for exemption to which it is entitled or otherwise comply with any reasonable certification,
identification, information, documentation or other reporting requirement concerning nationality, residence, identity or connection with the Taxing Jurisdiction if (a)&nbsp;compliance is required by applicable law, regulation, administrative
practice or treaty as a precondition to exemption from all or part of the Taxes, (b)&nbsp;the holder (or beneficial owner) is able to comply with these requirements without undue hardship and (c)&nbsp;we have given the holders (or beneficial owners)
at least 30 calendar days prior notice that they will be required to comply with such requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that such Taxes are imposed by reason of any estate, inheritance, gift, sales, transfer or
personal property taxes imposed with respect to the Euro notes, except as otherwise provided in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that any such Taxes would not have been imposed but for the presentation of such Euro notes,
where presentation is required, for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever is later, except to the extent that the holder
would have been entitled to additional Tax amounts had the Euro notes been presented for payment on any date during such <FONT STYLE="white-space:nowrap">30-day</FONT> period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any Taxes imposed under Sections 1471-1474 of the Internal Revenue Code of 1986, as amended, any
applicable U.S. Treasury Regulations promulgated thereunder, or any judicial or administrative interpretations of any of the foregoing (see &#147;United States Federal Income Tax Considerations&#151;Foreign Account Tax Compliance Act,&#148; relating
to the regime commonly known as FATCA); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any combination of items 1 through 5 above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II, as the issuer, and Teva, as the guarantor, will pay any present or future stamp, court or documentary taxes or any other
excise or property taxes, charges or similar levies that arise from the execution, delivery, enforcement or registration of the Euro notes or any other document or instrument in relation thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes may be redeemed as a whole, but not in part, at the option of Teva Finance II, Teva or any successor to Teva Finance II or Teva,
as the case may be, at any time prior to maturity, upon the giving of not less than 10 days&#146; nor more than 60 days&#146; notice of tax redemption to the trustee and the holders of the Euro notes, if Teva Finance II or Teva determines that, as a
result of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in or amendment to the laws, or any regulations or rulings promulgated under the laws of the Taxing
Jurisdiction or any political subdivision or taxing authority of or in the Taxing Jurisdiction affecting taxation, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in official position regarding the application or interpretation of the laws, regulations or rulings
referred to above, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which change or amendment becomes effective or, in the case of a change in official position, is announced on or
after the issuance of Euro notes, Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case may be, is or will become obligated to pay additional tax amounts with respect to the Euro notes, as described above under
&#147;&#151;Additional Tax Amounts,&#148; provided that Teva Finance II or Teva (or any of their respective successors) determines that such obligation cannot be avoided by Teva Finance II or Teva (or any of their respective successors), as the case
may be, taking reasonable measures available to it. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption price will be equal to 100% of the principal amount of the Euro notes
plus accrued and unpaid interest, if any, to, but not including, the date fixed for redemption. The date and the applicable redemption price will be specified in the notice of tax redemption, which notice will be given not earlier than 90 days prior
to the earliest date on which Teva Finance II (or its successor) or, as the case may be, Teva (or its successor) would be obligated to pay such additional tax amounts if a payment in respect of the relevant Euro notes were actually due on such date.
The Euro notes can be redeemed if, at the time such notice of redemption is given, such obligation to pay such additional tax amounts remains in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to giving the notice of a tax redemption, Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case may be, will
deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a certificate signed by a duly authorized officer stating that Teva Finance II, Teva or any successor to Teva
Finance II or Teva, as the case may be, is entitled to effect the redemption and setting forth a statement of facts showing that the conditions precedent to the right of Teva Finance II, Teva or any successor to Teva Finance II or Teva, as the case
may be, to so redeem have occurred; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an opinion of independent legal counsel of recognized standing to that effect based on the statement of facts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Dutch Tax Considerations&#148; for additional information on potential Dutch withholding taxes in respect of
interest payments on the Euro notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Each of the following constitutes an event of default under the indenture with respect to the Euro notes:</I> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva Finance II&#146;s failure to pay when due the principal and premium, if any, on the Euro notes issued
under the indenture at maturity or upon redemption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva Finance II&#146;s failure to pay an installment of interest (including additional amounts, if any) on the
Euro notes issued under the indenture for 30 days after the date when due; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s failure to perform its obligations under its guarantee under the indenture relating to the Euro
notes; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as permitted by the indenture, the related guarantee by Teva shall be held in any final, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> judicial proceeding to be unenforceable or invalid or shall cease for any reason to be in full force and effect or Teva, or any person acting on behalf of Teva, shall deny or disaffirm its obligations
under that guarantee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s or Teva Finance II&#146;s failure to perform or observe any other term, covenant or agreement
contained in the indenture or the relevant Euro notes issued under it for a period of 60 days after written notice of such failure, requiring Teva or Teva Finance II, as the case may be, to remedy the same, shall have been given to Teva or Teva
Finance II, as the case may be, by the trustee or to Teva or Teva Finance II, as the case may be, and the trustee by the holders of at least 25% in aggregate principal amount of the Euro notes then outstanding (provided that such notice may not be
given with respect to any action taken, and reported publicly or to holders of the Euro notes, more than two years prior to such notice; provided further that the trustee shall have no obligation to determine when or if any holders have been
notified of any such action or to track when such <FONT STYLE="white-space:nowrap">two-year</FONT> period starts or concludes); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s or Teva Finance II&#146;s default under any Indebtedness (as defined below) for money borrowed by
it, the aggregate outstanding principal amount of which is in an amount in excess of $250&nbsp;million, for a period of 30 days after written notice to Teva Finance II by the trustee or to Teva Finance II and the trustee by holders of at least 25%
in aggregate principal amount of the relevant Euro notes then outstanding, which default: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is caused by Teva or Teva Finance II&#146;s, as the case may be, failure to pay when due principal or interest on
such Indebtedness by the end of the applicable grace period, if any, unless such Indebtedness is discharged; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results in the acceleration of such Indebtedness, unless such acceleration is waived, cured, rescinded or
annulled; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or Teva Finance II&#146;s bankruptcy, insolvency or reorganization (except as permitted hereunder, see
&#147;Consolidation, Merger or Assumption&#148; below). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that the trustee shall (other than
in the case of (vii)&nbsp;above, which shall result in the Euro notes becoming immediately due and payable), within 90 days of the occurrence of a default under the indenture, give to the registered holders of the Euro notes notice of all defaults
that have occurred and are continuing known to it, but the trustee shall be protected in withholding such notice if it, in good faith, determines that the withholding of such notice is in the best interest of such registered holders, except in the
case of a default in the payment of the principal of or interest on, any of the Euro notes when due or in the payment of any redemption or repurchase obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default under the indenture shall occur and be continuing, the trustee or the holders of at least 25% in aggregate principal
amount of the Euro notes then outstanding may declare the principal amount of such Euro notes due and payable, together with accrued and unpaid interest, if any, and then the trustee may, at its discretion, proceed to protect and enforce the rights
of the holders of Euro notes by appropriate judicial proceedings. Such declaration may be rescinded or annulled with the written consent of the holders of a majority in aggregate principal amount of Euro notes then outstanding. Any time period in
the indenture or the Euro notes to cure any actual or alleged default or event of default may be extended or stayed by a court of competent jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will contain a provision entitling the trustee, subject to the duty of the trustee during default to act with the required
standard of care, to be indemnified to its satisfaction by the holders of the Euro notes before proceeding to exercise any right or power under the indenture at the request of such holders. The indenture will provide that, subject to the conditions
set forth therein, the holders of a majority in aggregate principal amount of the Euro notes then outstanding shall have the right to direct the time, method, and place of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee with respect to such Euro notes by the indenture. Teva Finance II will
be required to furnish annually to the trustee a statement as to its compliance with all conditions and covenants under the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Indebtedness&#148; means, with respect to any person any liability for borrowed money which, in accordance with GAAP, would be reflected
on the balance sheet of such Person as a liability on the date as of which Indebtedness is to be determined, other than accounts payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of
business in connection with the obtaining of materials or services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Consolidation, Merger or Assumption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II may, without the consent of the holders of the Euro notes, consolidate with, merge into or transfer all or substantially all of
its respective assets to any other corporation, limited liability company, partnership, joint venture, association, joint stock company or trust organized under the laws of The Netherlands, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity assumes all of the obligations of Teva Finance II under the indenture and the Euro notes;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would
become an event of default, shall have happened and be continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the indenture, Teva may, without
the consent of the holders of Euro notes, consolidate with, merge into or transfer all or substantially all of its assets to any other corporation, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor corporation assumes all of the obligations of Teva under the indenture and the Euro notes; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would
become an event of default, shall have happened and be continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that so long as any Euro
notes are outstanding, all of Teva Finance II&#146;s capital stock or membership interests, as applicable, will be owned directly or indirectly by Teva or its successor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modifications and Amendments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring
Approval of Each Affected Holder </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture will provide that it cannot be modified or amended without the written consent or
the affirmative vote of the holder of each note affected by such change to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the maturity of the principal of or any installment of interest on such note; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of or interest on such note; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the currency of payment of that note or interest thereon; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right to institute suit for the enforcement of any payment on or with respect to such note;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify Teva&#146;s obligation to own, directly or indirectly, all of Teva Finance II&#146;s outstanding capital
stock or membership interests, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the redemption provisions of the indenture in a manner adverse to the holders of such Euro notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the applicable guarantee in a manner adverse to the holders of such Euro notes; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in aggregate principal amount of outstanding Euro notes necessary to modify or amend the
indenture or to waive any past default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in aggregate principal amount of Euro notes outstanding required for the adoption of a
resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Majority Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, the indenture may be modified or amended with the written consent of the holders of at least a majority in aggregate
principal amount of Securities affected at the time outstanding (voting as one class). Therefore, amendments to provisions contained in the base indenture will require the requisite vote of the Securities outstanding thereunder (including the Euro
notes offered hereby), while amendments to provisions contained in the fifth supplemental indenture will require the requisite vote of the Euro notes offered hereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring No Approval </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture or the Euro notes may be modified or amended by Teva Finance II, Teva and the trustee, without the consent of the holder of any note, for the purposes of, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securing the Euro notes or confirming and evidencing the release of security when such security is not required
under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding to Teva or Teva Finance II&#146;s covenants for the benefit of the holders of the Euro notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">surrendering any right or power conferred upon Teva or Teva Finance II; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing for the assumption of Teva or Teva Finance II&#146;s obligations to the holders of the Euro notes in
the case of a merger, consolidation, conveyance, transfer or lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the requirements of the SEC in order to effect or maintain the qualification of the indenture
under the Trust Indenture Act of 1939, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">curing any ambiguity, supplying any omission or correcting any defective provision contained in the indenture;
provided that such modification or amendment does not, in the good faith opinion of Teva Finance II&#146;s managing and supervisory directors, adversely affect the interests of the holders of Euro notes in any material respect; and provided,
further, that any amendment made solely to conform the provisions of the indenture to the description of the Euro notes contained in this prospectus supplement will not be deemed to adversely affect the interests of the holders of the Euro notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidencing the assumption by Teva (or any successor) of all obligations and release of the issuer; provided that
no event of default under the indenture shall have occurred and be continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidencing the acceptance of appointment by a successor trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to the Euro notes or releasing
guarantors in accordance with the indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding or modifying any other provisions which Teva Finance II or Teva, as the case may be, may deem necessary or
desirable and which will not adversely affect the interests of the holders of Euro notes in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Satisfaction
and Discharge </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II and Teva may satisfy and discharge their obligations under the indenture with respect to any Euro
notes while the Euro notes remain outstanding if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding Euro notes issued under the indenture have become due and payable at their scheduled maturity; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding Euro notes issued under the indenture have been called for redemption, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and, in either case, Teva Finance II has deposited with the trustee an amount sufficient to pay and
discharge all outstanding Euro notes issued under the indenture on the date of their scheduled maturity or the scheduled date of redemption, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and
the Euro notes will be governed by, and construed in accordance with, the law of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Concerning the Trustee and
Principal Paying Agent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon has been appointed by us as trustee, transfer agent and registrar with regard
to the Euro notes. The Bank of New York Mellon, London Branch, has been appointed by us as the principal paying agent with respect to the Euro notes and will act as common depositary. The Bank of New York Mellon, The Bank of New York Mellon, London
Branch or their affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. The Bank of New York Mellon and The Bank of New York Mellon, London Branch shall be under no obligation
to exercise any of the trusts or powers vested in them by the indenture at the request, order or direction of any of the holders of the Euro notes pursuant to the indenture, unless such holders shall have offered to the trustee and the principal
paying agent security or indemnity satisfactory to them against the costs, expenses and liabilities which might be incurred therein or thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions Relating To The Euro notes While Represented By The Global Euro notes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes issued on
the closing date will be issued in the form of global Euro notes in fully registered form without coupons representing the aggregate principal amount of the outstanding Euro notes. Each global note will be deposited with and registered in the name
of a common depositary for Euroclear and Clearstream or a nominee thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Book-entry interests will be limited to persons that have
accounts with Euroclear and/or Clearstream, or persons that hold interests through such participants. Euroclear and Clearstream will hold interests in the global Euro notes or depositary interest therein on behalf of their participants through
customers&#146; securities accounts in their respective names on the books of their respective depositaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except under the limited
circumstances described below under &#147;&#151;Physical Euro notes,&#148; owners of book-entry interests will not be entitled to receive physical delivery of the Euro notes. Instead, book-entry interests will be shown on, and transfers thereof will
be effected only through, records maintained in book-entry form by Euroclear and Clearstream and their participants. As long as the Euro notes are held in global form, the common depositary for Euroclear and/or Clearstream (or its nominee) will be
considered the sole holder of global Euro notes for all purposes under the indenture. As such, participants must rely on the procedures of Euroclear and Clearstream and indirect participants must rely on the procedures of the participants through
which they own book-entry interests in order to exercise any rights of holders under the indenture. The laws of some jurisdictions may require that certain purchasers of securities take physical delivery of such securities in definitive form. The
foregoing limitations may impair the ability to own, transfer or pledge book-entry interests. In addition, while the Euro notes are in global form, owners of interest in the global note will not have Euro notes registered in their names and will not
be considered the registered owners or &#147;holders&#148; thereof under the indenture for any purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance II will not impose
any fees or other charges in respect of the Euro notes; however, holders of the book-entry interests may incur fees normally payable in respect of the maintenance and operation of accounts in Euroclear and/or Clearstream. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the trustee nor any of its agents will have any responsibility or be liable for any
aspect of the records relating to the book-entry interests. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information below concerning Euroclear and Clearstream has been derived
from information obtained from Euroclear and Clearstream and other sources. None of Teva Finance II, Teva or the managers (or any person acting on their behalf) makes any representation or warranty regarding the accuracy or completeness thereof.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Physical Euro notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms
of the indenture, owners of book-entry interests will receive Euro notes in definitive form (the &#147;physical Euro notes&#148;) only in the following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Euroclear or Clearstream notifies Teva Finance II in writing that it is unwilling or unable to continue to act
as depositary for the Euro notes, or Euroclear or Clearstream ceases to be a &#147;clearing agency&#148; registered under the Exchange Act and a successor depositary for the global note is not appointed by Teva Finance II within 90 days of such
notice or cessation; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an Event of Default has occurred and is continuing and the registrar has received a request from Euroclear or
Clearstream on behalf of the members of, or participants in, Euroclear or Clearstream for the issuance of physical Euro notes in exchange for the global note. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In such an event, Teva Finance II will issue physical Euro notes in fully registered form without coupons in the name or names and issued in any approved
denominations, requested by or on behalf of Euroclear and/or Clearstream, as applicable (in accordance with their respectively customary procedures and based upon directions received from participants reflecting the beneficial ownership of
book-entry interests), and such physical Euro notes will bear a restrictive legend with respect to certain transfer restrictions, unless that legend is not required by the indenture or applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payments on Global Euro notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments
of any amounts (including principal, interest and additional amounts) on the global Euro notes will be made through the principal paying agent. Payments on the Euro notes will be made in euros at the specified office or agency of the principal
paying agent; provided that all such payments with respect to Euro notes represented by one or more global Euro notes deposited with and registered in the name of the common depositary for Euroclear and Clearstream or its nominee will be by wire
transfer of immediately available funds to the account specified in writing by the holder or holders thereof to the common depositary. The principal paying agent will, in turn, make such payments to the common depositary for Euroclear and
Clearstream. Such payments will then be distributed to participants of Euroclear and Clearstream in accordance with the relevant system&#146;s procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, at our option, if physical Euro notes are issued, we may make payments by wire transfer to the account specified by the holder or
holders thereof as notified to the principal paying agent in writing at least 15 days prior to such payment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the
indenture, each of Teva Finance II, Teva, the trustee and any agents of the foregoing (including the principal paying agent) will treat the registered holder of the global Euro notes (<B><I>e.g.</I></B>, the common depositary or its nominee) as the
absolute owner thereof for the purpose of receiving payments and for all other purposes. Consequently, none of Teva Finance II, Teva, the trustee or any of their respective agents has or will have any responsibility or liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any aspect of the records of Euroclear, Clearstream or any participant or indirect participant relating to or
payments made on account of a book-entry interest, for any such payments made by Euroclear, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Clearstream or any participant or indirect participants, or for maintaining, supervising or reviewing any of the records of Euroclear, Clearstream or any participant or indirect participant
relating to or payments made on account of a book-entry interest; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Euroclear, Clearstream or any participant or indirect participant. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments by participants to owners of book-entry interests held through participants are the responsibility of such participants, as is now
the case with securities held for the accounts of customers registered in &#147;street name.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Global Note </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event a global note, or any portion thereof, is redeemed, payment of all amounts in respect of the redemption will be made through the
principal paying agent in the manner described above. Euroclear and/or Clearstream, as applicable, will distribute the amount received by them in respect of the global note so redeemed to the holders of the book-entry interests in such global note.
Teva understands that under existing practices of Euroclear and Clearstream, if fewer than all of the Euro notes are to be redeemed at any time, Euroclear and Clearstream will credit their respective participants&#146; accounts on a proportionate
basis (with adjustments to prevent fractions) or on such other basis as they deem fair and appropriate; provided, however, that no book-entry interest of less than &#128;1,000 in principal amount may be redeemed in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Action by Owners of Book-Entry Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Euroclear and Clearstream have advised Teva that they will take any action permitted to be taken by a holder (including the presentation of
Euro notes for exchange as described above) only at the direction of one or more participants to whose account the book-entry interests in any global note are credited and only in respect of such portion to the aggregate principal amount of Euro
notes as to which such participant or participants has or have given such direction. Euroclear and Clearstream will not exercise any discretion in the granting of consents, waivers or the taking of any other action in respect of such global note.
However, if there is an Event of Default under the Euro notes, each of Euroclear and Clearstream reserve the right to exchange the global Euro notes for physical Euro notes, and to distribute such physical Euro notes to its participants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Clearance and Settlement under the Book-Entry System </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Initial Settlement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Book-entry
interests owned through Euroclear or Clearstream accounts will follow the settlement procedures applicable to conventional eurobonds in registered form. Book-entry interests will be credited to the securities custody accounts of Euroclear and
Clearstream holders on the business day following the settlement date against payment for value on the settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Secondary Market Trading
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The book-entry interests will trade through participants of Euroclear or Clearstream and will settle in <FONT
STYLE="white-space:nowrap">same-day</FONT> funds. Since the purchase determines the place of delivery, it is important to establish at the time of trading of any book-entry interests where both the purchaser&#146;s and seller&#146;s accounts are
located to ensure that settlement can be made on the desired value date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning Euroclear and Clearstream </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand the following with respect to Euroclear and Clearstream: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Euroclear and Clearstream hold securities for their respective participating organizations and facilitate the
clearance and settlement of securities transactions between their respective participants through electronic book-entry changes in accounts of such participants; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Euroclear and Clearstream provide to their participants, among other things, services for safekeeping,
administration, clearance and settlement of internationally traded securities and securities lending and borrowing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Euroclear and Clearstream interface with domestic securities markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Euroclear and Clearstream participants are financial institutions such as managers, underwriters, securities
brokers and dealers, banks, trust companies and certain other organizations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Indirect access to Euroclear or Clearstream is also available to others such as banks, brokers, dealers and trust
companies that clear through or maintain a custodian relationship with a Euroclear or Clearstream participant, either directly or indirectly. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Custody Risks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors that acquire,
hold and transfer interests in the Euro notes by book-entry through accounts with Euroclear and/or Clearstream or any other securities intermediary are subject to the laws and contractual provisions governing their relationship with their
intermediary, as well as the laws and contractual provisions governing the relationship between such an intermediary and each other intermediary, if any, standing between themselves and the individual securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures Subject to Change </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although
Euroclear and Clearstream have agreed to these procedures in order to facilitate transfers of securities among Euroclear and Clearstream, they are under no obligation to perform or continue to perform these procedures and these procedures may be
discontinued and may be changed at any time by either of them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_9"></A>DESCRIPTION OF THE USD NOTES AND THE GUARANTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Teva Finance III will issue $</I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I> aggregate principal
amount of&#8195;% Senior Notes due 2032 (for this section, the &#147;2032 USD notes&#148;) and Teva Finance IV will issue $</I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I> aggregate principal amount of&#8195;%
Senior Notes due 2030 (for this section, the &#147;2030 USD notes&#148; and, together with the 2032 USD notes, the &#147;USD notes&#148;). The 2032 USD notes will be issued under a senior indenture dated as of March&nbsp;14, 2018, by and among Teva
Finance III, Teva, as guarantor, and The Bank of New York Mellon, as trustee (for this section, the &#147;2032 USD notes base indenture&#148;), as supplemented by a fifth supplemental indenture, to be dated on or about
</I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I></I><B>&#8195;</B><I>, 2025, by and among Teva Finance III, Teva, as guarantor, and The Bank of New York Mellon, as trustee and paying agent (for this section, the &#147;fifth
supplemental indenture&#148;). The 2030 USD notes will be issued under a senior indenture, to be dated on or about &#8195;&#8195;&#8195;&#8195;, 2025, by and among Teva Finance IV, Teva, as guarantor, and The Bank of New York Mellon, as trustee (for
this section, the &#147;2030 USD notes base indenture&#148; and together with the 2032 USD Notes base indenture, the &#147;base indentures&#148;), as supplemented by a supplemental indenture, to be dated on or about&#8195;&#8195;&#8195;&#8195;,
2025, by and among Teva Finance IV, Teva, as guarantor, and The Bank of New York Mellon, as trustee and paying agent (for this section, the &#147;first supplemental indenture&#148;). The terms of the USD notes of each series include those provided
in the indentures. Teva will irrevocably and unconditionally guarantee the punctual payment by Teva Finance III and Teva Finance IV, as applicable, of the principal of and interest, if any, on the USD notes of each series and all other amounts due
and payable under the indentures. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description is only a summary of the material provisions of the USD notes of each
series and the related indenture and guarantee. We urge you to read these documents in their entirety because they, and not this description, define your rights as holders of the USD notes. You may request copies of these documents at our address
set forth in the section titled &#147;Incorporation of Certain Documents by Reference.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>When we refer to Teva or the
guarantor in this section, we refer only to Teva Pharmaceutical Industries Limited, an Israeli corporation. When we refer to Teva Finance III, Teva Finance IV or the issuer in this section, we refer to Teva Pharmaceutical Finance Netherlands III
B.V. or Teva Pharmaceutical Finance Netherlands IV B.V., as applicable, each an indirect, wholly-owned subsidiary of Teva organized as a Dutch private limited liability company. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>For this section, we refer to the 2032 USD notes base indenture, as supplemented by the fifth supplemental indenture, and the 2030 USD
notes base indenture, as supplemented by the first supplemental indenture, collectively as &#147;the indentures&#148; and each, base indenture as supplemented by the applicable supplemental indenture thereto, an &#147;indenture&#148;; and we refer
to the 2032 USD notes and the 2030 USD notes each as a series of USD notes and, collectively, as the &#147;USD notes.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brief Description of
the USD notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USD notes will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initially be limited to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> aggregate principal amount of the 2032 USD notes; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B> aggregate principal amount of the 2030 USD notes;
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">subject to reopening of the USD notes at the discretion of the issuer; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">accrue interest at a rate of <B></B><B></B><B></B><B>&#8195;</B>% per annum on the 2032 USD notes and <B></B><B></B><B></B><B>&#8195;</B>% per annum on the
2030 USD notes, in each case payable semi-annually in arrears on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>and <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>of each year, beginning on
<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2025; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">constitute general unsecured obligations of the issuer; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">be redeemable (in addition to being redeemable as set forth below under &#147;&#151;Tax Redemption&#148;) at the
option of Teva Finance III or Teva Finance IV, as applicable, in whole or in part, at any time and from time to time, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice, at the redemption prices described under
&#147;&#151;Optional Redemption by the Issuer&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mature on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2032, in the case of the 2032 USD notes and
on <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2030, in the case of the 2030 USD notes, in each case unless earlier redeemed by the issuer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures do not contain any financial covenants or restrictions on the amount of additional indebtedness that Teva, Teva Finance III or
Teva Finance IV, as applicable or any of Teva&#146;s other subsidiaries may incur except as described in &#147;&#151;Certain Covenants&#148; below. The indentures do not protect you in the event of a highly leveraged transaction or change of control
of Teva, Teva Finance III or Teva Finance IV, as applicable. The indentures do not contain a covenant regulating the offer and/or payment of a consent fee to holders. The USD notes do not contain any sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following consummation of the offering and application of the proceeds therefrom, $<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>
million of Securities (as defined in the base indentures) will be outstanding under the 2032 USD notes base indenture, and holders of such Securities, including the holders of the 2032 USD notes, will vote together as a single class with respect to
certain matters thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following consummation of the offering, additional Securities (as defined in the base indentures) may be
issued from time to time under the 2030 USD notes base indenture. Holders of Securities outstanding under the 2030 USD notes base indenture, including the holders of the 2030 USD notes, will vote together as a single class with respect to certain
matters thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III and Teva Finance IV may, without the consent of the holders, issue additional USD notes of any
series under their respective indentures with the same terms (except for the issue date, issue price and, in some cases, the first payment of interest or interest accruing prior to the issue date of such additional USD notes) and with the same CUSIP
number as the USD notes of such series offered hereby in an unlimited aggregate principal amount; provided that if the additional USD notes of a series are not fungible with the USD notes of such series for United States federal income tax purposes,
such additional USD notes will have a separate CUSIP&nbsp;number. We may also from time to time repurchase USD notes in open market purchases or negotiated transactions without giving prior notice to holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may present definitive registered USD notes for registration of transfer and exchange, without service charge, at our office or agency in
New York City, which shall initially be the office or agency of the trustee in New York City. For information regarding registration of transfer and exchange of global registered USD notes, see &#147;&#151;Form, Denomination and Registration&#148;
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Guarantees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will irrevocably and unconditionally guarantee the punctual payment when due, whether at maturity, upon redemption, by acceleration or
otherwise, of the principal of and interest (including any additional amounts in respect of taxes as provided herein), if any, on the USD notes of each series as well as all other amounts due and payable under the indentures. The respective
guarantees will be enforceable by the trustee, the holders of the applicable USD notes and their successors, transferees and assigns. Teva will also guarantee the Euro notes issued in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each guarantee will be an unsecured senior obligation of Teva. As indebtedness of Teva, after giving effect to the offerings contemplated
hereby, each guarantee will rank: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to the rights of creditors under indebtedness expressly subordinated to the guarantee (at March&nbsp;31,
2025, Teva had no subordinated indebtedness outstanding); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">equally with other unsecured indebtedness of Teva from time to time outstanding other than any that is
subordinated to the guarantee (at March&nbsp;31, 2025, Teva had approximately $16,687&nbsp;million of senior unsecured indebtedness outstanding); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to Teva&#146;s secured indebtedness up to the value of the collateral securing that
indebtedness (at March&nbsp;31, 2025, Teva had no secured indebtedness outstanding); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">effectively junior to the indebtedness and other liabilities of Teva&#146;s subsidiaries (other than the issuer)
(at March&nbsp;31, 2025, Teva&#146;s subsidiaries, other than finance subsidiaries, had a <I>de minimis </I>amount of indebtedness outstanding). </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment of Interest and Principal </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest on the
USD notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2032 USD notes and the 2030 USD notes will bear interest at the rate of <B>&#8195;</B><B></B><B></B><B></B>% per
year and <B>&#8195;</B><B></B><B></B><B></B>% per year, respectively, payable semi-annually in arrears on and of each year, beginning <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2025, to the holders of record at the close of business
on the preceding <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>and <B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, respectively, whether or not a Business Day (as defined below). If an interest payment date for the USD notes
falls on a day that is not a Business Day, interest will be payable on the next succeeding Business Day with the same force and effect as if made on such interest payment date and no interest shall accrue thereon on account of such delay. Interest
on the USD notes will be computed on the basis of a <FONT STYLE="white-space:nowrap">360-day</FONT> year comprised of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months, and will accrue from
<B>&#8195;</B><B>&#8195;</B><B>&#8195;</B><B>&#8195;</B>, 2025, or from the most recent interest payment date to which interest has been paid to, but not including, the next interest payment date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Business Day&#148; for this section means a day other than (i)&nbsp;a Saturday or Sunday, (ii)&nbsp;a day on which banks in New York,
New York are authorized or obligated by law or executive order to remain closed or (iii)&nbsp;a day on which the trustee&#146;s corporate trust office is closed for business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mechanics of Payment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as
provided below, Teva Finance III or Teva Finance IV, as applicable, will pay interest on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the global registered USD notes to The Depository Trust Company (&#147;DTC&#148;) in immediately available funds;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any definitive registered USD notes having an aggregate principal amount of $5,000,000 or less by check mailed to
the holders of these USD notes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any definitive registered USD notes having an aggregate principal amount of more than $5,000,000 by wire transfer
in immediately available funds at the election of the holders of these USD notes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At maturity, Teva Finance III or Teva
Finance IV, as applicable, will pay interest on the definitive registered USD notes at our office or agency in New York City, which initially will be the office or agency of the trustee in New York City. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, will pay principal and premium, if any, on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the global registered USD notes to DTC in immediately available funds; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any definitive registered USD notes at our office or agency in New York City, which initially will be the office
or agency of the trustee in New York City. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference to payments of interest in this section, unless the context
otherwise requires, refer to the payment of interest and additional amounts in respect to taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selection and Notice </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If less than all of the USD notes of any series are to be redeemed at any time, the trustee or the registrar (as applicable) will select USD
notes of such series for redemption on a pro rata basis (or based on a method that most nearly approximates a pro rata selection as the trustee or the registrar deems fair and appropriate), unless otherwise required by law or applicable stock
exchange or depository requirements. Neither the trustee nor the registrar will be liable for any selections made by it in accordance with this paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Issuer shall, not less than 10 nor more than 60 days prior to the redemption date, mail a notice of redemption to holders of such series
by electronic transmission, first-class mail, postage prepaid, at their respective addresses as they appear on the registration books of the registrar. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any note of any series is to be redeemed in part only, the notice of redemption that relates to that note of such series shall state the
portion of the principal amount thereof to be redeemed, in which case a portion of the original note of such series will be issued in the name of the holder thereof upon cancellation of the original note of such series. In the case of a global note,
an appropriate notation will be made on such note of such series to decrease the principal amount thereof to an amount equal to the unredeemed portion thereof. Subject to the terms of the applicable redemption notice (including any conditions
contained therein), USD notes of any series called for redemption become due on the date fixed for redemption. On and after the redemption date, interest ceases to accrue on USD notes of any series or portions of them called for redemption, unless
the redemption price is not paid on the redemption date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption by the Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer may redeem the USD notes of any series, in whole or in part, at any time or from time to time, on at least 10 days&#146;, but not
more than 60 days&#146;, prior notice delivered to the registered address of each holder of the USD notes to be redeemed, with a copy of such notice delivered to the trustee. The redemption prices will be equal to the greater of (1) 100% of the
principal amount of the USD notes to be redeemed or (2)&nbsp;the sum of the present values of the Remaining Scheduled Payments (as defined below) on the USD notes being redeemed discounted, on a semi-annual basis (assuming a <FONT
STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months), using a discount rate equal to the sum of the Treasury Rate (as defined below) plus 50 basis points, in the case of the 2032
USD notes, and 50 basis points, in the case of the 2030 USD notes, plus in each case accrued and unpaid interest thereon, if any, to, but not including, the redemption date; provided that if the issuer redeems the USD notes of any series on or after
the applicable Par Call Date for such series, the redemption price for such USD notes will be equal to 100% of the aggregate principal amount of such USD notes being redeemed, plus accrued and unpaid interest thereon, if any, to, but not including,
the redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notice of any redemption of any series of USD notes in connection with a corporate transaction (including an equity
offering, an incurrence of indebtedness or a change of control) may, at the issuer&#146;s discretion, be given prior to the completion thereof and any such redemption or notice may, at the issuer&#146;s discretion, be subject to one or more
conditions precedent, including, but not limited to, completion of the related transaction. If such redemption or purchase is so subject to satisfaction of one or more conditions precedent, such notice shall describe each such condition, and such
notice may be rescinded or the redemption date delayed in the event that any or all such conditions shall not have been satisfied by the redemption date. In addition, the issuer may provide in such notice that payment of the redemption price and
performance of its obligations with respect to such redemption may be performed by another person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Issue&#148;
means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term to the Par Call Date of the applicable series of USD notes to be redeemed that would be utilized, at the
time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term to the Par Call Date of such series of USD notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Price&#148; means, with respect to any redemption date,
(1)&nbsp;the average of the Reference Treasury Dealer Quotations for such redemption date after excluding the highest and lowest of such Reference Treasury Dealer Quotations or (2)&nbsp;if the Independent Investment Banker obtains fewer than five
such Reference Treasury Dealer Quotations, the average of all such quotations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means one of the
Reference Treasury Dealers appointed by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Par Call Date&#148; means (i)&nbsp;with respect to the 2032 USD
notes&#8195;&#8195;&#8195;&#8195;, 20&#8195;&#8195;(the date that is three months prior to the maturity date of the 2032 USD notes) and (ii)&nbsp;with respect to the 2030 USD notes&#8195;&#8195;&#8195;&#8195;, 20&#8195;&#8195;(the date that is three
months prior to the maturity date of the 2030 USD notes). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer&#148; means (i)&nbsp;each of BNP Paribas
Securities Corp., BofA Securities, Inc., HSBC Bank plc, Intesa Sanpaolo S.p.A. and J.P. Morgan SE and (ii)&nbsp;a Primary Treasury Dealer (as defined below) selected by BNP Paribas Securities Corp. and J.P. Morgan SE, or, in each case, their
respective affiliates or successors, each of which is a primary U.S.&nbsp;Government securities dealer in the United States. If any of the foregoing shall cease to be a Primary Treasury Dealer or is unable or unwilling to provide such services, we
will substitute another nationally recognized investment banking firm that is a Primary Treasury Dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer
Quotations&#148; means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as
a percentage of its principal amount) quoted in writing to the Independent Investment Banker by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third Business Day preceding such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Remaining Scheduled Payments&#148; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and
interest on such note as if redeemed on the applicable Par Call Date, determined at the interest rate to be applicable on such redemption date. If the applicable redemption date is not an interest payment date with respect to such note, the amount
of the next succeeding scheduled interest payment on such note will be reduced by the amount of interest accrued on such note to such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Treasury Rate&#148; means, with respect to any redemption date, the rate per year equal to the semi-annual equivalent yield to maturity
(computed as of the second Business Day immediately preceding such redemption date) of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable
Treasury Price for such redemption date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On and after the redemption date, interest will cease to accrue on the USD notes or any portion
of such USD notes as is called for redemption (unless we default in the payment of the redemption price and accrued interest). On or prior to the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the
redemption price of and accrued interest on the USD notes to be redeemed on such date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of the USD notes do not prevent Teva,
Teva Finance III or Teva Finance IV, as applicable, or any of Teva&#146;s other subsidiaries from purchasing USD notes on the open market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain
Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Secured Debt</I>. If Teva or any of its subsidiaries creates, incurs or assumes any lien on any of its
property (including a subsidiary&#146;s stock or debt) to secure other Debt, Teva will secure the USD notes on the same basis for so long as such other Debt is so secured, unless, after giving effect to such lien, the aggregate amount of the secured
Debt then outstanding (not including Debt secured by liens permitted below) plus the value of all sale and leaseback transactions described in paragraph (3)&nbsp;of &#147;&#151;Limitations on Sales and Leasebacks&#148; below would not exceed the
greater of (i) 10% of Teva&#146;s Consolidated Net Worth and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(ii)&nbsp;US$2,000,000,000 (or its equivalent in another currency or currencies). The restrictions do not apply to the following liens: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens existing as of the date when Teva Finance III or Teva Finance IV, as applicable, first issues the USD notes
pursuant to the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens on property created, incurred or assumed prior to, at the time of or within one year after the date of
acquisition, completion of construction or completion of improvement of such property to secure all or part of the cost of acquiring, constructing or improving all or any part of such property; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">landlord&#146;s, warehousemen&#146;s, material men&#146;s, carriers&#146;, workmen&#146;s, repairmen&#146;s and
other like liens arising in the ordinary course of business in respect of obligations which are not overdue or which are being contested in good faith in appropriate proceedings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">deposits or liens to secure the performance of bids, trade contracts, leases, statutory obligations, surety and
appeal bonds, performance bonds and other obligations of a like nature, in each case in the ordinary course of business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">(i) liens existing on any property at the time the property was acquired by Teva or its subsidiaries and
(ii)&nbsp;liens existing on any property of a corporation or other entity at the time it became or becomes a subsidiary of Teva; provided that, in the case of (i)&nbsp;and (ii), (x) the lien has not been created or assumed in contemplation of the
acquisition of such property or that corporation or other entity becoming a subsidiary of Teva, as applicable; and (y)&nbsp;the lien does not extend to any other property other than the property being acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens securing debt owing by a subsidiary to Teva or to one or more of its subsidiaries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase money liens upon or in any real property or equipment acquired by Teva or any of its subsidiaries in the
ordinary course of business to secure the purchase price of such property or equipment, or liens existing on such property or equipment at the time of its acquisition (other than any such liens created in contemplation of such acquisition that were
not incurred to finance the acquisition of such property), provided, however, that no such liens shall extend to or cover any properties of any character other than the real property or equipment being acquired; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens securing capital lease obligations in respect of property acquired; provided that no such lien shall extend
to or cover any assets other than the assets subject to such capitalized leases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens in favor of any governmental authority of any jurisdiction securing the obligation of Teva or any of its
subsidiaries pursuant to any contract or payment owed to that entity pursuant to applicable laws, regulations or statutes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liens over any receivable assets subject to a Qualified Securitization Transaction; provided that the aggregate
fair market value of all receivable assets secured in accordance with this subclause shall not exceed US$2,500,000,000 (or its equivalent in another currency or currencies) at any one time outstanding; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any extension, renewal, substitution or replacement of the foregoing, provided that the principal amount is not
increased (other than to pay fees and expenses, including premiums, related to such extension, renewal, substitution or replacement) and that such lien is not extended to other property (other than improvements thereon or replacements thereof).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Affiliate&#148; means, with respect to a specified person, another person that directly, or indirectly through
one or more intermediaries, Controls or is Controlled by or is under common Control with the person specified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Consolidated Net
Worth&#148; means the stockholders&#146; equity of Teva and its consolidated subsidiaries, as shown on the audited consolidated balance sheet of the guarantor&#146;s latest annual report to stockholders, prepared in accordance with accounting
principles generally accepted in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Control&#148; means the possession, directly or indirectly, of the power to direct or
cause the direction of the management or policies of a person, whether through the ability to exercise voting power, by contract or otherwise. &#147;Controlling&#148; and &#147;Controlled&#148; have meanings correlative thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Debt&#148; means, with respect to any person any liability for borrowed money which, in accordance with GAAP, would be reflected on the
balance sheet of such Person as a liability on the date as of which indebtedness is to be determined, other than accounts payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of business in
connection with the obtaining of materials or services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Qualified Securitization Transaction&#148; means any transaction or series
of transactions entered into by Teva or any of its subsidiaries pursuant to which Teva or such subsidiary sells, conveys or otherwise transfers to a Securitization Entity, or grants a security interest in for the benefit of a Securitization Entity,
any Receivable Assets (whether now existing or arising or acquired in the future), or otherwise contributes to the capital of such Securitization Entity, in a transaction in which such Securitization Entity finances its acquisition of or interest in
such Receivable Assets by selling or borrowing against such Receivable Assets; provided that such transaction is <FONT STYLE="white-space:nowrap">non-recourse</FONT> to Teva and its subsidiaries (except for Standard Securitization Undertakings).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Receivable Assets&#148; means ordinary course of business accounts receivable of Teva or any of its subsidiaries, and any assets
related thereto, including, without limitation, all collateral securing such accounts receivable, all contracts and contract rights and all guarantees or other obligations in respect of such accounts receivable, proceeds of such accounts receivable
and other assets (including contract rights) which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization transactions involving accounts receivable and/or receivables
discount without recourse schemes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Securitization Entity&#148; means a corporation or other entity (which may include a special
purpose vehicle and/or a financial institution) to which Teva or any of its subsidiaries transfers Receivable Assets for purposes of a securitization financing, and with respect to which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no portion of the Indebtedness or any other obligations (contingent or otherwise) of such entity (i)&nbsp;is
guaranteed by Teva or any subsidiary of Teva (other than the Securitization Entity) (excluding guarantees of obligations (other than the principal of, and interest on, Indebtedness) pursuant to Standard Securitization Undertakings), (ii) is recourse
to or obligates Teva or any subsidiary of Teva (other than the Securitization Entity) in any way other than pursuant to Standard Securitization Undertakings or (iii)&nbsp;subjects any asset of Teva or any subsidiary of Teva (other than the
Securitization Entity), directly or indirectly, contingently or otherwise, to the satisfaction thereof, other than pursuant to Standard Securitization Undertakings and other than any interest in the Receivable Assets (whether in the form of an
equity interest in such assets or subordinated indebtedness payable primarily from such financed assets) retained or acquired by Teva or any subsidiary of Teva, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither Teva nor any subsidiary of Teva has any material contract, agreement, arrangement or understanding
other than on terms no less favorable to Teva or such subsidiary than those that might be obtained at the time from a corporation or other entities that are not Affiliates of Teva, other than fees payable in the ordinary course of business in
connection with servicing receivables of such entity, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">neither Teva nor any subsidiary of Teva has any obligation to maintain or preserve such entity&#146;s financial
condition or cause such entity to achieve certain levels of operating results (it being understood that (i)&nbsp;obligations of Teva or other subsidiaries to transfer Receivable Assets to the Securitization Entity, (ii)&nbsp;obligations of Teva or
any other subsidiary to procure such transfers of Receivable Assets to the Securitization Entity, and (iii)&nbsp;Receivable Asset performance measures or credit enhancement measures shall not constitute an obligation to preserve the Securitization
Entity&#146;s financial condition or to cause it to achieve certain levels of operating results). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Standard
Securitization Undertakings&#148; means representations, warranties, covenants and indemnities reasonably customary (as determined by Teva acting in good faith) in accounts receivable securitization </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transactions and/or <I>receivables</I> discount without recourse schemes in the applicable jurisdictions, including, to the extent applicable, in a manner consistent with the delivery of a
&#147;true sale&#148;/&#147;absolute transfer&#148; opinion with respect to any transfer by Teva or any of its subsidiaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Limitations on Sales and Leasebacks</I>. Teva will not, and will not permit any subsidiary to, enter into any sale and leaseback
transaction covering any property after the date when Teva Finance III or Teva Finance IV, as applicable, first issues the USD notes pursuant to the applicable indenture unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale and leaseback transaction: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">involves a lease for a period, including renewals, of not more than five years; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">occurs within one year after the date of acquisition, completion of construction or completion of improvement
of such property; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is with Teva or one of its subsidiaries; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or any subsidiary, within one year after the sale and leaseback transaction shall have occurred, applies
or causes to be applied an amount equal to the value of the property so sold and leased back at the time of entering into such arrangement to the prepayment, repayment, redemption, reduction or retirement of any indebtedness of Teva or any
subsidiary that is not subordinated to the USD notes and that has a stated maturity of more than twelve months; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or any subsidiary would be entitled pursuant to the exceptions under &#147;&#151;Limitations on Secured
Debt&#148; above to create, incur, issue or assume indebtedness secured by a lien in the property without equally and ratably securing the USD notes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Other Covenants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures will contain certain other covenants regarding, among other matters, corporate existence and reports to holders of USD notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional
Tax Amounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Teva Finance III or Teva Finance IV, as applicable, as the issuer, nor Teva, as the guarantor, will withhold or
deduct from payments made with respect to the USD notes on account of any present or future Taxes unless such withholding or deduction is required by law. The term &#147;Taxing Jurisdiction&#148; as used herein means with respect to the USD notes,
The Netherlands, Israel or any jurisdiction where a successor to Teva Finance III or Teva Finance IV, as applicable, or Teva is incorporated or organized or considered to be a resident, if other than The Netherlands or Israel, respectively, or any
jurisdiction through which payments will be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Taxes&#148; means, with respect to payments on the USD notes, all taxes,
withholdings, duties, assessments or governmental charges of whatever nature imposed or levied by or on behalf of any Taxing Jurisdiction or any political subdivision thereof or any authority or agency therein or thereof having power to tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Teva Finance III or Teva Finance IV, as applicable, or Teva is required to withhold or deduct on account of any such Taxes
from any payment made under or with respect to the USD notes, Teva&nbsp;Finance III or Teva Finance IV, as applicable, or Teva, as the case may be, will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withhold or deduct such amounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay such additional Tax amounts so that the net amount received by each holder or beneficial owner of the
relevant USD notes, including those additional Tax amounts, will equal the amount that such holder or beneficial owner would have received if such Taxes had not been required to be withheld or deducted; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay the full amount withheld or deducted to the relevant tax or other authority in accordance with applicable
law, except that no such additional amounts will be payable in respect of any note: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that such Taxes are imposed or levied by reason of such holder (or the beneficial owner) having
some present or former connection with the Taxing Jurisdiction other than the mere holding (or beneficial ownership) of such note or receiving principal or interest payments on the USD notes (including but not limited to citizenship, nationality,
residence, domicile, or the existence of a business, permanent establishment, a dependent agent, a place of business or a place of management present or deemed present in the Taxing Jurisdiction); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any Taxes that would not have been so withheld or deducted but for the failure by the holder or
the beneficial owner of the USD notes to make a declaration of <FONT STYLE="white-space:nowrap">non-residence,</FONT> or any other claim or filing for exemption to which it is entitled or otherwise comply with any reasonable certification,
identification, information, documentation or other reporting requirement concerning nationality, residence, identity or connection with the Taxing Jurisdiction if (a)&nbsp;compliance is required by applicable law, regulation, administrative
practice or treaty as a precondition to exemption from all or part of the Taxes, (b)&nbsp;the holder (or beneficial owner) is able to comply with these requirements without undue hardship and (c)&nbsp;we have given the holders (or beneficial owners)
at least 30 calendar days prior notice that they will be required to comply with such requirement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that such Taxes are imposed by reason of any estate, inheritance, gift, sales, transfer or
personal property taxes imposed with respect to the USD notes, except as otherwise provided in the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the extent that any such Taxes would not have been imposed but for the presentation of such USD notes, where
presentation is required, for payment on a date more than 30 days after the date on which such payment became due and payable or the date on which payment thereof is duly provided for, whichever is later, except to the extent that the holder would
have been entitled to additional Tax amounts had the USD notes been presented for payment on any date during such <FONT STYLE="white-space:nowrap">30-day</FONT> period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in respect of any Taxes imposed under Sections 1471-1474 of the Internal Revenue Code of 1986, as amended, any
applicable U.S. Treasury Regulations promulgated thereunder, or any judicial or administrative interpretations of any of the foregoing (see &#147;United States Federal Income Tax Considerations&#151;Foreign Account Tax Compliance Act,&#148; relating
to the regime commonly known as FATCA); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any combination of items 1 through 5 above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, as the issuer, and Teva, as the guarantor, will pay any present or future stamp, court or
documentary taxes or any other excise or property taxes, charges or similar levies that arise from the execution, delivery, enforcement or registration of the USD notes or any other document or instrument in relation thereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Tax Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USD notes of any
series may be redeemed as a whole, but not in part, at the option of Teva Finance III or Teva Finance IV, as applicable, Teva or any successor to Teva Finance III or Teva Finance IV, as applicable, or Teva, as the case may be, at any time prior to
maturity, upon the giving of not less than 10 days&#146; nor more than 60 days&#146; notice of tax redemption to the trustee and the holders of the applicable series of USD notes, if Teva Finance III or Teva Finance IV, as applicable, or Teva
determines that, as a result of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in or amendment to the laws, or any regulations or rulings promulgated under the laws of the Taxing
Jurisdiction or any political subdivision or taxing authority of or in the Taxing Jurisdiction affecting taxation, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any change in official position regarding the application or interpretation of the laws, regulations or rulings
referred to above, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">which change or amendment becomes effective or, in the case of a change in official position, is announced
on or after the issuance of USD notes, Teva Finance III or Teva Finance IV, as applicable, Teva or any successor to Teva Finance III or Teva Finance IV, as applicable, or Teva, as the case may be, is or will become obligated to pay additional tax
amounts with respect to the applicable series of the USD notes, as described above under &#147;&#151;Additional Tax Amounts,&#148; provided that Teva Finance III or Teva Finance IV, as applicable, or Teva (or any of their respective successors)
determines that such obligation cannot be avoided by Teva Finance III or Teva Finance IV, as applicable, or Teva (or any of their respective successors), as the case may be, taking reasonable measures available to it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption price will be equal to 100% of the principal amount of the applicable series of USD notes plus accrued and unpaid interest, if
any, to, but not including, the date fixed for redemption. The date and the applicable redemption price will be specified in the notice of tax redemption, which notice will be given not earlier than 90 days prior to the earliest date on which Teva
Finance III or Teva Finance IV, as applicable, (or its successor) or, as the case may be, Teva (or its successor) would be obligated to pay such additional tax amounts if a payment in respect of the relevant USD notes were actually due on such date.
The USD notes can be redeemed if, at the time such notice of redemption is given, such obligation to pay such additional tax amounts remains in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to giving the notice of a tax redemption, Teva Finance III or Teva Finance IV, as applicable, Teva or any successor to Teva Finance III
or Teva Finance IV, as applicable, or Teva, as the case may be, will deliver to the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a certificate signed by a duly authorized officer stating that Teva Finance III or Teva Finance IV, as
applicable, Teva or any successor to Teva Finance III or Teva Finance IV, as applicable, or Teva, as the case may be, is entitled to effect the redemption and setting forth a statement of facts showing that the conditions precedent to the right of
Teva Finance III or Teva Finance IV, as applicable, Teva or any successor to Teva Finance III or Teva Finance IV, as applicable, or Teva, as the case may be, to so redeem have occurred; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an opinion of independent legal counsel of recognized standing to that effect based on the statement of facts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Dutch Tax Considerations&#148; for additional information on potential Dutch withholding taxes in respect of
interest payments on the USD notes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Each of the following constitutes an event of default under the applicable indenture with respect to each series of USD notes: </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, failure to pay when due the principal and
premium, if any, on such series of USD notes issued under the applicable indenture at maturity or upon redemption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, failure to pay an installment of interest
(including additional amounts, if any) on such series of USD notes issued under the applicable indenture for 30 days after the date when due; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s failure to perform its obligations under its guarantee under the applicable indenture relating to
such series of USD notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">except as permitted by the applicable indenture, the related guarantee by Teva shall be held in any final, <FONT
STYLE="white-space:nowrap">non-appealable</FONT> judicial proceeding to be unenforceable or invalid or shall cease for any reason to be in full force and effect or Teva, or any person acting on behalf of Teva, shall deny or disaffirm its obligations
under that guarantee; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, failure to perform or observe
any other term, covenant or agreement contained in the applicable indenture or the relevant USD notes issued under it for a period of 60 days after written notice of such failure, requiring Teva or Teva Finance III or Teva Finance IV, as applicable,
as the case may be, to remedy the same, shall have been given to Teva or Teva Finance III or Teva Finance IV, as applicable, as the case may be, by the trustee or to Teva or Teva Finance III or Teva Finance IV, as applicable, as the case may be, and
the trustee by the holders of at least 25% in aggregate principal amount of such series of USD notes then outstanding (provided that such notice may not be given with respect to any action taken, and reported publicly or to holders of such series of
USD notes, more than two years prior to such notice; provided further that the trustee shall have no obligation to determine when or if any holders have been notified of any such action or to track when such
<FONT STYLE="white-space:nowrap">two-year</FONT> period starts or concludes); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, default under any Indebtedness
(as defined below) for money borrowed by it, the aggregate outstanding principal amount of which is in an amount in excess of $250&nbsp;million, for a period of 30 days after written notice to Teva Finance III or Teva Finance IV, as applicable, by
the trustee or to Teva Finance III or Teva Finance IV, as applicable, and the trustee by holders of at least 25% in aggregate principal amount of the relevant USD notes then outstanding, which default: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is caused by Teva or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, as the case may be,
failure to pay when due principal or interest on such Indebtedness by the end of the applicable grace period, if any, unless such Indebtedness is discharged; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results in the acceleration of such Indebtedness, unless such acceleration is waived, cured, rescinded or
annulled; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, bankruptcy, insolvency or
reorganization (except as permitted hereunder, see &#147;Consolidation, Merger or Assumption&#148; below). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures will provide that the trustee shall (other than in the case of (vii)&nbsp;above, which shall result in the USD notes of the applicable series becoming immediately due and payable), within 90 days of the occurrence of a default under the
applicable indenture, give to the registered holders of the USD notes of such series notice of all defaults that have occurred and are continuing known to it, but the trustee shall be protected in withholding such notice if it, in good faith,
determines that the withholding of such notice is in the best interest of such registered holders, except in the case of a default in the payment of the principal of or interest on, any of the USD&nbsp;notes when due or in the payment of any
redemption or repurchase obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default under an indenture shall occur and be continuing, the trustee or the holders
of at least 25% in aggregate principal amount of the applicable USD notes of such series affected then outstanding may declare the principal amount of such series of USD notes due and payable, together with accrued and unpaid interest, if any, and
then the trustee may, at its discretion, proceed to protect and enforce the rights of the holders of such series of USD notes by appropriate judicial proceedings. Such declaration may be rescinded or annulled with the written consent of the holders
of a majority in aggregate principal amount of such series of USD notes then outstanding. Any time period in an indenture or the USD notes to cure any actual or alleged default or event of default may be extended or stayed by a court of competent
jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures will contain a provision entitling the trustee, subject to the duty of the trustee during default to act
with the required standard of care, to be indemnified to its satisfaction by the holders of the relevant USD&nbsp;notes before proceeding to exercise any right or power under the applicable indenture at the request of such holders. The indentures
will provide that, subject to the conditions set forth therein, the holders of a majority in aggregate principal amount of the USD notes of a series then outstanding shall have the right to direct the time, method, and place of conducting any
proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee with respect to such series of USD notes by the applicable indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, will be required to furnish annually to
the trustee a statement as to its compliance with all conditions and covenants under the applicable indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Indebtedness&#148;
means, with respect to any person any liability for borrowed money which, in accordance with GAAP, would be reflected on the balance sheet of such Person as a liability on the date as of which Indebtedness is to be determined, other than accounts
payable or any other indebtedness to trade creditors created or assumed by such person in the ordinary course of business in connection with the obtaining of materials or services. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Assumption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Finance III or
Teva Finance IV, as applicable, may, without the consent of the holders of the relevant USD notes, consolidate with, merge into or transfer all or substantially all of its respective assets to any other corporation, limited liability company,
partnership, joint venture, association, joint stock company or trust organized under the laws of The Netherlands, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor entity assumes all of the obligations of Teva Finance III or Teva Finance IV, as applicable, under
the applicable indenture and the relevant USD notes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would
become an event of default, shall have happened and be continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the indentures, Teva may, without
the consent of the holders of the relevant USD notes, consolidate with, merge into or transfer all or substantially all of its assets to any other corporation, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the successor corporation assumes all of the obligations of Teva under the applicable indenture and the relevant
USD notes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of such transaction, no event of default, and no event which, after notice or lapse of time, would
become an event of default, shall have happened and be continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures will provide that so long as any
relevant USD notes are outstanding, all of Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, capital stock or membership interests, as applicable, will be owned directly or indirectly by Teva or its successor. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modifications and Amendments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring
Approval of Each Affected Holder </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture will provide that it cannot be modified or amended without the written consent or
the affirmative vote of the holder of each note affected by such change to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the maturity of the principal of or any installment of interest on such note; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of or interest on such note; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the currency of payment of that note or interest thereon; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right to institute suit for the enforcement of any payment on or with respect to such note;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, obligations to maintain an office or
agency in New York City; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify Teva&#146;s obligation to own, directly or indirectly, all of Teva Finance III&#146;s or Teva Finance
IV&#146;s, as applicable, outstanding capital stock or membership interests, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the redemption provisions of such indenture in a manner adverse to the holders of such USD notes;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify the applicable guarantee in a manner adverse to the holders of such USD notes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in aggregate principal amount of the applicable outstanding USD notes of such series
necessary to modify or amend such indenture or to waive any past default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in aggregate principal amount of USD notes of the applicable series outstanding required
for the adoption of a resolution. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring Majority Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, each indenture may be modified or amended with the written consent of the holders of at least a majority in
aggregate principal amount of the applicable Securities affected at the time outstanding (voting as one class). Therefore, amendments to provisions contained in each base indenture will require the requisite vote of the applicable Securities
outstanding thereunder (including the applicable tranche of USD notes offered hereby), while amendments to provisions contained in the fifth supplemental indenture and the first supplemental indenture, as applicable, will require the requisite vote
of the applicable tranche of USD notes of such series offered hereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes Requiring No Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture or the USD notes related thereto may be modified or amended by Teva Finance III or Teva Finance IV, as applicable, Teva and the
trustee, without the consent of the holder of any note, for the purposes of, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securing any series of USD notes or confirming and evidencing the release of security when such security is not
required under such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding to Teva or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, covenants for the benefit of
the holders of the USD notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">surrendering any right or power conferred upon Teva or Teva Finance III or Teva Finance IV, as applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing for the assumption of Teva or Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable,
obligations to the holders of the USD notes of any series in the case of a merger, consolidation, conveyance, transfer or lease; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">complying with the requirements of the SEC in order to effect or maintain the qualification of such indenture
under the Trust Indenture Act of 1939, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">curing any ambiguity, supplying any omission or correcting any defective provision contained in such indenture;
provided that such modification or amendment does not, in the good faith opinion of Teva Finance III&#146;s or Teva Finance IV&#146;s, as applicable, managing and supervisory directors, adversely affect the interests of the holders of the relevant
USD notes in any material respect; and provided, further, that any amendment made solely to conform the provisions of such indenture to the description of the USD notes contained in this prospectus supplement will not be deemed to adversely affect
the interests of the holders of the USD notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidencing the assumption by Teva (or any successor) of all obligations and release of the issuer; provided that
no event of default under such indenture shall have occurred and be continuing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidencing the acceptance of appointment by a successor trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to a series or releasing guarantors in
accordance with such indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adding or modifying any other provisions which Teva Finance III or Teva Finance IV, as applicable, or Teva, as
the case may be, may deem necessary or desirable and which will not adversely affect the interests of the holders of USD notes in any material respect. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Satisfaction and Discharge </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, and Teva may satisfy and discharge their obligations under the applicable indenture with
respect to the relevant USD notes while such USD notes remain outstanding if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding USD notes with respect to such series issued under the applicable indenture have become due and
payable at their scheduled maturity; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all outstanding USD notes issued under the applicable indenture with respect to such series have been called for
redemption, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and, in either case, Teva Finance III or Teva Finance IV, as applicable, has deposited with the trustee an amount
sufficient to pay and discharge all outstanding USD notes issued under the applicable indenture on the date of their scheduled maturity or the scheduled date of redemption, as the case may be. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the USD
notes will be governed by, and construed in accordance with, the law of the State of New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee and Paying Agent
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bank of New York Mellon has been appointed by us as trustee, paying agent, transfer agent, registrar and custodian with regard to
the USD notes of each series. The Bank of New York Mellon or its affiliates may from time to time in the future provide banking and other services to us in the ordinary course of their business. The Bank of New York Mellon shall be under no
obligation to exercise any of the trusts or powers vested in it by the indentures at the request, order or direction of any of the holders of the relevant USD notes of a series pursuant to the applicable indenture, unless such holders shall have
offered to the trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred therein or thereby. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Denomination and Registration </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Denomination and Registration</I></B>. The USD notes of each series will be issued in fully registered form, without coupons, in
denominations of $200,000 principal amount and whole multiples of $1,000 in excess of $200,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Global USD notes; Book-Entry
Form</I></B>. The USD notes will be represented by permanent global USD notes in definitive, fully registered form without interest coupons. The global registered USD notes will be deposited with the trustee as custodian for DTC and registered in
the name of a nominee of DTC in New York, New York for the accounts of participants in DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as set forth below, the global
registered USD notes will be transferable, in whole or in part, only to another nominee of DTC or to a successor of DTC or its nominee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited purpose trust company organized under the laws of the State of New York; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">DTC was created to hold securities of institutions that have accounts with DTC and to
facilitate the clearance and settlement of securities transactions among its participants in securities through electronic book-entry changes in accounts of the participants, thereby eliminating the need for physical movement of securities
certificates. DTC&#146;s participants include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securities brokers and dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trust companies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearing corporations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Access to DTC&#146;s book-entry system is also available to others such as banks, brokers, dealers and trust companies that clear through or
maintain a custodial relationship with a participant whether directly or indirectly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the issuance of the global registered USD
notes, DTC will credit, on its book-entry registration and transfer system, the respective principal amounts of the individual beneficial interests represented by the global registered USD notes to the accounts of participants. The accounts credited
will be designated by the underwriters of the beneficial interests. Ownership of beneficial interests in the global registered USD notes is limited to participants or persons that may hold interests through participants. Ownership of beneficial
interests in the global registered USD notes is shown on, and the transfer of those ownership interests will be effected only through, records maintained by DTC (with respect to participants&#146; interests) and the participants (with respect to the
owners of beneficial interests in the global registered USD notes other than participants). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as DTC or its nominee is the
registered holder and owner of the global registered USD notes, DTC or its nominee, as the case may be, will be considered the sole legal owner of the USD notes represented by the global registered USD notes for all purposes under the indentures and
the USD notes. Except as set forth below, owners of beneficial interests in the global registered USD notes will not be entitled to receive definitive registered USD notes and will not be considered to be the owners or holders of any USD notes under
the global registered USD notes. Teva Finance III or Teva Finance IV, as applicable, understands that under existing industry practice, in the event an owner of a beneficial interest in the global registered USD notes desires to take any action that
DTC, as the holder of the global registered USD notes, is entitled to take, DTC would authorize the participants to take the action, and that participants would authorize beneficial owners owning through the participants to take the action or would
otherwise act upon the instructions of beneficial owners owning through them. No beneficial owner of an interest in the global registered USD notes will be able to transfer the interest except in accordance with DTC&#146;s applicable procedures, in
addition to those provided for under the indentures and, if applicable, those of Euroclear and Clearstream. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva
Finance IV, as applicable, will make payments of the principal and interest on the USD notes represented by the global registered USD notes registered in the name of and held by DTC or its nominee to DTC or its nominee, as the case may be, as the
registered owner and holder of the global registered USD notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, expects that DTC or
its nominee, upon receipt of any payment of principal or interest in respect of the global registered USD notes, will credit participants&#146; accounts with payments in amounts proportionate to their respective beneficial interests in the principal
amount of the global registered USD notes as shown on the records of DTC or its nominee. Teva Finance III or Teva Finance IV, as applicable, also expects that payments by participants and indirect participants to owners of beneficial interests in
the global registered USD notes held through such participants will be governed by standing instructions and customary practices, as is now the case with securities held for accounts of customers registered in the names of nominees for these
customers. The payments, however, will be the responsibility of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
participants and indirect participants, and none of Teva Finance III or Teva Finance IV, as applicable, Teva, the trustee or any paying agent will have any responsibility or liability for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any aspect of the records relating to, or payments made on account of, beneficial ownership interests in the
global registered USD notes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, supervising or reviewing any records relating to the beneficial ownership interests;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other aspect of the relationship between DTC and its participants; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relationship between the participants and indirect participants and the owners of beneficial interests in the
global registered USD notes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless and until they are exchanged in whole or in part for definitive registered USD
notes, the global registered USD notes may not be transferred except as a whole by DTC to a nominee of DTC or by a nominee of DTC to DTC or another nominee of DTC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Participants in DTC will effect transfers with other participants in the ordinary way in accordance with DTC&nbsp;rules and will settle
transfers in <FONT STYLE="white-space:nowrap">same-day</FONT> funds. Participants in Euroclear and Clearstream will effect transfers with other participants in the ordinary way in accordance with the rules and operating procedures of Euroclear and
Clearstream, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cross-market transfers between DTC, on the one hand, and directly or indirectly through Euroclear or
Clearstream participants, on the other, will be effected in DTC in accordance with DTC rules on behalf of Euroclear or Clearstream, as the case may be, by its respective depositary; however, these cross-market transactions will require delivery of
instructions to Euroclear or Clearstream, as the case may be, by the counterparty in the system in accordance with its rules and procedures and within its established deadlines (Brussels time). Euroclear or Clearstream, as the case may be, will, if
the transaction meets its settlement requirements, deliver instructions to its respective depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the global registered USD notes in DTC, and making
or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> funds settlement applicable to DTC. Euroclear participants and Clearstream participants may not deliver instructions directly to the
depositaries for Euroclear or Clearstream. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of time zone differences, the securities account of a Euroclear or Clearstream
participant purchasing an interest in the global registered USD notes from a DTC participant will be credited during the securities settlement processing day immediately following the DTC settlement date, and the credit of any transactions interests
in the global registered USD notes settled during the processing day will be reported to the relevant Euroclear or Clearstream participant on that day. Cash received in Euroclear or Clearstream as a result of sales of interests in the global
registered USD notes by or through a Euroclear or Clearstream participant to a DTC participant will be received with value on the DTC settlement date, but will be available in the relevant Euroclear or Clearstream cash account only as of the
Business Day following settlement in DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance III or Teva Finance IV, as applicable, expects that DTC will take any action
permitted to be taken by a holder of USD notes only at the direction of one or more participants to whose accounts at DTC interests in the global registered USD notes are credited and only in respect of the portion of the aggregate principal amount
of the USD notes as to which the participant or participants has or have given direction. However, if there is an event of default under a series of the USD notes, DTC will exchange the relevant global registered USD notes for definitive registered
USD notes, which it will distribute to its participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Teva Finance III or Teva Finance IV, as applicable, expects that DTC,
Euroclear and Clearstream will agree to the foregoing procedures in order to facilitate transfers of interests in the global registered USD notes among participants of DTC, Euroclear and Clearstream, DTC, Euroclear and Clearstream are under no
obligation to perform or continue to perform these procedures, and these procedures may be discontinued at any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time. None of Teva Finance III or Teva Finance IV, as applicable, Teva, the trustee or any paying agent have any responsibility for the performance by DTC, Euroclear or Clearstream or their
participants or indirect participants of their obligations under the rules and procedures governing their operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If DTC is at any
time unwilling or unable to continue as a depositary for the global registered USD notes or ceases to be a clearing agency registered under the Exchange Act and Teva Finance III or Teva Finance IV, as applicable, does not appoint a successor
depositary within 90 days, Teva Finance III or Teva Finance IV, as applicable, will issue definitive registered USD notes in exchange for the global registered USD notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Definitive USD notes. </I></B>Definitive registered USD notes may be issued in exchange for USD notes represented by global registered
USD notes only if Teva Finance III or Teva Finance IV, as applicable, does not appoint a successor depositary as set forth above under &#147;&#151;Global USD notes; Book-Entry Form&#148; or in other limited circumstances set forth in the indentures.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_10"></A>UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of the purchase, ownership and disposition of the notes. This
discussion only applies to notes that meet all of the following conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they are purchased by those initial holders who purchase notes at the respective &#147;issue price,&#148; which
will equal the first price to the public (not including bond houses, brokers or similar persons or organizations acting in the capacity of underwriters, placement agents or wholesalers) at which a substantial amount of the notes is sold for money;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">they are held as capital assets by U.S. Holders (as defined below). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">This discussion assumes that the notes are not issued with original issue discount as that term is defined in the
Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) and the U.S. Treasury Regulations. This discussion does not describe all of the tax consequences that may be relevant to holders in light of their particular circumstances or to
holders subject to special rules, such as: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain financial institutions, including banks; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers in securities or foreign currencies, traders in securities that elect to use the mark to market method of
accounting for their securities, regulated investment companies, real estate investment trusts or tax exempt entities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding notes as part of a hedge or other integrated investment, constructive sale or conversion
transaction or straddle; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates, former U.S. citizens or long-term residents of the United States, or entities covered by the
anti-inversion rules under the Code; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who actually or constructively own more than 10% of our stock by vote or value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the base erosion and anti-abuse tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holders who are members of an &#147;expanded group&#148; or &#147;modified expanded group&#148; with the Issuers
within the meaning of U.S. Treasury Regulations under Code Section&nbsp;385; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> and governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons required to recognize income for U.S. federal income tax purposes no later than when such income is taken
into account in applicable financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations, partnerships or other entities (or arrangements) classified or treated as partnerships for U.S.
federal income tax purposes (and investors therein); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity treated as a partnership for U.S. federal income tax purposes holds our notes, the tax treatment of a partner will generally
depend upon the status of the partner and the activities of the partnership. If you are a partnership or a partner in a partnership holding our notes, you should consult your tax advisors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is based on the Code, administrative pronouncements, judicial decisions and final, temporary and proposed U.S. Treasury
Regulations, changes to any of which subsequent to the date of this prospectus summary may affect the tax consequences described herein. We have not, and will not seek, any rulings from the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. Internal Revenue Service (the &#147;IRS&#148;) regarding the matters discussed below. This summary addresses only U.S. federal income tax consequences, and does not address the state, local
or foreign tax laws or the Medicare tax on net investment income. Persons considering the purchase of notes are urged to consult their own tax advisors with regard to the application of the U.S. federal income tax laws to their particular situations
as well as any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used herein, the term
&#147;U.S. Holder&#148; means a beneficial owner of a note that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or
organized in or under the laws of the United States or of any political subdivision thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust if it (i)&nbsp;is subject to the primary supervision of a court within the United States and one or more
&#147;United States persons&#148; (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&nbsp;has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a &#147;United States
person.&#148; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>If you are considering the purchase of notes, you should consult your own tax advisors concerning the
particular U.S. federal income tax consequences to you of the purchase, ownership and disposition of the notes, as well as the consequences to you arising under the laws of any other taxing jurisdiction. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be required to make payments of additional amounts to holders of the notes under certain circumstances, including those described under
&#147;Description of the Euro Notes and the Guarantees&#151;Optional Redemption by the Issuer,&#148; &#147;Description of the Euro Notes and the Guarantees&#151;Additional Tax Amounts,&#148; &#147;Description of the USD Notes and the
Guarantees&#151;Optional Redemption by the Issuer,&#148; &#147;Description of the USD Notes and the Guarantees&#151;Additional Tax Amounts,&#148; and &#147;Description of the USD Notes and the Guarantees&#151;Optional Redemption by the Issuer.&#148;
Our obligation to pay such excess amounts may implicate the provisions of the U.S. Treasury Regulations relating to &#147;contingent payment debt instruments.&#148; Under these regulations, however, a contingency will not cause a debt instrument to
be treated as a contingent payment debt instrument if, as of the issue date, such contingency is &#147;remote&#148; or is considered to be &#147;incidental.&#148; We intend to take the position that the possibility of any such additional amounts
does not result in the notes being treated as &#147;contingent payment debt instruments&#148; under the applicable U.S. Treasury Regulations. Our position is binding on you unless you disclose your contrary position in the manner required by the
applicable U.S. Treasury Regulations. It is possible that the IRS may take a different position, in which case you might, among other things, be required to accrue interest income at a higher rate than the stated interest rate and to treat as
ordinary interest income any gain realized on a disposition of the notes. The remainder of this discussion assumes that the notes will not be considered contingent payment debt instruments. You should consult your own tax advisors regarding the
possible application of the contingent payment debt instrument rules to the notes and the consequences thereof. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments of Interest </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foreign currency rules discussed below, the gross amount of interest on a note (which includes any foreign tax withheld) will
generally be &#147;qualified stated interest,&#148; as that term is defined in the Code and the U.S. Treasury Regulations, and will generally be taxable to a U.S. Holder as ordinary interest income at the time it is paid or accrued in accordance
with such U.S. Holder&#146;s method of accounting for tax purposes. In addition to interest on the notes, a U.S. Holder will be required to include in income any additional amounts paid in respect of any foreign tax withheld. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder receives a payment of interest on a note denominated in euro and such U.S. Holder uses the cash method of accounting for U.S.
federal income tax purposes, the U.S. Holder will be required to include in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
income (as ordinary income) the U.S. dollar value of the interest (including additional amounts) received on the notes, determined by translating the euro received at the spot rate on the date
such payment is received regardless of whether the payment is in fact converted into U.S. dollars. A U.S. Holder will not recognize exchange gain or loss with respect to the receipt of such payment, but may recognize exchange gain or loss
attributable to the actual disposition of the euro so received. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder receives a payment of interest on a note denominated in
euro and such U.S. Holder uses the accrual method of accounting for U.S. federal income tax purposes (or such U.S. Holder is otherwise required to accrue interest prior to receipt), the U.S. Holder may determine the amount of income recognized with
respect to interest (including additional amounts) received on the notes in accordance with either of two methods. Under the first method, a U.S. Holder will be required to include in income for each taxable year the U.S. dollar value of the
interest that has accrued during such year, determined by translating such interest at the average rate of exchange for the period or periods during which such interest accrued or, in the case of an accrual period that spans two taxable years of a
U.S. Holder, the part of the period within the taxable year. Under the second method, a U.S. Holder may elect to translate interest income at the spot rate on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the accrual period; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the portion of the accrual period within the applicable taxable year if the accrual period
straddles such U.S. Holder&#146;s taxable year; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date the stated interest payment is received if such date is within five business days of the end of the
accrual period. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This election will apply to all debt obligations that a U.S. Holder holds from year to year and cannot
be changed without the consent of the IRS. U.S. Holders should consult their own tax advisors as to the advisability of making the above election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not such election is made, with respect to notes denominated in euro, upon receipt of an interest payment on a note (including,
upon the sale of a note, the receipt of proceeds to the extent attributable to accrued but unpaid interest previously included in income), a U.S. Holder will recognize U.S. source ordinary income or loss in an amount equal to the difference, if any,
between the U.S. dollar value of such payment (determined by translating the euro received at the spot rate on the date such payment is received) and the U.S. dollar value of the interest income such U.S. Holder previously included in income with
respect to such payment. This exchange gain or loss will not be treated as an adjustment to interest income or expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Tax Credit
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income earned by a U.S. Holder will constitute foreign source income and be considered &#147;passive category
income&#148; or, in the case of certain U.S. Holders, &#147;general category income&#148; for U.S. federal income tax purposes, which may be relevant to a U.S. Holder in calculating the holder&#146;s foreign tax credit limitation. Any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> withholding tax paid with respect to the U.S. Holder at a rate applicable to such holder (including the withholding tax described under &#147;Israeli Tax Considerations&#151;Israeli Tax Liability on
Interest Payable by Teva to <FONT STYLE="white-space:nowrap">Non-Israeli</FONT> Residents&#148;) may be eligible for foreign tax credits (or, at such holder&#146;s election, a deduction in lieu of such credits) for U.S. federal income tax purposes,
subject to applicable limitations. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. The rules governing foreign tax credits are complex and, therefore, U.S. Holders should
consult their own tax advisors regarding the availability of foreign tax credits in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale, Exchange, Redemption,
Retirement, or Other Taxable Disposition of the Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the sale, exchange, redemption, retirement, or other taxable
disposition of a note, a U.S. Holder will recognize taxable gain or loss equal to the difference between the amount realized on the sale, exchange, redemption, retirement, or other taxable disposition and the U.S. Holder&#146;s adjusted tax basis in
the note. A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S.&nbsp;Holder&#146;s adjusted tax basis in a note generally will equal its initial cost of that note. For these purposes, the amount realized does not include any amount attributable to
accrued interest. Amounts attributable to accrued interest are treated as interest as described under &#147;&#151;Payments of Interest&#148; above. In the case of a Euro note, a U.S. Holder&#146;s initial cost generally will be the U.S. dollar value
of the euro paid for such note determined at the spot rate on the date of such purchase. If a U.S. Holder&#146;s note is sold, exchanged, redeemed, retired or otherwise disposed of in a taxable transaction for euro, the amount realized generally
will be the U.S. dollar value of the euro received based on the spot rate in effect on the date of sale, exchange, redemption, retirement or other taxable disposition. If a U.S. Holder is a cash method taxpayer and the notes are traded on an
established securities market, euro paid or received will be translated into U.S. dollars at the spot rate on the settlement date of the purchase or sale. A U.S. Holder that is an accrual method taxpayer may elect the same treatment with respect to
the purchase and sale of notes traded on an established securities market, provided that the election is applied consistently to all debt instruments from year to year. Such election cannot be changed without the consent of the IRS. If such U.S.
Holder is an accrual method taxpayer and does not make this election, the U.S.&nbsp;dollar equivalent of the amount realized will be determined by translating that amount at the U.S. dollar spot rate for euro on the date of the sale, exchange,
redemption, retirement or other taxable disposition, and the U.S.&nbsp;Holder generally will recognize foreign currency gain or loss (generally treated as ordinary income or loss) equal to the difference, if any, between the U.S. dollar equivalent
of the amount realized based on the spot rates in effect on the date of disposition and the settlement date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foreign
currency gain or loss rules discussed below, gain or loss realized by a U.S. Holder on the sale, exchange, redemption, retirement, or other taxable disposition of a note will generally be U.S. source capital gain or loss and will be long-term
capital gain or loss if at the time of sale, exchange, redemption, retirement, or other taxable disposition the note has been held for more than one year. Certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S.&nbsp;Holders are eligible
for a reduced rate of tax on long-term capital gains. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A portion of a U.S.
Holder&#146;s gain or loss with respect to a Euro note may be treated as foreign currency gain or loss with respect to the principal amount of such Euro note. Foreign currency gain or loss will be treated as ordinary income or loss and generally
will be U.S. source gain or loss. For these purposes, the principal amount of the Euro note is the purchase price for the Euro note calculated in euro on the date of purchase, and the amount of exchange gain or loss recognized is equal to the
difference between (i)&nbsp;the U.S. dollar value of the principal amount determined on the date of the sale, exchange, redemption, retirement or other taxable disposition of the Euro note and (ii)&nbsp;the U.S. dollar value of the principal amount
determined on the date the U.S. Holder purchased the Euro note. The amount of exchange gain or loss will be limited to the amount of overall gain or loss realized on the disposition of the Euro note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain or loss recognized on the sale or other taxable disposition of a Euro note that is attributable to fluctuations in currency exchange
rates with respect to the principal amount of such Euro note generally will be U.S. source ordinary income or loss and generally will not be treated as interest income or expense. Such gain or loss generally will equal the difference, if any,
between the U.S. dollar value of the U.S. Holder&#146;s euro purchase price for the note, translated at the spot rate of exchange on the date principal is received from the Issuers or the U.S. Holder disposes of the Euro note, and the U.S. dollar
value of the U.S. Holder&#146;s euro purchase price for the Euro note, translated at the spot rate of exchange on the date the U.S. Holder purchased such Euro note. In addition, upon sale or other taxable disposition of a Euro note, a U.S. Holder
may recognize exchange gain or loss attributable to amounts received with respect to accrued and unpaid stated interest, which will be treated as discussed above under &#147;&#151;Payments of stated interest.&#148; However, upon a sale or other
taxable disposition of a Euro note, a U.S. Holder will recognize any exchange gain or loss (including with respect to accrued stated interest) only to the extent of total gain or loss realized by such U.S. Holder on such disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain or loss a U.S. Holder recognizes on the sale or other taxable disposition of the notes in excess of exchange gain or loss attributable to
such disposition generally will be U.S. source capital gain or loss. Such gain or loss generally will be long-term capital gain or loss if a U.S. Holder has held the notes for more than one year. For
<FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders, long-term capital gains are generally eligible for reduced rates of taxation. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">deductibility of capital losses is subject to limitations. A U.S. Holder should consult its own tax advisor
regarding </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the deductibility of capital losses in its particular circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reportable Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S.
Treasury Regulations meant to require the reporting of certain tax shelter transactions could be interpreted to cover transactions generally not regarded as tax shelters, including certain foreign currency transactions. Under the applicable U.S.
Treasury Regulations, certain transactions are required to be reported to the IRS, including, in certain circumstances, a sale, exchange, redemption, retirement or other taxable disposition of a foreign currency note, or foreign currency received in
respect of a foreign currency note, to the extent that such sale, exchange, redemption, retirement or other taxable disposition results in a tax loss in excess of a threshold amount. Holders considering the purchase of notes should consult with
their own tax advisors to determine the tax return obligations, if any, with respect to an investment in the notes, including any requirement to file IRS Form 8886 (Reportable Transaction Disclosure Statement). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Backup Withholding and Information Reporting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns may be filed with the IRS in connection with payments on the notes and the proceeds from a sale, exchange, redemption,
retirement, or other taxable disposition of the notes. A U.S. Holder will be subject to U.S. backup withholding tax on these payments if the U.S. Holder fails to provide its taxpayer identification number to the paying agent and comply with certain
certification procedures or does not otherwise establish an exemption from backup withholding. The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the U.S. Holder&#146;s U.S. federal income tax
liability and may entitle the U.S. Holder to a refund, provided that the required information is furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Specified foreign financial
assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders that own &#147;specified foreign financial assets&#148; with an aggregate value in excess of $50,000
are generally required to file an information statement along with their tax returns, currently on Form 8938, with respect to such assets. &#147;Specified foreign financial assets&#148; include any financial accounts held at a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> financial institution, as well as securities issued by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> issuer (which may include notes issued in certificated form) that are not held in accounts
maintained by financial institutions. Higher reporting thresholds apply to certain individuals living abroad and to certain married individuals. Regulations extend this reporting requirement to certain entities that are treated as formed or availed
of to hold direct or indirect interests in specified foreign financial assets based on certain objective criteria. U.S. Holders who fail to report the required information could be subject to substantial penalties. In addition, the statute of
limitations for assessment of tax would generally be extended. Prospective investors should consult their own tax advisors concerning the application of these rules to their investment in the notes, including the application of the rules to their
particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Account Tax Compliance Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Sections 1471 through 1474 of the Code (provisions commonly known as &#147;FATCA&#148;), a &#147;foreign financial
institution&#148; may be required to withhold U.S. tax on certain &#147;foreign passthru payments&#148; made after December&nbsp;31, 2018, to the extent such payments are treated as attributable to certain U.S. source payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obligations issued on or prior to the date that is six months after the date on which applicable final U.S.&nbsp;Treasury Regulations defining
&#147;foreign passthru payments&#148; are filed generally would be &#147;grandfathered&#148; unless such obligations are materially modified after such date. The IRS has proposed to extend the start of this obligation to withhold on &#147;foreign
passthru payments&#148; to two years after applicable final U.S. Treasury Regulations defining &#147;foreign passthru payments&#148; are filed. As of the date of this prospectus supplement, applicable final U.S. Treasury Regulations have not yet
been filed. Accordingly, if Teva, Teva Finance II, Teva&nbsp;Finance III or Teva Finance IV is treated as a foreign financial institution, FATCA would apply to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payments on the notes only if there is a significant modification of the notes for U.S. federal income tax purposes after the expiration of this grandfathering period. <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> governments have entered into, and others are expected to enter into, intergovernmental agreements with the United States to implement FATCA in a manner that alters the rules described herein. Under such
intergovernmental agreements, the Issuers may be required to report certain information regarding investors to tax authorities in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> jurisdiction, which information may be shared with tax authorities
in the United States. U.S. Holders should consult their own tax advisors on how these rules may apply to their investment in the notes. In the event any withholding under FATCA is imposed with respect to any payments on the notes, there generally
will be no additional amounts payable to compensate for the withheld amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_11"></A>DUTCH TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of certain material Dutch tax considerations relating to the purchase, ownership and disposition of the notes by
holders of notes<I>. </I>It is not, however, a complete analysis of all the potential tax considerations that may be applicable to all potential investors. Each prospective holder of notes should consult a professional tax adviser with respect to
the potential Dutch tax consequences of an investment in the notes. The following summary is based on Dutch tax law as applied and interpreted by Dutch courts and as published and in effect on the date of this prospectus supplement, without
prejudice to any amendments introduced at a later date and implemented with or without retroactive effect. For the purposes of this section, &#147;Dutch Taxes&#148; shall mean taxes of whatever nature levied by or on behalf of The Netherlands or any
of its subdivisions or taxing authorities. &#147;The Netherlands&#148; means the part of the Kingdom of The Netherlands located in Europe. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Scope
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regardless of whether or not a holder of notes is, or is treated as being, a resident of The Netherlands, this summary does not
apply to a holder of notes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that has a substantial interest (<I>aanmerkelijk belang</I>), or a fictitious substantial interest (<I>fictief
aanmerkelijk belang</I>), in the Issuer, nor when, in the case of an individual, his partner (statutory defined term) or one of certain relatives of the holder of notes has a (fictitious) substantial interest. Generally, a holder of notes has a
substantial interest if such holder, alone or, in the case of an individual, together with his partner, directly or indirectly: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">owns, or holds certain rights on, shares representing five percent or more of the total issued and outstanding
capital of the Issuer, or of the total issued and outstanding capital of any class of shares of the Issuer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">holds rights to directly or indirectly acquire shares, whether or not already issued, representing five percent
or more of the total issued and outstanding capital of the Issuer, or of the total issued and outstanding capital of any class of shares of the Issuer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">owns, or holds certain rights on, profit participating certificates that relate to five percent or more of the
annual profit of the Issuer or to five percent or more of the liquidation proceeds of the Issuer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who is an individual and who may be taxed in box 1 for the purposes of Dutch income tax
(<I>inkomstenbelasting</I>) as an entrepreneur (<I>ondernemer</I>) having an enterprise (<I>onderneming</I>) to which the notes are attributable, or who may otherwise be taxed in box 1 with respect to benefits derived from the notes;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to whom the notes and the income from the notes are attributed based on the separated private assets
(<I>afgezonderd particulier vermogen</I>) provision of the Dutch Income Tax Act 2001 (<I>Wet inkomstenbelasting 2001</I>) and the Dutch Gift and Inheritance Act 1956 (<I>Successiewet 1956</I>); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which is a corporate entity and an exempt investment institution (<I>vrijgestelde beleggingsinstelling</I>) or
investment institution (<I>beleggingsinstelling</I>) for Dutch corporate income tax purposes, a pension fund, or otherwise not a taxpayer or exempt for Dutch corporate income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which is an entity which is a resident of Aruba, Cura&ccedil;ao or Sint Maarten that has an enterprise which is
carried on through a (deemed) permanent establishment or a permanent representative on Bonaire, Sint Eustatius or Saba, and the notes are attributable to such (deemed) permanent establishment or permanent representative; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that is an affiliated entity of the Issuer for the purposes of the Dutch Withholding Tax Act 2021 (<I>Wet
bronbelasting 2021</I>), i.e. an entity that directly or indirectly, individually or jointly as part of a qualifying unit (<I>kwalificerende eenheid</I>), holds a controlling interest in the Issuer; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">which is not considered to be the beneficial owner (<I>uiteindelijk gerechtigde</I>) of the notes and/or the
benefits derived from the notes. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any payments made under the notes will not be subject to withholding or deduction for, or on account of, any Dutch Taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Resident holders: A
holder of notes who is an individual and a resident, or treated as being a resident of The Netherlands for the purposes of Dutch income tax, must record the notes as assets that are held in box 3 for Dutch income tax purposes. Taxable income derived
from the notes is not based on the income or capital gains actually realized by the holder of notes but calculated based on a deemed return on the yield basis (<I>rendementsgrondslag</I>) at the beginning of each calendar year insofar the yield
basis exceeds a threshold (<I>heffingsvrij vermogen</I>) of EUR 57,684 (2025 amount). The yield basis is equal to the fair market value of certain qualifying assets held by the holder of notes, less the fair market value of certain qualifying
liabilities at the beginning of each calendar year. The notes will be included as investment assets at their fair market value in the yield basis of the holder of notes and may generate deemed return of up to 5.88&nbsp;percent (preliminary 2025
rate) which is taxed at a flat rate of 36&nbsp;percent (2025 rate). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;6, 2024, the Dutch Supreme Court ruled that, in certain
cases, the current box 3 income tax regime is incompatible with Article 1 of the First Protocol to the European Convention on Human Rights (the &#147;Convention&#148;), read in conjunction with Article 14 of the Convention (the
&#147;Decision&#148;). In short, this incompatibility arises where the deemed return calculated under the box 3 regime exceeds the actual return realized by the taxpayer in respect of the relevant investment assets, provided that the taxpayer is
able to demonstrate this discrepancy in accordance with the criteria set out in the Decision. On March&nbsp;13, 2025, a legislative proposal was submitted to the Dutch Parliament codifying how taxpayers may demonstrate a lower actual return on their
relevant investment assets &#150; including, for example, the notes &#150; than the deemed return under Box 3 (the &#147;Bill&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of notes are advised to monitor the legislative process of the Bill and consult their own tax adviser to assess the potential impact
of the Decision and the Bill on their individual tax position and to ensure that Dutch income tax is levied in accordance with the applicable legislation as in effect at the relevant time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-resident</FONT> holders: a holder of notes who is an individual will not be subject to income tax in
respect of benefits derived from the notes, unless such holder of notes is entitled to a share in the profits of an enterprise or a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net worth of an enterprise, other than by way of the
holding of securities, which is effectively managed in The Netherlands and to which enterprise the notes are attributable </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate income tax
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(deemed) Resident holders: a holder of notes which is a corporate entity is subject to corporate income tax in respect of benefits
derived from the notes at a rate of up to 25.8&nbsp;percent (2025 rate). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-resident</FONT> holders: a
holder of notes which is a corporate entity will not be subject to corporate income tax, unless such holder has, other than by way of the holding of securities, an interest in an enterprise, which is effectively managed in The Netherlands and to
which enterprise the notes are attributable, or has an enterprise which is carried on through a (deemed) permanent establishment or a permanent representative in the Netherlands and to which enterprise the notes are attributable. In such case the
holder of notes will be taxed in respect of benefits derived from the notes a rate of up to 25.8&nbsp;percent (2025 rate). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gift tax or inheritance tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No Dutch gift tax or inheritance tax is due in respect of any gift of the notes by, or inheritance of the notes on the death of, a holder of
notes, except if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time of the gift or death of the holder of notes, the holder of notes is resident, or deemed to be
resident, in The Netherlands; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the holder of notes passes away within 180 days after the date of the gift of the notes and is not, or is not
deemed to be, at the time of the gift, but is, or is deemed to be, at the time of his death, resident in The Netherlands; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the gift of the notes is made under a condition precedent and the holder of notes is resident, or deemed to be
resident, in The Netherlands at the time the condition is fulfilled. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of Dutch gift or inheritance tax, an
individual who is of Dutch nationality will be deemed to be resident in The Netherlands if he has been a resident in The Netherlands at any time during the ten years preceding the date of the gift or his death. For purposes of Dutch gift tax, any
individual, irrespective of his nationality, will be deemed to be resident in The Netherlands if he has been a resident in The Netherlands at any time during the 12 months preceding the date of the gift. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No other Dutch Taxes,
including value added tax and taxes of a documentary nature, such as capital tax, stamp or registration tax or duty, are payable by or on behalf of a holder of notes by reason only of the issue, acquisition or transfer of the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Residency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of notes will
not become resident, or a deemed resident, in The Netherlands for tax purposes by reason only of the Issuer&#146;s performance, or the holder&#146;s acquisition (by way of issue or transfer to it), holding and/or disposal of the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_12"></A>ISRAELI TAX CONSIDERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of certain material Israeli tax considerations relating to the ownership of the notes by persons who are not
residents of the State of Israel for Israeli tax purposes. It is not, however, a complete analysis of all the potential tax considerations that may be applicable to all potential investors. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The following discussion is for general information only. It is also applicable to beneficial owners of the notes. Investors considering
the purchase of the notes should consult their own tax advisors with respect to the application of Israeli income tax laws to their particular situations as well as any tax consequences arising under any
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> taxing jurisdiction or under any applicable tax treaty. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israeli Tax Liability on Interest
Payable by Teva to <FONT STYLE="white-space:nowrap">Non-Israeli</FONT> Residents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An individual is subject to tax on interest at a
reduced rate of up to 25%. The reduced rate is not available to an individual, if interest expenses are claimed as tax deductions with respect to the notes, if the individual is a &#147;substantial shareholder,&#148; (&#147;substantial
shareholder&#148; for these purposes is a shareholder who holds directly or indirectly, including with others, at least 10% of any means of control in the company), if the individual is an employee, a service provider or a supplier of the company
paying out the interest or there is a special relationship between the individual and the company paying out the interest (unless certain conditions are met), or if the interest is a business income of the individual. In such cases, the individual
will be subject to tax on the interest at his marginal tax rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individuals who are subject to tax in Israel are also subject to an
additional tax at a rate of 3% on annual income exceeding a certain threshold (NIS 721,560 for the years 2025 to 2027, and from 2028 and thereafter, such amount will be linked to the annual change in the Israeli Consumer Price Index), including, but
not limited to, income derived from interest. In addition, starting from 2025, an additional tax at a rate of 2% is imposed on taxable income which derived from &#147;capital sources&#148; (which includes income derived from interest) exceeding the
same threshold. Meaning, starting from 2025, taxable income derives from capital sources (including interest) exceeding the aforementioned threshold is subject to additional tax at a total rate of 5%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate entities are subject to corporate tax on their interest income. The corporate tax rate is currently 23%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Israeli</FONT> residents are required to file an income tax return in Israel if they have Israeli sourced
interest income, unless the full amount of tax was withheld. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Taxes on Interest Payable by Teva to
<FONT STYLE="white-space:nowrap">Non-Israeli</FONT> Residents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Israeli company paying interest on a note denominated in a
foreign currency to an individual who is a <FONT STYLE="white-space:nowrap">non-Israeli</FONT> resident is required to withhold tax at a rate of 25%, except for (i)&nbsp;interest paid to a &#147;substantial shareholder&#148; (as defined above), or
(ii)&nbsp;interest paid to an employee, a service provider or a supplier of such Israeli company, who are subject to withholding tax according to the highest marginal tax rate applicable to individuals. Tax liability with respect to interest paid to
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents by an Israeli company may be reduced under an applicable tax treaty. To benefit from such reduced rate under an applicable tax treaty, such
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents should file an Israeli tax return based on such lower rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An Israeli
company paying interest on a similar note to a corporate entity will be subject to withholding tax in accordance with the applicable corporate tax rate for the year in which the interest is paid, such rate is currently 23%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aforementioned might only apply if Teva as a guarantor pays interest on the notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We note that any payment in excess of the principal amount (whether upon maturity or early redemption) might be considered as interest for
Israeli tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Original Issue Discount</I>. For Israeli income tax purposes, any principal amount
reflecting original issue discount is generally treated in the same manner as interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent notes are redeemed by Teva as
described under &#147;Description of the Euro Notes and the Guarantees&#151;Tax Redemption&#148; and &#147;Description of the USD Notes and the Guarantees&#151;Tax Redemption,&#148; holders of notes will be required to present withholding tax
exemption certificates issued by the Israeli Tax Authority to prevent withholding on account of Israeli taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva, Teva Finance II,
Teva Finance III and Teva Finance IV have agreed to pay certain additional amounts in connection with withholding taxes or deductions that may be imposed by Israeli or Dutch authorities. See &#147;Description of the Euro Notes and the
Guarantees&#151;Additional Tax Amounts&#148; and &#147;Description of the USD Notes and the Guarantees&#151;Additional Tax Amounts.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_13"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">BNP PARIBAS, BofA Securities Europe SA, HSBC Continental Europe, Intesa Sanpaolo S.p.A. and J.P.&nbsp;Morgan SE are acting as the
representatives of each of the underwriters named in the first table set out below in respect of the Euro notes, BNP Paribas Securities Corp., BofA Securities, Inc., HSBC Bank plc, Intesa Sanpaolo S.p.A. and J.P. Morgan SE are acting as the
representatives of each of the underwriters named in the second table set out below in respect of the USD notes. Subject to the terms and conditions of an underwriting agreement (the &#147;Underwriting Agreement&#148;), by and among the Issuers,
Teva and the underwriters set forth below (collectively, the &#147;Underwriters&#148; and each, an &#147;Underwriter&#148;), each Underwriter has severally agreed to purchase from us, and we have agreed to sell to such Underwriter, the principal
amount of notes set forth opposite such Underwriter&#146;s name in the tables below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount<BR>of the Euro<BR>notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities Europe SA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC Continental Europe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Europe AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs Bank Europe SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Bank Europe N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG Securities (Europe) N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount<BR>of the 2032 USD<BR>notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount<BR>of the 2030 USD<BR>notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs Bank Europe SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG Securities Americas Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the Underwriting Agreement, the Underwriters have agreed,
severally and not jointly, to purchase all of the notes sold under the Underwriting Agreement if any notes are purchased. The Underwriters may offer and sell notes through certain of their affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an Underwriter defaults, the Underwriting Agreement provides that the purchase commitments of the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may be increased, the commitments of the defaulting Underwriter may be assumed by other persons satisfactory to us or the Underwriting Agreement may be terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters are offering the notes, subject to prior sale, when, as and if issued to
and accepted by them, subject to approval of legal matters by their counsel, including the validity of the notes, and other conditions contained in the Underwriting Agreement, such as the receipt by the Underwriters of officers&#146; certificates
and legal opinions. The Underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A. is not a U.S. registered broker-dealer, and will not effect any offers or sales of any notes in the United States
unless it is through one or more U.S. registered broker-dealers as permitted by the regulations of the Financial Industry Regulatory Authority, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
representatives have advised us that the underwriters propose initially to offer the notes to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers at such price less a concession
not in excess of &#8195;&#8195;% of the principal amount of the notes. After the initial offering, the public offering price, concession or any other term of the offering may be changed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expenses of the offering, not including the underwriting discount, are estimated at $&#8195;&#8195;&#8195;&#8195; and are payable by us.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization and Short Positions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the Underwriters or parties acting on their behalf may engage in over-allotment and stabilizing transactions or purchases and
passive market making for the purpose of pegging, fixing or maintaining the prices of the notes in accordance with Regulation M under the Exchange Act: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Over-allotment involves sales by the Underwriters of notes in excess of the number of notes the Underwriter is
obligated to purchase, which creates a short position. Since the Underwriters in this offering do not have an option to purchase additional securities, their short position will be a naked short position. A naked short position can only be closed
out by buying notes in the open market. A naked short position is more likely to be created if the Underwriters are concerned that there could be downward pressure on the prices of the notes in the open market after pricing that could adversely
affect investors who purchase in this offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions permit bids to purchase the notes so long as the stabilizing bids do not exceed a
specified maximum. These stabilizing transactions as well as other purchases made by the Underwriters for their own accounts may have the effect of raising or maintaining the market prices of the notes or preventing or retarding a decline in the
market prices of the notes. As a result, the prices of the notes may be higher than the prices that might otherwise exist in the open market. These transactions, if commenced, may be discontinued at any time. The Underwriters also may impose a
penalty bid. This occurs when a particular Underwriter repays to the Underwriters a portion of the Underwriters&#146; discount received by it because the representatives have repurchased notes sold by or for the account of such Underwriter in
stabilizing or short covering transactions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In the case of the Euro notes, if these activities are commenced, they must end no later than the earlier of 30
days after the date of issuance of the notes and 60 days after the date of the allotment of the notes. These transactions may be effected in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market
or otherwise. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Underwriters make any representations or predictions as to the direction or magnitude
of any effect that the transactions described above may have on the prices of the notes. In addition, neither we nor the Underwriters make representations that the representatives will engage in these stabilizing transactions or that any
transaction, once commenced, will not be discontinued without notice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Issuers and Teva have agreed with the Underwriters that, unless they receive prior written consent of BNP PARIBAS, BNP Paribas Securities
Corp., BofA Securities Europe SA, BofA Securities, Inc., HSBC Continental Europe, HSBC Bank plc, Intesa Sanpaolo S.p.A. and J.P. Morgan SE, they may not, subject to certain customary exceptions, from the date of the Underwriting Agreement to the
closing date of this offering, directly or indirectly, offer, sell, or contract to sell, or otherwise dispose of any debt securities (other than the notes offered hereby) issued or guaranteed by the Issuers or Teva. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to
indemnify the several Underwriters against liabilities relating to this offering, including liabilities under the Securities Act, and liabilities arising from breaches of certain representations and warranties contained in the Underwriting
Agreement, and to contribute to payments that the Underwriters may be required to make for these liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stamp Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of the notes offered by this prospectus supplement may be required to pay stamp taxes and other charges under the laws and practices
of the country of purchase, in addition to the offering price listed on the cover page of this prospectus supplement. Accordingly, we urge you to consult a tax advisor with respect to whether you may be required to pay taxes or charges, as well as
any other consequences that may arise under the laws of the country of purchase. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canadian Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions </I>or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the notes must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a
purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT>
Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest
in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Israeli Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement does not constitute a prospectus under the Israeli Securities Law, 5728-1968 (the &#147;Israeli Securities
Law&#148;) and has not been filed with, or approved by, the Israel Securities Authority and is not, and under no circumstances is to be construed as, an advertisement or a public offering of securities in Israel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Israel, this prospectus supplement may be distributed only to, and the notes may only be offered to, </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">persons who qualify as one of the types of investors listed in the First Addendum to the Israeli Securities
Law, subject to and in accordance with the requirements set forth in the First Addendum to the Israeli Securities Law, and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who have confirmed in writing that they are acquiring the notes for their own account and not with a view to,
or for resale in connection with any distribution thereof, except to the extent permitted under the First Addendum to the Israeli Securities Law, for resale to investors of the type listed therein. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of the manufacturer&#146;s product approval process, the target market assessment in respect of the notes has led to
the conclusion that: (i)&nbsp;the target market for the notes is eligible counterparties and professional clients only, each as defined in MiFID II; and (ii)&nbsp;all channels for distribution of the notes to eligible counterparties and professional
clients are appropriate. A distributor should take into consideration the manufacturer&#146;s target market assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the
notes (by either adopting or refining the manufacturer&#146;s target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Underwriter has represented and agreed that it has not offered, sold or otherwise made available and will not offer, sell or otherwise
make available any notes to any retail investor in the European Economic Area. For the purposes of this provision the expression &#147;retail investor&#148; means a person who is one (or more) of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client as defined in point (11)&nbsp;of Article 4(1) of MiFID II; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of Directive 2016/97/EU (as amended), where that customer would not qualify as a
professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not a qualified investor as defined in Article 2 of the Prospectus Regulation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, no key information document required by the PRIIPs Regulation for offering or selling the notes or otherwise making them
available to retail investors in the EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. This prospectus supplement has
been prepared on the basis that any offer of notes in any Member State of the EEA will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of the notes. This prospectus supplement
is not a prospectus for the purposes of the Prospectus Regulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dutch Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement is directed only at qualified investors as defined in the Prospectus Regulation. The notes have not, may not and
will not be offered, sold or delivered in the Netherlands, other than to qualified investors (<I>gekwalificeerde beleggers</I>). This prospectus supplement must not be acted on or relied on by persons who are not qualified investors (as defined in
the Prospectus Regulation). Any investment or investment activity to which this prospectus supplement relates is available only to qualified investors and will be engaged in only with qualified investors. Recipients of this prospectus supplement are
not permitted to transmit it to any other person. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This issue and distribution of this prospectus supplement is restricted by law. This offering memorandum is not being distributed by, nor has
it been approved for the purposes of section 21 of the Financial Services and Markets Act 2000 by, a person authorized under the Financial Services and Markets Act 2000. In the United Kingdom, this prospectus supplement is being distributed only to,
and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments
falling within Article 19 (5) of the Order and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order, or (iii)&nbsp;are persons to whom an invitation or inducement to engage in investment activity (within the meaning of
Section&nbsp;21 of the Financial Services and Markets Act 2000 in connection with the issue or sale of any notes may otherwise be lawfully communicated or caused to be communicated) (all such persons together being referred to as &#147;relevant
persons&#148;). This prospectus supplement must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment activity to which this prospectus supplement relates is
only available to, and will be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this offering memorandum or any of its contents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of each manufacturer&#146;s product approval process, the target market assessment in respect of the notes has led to
the conclusion that: (i)&nbsp;the target market for the notes is only ECPs, as defined in the COBS, and professional clients, as defined in UK MiFIR; and (ii)&nbsp;all channels for distribution of the notes to ECPs and professional clients are
appropriate. A distributor should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to the UK MiFIR Product Governance Rules is responsible for undertaking its own target market assessment in
respect of the notes (by either adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to
any retail investor in the UK. For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client, as defined in point (8)&nbsp;of Article 2 of Regulation (EU) No.&nbsp;2017/565 as it forms part of domestic law by
virtue of the EUWA; (ii)&nbsp;a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97; or (iii)&nbsp;not a qualified investor as defined in Article 2 of
Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA, where that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article&nbsp;2(1) of Regulation (EU) No.&nbsp;600/2014 as it forms part
of domestic law by virtue of the EUWA. Consequently, no key information document required by the PRIIPs Regulation as it forms part of domestic law by virtue of the EUWA for offering or selling the securities or otherwise making them available to
retail investors in the UK has been or will be prepared and, therefore, offering or selling the securities or otherwise making them available to any retail investor in the UK may be unlawful under the PRIIPs Regulation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Italy Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of the
notes has not been registered with or cleared by the Italian Securities Exchange Commission (<I>Commissione Nazionale per le Societ&agrave; e la Borsa</I>, &#147;CONSOB&#148;) pursuant to Italian securities legislation and, therefore, no notes may
be offered, sold or delivered, nor may copies of this prospectus supplement or of any other document relating to the notes be distributed in the Republic of Italy, except: (a)&nbsp;to qualified investors (<I>investitori qualificati</I>) as defined
in Article 100 of Legislative Decree No.&nbsp;58 of 24&nbsp;February 1998, as amended (the &#147;Financial Services Act&#148;) and Article <FONT STYLE="white-space:nowrap">34-ter,</FONT> first paragraph, letter b) of CONSOB Regulation No.&nbsp;11971
of 14&nbsp;May 1999, as amended from time to time (&#147;Regulation No.&nbsp;11971&#148;); or (b)&nbsp;in other circumstances which are exempted from the rules on public offerings pursuant to Article 100 of the Financial Services Act and Article <FONT
STYLE="white-space:nowrap">34-ter</FONT> of Regulation No.&nbsp;11971. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer, sale or delivery of the notes or distribution of copies
of this prospectus supplement or any other document relating to the notes in the Republic of Italy under (a)&nbsp;or (b) above may and will be effected in accordance with all Italian securities, tax, exchange control and other applicable laws and
regulations, and, in particular, must be: (i)&nbsp;made by an investment firm, bank or financial intermediary permitted to conduct such activities in the Republic of Italy in accordance with the Financial Services Act, CONSOB Regulation
No.&nbsp;16190 of 29&nbsp;October 2007 (as amended from time to time) and Legislative Decree No.&nbsp;385 of 1&nbsp;September 1993, as amended (the &#147;Banking Act&#148;); and (ii)&nbsp;in compliance with Article 129 of the Banking Act, as
amended, and the implementing guidelines of the Bank of Italy, as amended from time to time, pursuant to which the Bank of Italy may request information on the issue or the offer of securities in the Republic of Italy; and (iii)&nbsp;in compliance
with any other applicable laws and regulations or requirements imposed by CONSOB or any other Italian authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any investor purchasing the notes is solely responsible for ensuring that any offer or
resale of the notes it purchased in this offering occurs in compliance with applicable Italian laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that in
accordance with Article <FONT STYLE="white-space:nowrap">100-bis</FONT> of the Financial Services Act, where no exemption from the rules on public offerings applies under (a)&nbsp;and (b) above, the subsequent resale of the notes on the secondary
market in Italy must be made in compliance with the public offer and the prospectus requirement rules provided under the Financial Services Act and Regulation No.&nbsp;11971. Failure to comply with such rules may result in the subsequent <FONT
STYLE="white-space:nowrap">re-sale</FONT> of such notes being declared null and void and in the liability of the intermediary transferring the notes for any damages suffered by the investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hong Kong Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contents of
this prospectus supplement have not been reviewed by any regulatory authority in Hong&nbsp;Kong. The notes may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made
thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation or document relating to
the notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in
Hong&nbsp;Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning
of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Japan Legal Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Act No.&nbsp;25 of 1948, as
amended, (the &#147;Financial Instruments and Exchange Law&#148;) and each Underwriter has agreed that it will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used
herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a
resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for subscription
or purchase, of the notes may not be circulated or distributed, nor may the notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than
(i)&nbsp;to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act, 2001 of Singapore (as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of SFA, or (ii)&nbsp;to an
accredited investor (as defined in Section&nbsp;4A of the SFA) pursuant to and in accordance with the conditions specified in Section&nbsp;275 of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Solely for the purposes of their obligations pursuant to sections 309B(1)(a) and 309B(1)(c) of the SFA, the Issuers have determined, and
hereby notify all relevant persons (as defined in Section&nbsp;309A of the SFA) that the notes are &#147;prescribed capital markets products&#148; (as defined in the Securities and Futures (Capital markets Products) Regulations 2018) and Excluded
Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment
Products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Underwriter has represented and agreed that it will comply with applicable laws and
regulations in each jurisdiction in which it acquires, offers, sells or delivers the notes, or has in its possession or distributes any prospectus supplement relating to the notes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Switzerland Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes
described herein may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (&#147;FinSA&#148;) except in reliance on article 36 paragraph 1 subsection c FinSA (minimum investment size
of CHF 100,000 per investor) and no application has been or will be made to admit the notes to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this prospectus supplement nor any other offering or
marketing material relating to the notes constitutes a prospectus or a similar communication as such terms are understood pursuant to articles 35 et seqq. and article 69 of the FinSA. Each Underwriter has represented and agreed that it has not
offered, sold or advertised and will not offer, sell or advertise, directly or indirectly, notes in or into Switzerland, and that it has not distributed, or otherwise made available, and will not distribute or otherwise make available, this
prospectus supplement or any other offering or marketing material relating to the notes publicly in Switzerland, except in reliance on the exemption of article 36 paragraph 1 subsection c FinSA (minimum investment size of CHF 100,000 per investor).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taiwan Legal Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes may
be made available for purchase outside Taiwan by investors residing in Taiwan (either directly or through properly licensed Taiwan intermediaries acting on behalf of such investors) but may not be offered or sold in Taiwan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The notes are new issues of securities for which there are currently no trading markets. Although one or more of the underwriters may make
markets in the notes, they are not obligated to do so and may discontinue their market-making activities at any time without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application has been made to Euronext Dublin for the Euro notes to be admitted to the Official List and trading on the Global Exchange Market
which is the exchange regulated market of Euronext Dublin. The Global Exchange Market is not a regulated market for the purposes of MiFID II. You should note, however, that there is currently no trading market for the Euro notes, and we cannot
assure you that an active or liquid market for the Euro notes will develop. The USD notes will not be listed on any securities exchange or included in any automated quotation system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If active markets for the notes fails to develop or be sustained, the trading prices of the notes could fall, and even if active trading
markets were to develop, the notes could trade at prices that may be lower than their respective initial offering prices. The trading prices of the notes will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prevailing interest rates and interest rate volatility; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the markets for similar securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition, results of operations and prospects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the publication of earnings estimates or other research reports and speculation in the press or investment
community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated results of acquisitions and divestitures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in our industry and competition; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general market and economic conditions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, we cannot assure you that you will be able to sell the notes at attractive
prices or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. From time to time, the Underwriters and their respective
affiliates have directly and indirectly provided investment and/or commercial banking services to us or our affiliates, and may do so in the future, for which they have received customary compensation and expense reimbursement, including, but not
limited to, serving as financial advisors to us and assisting in obtaining financing and acting as lenders under our credit facilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of the Underwriters or their affiliates are lenders, agents, arrangers and/or bookrunners under the Sustainability-Linked Revolving
Credit Agreement and/or holders of our senior notes, including the Tender Offer Notes. To the extent we use the net proceeds of this offering to reduce indebtedness outstanding under our Sustainability-Linked Revolving Credit Agreement or our senior
notes, including the Tender Offer Notes, such Underwriters or their affiliates may receive a portion of the net proceeds from this offering (in excess of any Underwriters&#146; discounts, if applicable). BNP PARIBAS, BofA Securities Europe SA, HSBC
Continental Europe, Intesa Sanpaolo S.p.A. and J.P. Morgan SE, or their respective affiliates, are acting as the dealer managers for the Tender Offer. The Underwriters will receive a fee in a customary amount in connection with the Tender Offer
pursuant to the Underwriting Agreement. For more information on the Tender Offer, see &#147;Summary&#151;Recent Developments&#151;Tender Offer.&#148; Additionally, certain of the Underwriters that have a lending relationship with us and their
respective affiliates routinely hedge, and certain other of the Underwriters and their respective affiliates may hedge, their credit exposure to us consistent with their customary risk management policies. Typically, these Underwriters and their
respective affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, which may include
the notes offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the notes offered hereby. Additionally, certain of the Underwriters or their affiliates had previously been included as <FONT
STYLE="white-space:nowrap">co-defendants</FONT> in certain of the shareholder litigation to which we are subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course
of their various business activities, the Underwriters and their respective affiliates may make or hold a broad array of investments, including serving as counterparties to certain derivative and hedging arrangements, and actively trade debt and
equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or
instruments of Teva or the Issuers, including the Tender Offer Notes. The Underwriters and their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or
instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_14"></A>LISTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Application has been made to
Euronext Dublin for the Euro notes to be admitted to the Official List and trading on the Global Exchange Market which is the exchange regulated market of Euronext Dublin. The Global Exchange Market is not a regulated market for the purposes of
MiFID II. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arthur Cox Listing Services Limited is acting solely in its capacity as listing agent for us in connection with the Euro notes
and is not itself seeking admission of the Euro notes to trading on the Global Exchange Market of Euronext Dublin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no
material adverse change in our prospects since December&nbsp;31, 2024, which is the date to which our most recent audited financial statements have been made publicly available. There has been no significant change in the financial or trading
position of Teva, Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V., Teva Pharmaceutical Finance IV B.V. or Teva since March&nbsp;31, 2025. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ISINs, Common Codes and CUSIPs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Euro notes have been accepted for clearance through Euroclear and Clearstream. The ISIN of the Euro notes is&#8195;&#8195;&#8195;&#8195;.
The common code of the Euro notes is&#8195;&#8195;&#8195;&#8195;. The address of Euroclear is 1 Boulevard du Roi Albert II, <FONT STYLE="white-space:nowrap">B-1210</FONT> Brussels, Belgium and the address of Clearstream is 42 Avenue JF Kennedy, <FONT
STYLE="white-space:nowrap">L-1855</FONT> Luxembourg. The USD notes have been accepted for clearance through DTC. The ISIN of the 2032 USD notes is&#8195;&#8195;&#8195;&#8195;and the CUSIP of the 2032 USD notes is&#8195;&#8195;&#8195;&#8195;. The
ISIN of the 2030 USD notes is&#8195;&#8195;&#8195;&#8195;and the CUSIP of the 2030 USD notes is&#8195;&#8195;&#8195;&#8195;. The address of DTC is 55 Water Street, 25th Floor, New York, New York 10041. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Available Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long
as the Euro notes are listed on the Official List of Euronext Dublin and admitted to trading on the Global Exchange Market hard copies of the following documents will be available for inspection from our registered office and the specified office of
the trustee: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva Pharmaceutical Finance Netherlands II B.V.&#146;s, Teva Pharmaceutical Finance Netherlands III B.V.&#146;s
and Teva Pharmaceutical Finance IV B.V.&#146;s constitutional documents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Teva&#146;s most recently published consolidated audited annual financial statements, including for the years
ended December&nbsp;31, 2024 and 2023, together with the audit reports issued in connection therewith. We currently file with the SEC and make publicly available audited consolidated accounts on an annual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the senior indentures (including the guarantees); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any supplemental indentures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_15"></A>CERTAIN INSOLVENCY LAW CONSIDERATIONS; LIMITATIONS ON
VALIDITY AND ENFORCEABILITY OF THE NOTES AND THE INDENTURES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of certain insolvency and other legal
considerations in the jurisdiction in which each Issuer is incorporated, and a summary of certain limitations on the validity and enforceability of the notes and the indentures. The description is only a summary and does not purport to be complete
or to discuss all of the limitations or considerations that may affect the validity or enforceability of the notes and the applicable indenture. In addition, the laws of more than one jurisdiction could potentially apply in respect of certain
matters and laws in multiple jurisdictions could result in disputes over which jurisdiction&#146;s law should apply, which could adversely affect your rights and your ability to enforce your rights and collect payment in full under the notes and the
applicable indenture. Prospective investors in the notes should consult their own legal advisors with respect to all such limitations and considerations. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Union </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Issuer is a company
incorporated under the laws of a Member State or Member States of the European Union (in this section references to Member States relate to member states of the European Union excluding Denmark), and in this case under the laws of the Netherlands.
The below guidance as to centre of main interests and any cross-border proceedings within the EU should be construed as a description of the current law as at the date of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Regulation (EU) 2015/848 of the European Parliament and of the Council of 20&nbsp;May 2015 on insolvency proceedings (recast), as
amended (the &#147;EU Insolvency Regulation&#148;), which applies within all Member States, the courts of the Member State in which a company&#146;s &#147;centre of main interests&#148; (&#147;COMI&#148;) (which according to Article 3(1) of the EU
Insolvency Regulation is &#147;the place where the debtor conducts the administration of its interests on a regular basis and which is ascertainable by third parties&#148;) is situated shall have jurisdiction to commence main insolvency proceedings
relating to such debtor. The determination of where a debtor has its COMI is a question of fact on which the courts of the different Member States may have differing and even conflicting views. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there is a rebuttable presumption under Article 3(1) of the EU Insolvency Regulation that a debtor has its COMI in the Member State
in which it has its registered office in the absence of proof to the contrary (which presumption shall not apply if the registered office has been moved to another Member State within the three-month period prior to the request for the opening of
insolvency proceedings), Article 3(1), second sentence, of the EU Insolvency Regulation states that the COMI &#147;shall be the place where the debtor conducts the administration of its interests on a regular basis and which is ascertainable by
third parties.&#148; The courts have taken into consideration a number of factors in determining the COMI of a debtor, including, in particular, where board meetings are held, the location where the debtor conducts the majority of its business or
has its head office and the location where the majority of the debtor&#146;s creditors are established. Recital 30 of the EU Insolvency Regulation states that the presumption should be rebutted where the company&#146;s central administration is
located in a Member State other than that of its registered office, and where a comprehensive assessment of all the relevant factors establishes, in a manner that is ascertainable by third parties, that the company&#146;s actual centre of management
and supervision and of the management of its interests is located in that other Member State. A debtor&#146;s COMI is not a static concept and may change from time to time but is determined for the purposes of deciding which courts have competent
jurisdiction to commence insolvency proceedings at the time of the filing of the insolvency petition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the COMI of a debtor is and will
remain located in the state in which it has its registered office, the main insolvency proceedings in respect of the debtor under the EU Insolvency Regulation would be commenced in such jurisdiction and accordingly a court in such jurisdiction would
be entitled to commence the types of insolvency proceedings referred to in Annex A to the EU Insolvency Regulation. Insolvency proceedings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commenced in one Member State under the EU Insolvency Regulation are to be recognized in the other EU Member States, although territorial (secondary) insolvency proceedings may be commenced in
another Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the COMI of a debtor is in a Member State, under Article 3(2) of the EU Insolvency Regulation, the courts of
another Member State have jurisdiction to commence territorial (secondary) insolvency proceedings against that debtor only if such debtor has an &#147;establishment&#148; (within the meaning and as defined in Article 2(10) of the EU Insolvency
Regulation) in the territory of such other Member State. An &#147;establishment&#148; is defined to mean &#147;any place of operations where a debtor carries out or has carried out in the <FONT STYLE="white-space:nowrap">3-month</FONT> period prior
to the request to open main insolvency proceedings a <FONT STYLE="white-space:nowrap">non-transitory</FONT> economic activity with human means and assets.&#148; Accordingly, the opening of territorial (secondary) insolvency proceedings in another EU
Member State will also be possible if the debtor had an establishment in such EU Member State in the three-month period prior to the request for commencement of main insolvency proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effects of those territorial proceedings are restricted to the assets of the debtor situated in the territory of such other Member State.
Where main proceedings in the Member State in which the debtor has its COMI have not yet been commenced, territorial insolvency proceedings may only be commenced in another Member State where the debtor has an establishment where either
(i)&nbsp;insolvency proceedings cannot be commenced in the Member State in which the debtor&#146;s COMI is situated because of the conditions laid down by that Member State&#146;s law; or (ii)&nbsp;the opening of territorial insolvency proceedings
is requested by (i)&nbsp;a creditor whose claim arises from or is in connection with the operation of an establishment situated within the territory of the Member State where the opening of territorial proceedings is requested, or (ii)&nbsp;a public
authority which, under the law of the Member State within the territory of which the establishment is situated, has the right to request the opening of insolvency proceedings. Irrespective of whether the insolvency proceedings are main or secondary
insolvency proceedings, such proceedings will, subject to certain exceptions, be governed by the <I>lex fori concursus</I>, i.e., the local insolvency law of the court that has assumed jurisdiction over the insolvency proceedings of the debtor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The courts of all Member States must recognize the judgment of the court commencing main proceedings, which will be given the same effect in
the other Member States so long as no secondary proceedings have been commenced there. The insolvency administrator appointed by a court in a Member State which has jurisdiction to commence main proceedings (because the debtor&#146;s COMI is there)
may exercise the powers conferred on it by the laws of that Member State in another Member State (such as to remove assets of the debtor from that other Member State) subject to certain limitations, as long as no insolvency proceedings have been
commenced in that other Member State or no preservation measures have been taken to the contrary further to a request to commence insolvency proceedings in that other Member State where the debtor has assets. The EU Insolvency Regulation has created
a treatment for groups of companies experiencing difficulties by the commencement of group coordination proceedings and the appointment of an insolvency practitioner in order to facilitate the effective administration of the insolvency proceedings
of the group&#146;s members. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effects of EU Directive 2019/1023 on Restructuring and Insolvency </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2019, the Directive (EU) 2019/1023 of the European Parliament and the Council of June&nbsp;20, 2019, on preventive
restructuring frameworks, on discharge of debt and disqualifications, and on measures to increase the efficiency of procedures concerning restructuring, insolvency and discharge of debt, and amending Directive (EU) 2017/1132 (&#147;EU Restructuring
Directive&#148;) entered into force. The Member States were required to pass national laws to implement the directive by July&nbsp;17, 2021, at the latest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU Restructuring Directive aims to harmonize the laws and procedures of Member States concerning preventive restructurings and
insolvencies, to put in place key principles for all member states on effective preventive restructuring and second chance frameworks, and measures to make all types of insolvency procedures more efficient by reducing their length and associated
costs and improving their quality. The key feature of the EU Restructuring Directive is the introduction of a preventive restructuring framework. The EU Restructuring Directive sets out minimum EU standards to be applied by the Member States (i.e.,
minimum </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
harmonization). Whereas certain features of the EU Restructuring Directive need to be transposed into national legislation, the EU Restructuring Directive left a large degree of discretion
regarding the implementation of certain other features. In particular, when implementing the EU Restructuring Directive, Member States were required to ensure that, under their national laws, companies will have access to a <FONT
STYLE="white-space:nowrap">pre-insolvency</FONT> restructuring framework which permits a haircut of debt and other restructuring measures on the basis of a majority vote with a majority of not more than 75% of the amount of claims in each class and
where applicable a majority by numbers (meaning, for instance, that an opposing creditor can be outvoted by the majority). The EU Restructuring Directive also provides for cross-class cramdown, i.e., even if the creditors of one class voting on the
restructuring plan did not consent to the restructuring plan with the required majority, the restructuring plan might still be adopted and take effect for the dissenting creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the EU Restructuring Directive provides for a stay on enforcement, which needed to be transposed into national legislation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of the EU Restructuring Directive into national legislation in some cases also includes priority ranking for new financing.
Although the EU Restructuring Directive foresees a number of safeguards protecting creditors from abuse and although the EU Restructuring Directive has been implemented differently in individual Member States, the change to the domestic insolvency
law of some Member States might have considerable repercussions for the position of creditors of a Member State legal entity. The description of the current Member State domestic insolvency regimes must, therefore, be read carefully. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Netherlands </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where debtors have their
COMI or an &#147;establishment&#148; in the Netherlands they may become subject to Dutch insolvency proceedings governed by Dutch insolvency laws. This is particularly relevant to the Issuers which are all incorporated under the laws of the
Netherlands and have their statutory seat (<I>statutaire zetel</I>) in the Netherlands, and which are therefore presumed (subject to proof to the contrary and exceptions under the EU Insolvency Regulation) to have their COMI in the Netherlands. See
further &#147;&#151;<I>European Union</I>&#148; above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dutch insolvency laws differ significantly from insolvency proceedings in the U.S.
and other jurisdictions, and may make it more difficult for you to recover the amount you would normally expect to recover in a liquidation or bankruptcy proceeding in the U.S. or another jurisdiction. There are circumstances under Dutch insolvency
law in which the granting by an Issuer of security and guarantees can be challenged. The following is a brief description of certain aspects of the Dutch insolvency laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are two insolvency regimes under Dutch law in relation to corporations. The first, a suspension of payments (surseance <I>van
betaling</I>), is intended to facilitate the reorganization of a debtor&#146;s debts and enable the debtor to continue as a going concern. The second, bankruptcy (<I>faillissement</I>), is primarily designed to liquidate the assets of a debtor and
distribute the proceeds thereof to its creditors. In practice a suspension of payments often results in the bankruptcy of the debtor. Both insolvency regimes are set forth in the Dutch Bankruptcy Act (<I>Faillissementswet</I>). A general description
of the principles of both insolvency regimes is set out below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the debtor can make an application for a suspension of payments, and
only if it foresees that it will be unable to continue to pay its debts as they fall due. Once the application has been filed, a court will immediately (<I>dadelijk</I>) grant a provisional suspension of payments and appoint one or more
administrators (<I>bewindvoerders</I>). A meeting of creditors is required to decide on the definitive suspension of payments. If a draft composition (<I>ontwerp akkoord</I>) is filed simultaneously with the application for a moratorium of payments,
the court can order that the composition will be processed before a decision about a definitive moratorium. If the composition is accepted and subsequently ratified by the court (<I>gehomologeerd</I>), the provisional moratorium ends. The definitive
moratorium will generally be granted, unless a qualified minority (meaning, more than <FONT STYLE="white-space:nowrap">one-quarter</FONT> of the amount of claims held by creditors represented at the creditors&#146; meeting or more than <FONT
STYLE="white-space:nowrap">one-third</FONT> of the number of creditors of the amount of claims held by creditors) of the unsecured, <FONT STYLE="white-space:nowrap">non-preferential,</FONT> creditors declare
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against it or if there is a valid fear that the debtor will try to prejudice the creditors during a suspension of payments or if there is no prospect that the debtor will be able to satisfy its
creditors in the (near) future. That the debtor must be able to satisfy its creditors does not mean that they must be paid in full. It suffices that creditors can be satisfied to some extent (for example, by receiving a percentage of their claims
within the framework of a composition). Other than in the case of the ordering by a competent court of a statutory stay of execution of up to two months (extendable by another period of up to two months) imposed by court order, a suspension of
payments will only affect unsecured, <FONT STYLE="white-space:nowrap">non-preferential</FONT> creditors. During such stay of execution, a secured creditor may not, without the court&#146;s consent (i)&nbsp;claim the asset subject to the security
right if it is under the control of (<I>in de macht van</I>) the debtor subject to a suspension of payments or (ii)&nbsp;seek recourse against the asset. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Dutch law, a debtor can be declared bankrupt when it has ceased to pay its debts. Bankruptcy can be requested by a creditor of the
debtor or the holder of a security interest over a claim from such creditor, when there is at least one other creditor. At least one of the claims (of the creditor requesting bankruptcy or the other creditor) needs to be due and payable. Bankruptcy
can also be declared in certain circumstances when a debtor is subject to a suspension of payments. The debtor can also request the application of bankruptcy proceedings itself, provided it has obtained prior approval of its general meeting to file
an application for its own bankruptcy. The articles of association of the debtor can preclude the necessity of such general meeting approval. Furthermore, the Public Prosecution Service (<I>het Openbaar Ministerie</I>) can request the application of
bankruptcy proceedings for reasons of public interest (<I>openbaar belang</I>). In Dutch bankruptcy proceedings, a debtor&#146;s assets are generally liquidated and the proceeds distributed to the debtor&#146;s creditors according to the relative
priority of those creditors&#146; claims and, to the extent certain creditors&#146; claims have equal priority, in proportion to the amount of such claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain parties, such as secured creditors, can benefit from special rights. Secured creditors, such as pledgees and mortgagees, may enforce
their rights separately from bankruptcy and do not have to contribute to the liquidation costs; however, enforcement of the security interest might be subject to the following: (i)&nbsp;a statutory stay of execution of up to two months (extendable
by another period of up to two months) imposed by court order pursuant to Article 63a of the Dutch Bankruptcy Act (which may be a total period of eight months if the similar statutory stay of execution under Article 241a of the Dutch Bankruptcy Act
(referred to above) is first applied during suspension of payments), which has the same effects as set forth above for stays of execution in suspensions of payment; (ii)&nbsp;a receiver in bankruptcy (<I>curator</I>) can force a secured party to
foreclose its security interest within a reasonable time (as determined by the receiver in bankruptcy pursuant to Article 58(1) of the Dutch Bankruptcy Act), failing which the receiver in bankruptcy will be entitled to sell the relevant rights or
assets and distribute the proceeds to the secured party after a deduction of liquidation costs; and (iii)&nbsp;excess proceeds of enforcement must be returned to the company&#146;s receiver in bankruptcy and may not be offset against an unsecured
claim of the company&#146;s secured creditor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A suspension of payment and bankruptcy proceedings against Dutch debtors would allow
secured creditors (and in the case of suspension of payments also preferential creditors (including tax and social security authorities)) to satisfy their claims by proceeding against the assets (that secure their claims) as if there were no
bankruptcy or suspension of payments. However, a statutory stay of execution as described above may be ordered by the competent court both in a suspension of payments and bankruptcy. Furthermore, certain preferred creditors have a preference by
virtue of law. Unlike secured creditors, preferred creditors are not entitled to foreclose on assets of the bankrupt. They do have priority in the distribution of the proceeds of the bankrupt debtor&#146;s assets. Restrictions on the enforcement of
security interests may apply. For instance, higher ranking rights must be respected. These may include secured creditors and tax and social security authorities. A statutory stay of execution of security rights and other rights, as described above,
may be imposed. Furthermore, a receiver in bankruptcy can force a secured creditor to enforce its security right within a reasonable period of time, failing which the receiver in bankruptcy will be entitled to sell the secured assets, if any, and
the secured creditor will have a preferred claim in respect of the proceeds, meaning that the secured creditor will have to share in the bankruptcy costs, which may be significant. Excess proceeds of any enforcement must be returned to the bankrupt
estate; they may not be set off against an unsecured claim of the secured creditor. Such <FONT STYLE="white-space:nowrap">set-off</FONT> may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allowed prior to the bankruptcy, although at that time it may be subject to clawback in the case of fraudulent conveyance or bad faith in obtaining the claim used for the <FONT
STYLE="white-space:nowrap">set-off.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any pending executions of judgments against the debtor will be suspended by operation of law
when a suspension of payments is granted, and will terminate by operation of law when bankruptcy is declared. In addition, all attachments on the debtor&#146;s assets will cease to have effect upon the suspension of payments having become
definitive, a composition having been ratified by the court or the declaration of bankruptcy (as the case may be) subject to the ability of the court to set an earlier date for such termination. Litigation pending on the date of the bankruptcy order
is automatically stayed. Both a suspension of payments and bankruptcy have retroactive effect from 00.00 hours of the day on which the suspension of payments or the bankruptcy of the relevant Dutch company is declared. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both in a definitive suspension of payments and bankruptcy, a composition (<I>akkoord</I>) may be offered to creditors. A composition will be
binding for all unsecured and <FONT STYLE="white-space:nowrap">non-preferential</FONT> creditors if it is: (i)&nbsp;approved by a simple majority (<I>gewone meerderheid</I>) of the number of creditors represented at the creditors&#146; meeting,
representing at least 50% of the amount of the claims that are acknowledged and conditionally admitted; and (ii)&nbsp;subsequently ratified (<I>gehomologeerd</I>) by the court. Consequently, Dutch insolvency law could preclude or inhibit the ability
of the holders of the notes to effect a restructuring and could reduce the recovery of a holder of notes in a Dutch suspension of payments proceeding or bankruptcy. Interest accruing on and after the date on which a suspension of payments or
bankruptcy is granted cannot be claimed in a composition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All unsecured, <FONT STYLE="white-space:nowrap">pre-bankruptcy</FONT> claims
will have to be verified in the insolvency proceedings in order to be entitled to vote and, in a bankruptcy liquidation, entitled to distributions. If the bankruptcy has ended with a composition, a claim that has not been submitted for verification
within the deadline set therefore can no longer be enforced. Any remaining funds will be distributed to the company&#146;s shareholders. &#147;Verification&#148; under Dutch law means, in the case of a suspension of payments, that the treatment of a
disputed claim for voting purposes is determined and, in the case of a bankruptcy, the unsecured, <FONT STYLE="white-space:nowrap">pre-bankruptcy</FONT> claims are submitted to the receiver in bankruptcy for verification, and the receiver in
bankruptcy then makes a determination as to the claim&#146;s existence, ranking and value and whether and to what extent it should be admitted in the bankruptcy proceedings (for voting). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In case of bankruptcy, creditors who wish to dispute the receiver in bankruptcy&#146;s verification of their claims will be referred to a
claim validation proceeding (<I>renvooiprocedure</I>) in order to establish the amount and rank of the disputed claim, while in a suspension of payments the court will decide how a disputed claim will be treated for voting purposes. These procedures
could cause holders of notes to recover less than the principal amount of their notes or less than they could recover in a U.S. liquidation proceeding. The claim validation (<I>renvooi) </I>proceedings could also cause payments to the holders of
notes to be delayed. The claim of a creditor, other than a claim to the extent that it is secured by Dutch law security, may be limited depending on the date the claim becomes due and payable in accordance with its terms. Claims that fall due more
than one year after the date of the bankruptcy, will be valued for distribution purposes for fair value as per the date one year after the bankruptcy was declared. Claims that become payable within one year after the bankruptcy was declared will be
considered payable from the day the bankruptcy was declared. Interest on claims accruing after the bankruptcy order date cannot be admitted unless secured by a pledge or mortgage, in which case interest will be admitted <I>pro memoria</I>, such as
in case of the notes. To the extent that interest is not covered by the proceeds of the security, the creditor may not derive any rights from the admission. No interest is payable in respect of unsecured claims as of the date of a bankruptcy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Dutch Scheme </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the entry
into force of the Act on Court Confirmation of Extrajudicial Restructuring Plans (<I>Wet homologatie onderhands </I>akkoord) (&#147;<B>CERP</B>&#148;) on 1&nbsp;January 2021, debtors now have the possibility to offer a composition outside bankruptcy
or moratorium of payments proceedings. The CERP provides for a proceeding to restructure debts of companies in financial distress outside insolvency proceedings (the &#147;<B>Dutch Scheme</B>&#148;). The
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
CERP provides that a debtor or a court-appointed restructuring expert may offer creditors (including secured creditors) and shareholders a composition plan. Upon confirmation by the court, such
plan is binding on the creditors and shareholders to which it has been offered and changes their rights. A composition plan under the CERP can also extend to claims against group companies of the debtor on the account of securities and guarantees
for the debtor&#146;s obligations, if <I>inter alia </I>(i)&nbsp;the relevant group companies are reasonably expected to be unable to continue to pay their debts as they fall due and (ii)&nbsp;the Dutch courts would have jurisdiction if the relevant
group company would offer its creditors and shareholders a composition plan under the CERP. Jurisdiction of the Dutch courts under the CERP may extend to entities incorporated or residing outside the Netherlands on the basis that there is a
connection with the jurisdiction of the Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CERP, voting on a composition plan is done in classes. Approval by a class
requires a decision adopted with a majority of <FONT STYLE="white-space:nowrap">two-third</FONT> of the claims of that class that have voted on the plan or, in the case of a class of shareholders, <FONT STYLE="white-space:nowrap">two-thirds</FONT>
of the shares of that class that have voted on the plan. The CERP provides for the possibility for a composition plan to be binding on a <FONT STYLE="white-space:nowrap">non-consenting</FONT> class (cross-class cram down). Under the CERP, the court
will confirm a composition plan if at least one class of creditors (other than a class of shareholders) that can be expected to receive a distribution in case of a bankruptcy of the debtor approves the plan, unless there is a ground for refusal. The
court can, <I>inter alia</I>, refuse confirmation of a composition plan on the basis of (i)&nbsp;a request by an affected creditor of a consenting class if the value of the distribution that such creditor receives under the plan is lower than the
distribution it can be expected to receive in case of a bankruptcy of the debtor or (ii)&nbsp;a request of an affected creditor of a <FONT STYLE="white-space:nowrap">non-consenting</FONT> class, if the plan provides for a distribution of value that
deviates from the statutory or contractual ranking and priority to the detriment of that class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CERP, the court may grant a
stay on enforcement of a maximum of 4 months, with a possible extension of 4 months. During such period, <I>inter alia</I>, all enforcement action against the assets of (or in the possession of) the debtor is suspended, including action to enforce
security over the assets of the debtor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, during such stay a pledgee of claims may not collect nor notify the debtors of such
pledged claims of its rights of pledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CERP, claims of creditors against the Issuers can be compromised as a result of a
composition plan adopted and confirmed in accordance with the CERP. A composition plan under the CERP can extend to claims against entities that are not incorporated under Dutch law and/or are residing outside the Netherlands. Accordingly, the CERP
can affect the rights of the trustee and/or the holders of the notes under the indentures and therefore the notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_16"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters with respect to United States and New York law with respect to the validity of the notes offered by this prospectus
supplement will be passed upon for the Issuers by Kirkland&nbsp;&amp; Ellis LLP, New&nbsp;York, New York. Certain legal matters with respect to Israeli law with respect to the validity of the notes offered by this prospectus supplement will be
passed upon for Teva by Agmon with Tulchinsky Law Firm, Israel. Certain legal matters with respect to Dutch law will be passed upon for the Issuers by Van Doorne N.V., Netherlands. Certain legal matters relating to this offering will be passed upon
for the underwriters with respect to United States and New York law, by Baker&nbsp;&amp; McKenzie LLP, London, United Kingdom, and, with respect to Israeli law, by Herzog, Fox&nbsp;&amp; Neeman, Israel. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_17"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included
in the Report of Teva Management on Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2024 have been so incorporated in reliance on the report of Kesselman&nbsp;&amp; Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_18"></A>WHERE YOU CAN FIND MORE INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information that Teva files with or furnishes to the SEC after the date of this prospectus supplement and accompanying prospectus and
through the closing date of this offering, and that is incorporated by reference herein, will automatically update and supersede the information in this prospectus supplement and accompanying prospectus. You should review the SEC filings and reports
that we incorporate by reference to determine if any of the statements in this prospectus supplement and accompanying prospectus or in any documents previously incorporated by reference have been modified or superseded. We file annual and quarterly
reports and other information with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy,
information statements and other material that are filed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval (&#147;EDGAR&#148;) system and filed electronically with the SEC. We began filing through the EDGAR system on
October&nbsp;31, 2002. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our American Depositary Shares are quoted on the New York Stock Exchange under the symbol &#147;TEVA.&#148; You
may inspect certain reports and other information concerning us at the offices of the Financial Industry Regulatory Authority, 1735 K Street, N.W., Washington, D.C. 20006. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available on our website at http://www.tevapharm.com. Such information on our website is not part of this
prospectus supplement or the accompanying prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom830217_19"></A>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of the SEC allow us to incorporate by reference information into this prospectus supplement and the accompanying
prospectus. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus, and information that we file later with the SEC will automatically update and supersede this information.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents filed with the SEC are incorporated into this prospectus supplement
and the accompanying prospectus by reference: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0000818686/000119312525020826/d865574d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed on February&nbsp;5, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/818686/000119312525114889/d907688d10q.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the period ended March&nbsp;31, 2025, filed on May&nbsp;7, 2025; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all documents (other than current reports furnished under Items 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date hereof and until this
offering is completed, which shall be deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for
purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in this prospectus supplement and the accompanying prospectus or in any other subsequently filed document which is incorporated or deemed
to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement and the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also obtain copies of these documents free of charge by contacting us at our address or telephone number set forth
below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Teva Pharmaceutical Industries Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 Dvora
HaNevi&#146;a Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Tel Aviv, 6944020, Israel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-914-8213</FONT></FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>American Depositary Shares, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>each representing one Ordinary Share, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase Contracts and Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE IV, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE V, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE VI, LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS IV B.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Debt Securities, fully and unconditionally guaranteed by </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Teva Pharmaceutical Industries Limited and its finance subsidiaries (&#147;Teva,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148;
or &#147;our&#148;) may offer and sell from time to time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">American Depositary Shares (&#147;ADSs&#148;), each representing one ordinary share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">senior or subordinated debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">purchase contracts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">units. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">This prospectus describes some of the general terms that may apply to the securities. Teva will provide the specific terms and public offering
prices of these securities in supplements to this prospectus. Before investing, you should carefully read this prospectus and any related prospectus supplement, including any document incorporated or deemed incorporated by reference into this
prospectus or any prospectus supplement. The prospectus supplements may also add, update or change information contained in this prospectus. Our registration of securities covered by this prospectus does not mean that we will offer or sell any
securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">We may sell these securities to or through one or more underwriters, dealers or agents, or directly to purchasers, on a
continuous or delayed basis. The names of any underwriters, dealers or agents will be stated in a supplement to this prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our ADSs
are quoted on the New York Stock Exchange (the &#147;NYSE&#148;) under the symbol &#147;TEVA.&#148; On February&nbsp;6, 2025, the last reported sale price for the ADSs on the NYSE was $17.29. If we decide to list any of these securities on a
national securities exchange upon issuance, the applicable prospectus supplement to this prospectus will identify the exchange and the date when we expect trading to begin. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Our principal executive offices are located at 124 Dvora Hanevi&#146;a Street, Tel Aviv, 6944020, Israel, and our telephone number is <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+972-3-914-8213</FONT></FONT></FONT>


<IMG SRC="g830217g84p82.jpg" ALT="LOGO" STYLE="width:0.141368in;height:0.141368in;">
. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>You should carefully read this prospectus and any accompanying prospectus supplement, together with the documents incorporated by reference
herein and therein, and any free writing prospectus, before you make an investment decision. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Investing in our securities involves risks. You should consider the risk factors described in any accompanying prospectus supplement and the
documents we incorporate by reference. See &#147;<A HREF="#tx830217_4">Risk Factors</A>&#148; on page 4 of this prospectus. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is February&nbsp;7, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_2">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_3">FINANCE SUBSIDIARIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_5">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_7">DESCRIPTION OF ORDINARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_8">DESCRIPTION OF AMERICAN DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_9">DESCRIPTION OF DEBT SECURITIES AND GUARANTEES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_10">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_11">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_12">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_13">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_15">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_16">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx830217_17">ENFORCEMENT OF CIVIL LIABILITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a shelf registration statement (the &#147;Registration Statement&#148;) that Teva and the other registrants filed
with the United States Securities and Exchange Commission (the &#147;SEC&#148;) as a &#147;well-known seasoned issuer&#148; as defined in Rule&nbsp;405 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), utilizing a
&#147;shelf&#148; registration process. Under this shelf process, any of the registrants may, from time to time, sell the securities described in this prospectus in one or more offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities which we may offer and the related guarantees, if any, of those
securities. Each time we sell securities we will provide a prospectus supplement that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this
prospectus. You should read both this prospectus and any prospectus supplement together with additional information described below under the heading &#147;Where You Can Find More Information&#148; before purchasing any of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide any information or to make any representation other than those contained or incorporated by reference
in this prospectus. &#147;Incorporated by reference&#148; means that we can disclose important information to you by referring you to another document filed separately with the SEC. We have not authorized any other person to provide you with
different information. We are not responsible for, and can provide no assurance as to the reliability of, any information that others may give to you. We are not making, and we will not make, an offer to sell securities in any jurisdiction where the
offer or sale is not permitted. You should assume that the information appearing in this prospectus and any supplement to this prospectus is current only as of the dates on their respective covers. Our business, financial condition, results of
operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, references in this prospectus and any
supplement to this prospectus to &#147;Teva,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Teva Pharmaceutical Industries Limited and its subsidiaries, collectively. References to &#147;Teva Finance IV LLC&#148; refer to Teva
Pharmaceutical Finance IV, LLC. References to &#147;Teva Finance V LLC&#148; refer to Teva Pharmaceutical Finance V, LLC. References to &#147;Teva Finance VI LLC&#148; refer to Teva Pharmaceutical Finance VI, LLC. References to the &#147;LLCs&#148;
refer to Teva Finance IV LLC, Teva Finance V LLC and Teva Finance VI LLC. References to &#147;Teva Finance Netherlands II&#148; refer to Teva Pharmaceutical Finance Netherlands II B.V. References to &#147;Teva Finance Netherlands III&#148; refer to
Teva Pharmaceutical Finance Netherlands III B.V. References to &#147;Teva Finance Netherlands IV&#148; refer to Teva Pharmaceutical Finance Netherlands IV B.V. References to the &#147;Netherlands BVs&#148; refer to Teva Finance Netherlands II, Teva
Finance Netherlands III and Teva Finance Netherlands IV. References to the &#147;finance subsidiaries&#148; refer to the LLCs, and the Netherlands BVs, collectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_2"></A>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Business Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a global
pharmaceutical company, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery and expanded development of modern medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the
world. Today, our global network of capabilities enables our approximately 37,000 employees across 57 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes for millions of patients
every day. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva was incorporated in Israel on February&nbsp;13, 1944 and is the successor to a number of Israeli corporations, the oldest
of which was established in 1901. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business Segments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We operate our business through three segments: United States (previously referred to as the North America segment), Europe and International
Markets. Each business segment manages our entire product portfolio in its region, including generics, which includes biosimilars
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;over-the-counter&nbsp;(&#147;OTC&#148;)</FONT></FONT> products, as well as innovative medicines. This structure enables strong alignment and integration between operations,
commercial regions, R&amp;D and our global marketing and portfolio function, optimizing our product lifecycle across therapeutic areas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these three segments, we have other activities, primarily the sale of active pharmaceutical ingredients (&#147;API&#148;) to
third parties, certain contract manufacturing services and <FONT STYLE="white-space:nowrap">an&nbsp;out-licensing&nbsp;platform</FONT> offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_3"></A>FINANCE SUBSIDIARIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva has organized various finance subsidiaries for the purpose of issuing debt securities. There are no separate financial statements of the
finance subsidiaries in this prospectus because these entities are, or will be treated as, subsidiaries of Teva for financial reporting purposes. We do not believe the financial statements would be helpful to the holders of the securities of these
entities because: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Teva is a reporting company under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)
and owns, directly or indirectly, all of the voting interests of these entities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these entities do not have any independent operations and do not propose to engage in any activities other than
issuing securities and investing the proceeds in Teva or its affiliates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">these entities&#146; obligations under the securities will be fully and unconditionally guaranteed by Teva. These
entities are exempt from the information reporting requirements of the Exchange Act. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance IV LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance IV LLC is a limited liability company that was formed on December&nbsp;1, 2008 under the Delaware Limited Liability Company Act,
as amended. Its address is 400 Interpace Parkway, Building A, Parsippany, NJ 07054, telephone number (800) <FONT STYLE="white-space:nowrap">545-8800.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance V LLC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance V
LLC is a limited liability company that was formed on December&nbsp;1, 2011 under the Delaware Limited Liability Company Act, as amended. Its address is 400 Interpace Parkway, Building A, Parsippany, NJ 07054, telephone number (800) <FONT
STYLE="white-space:nowrap">545-8800.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance VI LLC </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva Finance VI LLC is a limited liability company that was formed on December&nbsp;1, 2011 under the Delaware Limited Liability Company Act,
as amended. Its address is 400 Interpace Parkway, Building A, Parsippany, NJ 07054, telephone number (800) <FONT STYLE="white-space:nowrap">545-8800.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands II </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva
Finance Netherlands II is a Dutch private limited liability company that was formed on October&nbsp;16, 2013. Its address is Busweg 1, 2031 DA Haarlem, Netherlands, telephone number +31 <FONT STYLE="white-space:nowrap">(0)20-2193000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands III </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva
Finance Netherlands III is a Dutch private limited liability company that was formed on September&nbsp;21, 2015. Its address is Busweg 1, 2031 DA Haarlem, Netherlands, telephone number +31 <FONT STYLE="white-space:nowrap">(0)20-2193000.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands IV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva
Finance Netherlands IV is a Dutch private limited liability company that was formed on April&nbsp;22, 2016. Its address is Busweg 1, 2031 DA Haarlem, Netherlands, telephone number +31 <FONT STYLE="white-space:nowrap">(0)20-2193000.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risk. Please see the risks incorporated by reference from our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> the risk factors described under the caption &#147;Risk Factors&#148; in any applicable prospectus supplement and any risk factors set
forth in our other filings with the SEC. See &#147;Where You Can Find More Information&#151;Incorporation by Reference.&#148; Our business, financial condition, liquidity or results of operations could be materially adversely affected by any of
these risks. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus and any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_5"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure and analysis in this prospectus, including statements that are predictive in nature, or that depend upon or refer to future
events or conditions, contain or incorporate by reference some forward-looking statements within the meaning of Section&nbsp;21E of the Exchange Act and Section&nbsp;27A of the Securities Act, which are based on management&#146;s current beliefs and
expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.
You can identify these forward-looking statements by the use of words such as &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;target,&#148; &#147;may,&#148; &#147;project,&#148; &#147;guidance,&#148;
&#147;intend,&#148; &#147;plan,&#148; &#147;believe&#148; and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance.&nbsp;Important factors that could cause or
contribute to such differences include risks relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully compete in the marketplace, including: that we are substantially dependent on our
generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in additional costs
and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products; competition for our innovative medicines; our ability to achieve expected results from investments in our product
pipeline; our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably
commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and the effectiveness of our patents and other measures to protect our
intellectual property rights, including any potential challenges to our Orange Book patent listings in the U.S.; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional
transactions or make new investments and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our business and operations in general, including: the impact of global economic conditions and other
macroeconomic developments and the governmental and societal responses thereto; the widespread outbreak of an illness or any other communicable disease, or any other public health crisis; effectiveness of our optimization efforts; significant
disruptions of information technology systems, including cybersecurity attacks and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting
business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel; our ability to attract, hire, integrate and retain
highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units
and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory
environments; the effects of governmental and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage;
increased legal and regulatory action in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our
ability to comply with and operate under our deferred prosecution agreement with the U.S. Department of Justice; potential liability for intellectual property right infringement; product liability
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
claims; failure to comply with complex Medicare, Medicaid and other governmental programs reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks;
and the impact of ESG issues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the state of war declared in Israel and the military activity in the region, including the risk of
disruptions to our operations and facilities, such as our manufacturing and R&amp;D facilities, located in Israel, the impact of our employees who are military reservists being called to active military duty, and the impact of the war on the
economic, social and political stability of Israel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as
credit risks; potential impairments of our long-lived assets; the impact of geopolitical conflicts including the state of war declared in Israel and the conflict between Russia and Ukraine; potential significant increases in tax liabilities; the
effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and the impact of any future failure to establish and maintain effective internal control over our
financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements contained or incorporated by reference herein involve a number of
known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. You should
understand that many important factors, in addition to those discussed or incorporated by reference in this prospectus, could cause our results to differ materially from those expressed in the forward-looking statements. Potential factors that could
affect our results, include, in addition to others not described in this prospectus, those referenced under &#147;Risk Factors.&#148; These are factors that we think could cause our actual results to differ materially from our expected results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any
forward-looking statements or other information contained in this prospectus, whether as a result of new information, future events or otherwise, except as may be required by law. You are advised, however, to consult any additional disclosures we
make in our Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our subsequently filed Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> and Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K&nbsp;that</FONT> are filed with the SEC. See &#147;Risk Factors.&#148; Other factors besides those listed here could also adversely affect us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, the net proceeds from the sale of securities offered by Teva or the finance
subsidiaries will be used for general corporate purposes, which may include additions to working capital, investments in or extensions of credit to our subsidiaries and the repayment of indebtedness. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_7"></A>DESCRIPTION OF ORDINARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following is a summary of the terms of Teva ordinary shares, including certain provisions contained in Teva&#146;s memorandum of
association, as amended (the &#147;Memorandum&#148;), Teva&#146;s articles of association, as amended (the &#147;Articles&#148;), and applicable Israeli laws in effect on the date of the Registration Statement of which this prospectus forms a part.
This summary is qualified by reference to the full text of the Memorandum and the Articles, which are incorporated by reference as exhibits hereto. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of Ordinary Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The par
value of Teva&#146;s ordinary shares is NIS 0.10 per share, and all issued and outstanding ordinary shares are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Holders of ordinary shares are entitled to participate equally in
the receipt of dividends and other distributions and, in the event of liquidation, in all distributions after the discharge of liabilities to creditors. All ordinary shares represented by the ADSs will be issued in registered form only. The Israeli
Companies Law, 5759-1999 (the &#147;Companies Law&#148;) and the Articles do not provide for preemptive rights to the holders of Teva&#146;s shares. Each Teva ordinary share entitles the holder thereof to one vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Memorandum nor the Articles or the laws of the State of Israel restrict the ownership or voting of Teva&#146;s ordinary shares or
ADSs by <FONT STYLE="white-space:nowrap">non-residents</FONT> or persons who are not citizens of Israel, except with respect to citizens or residents of countries that are in a state of war with Israel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Shareholder Meetings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Companies Law and the Articles, Teva is required to hold an annual general meeting every calendar year, no later than 15 months after the previous annual general meeting. In addition, Teva is required to convene a special meeting of shareholders as
required under applicable law, provided that a demand by a shareholder to convene a special shareholders meeting must set forth the matters to be considered at the meeting and otherwise comply with all other requirements of applicable law and the
Articles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Board of Directors receives a demand to convene a special meeting satisfying the above conditions, it must announce the
scheduling of the meeting within 21 days after the demand was delivered, subject to the relevant requirements of the Companies Law and the regulations thereunder. If the Board of Directors fails to do so, the party who demanded to convene the
special meeting may convene the meeting itself, subject to the provisions of the Companies Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agenda of a general meeting is
determined by the Board of Directors. The agenda must also include matters for which the convening of a special meeting was demanded, as well as any matter requested by each shareholder who is entitled pursuant to applicable law to submit a proposal
for the agenda of a general meeting. Any such proposal request must be delivered, in person or by certified mail, to Teva&#146;s registered office. Any such demands or requests must comply with the requirements of applicable law, applicable stock
exchange rules and the Articles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, the regulations thereunder and the Articles, Teva is generally required to announce the convening of general
meetings at least 35 days in advance, but is not required to deliver personal notices of a general meeting or of any adjournment thereof to shareholders. Teva may reasonably determine the method of publicizing the convening of general meetings,
including by publishing a notice on its website, in one or more daily newspapers in Israel or in one or more international wire services, by filing the proxy with the SEC, and any such publication will be deemed to have been duly given and delivered
on the date of such publication. Shareholders as of the record date determined in respect of the general meeting are entitled to participate in and vote at the meeting. The Articles require that <FONT STYLE="white-space:nowrap">in-person</FONT>
shareholder meetings shall be convened </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Israel, unless Teva&#146;s center of management has been transferred to another country in accordance with the Articles, provided however that shareholder meetings may be conducted in other
formats (in lieu of or in addition to in person meetings), including a virtual format. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting and Quorum Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The quorum required for a general meeting of shareholders is at least two shareholders present in person or by proxy or represented by an
authorized representative, who jointly hold at least 25% of our <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital. If a meeting is adjourned for lack of a quorum, it will generally be adjourned to the same time and place on the same day
of the following week unless the Board of Directors sets another date, time and place in a notice to all persons who are entitled to receive notice of general meetings. Should no legal quorum be present at such reconvened meeting a half hour
following the time set for such meeting, the necessary quorum consists of any two shareholders present, in person or by proxy, who jointly hold at least 20% of Teva&#146;s <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who intends to vote at a meeting must demonstrate ownership of shares in accordance with the Companies Law and the regulations
promulgated thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Resolutions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law provides that resolutions on certain matters, such as amending a company&#146;s articles of association, exercising the
authority of the Board of Directors in certain circumstances, appointing auditors, approving certain transactions, increasing or decreasing the registered share capital and approving certain mergers, must be approved by the shareholders at a general
meeting. A company may determine in its articles of association certain additional matters with respect to which decisions will be made by the shareholders at a general meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, under the Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights
represented at a general meeting in person or by proxy and voting, unless a different majority is required by law or the Articles. Pursuant to the Companies Law and the Articles, certain shareholder resolutions (for example, resolutions amending
many of the provisions of the Articles) require the affirmative vote of at least 75% of the voting rights represented at a general meeting and voting in person or by proxy, and certain other amendments to the Articles require the affirmative vote of
at least 85% of the voting rights represented in a general meeting voting in person or by proxy, unless the Board of Directors sets a lower percentage, by a supermajority of three-quarters of the voting directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain
exceptions, the Companies Law generally requires that a merger (which, for these purposes, is defined as involving two Israeli companies) be approved by both the Board of Directors and by the shareholders of each of the merging companies and, with
respect to the target company, if its share capital is divided into more than one class, the approval of each class of shares is required (in accordance with the majority and legal quorum requirements set forth in the Companies Law and the
Articles). However, a merger may not be approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (disregarding any abstentions), after excluding the shares held by the other party
to the merger, by any person who holds 25% or more of the other party to the merger or by anyone on their behalf, including the relatives of or corporations controlled by these persons, unless an Israeli court determines otherwise at the request of
shareholders holding at least 25% of the voting rights of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In approving a merger, the Board of Directors of both merging
companies must determine that there is no reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the
proposed merger, an Israeli court may prevent or delay the merger if it concludes that there exists a reasonable concern that, as a result of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merger, the surviving company will not be able to satisfy the obligations of the merging parties. A court may also issue other instructions for the protection of creditors&#146; rights in
connection with a merger. Further, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposals for the approval of the merger were filed with the Israeli Registrar of Companies; and (ii) 30 days
have passed since the merger was approved by the shareholders of each party to the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Law, subject to certain
exceptions, an acquisition of shares in a public company must be made by means of a tender offer if, as a result of the acquisition, the purchaser would hold (i) 25% or more of the voting rights of the company if there is no other holder of 25% or
more of the company&#146;s voting rights; or (ii)&nbsp;more than 45% of the voting rights of the company if there is no other holder of more than 45% of the company&#146;s voting rights. This requirement does not apply to certain events set forth in
the Companies Law, including a purchase of shares by an offeree in a &#147;private placement&#148; that receives specific shareholder approval. The Board of Directors must either give the shareholders its opinion as to the advisability of the tender
offer or explain why it is unable to do so. The Board of Directors must also disclose any personal interest of any of its members in the proposed acquisition. The tender offer may be consummated only if (i)&nbsp;at least 5% of the company&#146;s
voting rights will be acquired; and (ii)&nbsp;the majority of the offerees who responded to the offer accepted the offer, excluding offerees who are controlling shareholders of the offeror, offerees who hold 25% or more of the voting rights in the
company or who have a personal interest in accepting the tender offer, or anyone on their behalf or on behalf of the offeror including the relatives of or corporations controlled by these persons. Notwithstanding the above, a recent amendment to the
regulations promulgated under the Israeli Companies Law provides certain relief to Israeli companies whose shares are listed outside of Israel on certain stock exchanges, including the NYSE (the &#147;Amended Relief Regulations&#148;). The Amended
Relief Regulations provide certain dual-listed Israeli companies whose shares are traded on a stock exchange in Israel and outside of Israel an exemption from the above limitations, but only in circumstances where the law of the foreign country in
which such company is traded restricts the acquisition of control by a certain percentage of the company or if the acquisition of control by a certain percentage of the company obligate the purchaser to provide a tender offer also to shareholders
from the public. Therefore, currently this relief does not apply to companies traded on NYSE. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Law, a person may not
acquire shares in a public company if, after the acquisition, he will hold more than 90% of the shares or more than 90% of any class of shares of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the
particular class, which we refer to as a full tender offer. The Companies Law also generally provides that as long as a shareholder in a public company holds more than 90% of the company&#146;s shares or of a class of shares, that shareholder shall
be precluded from purchasing any additional shares. In order that all of the shares that the purchaser offered to purchase be transferred to the purchaser by operation of law, one of the following must have occurred: (i)&nbsp;the shareholders who
declined or who did not respond to the full tender offer hold less than 5% of the company&#146;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not have a personal interest in accepting the full
tender offer accepted the offer, or (ii)&nbsp;the shareholders who declined or who did not respond to the full tender offer hold less than 2% of the company&#146;s outstanding share capital or of the relevant class of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conditions set forth above are not met, the purchaser may not acquire shares of the company from shareholders who accepted the full
tender offer to the extent that following such acquisition, the purchaser would own more than 90% of the company&#146;s issued and outstanding share capital or more than 90% of the particular class of shares with respect to which the full tender
offer was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder that had his or her shares so transferred, whether he or she accepted the full tender offer or not, has the
right, within six months from the date of acceptance of the full tender offer, to petition the court to determine that the full tender offer was for less than fair value and that the fair value should be paid as determined by the court. However,
subject to certain conditions, the purchaser may provide in its offer that shareholders who accept the full tender offer will not be entitled to such rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board of Directors consists of three classes of directors plus the chief executive officer, who is not part of any class. One of the
classes is elected each year by the shareholders at our annual meeting for a term of approximately three years. Elected directors cannot be removed from office by the shareholders until the expiration of their term of office, unless they violate
their duties of care or loyalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Companies Law, we have elected to comply with SEC and NYSE requirements for
independent directors on the Board and audit and compensation committees, in lieu of the Israeli requirements for statutory independent directors and audit committee and compensation committee composition. Following such election, we no longer
designate any of our directors as statutory independent directors or designated independent directors under Israeli law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of
our ordinary shares representing a majority of the voting power represented at a shareholders&#146; meeting and voting at the meeting have the power to elect all of the directors up for election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, the Board of Directors formulates company policy and supervises the performance of the chief executive officer. Subject to the
provisions of the Companies Law and the Articles, any Teva power that has not been conferred upon another body may be exercised by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither our Memorandum or Articles, nor Israeli law, mandate retirement of directors at a certain age, or share ownership for a
director&#146;s qualification. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conflicts of Interest </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Approval of Related Party Transactions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law requires that an &#147;office holder&#148; (as defined in the Companies Law) of a company promptly disclose any personal
interest that he or she may have and all related material information known to him or her, in connection with any existing or proposed transaction of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, the Articles and Teva&#146;s related party transactions policy, any transaction with an office holder or in
which the office holder has a personal interest (other than with respect to such office holder&#146;s Terms of Office and Employment) needs to be evaluated in order to determine whether such transaction is an &#147;extraordinary transaction&#148;
(defined as a transaction not in the ordinary course of business, not on market terms or likely to have a material impact on the company&#146;s profitability, assets or liabilities). The term &#147;Terms of Office and Employment,&#148; as defined in
the Companies Law, includes compensation, equity-based awards, releases from liability, indemnification and insurance, severance and other benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, the Articles and Teva related party transactions policy, in the event that the audit committee determines that
a transaction is an extraordinary transaction, such transaction will require the approval of the audit committee and Board of Directors, and in some circumstances shareholder approval may also be required. If, however, it is determined that the
transaction is not an extraordinary transaction, the transaction can be approved by the Board of Directors or by a committee of the Board of Directors authorized by the Board of Directors for such purposes, or according to company policy approved by
the Board of Directors or such committee of the Board of Directors. The approval may be for a particular transaction or more generally for certain types of transactions. Such a transaction may only be approved if it is determined to be in the best
interests of Teva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A person with a personal interest in the matter generally may not be present at meetings of the Board of Directors or
certain committees where the matter is being considered and, if a member of the Board of Directors or a committee, may generally not vote on the matter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transactions with Controlling Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Israeli law, extraordinary transactions with a controlling shareholder or in which the controlling shareholder has a personal interest
and any engagement with a controlling shareholder or a controlling shareholder&#146;s relative with respect to the provision of services to the company or with their Terms of Office and Employment as an office holder or their employment, if they are
not office holders, generally require the approval of the audit committee (or with respect to Terms of Office and Employment, the compensation committee), the Board of Directors and the shareholders. If required, shareholder approval must include at
least a majority of the shareholders who do not have a personal interest in the transaction and are present and voting at the meeting (abstentions are disregarded), or, alternatively, that the total shareholdings of the disinterested shareholders
who vote against the transaction cannot represent more than two percent of the voting rights in the company. Transactions for a period of more than three years generally need to be brought for approval in accordance with the above procedures every
three years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder who holds 25% or more of the voting rights in a company is considered a controlling shareholder for these
purposes if no other shareholder holds more than 50% of the voting rights. If two or more shareholders are interested parties in the same transaction, their shareholdings are combined for the purposes of calculating percentages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Approval of Director and Executive Officer Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by the Companies Law, we have adopted a compensation policy regarding the Terms of Office and Employment of our office holders (the
&#147;Compensation Policy&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Companies Law, arrangements between Teva and its office holders must generally be
consistent with the Compensation Policy. However, under certain circumstances, we may approve an arrangement that is not consistent with the Compensation Policy, if such arrangement is approved by a special disinterested majority of our
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, pursuant to the Companies Law, the Terms of Office and Employment of office holders generally require the
approval of the compensation committee and the Board of Directors. The Terms of Office and Employment of directors (including those of a chief executive officer who is a director) further require the approval of the shareholders by a simple
majority; with respect to a chief executive officer who is not a director, the approval of the shareholders by the special disinterested majority is also generally required. Pursuant to regulations promulgated under the Companies Law, shareholder
approval is not required with respect to the remuneration granted to a director or a chief executive officer for the period following his or her appointment until the next general meeting of shareholders, provided such remuneration is approved by
the compensation committee and the Board of Directors, is consistent with the Compensation Policy and is on similar or less favorable terms than those of such person&#146;s predecessor. In addition, under certain circumstances, shareholder approval
is not required with respect to the Terms of Office and Employment of a candidate to be engaged as Teva&#146;s chief executive officer if the compensation committee determines that such engagement will be frustrated if shareholder approval is
sought, provided that the terms are consistent with the Compensation Policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, if the Terms of Office and
Employment of office holders who are not directors are not approved by the shareholders (where such approval is required), the compensation committee and the Board of Directors may nonetheless approve such terms. In addition, <FONT
STYLE="white-space:nowrap">non-material</FONT> amendments of the Terms of Office and Employment of office holders who are not directors may be approved by the compensation committee only, provided such amendments are consistent with the Compensation
Policy, and <FONT STYLE="white-space:nowrap">non-material</FONT> amendments of the Terms of Office and Employment of executive officers other than the chief executive officer may be approved by the chief executive officer only, provided also that
such approval is permitted under the Compensation Policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Insurance, Exemption and Indemnification of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Companies Law provides that a company may not exempt or indemnify a director or an executive officer, or enter into an insurance contract,
which would provide coverage for any liability incurred as a result of any of the following: (i)&nbsp;a breach by the director and/or executive officer of his or her duty of loyalty unless, with respect to insurance coverage or indemnification, due
to a breach of his or her duty of loyalty to the company committed in good faith and with reasonable grounds to believe that such act would not prejudice the interests of the company; (ii)&nbsp;a breach by the director and/or the executive officer
of his or her duty of care to the company committed intentionally or recklessly (other than if solely done in negligence); (iii) any act or omission done with the intent of unlawfully realizing personal gain; or (iv)&nbsp;a fine, monetary sanction,
forfeit or penalty imposed upon a director and/or executive officer. In addition, the Companies Law provides that directors and executive officers can be exempted in advance with respect to liability for damages caused as a result of a breach of
their duty of care to the company (but not for such breaches committed intentionally or recklessly, as noted above, or in connection with a distribution (as defined in the Companies Law)). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to indemnification and release agreements, we release our directors and executive officers from liability and indemnify them to the
fullest extent permitted by law and the Articles. Under these agreements, our undertaking to indemnify each director and executive officer for certain payments and expenses as well as monetary liabilities imposed by a court judgment (including a
settlement or an arbitrator&#146;s award that was approved by a court), which indemnification of monetary liabilities (i)&nbsp;shall be limited to matters that are connected or otherwise related to certain events or circumstances set forth therein,
and (ii)&nbsp;shall not exceed $200&nbsp;million in the aggregate per director or executive officer. Under Israeli law, indemnification is subject to other limitations, including those described above. Subject to applicable law, we may also
indemnify our directors and officers following specific events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors and executive officers are also covered by directors&#146;
and officers&#146; liability insurance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Companies Law, dividends may generally be distributed only out of profits, provided that there is no reasonable concern that the
distribution will prevent us from satisfying our existing and anticipated obligations when they become due. In accordance with the Companies Law and the Articles, the decision to distribute dividends and the amount to be distributed is made by the
Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange Controls </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-residents</FONT> of Israel who purchase ADSs with U.S. dollars or other
<FONT STYLE="white-space:nowrap">non-Israeli</FONT> currency will be able to receive dividends, if any, and any amounts payable upon the dissolution, liquidation or winding up of the affairs of Teva, in U.S. dollars at the rate of exchange
prevailing at the time of conversion. Dividends to <FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents are subject to withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_8"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This section summarizes certain information regarding the American Depositary Shares (&#147;ADSs&#148;) of Teva Pharmaceutical Industries
Limited (the &#147;Company&#148;), each of which represents one ordinary share of the Company. The following description is only a summary and does not purport to be complete and is qualified by reference to the Memorandum, the Articles, and our
Second Amended and Restated Deposit Agreement, by and among the Company, Citibank, N.A. (&#147;Citibank&#148;), as depositary, and the holders and beneficial owners of ADSs issued thereunder, dated as of December&nbsp;4, 2018 (the &#147;Deposit
Agreement&#148;), each of which is incorporated by reference as exhibits hereto. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>American Depositary Shares and Receipts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ADSs represent ownership
interests in securities that are on deposit with the depositary bank. ADSs may be represented by certificates that are commonly known as &#147;American Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary bank typically appoints a custodian
to safekeep the securities on deposit. Citibank, having its principal office at 388 Greenwich Street, New York, New York 10013, U.S.A., is acting as depositary bank for our ADSs and the custodians are Citibank Tel Aviv and Citibank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has appointed Citibank as depositary bank pursuant to the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive one ordinary share on deposit with the custodian. An ADS also represents the right to receive any
other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. The custodian, the depositary bank
and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees.
Beneficial ownership in the deposited property will under the terms of the Deposit Agreement be vested in the beneficial owners of the ADSs. The depositary bank, the custodian and their respective nominees will be the record holders of the deposited
property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. Owners of ADSs will be able to exercise beneficial ownership interests in the deposited property only through the registered holders of
the ADSs, by the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and by the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly through the custodian
or their respective nominees, in each case upon the terms of the Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Owners of ADSs become a party to the Deposit
Agreement and will be bound to its terms and to the terms of any ADR that represents ADSs. The Deposit Agreement and the ADR specify the rights and obligations of the Company, the depositary bank and the ADS owners. The Deposit Agreement and the
ADRs are governed by New York law. However, the Company&#146;s obligations to the holders of ordinary shares will continue to be governed by the laws of the State of Israel, which may be different from the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Owners of ADSs may hold ADSs either by means of an ADR registered in their name, through a brokerage or safekeeping account, or through an
account established by the depositary bank in their name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration system&#148; or &#147;DRS&#148;). The
direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank
to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company, or DTC, the central book-entry clearing and settlement system for equity securities in the United
States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs generally have the right to receive distributions made by the Company on the securities deposited with the custodian. Receipt
of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the Deposit Agreement in proportion to the number of ADSs held as of a specified
record date, after deduction of the applicable fees, taxes and expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Cash </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Company makes a cash distribution for the securities on deposit with the custodian, the Company will deposit the funds with the
depositary bank or the custodian on behalf of the depositary bank. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds to be converted into U.S. dollars and for the distribution of the
U.S. dollars to the holders, subject to the laws and regulations of the State of Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion into U.S. dollars will take place
only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in
respect of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable
by holders under the terms of the Deposit Agreement. The depositary bank will hold any cash amounts it is unable to distribute in <FONT STYLE="white-space:nowrap">a&nbsp;non-interest&nbsp;bearing</FONT> account for the benefit of the applicable
holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the
Company makes a free distribution of shares for the securities on deposit with the custodian, the Company will deposit the applicable number of shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will either
distribute to holders new ADSs representing the ordinary shares deposited or modify <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS-to-shares&nbsp;ratio,</FONT></FONT> in which case each ADS held by holders will
represent rights and interests in the additional ordinary shares or preference shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a
cash distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of new ADSs or the modification of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS-to-ordinary&nbsp;shares</FONT></FONT> ratio upon a distribution of ordinary shares or preference shares will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the Deposit Agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. No such distribution of new ADSs will
be made if it would violate a law (i.e., the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the shares received upon the terms described in the
Deposit Agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Elective Distributions of Cash or Shares
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Company intends to distribute a dividend payable at the election of shareholders either in cash or in additional shares,
it will give prior notice thereof to the depositary bank and will indicate whether it wishes the elective distribution to be made available to holders. In such case, the Company will assist the depositary bank in determining whether such
distribution is lawful and reasonably practicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will make the election available to holders only if it is reasonably
practicable and if the Company has provided all of the documentation contemplated in the Deposit Agreement. In such case, the depositary bank will establish procedures, in consultation with the Company, to enable holders to elect to receive either
cash or additional ADSs, in each case as described in the Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the election is not made available to holders, holders
will receive either cash or additional ADSs, depending on what a shareholder under Israeli law would receive upon failing to make an election, as more fully described in the Deposit Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distribution of Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the
Company intends to distribute rights to purchase additional ordinary shares, it will give prior notice to the depositary bank and will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to
purchase additional ADSs to holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will establish procedures, in consultation with the Company, to distribute
rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if the Company provides all of the documentation
contemplated in the Deposit Agreement (such as opinions to address the lawfulness of the transaction). Holders may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of their rights. The
depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than in the form of ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will<I></I><I>&nbsp;not</I>&nbsp;distribute the rights to holders if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company does not timely request that the rights be distributed to holders or the Company requests that the
rights not be distributed to holders; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company fails to deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is not reasonably practicable to distribute the rights. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The
proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Company
intends to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, it will notify the depositary bank in advance and will indicate whether it wishes that such distribution be made to holders of ADSs. If
so, the Company will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. If it is reasonably practicable to distribute such property to holders and if the Company provides all of the
documentation contemplated in the Deposit Agreement, the depositary bank will distribute the property to the holders in a manner it, in consultation with the Company, deems practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the Deposit
Agreement. In order to pay such taxes and governmental charges, the depositary bank may, in consultation with the Company, sell all or a portion of the property received. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will<I></I><I>&nbsp;not</I>&nbsp;distribute the property to holders and will sell the property if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company does not request that the property be distributed to holders or if the Company asks that the property
not be distributed to holders; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company does not deliver satisfactory documents to the depositary bank; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary bank determines, in consultation with the Company, that all or a portion of the distribution to
holders is not reasonably practicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proceeds of such a sale will be distributed to holders as in the case of a
cash distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whenever the Company intends to redeem any of the securities on deposit with the custodian, it will notify the depositary bank in advance. If
it is practicable and if the Company provides all of the documentation contemplated in the Deposit Agreement, the depositary bank will provide notice of the redemption to the holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary
bank will convert the redemption funds received into U.S. dollars upon the terms of the Deposit Agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary
bank. Holders may have to pay fees, expenses, taxes and other governmental charges upon the redemption of their ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a<I></I><I>&nbsp;pro
rata</I>&nbsp;basis, as the depositary bank may determine in consultation with the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes Affecting Ordinary Shares and Preference Shares
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ordinary shares held on deposit for ADSs may change from time to time. For example, there may be a change in nominal or par value,
<FONT STYLE="white-space:nowrap">a&nbsp;split-up,&nbsp;cancellation,</FONT> consolidation or reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such change were to occur, the ADSs would, to the extent permitted by law, represent the right to receive the property received or
exchanged in respect of the new ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to holders, amend the Deposit Agreement, the applicable ADRs and the applicable registration statement(s) on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-6,&nbsp;call</FONT> for the exchange of existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary bank may
not lawfully distribute such property to holders, the depositary bank may sell such property and distribute the net proceeds to holders as in the case of a cash distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice from the custodian confirming (i)&nbsp;that a deposit of ordinary shares has been made pursuant to the requirements of
the Deposit Agreement, (ii)&nbsp;that all required documentation has been received, and (iii)&nbsp;the person(s) to whom ADSs are deliverable and the number of ADSs to be delivered, the depositary bank will issue, subject to the terms of the Deposit
Agreement, applicable law and payment of all applicable charges, taxes and other governmental fees, ADSs to the persons named in the custodian&#146;s notice. The depositary bank will only issue ADSs in whole numbers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When a holder makes a deposit of ordinary shares, such holder will be responsible for transferring good and valid title to the depositary
bank. As such, holders will be deemed to represent and warrant that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ordinary shares are duly authorized, validly issued, fully
<FONT STYLE="white-space:nowrap">paid,&nbsp;non-assessable&nbsp;and</FONT> legally obtained; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or
exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the person making the deposit is duly authorized to deposit the ordinary shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge,
mortgage or adverse claim, and the ADSs issuable upon such deposit will not be &#147;restricted securities&#148; (as defined in the Deposit Agreement); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ordinary shares presented for deposit have not been stripped of any rights or entitlements.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the representations or warranties are incorrect in any way, the Company and the depositary bank may, at
holders&#146; cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer, Combination and
Split of ADRs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders are entitled to transfer, combine or split up their ADRs and the ADSs evidenced thereby. For transfers of ADRs,
holders will have to surrender the ADRs to be transferred to the depositary bank and also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide any transfer stamps required by the State of New York or the United States; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to
the terms of the Deposit Agreement, upon the transfer of ADRs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To have ADRs either combined or split up, holders must
surrender the ADRs in question to the depositary bank with a request to have them combined or split up, and holders must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the Deposit Agreement, upon a
combination or split up of ADRs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Ordinary Shares upon Cancellation of ADSs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs are entitled to present their ADSs to the depositary bank for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Holders&#146; ability to withdraw the ordinary shares may be limited by U.S. and Israeli legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares
represented by ADSs, holders will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares being withdrawn. Holders assume the risk for delivery of all
funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the Deposit Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If holders hold ADSs
registered in their name, the depositary bank may ask such holders to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel the ADSs. The withdrawal of
the ordinary shares represented by the ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. The depositary bank will only accept ADSs for cancellation that represent a
whole number of securities on deposit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders have the right to withdraw the securities represented by ADSs at any time except for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed,
or (ii)&nbsp;ordinary shares are immobilized on account of a shareholders&#146; meeting or a payment of dividends; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">outstanding obligations to pay fees, taxes and similar charges; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on
deposit. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Deposit Agreement may not be modified to impair holders&#146; right to withdraw the
securities represented by their ADSs, except to comply with mandatory provisions of law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports and Communications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will furnish to the depositary bank all notices of shareholders&#146; meetings, proxy soliciting material and other reports and
communications that are made generally available to the holders of ordinary shares and English translations of the same (including a summary, in English, of any applicable provisions or proposed provisions of the Articles that may be relevant to
such notices, reports and communications). The depositary bank will make such notices, reports and communications available for inspection by holders of ADSs at its principal office when furnished by the Company pursuant to the Deposit Agreement
and, upon request by the Company, will mail such notices, reports and communications to holders at the Company&#146;s expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs generally have the right under the Deposit Agreement to instruct the depositary bank to exercise the voting rights for the
ordinary shares represented by their ADSs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Company&#146;s request, the depositary bank will distribute to holders any notice of
shareholders&#146; meeting received from the Company together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by
proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the depositary bank to carry out
voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. The Company cannot assure that holders will receive voting materials in time to enable them to return voting instructions to the
depositary bank in a timely manner. Securities for which no voting instructions have been received will not be voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fees and Charges </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs will be required to pay the following service fees to the depositary bank: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Service</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(1) Issuance of ADSs (e.g., an issuance upon a deposit of shares, upon a change in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS(s)-to-share(s)&nbsp;ratio,</FONT></FONT> or for any other reason),
excluding issuances as a result of distributions described in paragraph (4)&nbsp;below.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(2) Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited shares, upon a change in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;ADS(s)-to-share(s)&nbsp;ratio,</FONT></FONT> or for
any other reason).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) cancelled.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(3) Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(4) Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(5) Distribution of securities other than ADSs or rights to purchase additional ADSs <FONT STYLE="white-space:nowrap">(e.g.,&nbsp;spin-off&nbsp;shares).</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(6) ADS Services.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the depositary bank.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of ADSs will also be responsible to pay certain fees and expenses incurred by the
depositary bank and certain taxes and governmental charges such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">taxes and other governmental charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fees related to the transfer and registration of ordinary shares charged by the registrar and transfer agent
(i.e., upon deposit and withdrawal of ordinary shares); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expenses for cable, telex and fax transmissions and for delivery of securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expenses incurred for converting foreign currency into U.S. dollars; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expenses incurred in connection with compliance with exchange control regulations and other regulatory
requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fees and expenses incurred in connection with the delivery or servicing of ordinary shares on deposit.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depositary fees payable upon the issuance and cancellation of ADSs are typically paid to the depositary bank by the
brokers (on behalf of their clients) receiving the newly issued ADSs from the depositary bank and by the brokers (on behalf of their clients) delivering the ADSs to the depositary bank for cancellation. The brokers in turn charge these fees to their
clients. Depositary fees payable in connection with distributions of cash or securities to holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as of the applicable ADS record date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Depositary fees payable for cash distributions are generally deducted from the cash being distributed. In the case of distributions other
than cash (<I>i.e.</I>, stock dividend, rights), the depositary bank charges the applicable fee to the ADS record date holders concurrent with the distribution. In the case of ADSs registered in the name of the investor (whether certificated or
uncertificated in direct registration), the depositary bank sends invoices to the applicable record date ADS holders. In the case of ADSs held in brokerage and custodian accounts (via DTC), the depositary bank generally collects its fees through the
systems provided by DTC (whose nominee is the registered holder of the ADSs held in DTC) from the brokers and custodians holding ADSs in their DTC accounts. The brokers and custodians who hold their clients&#146; ADSs in DTC accounts in turn charge
their clients&#146; accounts the amount of the fees paid to the depositary banks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of refusal to pay the depositary fees, the
depositary bank may, under the terms of the Deposit Agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees from any distribution to be made to the holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fees and charges holders may be required to pay may vary over time and may be changed by the Company and by the depositary bank. Holders
will receive prior notice of such changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may reimburse the Company for certain expenses incurred by the Company in
respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the depositary fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Company and the depositary bank
may agree from time to time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may agree with the depositary bank to modify the Deposit Agreement at any time without holders&#146; consent. The Company
undertakes to give holders 30 days&#146; prior notice of any modifications that would materially prejudice any of their substantial rights under the Deposit Agreement. Modifications to the Deposit Agreement shall be deemed not to materially
prejudice holders&#146; substantial existing rights if such modifications are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the
fees and charges holders are required to pay. In addition, the Company may not be able to provide holders with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders will be bound by the modifications to the Deposit Agreement if they continue to hold
ADSs after the modifications to the Deposit Agreement become effective. The Deposit Agreement cannot be amended to prevent holders from withdrawing the ordinary shares represented by their ADSs (except in order to comply with applicable by law).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has the right to direct the depositary bank to terminate the Deposit Agreement. Similarly, the depositary bank may in certain
circumstances on its own initiative terminate the Deposit Agreement. In either case, the depositary bank must give notice to holders at least 30 days before termination. Until termination, holders&#146; rights under the Deposit Agreement will be
unaffected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such
property until holders request the cancellation of their ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for holders in <FONT
STYLE="white-space:nowrap">a&nbsp;non-interest&nbsp;bearing</FONT> account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for holders still outstanding (after deduction
of applicable fees, taxes and expenses). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain ADS holder records at its depositary office. Holders may inspect such records at such office during regular
business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the Deposit Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank will maintain in New York City (Borough of Manhattan) facilities to record and process the issuance, cancellation, <FONT
STYLE="white-space:nowrap">combination,&nbsp;split-up&nbsp;and</FONT> transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Obligations and Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Deposit Agreement limits the obligations of the Company and the depositary bank to the holders of ADSs as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank are obligated only to take the actions specifically stated in the Deposit
Agreement without negligence or bad faith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">both the Company and the depositary bank disclaim any liability for any failure to carry out voting instructions,
for any manner in which a vote is cast or for the effect of any vote, provided they act in good faith and in accordance with the terms of the Deposit Agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">both the Company and the depositary bank disclaim any liability for any failure to accurately determine the
lawfulness or practicality of any action, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for the value of ordinary shares or any distribution or interest thereon, for any tax
consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the Deposit Agreement; for any action of or failure to act by, or any information provided or not
provided by, DTC or any DTC participant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary bank disclaims any liability for the content of any information submitted to it by the Company for
distribution to holders or for any inaccuracy of any translation thereof or for the failure or timeliness of any notice from the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank will not be obligated to perform any act that is inconsistent with the terms
of the Deposit Agreement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank disclaim any liability if the Company or the custodian or the depositary bank
are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the Deposit Agreement, by reason of any provision, present or future
of any applicable law or regulation, or by reason of present or future provision of any provision of our Articles, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond the
Company&#146;s control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise,
any discretion provided for in the Deposit Agreement or in the Articles or in any provisions of or governing the securities on deposit; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank further disclaim any liability for any action or inaction in reliance on the
advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by the Company or the depositary bank in good
faith to be competent to give such advice or information; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank also disclaim liability for the inability of certain holders to benefit from
any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the Deposit Agreement, made available to such holders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank also disclaim liability for any action or inaction of any clearing or
settlement system (and any participant thereof) for the deposited property or the ADSs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank may rely without any liability upon any written notice, request or other
document believed to be genuine and to have been signed or presented by the proper parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Company and the depositary bank also disclaim liability for any consequential or punitive damages for any
breach of the terms of the Deposit Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. The
Company, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. Holders
will be liable for any deficiency if the sale proceeds do not cover the taxes that are due. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary bank may refuse to issue ADSs,
to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds
and reduced tax withholding for any distributions on behalf of holders. However, holders may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the Company, the
depositary bank and the custodian may require to fulfill legal obligations. Holders are required to indemnify the Company, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Conversion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the Deposit Agreement. Holders may have to
pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the conversion of foreign currency is not practical or lawful, or if any required
approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to holders for
whom the conversion and distribution is lawful and practical; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">distribute the foreign currency to holders for whom the distribution is lawful and practical; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold the foreign currency (without liability for interest) for the applicable holders. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_9"></A>DESCRIPTION OF DEBT SECURITIES AND GUARANTEES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any of the finance subsidiaries may elect to offer debt securities. The following description of debt securities sets forth the material
terms and provisions of the debt securities to which any prospectus supplement may relate. Our senior debt securities would be issued under a senior indenture between Teva and a banking or financial institution, as trustee. Teva&#146;s subordinated
debt securities would be issued under a subordinated indenture between Teva and a banking or financial institution, as trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
senior debt securities of each finance subsidiary would be issued under a senior indenture among that entity, Teva, as guarantor, and a banking or financial institution, as trustee. The subordinated debt securities of each finance subsidiary would
be issued under a subordinated indenture among that entity, Teva, as guarantor, and a banking or financial institution, as trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
of the indentures are sometimes referred to in this prospectus collectively as the &#147;indentures&#148; and each, individually, as an &#147;indenture.&#148; All senior indentures are sometimes referred to in this prospectus collectively as the
&#147;senior indentures&#148; and each, individually, as a &#147;senior indenture.&#148; All subordinated indentures are sometimes referred to in this prospectus collectively as the &#147;subordinated indentures&#148; and each, individually, as a
&#147;subordinated indenture.&#148; The particular terms of the debt securities offered by any prospectus supplement, and the extent to which the general provisions described below may apply to the offered debt securities, will be described in the
applicable prospectus supplement. The indentures will be qualified under the Trust Indenture Act of 1939, as amended. The terms of the debt securities will include those stated in the indentures and those made part of the indentures by reference to
the Trust Indenture Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the following summaries of the material terms and provisions of the indentures and the related debt
securities are not complete, you should refer to the forms of the indentures and the debt securities for complete information on some of the terms and provisions of the indentures, including definitions of some of the terms used below, and the debt
securities. The senior indentures and subordinated indentures are substantially identical to one another, except for specific provisions relating to subordination contained in the subordinated indentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the indentures
do not limit the aggregate principal amount of debt securities which may be issued thereunder. Unless otherwise provided in a prospectus supplement, the senior debt securities will be the issuer&#146;s direct, unsecured and unsubordinated general
obligations and will have the same rank in liquidation as all of the issuer&#146;s other unsecured and unsubordinated debt. The subordinated debt securities will be unsecured obligations of the issuer, subordinated in right of payment to the prior
payment in full of all senior indebtedness of the issuer with respect to such series, as described below under &#147;Subordination of the Subordinated Debt Securities&#148; and in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer may issue debt
securities from time to time in one or more series. The provisions of the indentures allow the issuer to &#147;reopen&#148; a previous issue of a series of debt securities and issue additional debt securities of that series, as well as debt
securities of other series. The debt securities may be denominated and payable in U.S. dollars or foreign currencies. The issuer may also issue debt securities from time to time with the principal amount or interest payable on any relevant payment
date to be determined by reference to one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. Holders of these types of debt securities will receive payments of principal or interest that depend upon
the value of the applicable currency, security or basket of securities, commodity or index on the relevant payment dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Debt securities
may bear interest at a fixed rate, which may be zero, a floating rate, or a rate which varies during the lifetime of the debt security. Debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing
market rate may be sold at a discount below their stated principal amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms Specified in the Applicable Prospectus Supplement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will contain, where applicable, the following terms of and other information relating to any offered debt
securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific designation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities, their purchase price and denomination;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency in which the debt securities are denominated and/or in which principal, premium, if any, and/or
interest, if any, is payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date of maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates or the method by which the calculation agent will determine the interest rate or
rates, if any; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest payment dates, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places for payment of the principal of and any premium and/or interest on the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any repayment, redemption, prepayment or sinking fund provisions, including any redemption notice provisions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will issue the debt securities in definitive form and under what terms and conditions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms on which holders of the debt securities may convert or exchange these securities into or for ADSs or
other of our securities or of an entity unaffiliated with us, any specific terms relating to the adjustment of the conversion or exchange feature and the period during which the holders may make the conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information as to the methods for determining the amount of principal or interest payable on any date and/or the
currencies, securities or baskets of securities, commodities or indices to which the amount payable on that date is linked; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agents for the debt securities, including trustees, depositaries, authenticating or paying agents, transfer
agents or registrars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances the issuer will pay additional amounts on debt securities for any tax,
assessment or governmental charge withheld or deducted and, if so, whether we will have the option to redeem those debt securities rather than pay the additional amounts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any material Israeli, U.S. federal and, if applicable, Dutch income tax consequences, including, but not limited
to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax considerations applicable to any discounted debt securities or to debt securities issued at par that are
treated as having been issued at a discount for United States federal income tax purposes; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">tax considerations applicable to any debt securities denominated and payable in foreign currencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether certain payments on the debt securities will be guaranteed under a financial insurance guaranty policy
and the terms of that guaranty; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be secured; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable selling restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the issued debt securities are a green bond, social bond, sustainability bond or sustainability-linked
bond; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms of the debt securities, including any modifications to or additional events of default,
covenants or modified or eliminated acceleration rights, and any terms required by or advisable under applicable laws or regulations, including laws and regulations relating attributes required for the debt securities to be afforded certain capital
treatment for bank regulatory or other purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the debt securities may be issued as original issue discount
securities. Original issue discount securities bear no interest or bear interest at below-market rates and may be sold at a discount below their stated principal amount. The applicable prospectus supplement will contain information relating to
income tax, accounting, and other special considerations applicable to original issue discount securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration and Transfer of Debt
Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders may present debt securities for exchange, and holders of registered debt securities may present these securities
for transfer, in the manner, at the places and subject to the restrictions stated in the debt securities and described in the applicable prospectus supplement. The issuer will provide these services without charge except for any tax or other
governmental charge payable in connection with these services and subject to any limitations or requirements provided in the applicable indenture or the supplemental indenture or issuer order under which that series of debt securities is issued. If
any of the securities are held in global form, the procedures for transfer of interests in those securities will depend upon the procedures of the depositary for those global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture
provides holders of debt securities with remedies if the issuer and/or guarantor, as the case may be, fails to perform specific obligations, such as making payments on the debt securities, or if the issuer and/or guarantor, as the case may be,
becomes bankrupt. Holders should review these provisions and understand which actions trigger an event of default and which actions do not. Each indenture permits the issuance of debt securities in one or more series, and, in many cases, whether an
event of default has occurred is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">series-by-series</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An event of default is defined under the indentures, with respect to any series of debt securities issued under that indenture, as any one or
more of the following events, subject to modification in a supplemental indenture, each of which we refer to in this prospectus as an event of default, having occurred and be continuing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default is made in the payment of principal in respect of the securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default is made for more than 30 days in the payment of interest in respect of the securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer and/or guarantor, as the case may be, fails to perform any of its other obligations under the
securities and this failure has continued for a specified period following service of notice on the issuer and/or guarantor requiring the same to be remedied; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuer&#146;s and/or guarantor&#146;s, as the case may be, bankruptcy, insolvency or reorganization under any
applicable bankruptcy, insolvency or insolvency related reorganization law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an order is made or an effective resolution is passed for the winding up or liquidation of the issuer and/or
guarantor, as the case may be; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided in the supplemental indenture or issuer order, if any, under which that
series of debt securities is issued. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Acceleration of Debt Securities Upon an Event of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that, unless otherwise set forth in a supplemental indenture: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default occurs due to the default in payment of principal of, or any premium or interest on, any
series of debt securities issued under the indenture, or due to the default in the performance or breach of any other covenant or warranty of the issuer and/or guarantor, as the case may be, applicable to that series of debt securities but not
applicable to all outstanding debt securities issued under that indenture occurs and is continuing, either the trustee or the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of each affected series,
voting as one class, by notice in writing to the issuer and guarantor, as the case may be, may declare the principal of and accrued interest on the debt securities of such affected series (but not any other debt securities issued under that
indenture) to be due and payable immediately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default occurs due to specified events of bankruptcy, insolvency or reorganization of the issuer
and/or the guarantor, as the case may be, the principal of all debt securities and interest accrued on the debt securities to be due and payable immediately; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default due to a default in the performance of any other of the covenants or agreements in the
indenture applicable to all outstanding debt securities issued under the indenture occurs and is continuing, either the trustee or the holders of not less than 25% in aggregate principal amount of all outstanding debt securities issued under the
indenture for which any applicable supplemental indenture does not prevent acceleration under the relevant circumstances, voting as one class, by notice in writing to the issuer and/or guarantor, as the case may be, may declare the principal of all
debt securities and interest accrued on the debt securities to be due and payable immediately. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Annulment of Acceleration and Waiver
of Defaults </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, if any and all events of default under the indenture, other than the
<FONT STYLE="white-space:nowrap">non-payment</FONT> of the principal of the securities that has become due as a result of an acceleration, have been cured, waived or otherwise remedied, then the holders of a majority in aggregate principal amount of
all series of outstanding debt securities affected, voting as one class, may annul past declarations of acceleration or waive past defaults of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification of Trustee for Actions Taken on Your Behalf </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that the trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in
accordance with the direction of the holders of debt securities issued under that indenture relating to the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred upon
the trustee. In addition, each indenture contains a provision entitling the trustee, subject to the duty of the trustee to act with the required standard of care during a default, to be indemnified to its reasonable satisfaction by the holders of
debt securities issued under the indenture before proceeding to exercise any right or power at the request of holders. Subject to these provisions and specified other limitations, the holders of a majority in aggregate principal amount of each
series of outstanding debt securities of each affected series, voting as one class, may direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the
trustee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Actions by You as an Individual Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that no individual holder of debt securities may institute any action against us under that indenture, except actions
for payment of overdue principal and interest, unless the following actions have occurred: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder must have previously given written notice to the trustee of the continuing default;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in aggregate principal amount of the outstanding debt securities of each
affected series, treated as one class, must have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">requested the trustee to institute that action; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offered the trustee reasonable indemnity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee must have not instituted that action within 60 days after receipt of the request referred to above;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of a majority in principal amount of the outstanding debt securities of each affected series, voting
as one class, must not have given directions to the trustee inconsistent with those of the holders referred to above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture contains a covenant that the issuer and guarantor, if applicable, will file annually with the trustee a certificate of no
default or a certificate specifying any default that exists. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge, Defeasance and Covenant Defeasance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuer has the ability to eliminate most or all of its obligations on any series of debt securities prior to maturity if it complies with
the following provisions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Discharge of Indenture</I></B>. The issuer may discharge all of its obligations, other than as to
transfers and exchanges, under the indenture after it has: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">paid or caused to be paid the principal of and interest on all of the outstanding debt securities in accordance
with their terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivered to the applicable trustee for cancellation all of the outstanding debt securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">irrevocably deposited with the applicable trustee cash or, in the case of a series of debt securities payable
only in U.S. dollars, U.S. government obligations in trust for the benefit of the holders of any series of debt securities issued under the indenture that have either become due and payable, or are by their terms due and payable, or are scheduled
for redemption, within one year, in an amount certified to be sufficient to pay on each date that they become due and payable, the principal of and interest on, and any mandatory sinking fund payments for, those debt securities. However, the deposit
of cash or U.S. government obligations for the benefit of holders of a series of debt securities that are due and payable, or are scheduled for redemption, within one year will discharge obligations under the applicable indenture relating only to
that series of debt securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Defeasance of a Series of Securities at Any Time</I></B>. The issuer may also
discharge all of its obligations, other than as to transfers and exchanges, under any series of debt securities at any time, which we refer to as defeasance in this prospectus. The issuer may be released with respect to any outstanding series of
debt securities from the obligations imposed by the covenants described above limiting consolidations, mergers, asset sales and leases, and elect not to comply with those sections without creating an event of default. Discharge under those
procedures is called covenant defeasance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defeasance or covenant defeasance may be effected only if, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer irrevocably deposits with the relevant trustee cash or, in the case of debt securities payable only in
U.S. dollars, U.S. government obligations, as trust funds in an amount certified to be sufficient to pay on each date that they become due and payable, the principal of and interest on, and any mandatory sinking fund payments for, all outstanding
debt securities of the series being defeased; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer delivers to the relevant trustee an opinion of counsel to the effect that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of the series of debt securities being defeased will not recognize income, gain or loss for United
States federal income tax purposes as a result of the defeasance or covenant defeasance; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the defeasance or covenant defeasance will not otherwise alter those holders&#146; United States federal income
tax treatment of principal and interest payments on the series of debt securities being defeased; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of a defeasance, this opinion must be based on a ruling of the Internal Revenue Service or a change
in United States federal income tax law occurring after the date of this prospectus, since that result would not occur under current tax law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent of Holders</I></B>. The issuer and the relevant trustee may enter into supplemental indentures without the
consent of the holders of debt securities issued under each indenture to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">secure any debt securities or to confirm and evidence the release of security when such release is permitted
under such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidence the assumption by a successor corporation of our obligations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add covenants for the protection of the holders of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delete or modify any Events of Default with respect to a new series being established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add or change any provisions of such indenture regarding restrictions on the payment of principal or premium if
such modification does not adversely affect holders of such debt securities in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or eliminate any provisions of such indenture if such change or elimination becomes effective when no
securities affected are outstanding; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cure any ambiguity, omission, mistake, defect or error or correct any inconsistency; or to surrender any right or
power of an issuer or guarantors; or to make such other provisions that shall not adversely affect the interests of the holders in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish the forms or terms of debt securities of any series or to authorize the issuance of additional
securities of a series; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidence the assumption by the guarantor of all obligations and release of issuer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evidence the acceptance of appointment by a successor trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supplement such indenture to permit defeasance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add, change or eliminate provisions of such indenture to qualify under the Trust Indenture Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the minimum denomination of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit the authentication and delivery of additional series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add guarantors or <FONT STYLE="white-space:nowrap">co-obligors</FONT> to a series or to release guarantors in
accordance with such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make such provisions as necessary to exchange securities pursuant to a registration rights or similar agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conform provisions of such indenture with respect to a series to the provisions of the applicable
&#147;Description of Notes&#148;; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any other change that does not adversely affect in any material respect the interests of holders of such
securities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Modification with Consent of Holders</I></B>. Each issuer and the trustee, with the consent of the
holders of not less than a majority in aggregate principal amount of each affected series of outstanding debt securities, voting as one class, may add any provisions to, or change in any manner or eliminate any of the provisions of, the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indenture or modify in any manner the rights of the holders of those debt securities. However, the issuer and the trustee may not make any of the following changes to any outstanding debt
security without the consent of each holder that would be affected by the change: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extend the final maturity of the security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate or extend the time of payment of interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce any amount payable on redemption; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the currency in which the principal, including any amount of original issue discount, premium, or interest
on the security is payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify or amend the provisions for conversion of any currency into another currency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of any original issue discount security payable upon acceleration or provable in bankruptcy;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">alter the terms on which holders of the debt securities may convert or exchange debt securities for stock or
other securities or for other property or the cash value of the property, other than in accordance with the antidilution provisions or other similar adjustment provisions included in the terms of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right of any holder to institute suit for the enforcement of any payment on any debt security when
due; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of debt securities the consent of whose holders is required for modification of the
Indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form of Debt Security </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt security will be represented either by a certificate issued in definitive form to a particular investor or by one or more global
securities representing the entire issuance of securities. Both certificated securities in definitive form and global securities may be issued in registered form, where the issuer&#146;s obligation runs to the holder of the security named on the
face of the security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Definitive securities name you or your nominee as the owner of the security and in order to transfer or exchange
these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee, registrar, paying agent or other agent, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Global securities name a depositary or its nominee as the owner of the debt securities represented by these global securities. The depositary
maintains a computerized system that will reflect each investor&#146;s beneficial ownership of the securities through an account maintained by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully
below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Registered Global Securities</I></B>. The issuer may issue the debt securities in the form of one or more fully registered global
securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In those cases, one or more registered global securities will be issued
in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive
registered form, a registered global security may not be transferred except as a whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees. If not
described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the prospectus supplement relating to those securities. We anticipate that the
following provisions will apply to all depositary arrangements: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a registered global security will be limited to
persons, called participants, that have accounts with the depositary or persons that may hold interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer
system, the participants&#146; accounts with the respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters or selling agents participating in the distribution of the securities will
designate the accounts to be credited. Ownership of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records maintained by the depositary, with respect to
interests of participants, and on the records of participants, with respect to interests of persons holding through participants. The laws of some states may require that some purchasers of securities take physical delivery of these securities in
definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in registered global securities. So long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary
or its nominee, as the case may be, will be considered the sole owner or holder of the securities represented by the registered global security for all purposes under the applicable indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities
represented by the registered global security registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be considered the owners or holders of the securities under the
applicable indenture. Accordingly, each person owning a beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures
of the participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture. We understand that under existing industry practices, if we request any action of holders or if an owner of a
beneficial interest in a registered global security desires to give or take any action that a holder is entitled to give or take under the applicable indenture, the depositary for the registered global security would authorize the participants
holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to give or take that action or would otherwise act upon the instructions of beneficial owners holding
through them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal, premium, if any, and interest payments on debt securities represented by a registered global security registered
in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the registered global security. None of the issuer, the guarantor, if applicable, the trustee or any other agent
of the issuer, guarantor or agent of the trustee will have any responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining,
supervising or reviewing any records relating to those beneficial ownership interests. We expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment of principal, premium, interest
or other distribution of underlying securities or other property to holders on that registered global security, will immediately credit participants&#146; accounts in amounts proportionate to their respective beneficial interests in that registered
global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a registered global security held through participants will be governed by standing customer instructions
and customary practices, as is now the case with the securities held for the accounts of customers registered in &#147;street name,&#148; and will be the responsibility of those participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the depositary for any of these securities represented by a registered global security is at any time unwilling or unable to continue as
depositary or ceases to be a clearing agency registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by the issuer within 90 days, the issuer will issue securities in
definitive form in exchange for the registered global security that had been held by the depositary. In addition, the issuer may, at any time and in its sole discretion, decide not to have any of the securities represented by one or more registered
global securities. If the issuer makes that decision, it will issue securities in definitive form in exchange for all of the registered global security or securities representing those securities. Any securities issued in definitive form in exchange
for a registered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
global security will be registered in the name or names that the depositary gives to the relevant trustee or other relevant agent of ours or theirs. It is expected that the depositary&#146;s
instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the depositary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guarantees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva will fully and
unconditionally guarantee payment in full to the holders of the debt securities issued by the finance subsidiaries pursuant to this prospectus. The guarantee is set forth in, and forms part of, the finance subsidiary indenture under which the debt
securities will be issued. If, for any reason, the issuer does not make any required payment in respect of its debt securities when due, the guarantor will cause the payment to be made to or to the order of the trustee. The guarantee will be on a
senior basis when the guaranteed debt securities are issued under the senior indenture, and on a subordinated basis to the extent the guaranteed debt securities are issued under the subordinated indenture. The extent to which the guarantee is
subordinated to other indebtedness of the guarantor will be substantially the same as the extent to which the subordinated debt issued by the issuer is subordinated to the other indebtedness of the issuer as described below under
&#147;&#151;Subordination of the Subordinated Debt Securities.&#148; The holder of the guaranteed security may sue the guarantor to enforce its rights under the guarantee without first suing any other person or entity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination of the Subordinated Debt Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subordinated debt securities issued by an issuer will, to the extent set forth in the applicable subordinated indenture, be subordinate in
right of payment to the prior payment in full of all senior indebtedness of the issuer, whether outstanding at the date of the subordinated indenture or incurred after that date. In the event of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any insolvency or bankruptcy case or proceeding, or any receivership, liquidation, reorganization or other
similar case or proceeding in connection therewith, relative to the issuer or to its creditors, as such, or to its assets; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any voluntary or involuntary liquidation, dissolution or other winding up of the issuer, whether or not involving
insolvency or bankruptcy; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any assignment for the benefit of creditors or any other marshalling of assets and liabilities of the issuer,
then the holders of senior indebtedness of the issuer will be entitled to receive payment in full of all amounts due or to become due on or in respect of all its senior indebtedness, or provision will be made for the payment in cash, before the
holders of the subordinated debt securities of the issuer are entitled to receive or retain any payment on account of principal of, or any premium or interest on, or any additional amounts with respect to, the subordinated debt securities. The
holders of senior indebtedness of the issuer will be entitled to receive, for application to the payment of the senior indebtedness, any payment or distribution of any kind or character, whether in cash, property or securities, including any payment
or distribution which may be payable or deliverable by reason of the payment of any other indebtedness of the issuer being subordinated to the payment of its subordinated debt securities. This payment may be payable or deliverable in respect of its
subordinated debt securities in any case, proceeding, dissolution, liquidation or other winding up event. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By reason of
subordination, in the event of liquidation or insolvency of the issuer, holders of senior indebtedness of the issuer and holders of other obligations of the issuer that are not subordinated to its senior indebtedness may recover more ratably than
the holders of subordinated debt securities of the issuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the payment in full of all senior indebtedness of the issuer, the
rights of the holders of subordinated debt securities of the issuer will be subrogated to the rights of the holders of its senior indebtedness to receive payments or distributions of cash, property or securities of the issuer applicable to its
senior indebtedness until the principal of, any premium and interest on, and any additional amounts with respect to, its subordinated debt securities have been paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No payment of principal, including redemption and sinking fund payments, of, or any premium
or interest on, or any additional amounts with respect to the subordinated debt securities of the issuer, or payments to acquire these securities, other than pursuant to their conversion, may be made: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if any senior indebtedness of the issuer is not paid when due and any applicable grace period with respect to the
default has ended and the default has not been cured or waived or ceased to exist; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the maturity of any senior indebtedness of the issuer has been accelerated because of a default.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The subordinated indentures do not limit or prohibit the issuer from incurring additional senior indebtedness, which
may include indebtedness that is senior to its subordinated debt securities, but subordinate to the issuer&#146;s other obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
subordinated indentures provide that these subordination provisions, insofar as they relate to any particular issue of subordinated debt securities by the issuer, may be changed prior to the issuance. Any change would be described in the applicable
prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York Law to Govern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the debt securities will be governed by the laws of the State of New York. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_10"></A>DESCRIPTION OF PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva may issue purchase contracts for the purchase or sale of debt or equity securities issued by Teva, a basket of such securities, an index
or indices of such securities or any combination of the above as specified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each purchase
contract will entitle the holder thereof to purchase or sell, and obligate us to sell or purchase, on specified dates, such securities at a specified purchase price, which may be based on a formula, all as set forth in the applicable prospectus
supplement. The applicable prospectus supplement will also specify the methods by which the holders may purchase or sell such securities and any acceleration, cancellation or termination provisions or other provisions relating to the settlement of a
purchase contract and any security arrangements or requirements with respect thereto. Alternatively, if provided in the applicable prospectus supplement, purchase contracts may require holders to satisfy their obligations thereunder when the
purchase contracts are issued. Any purchase contracts we issue will be physically settled by delivery of our ordinary shares or other securities to which they relate. Teva&#146;s obligation to settle such
<FONT STYLE="white-space:nowrap">pre-paid</FONT> purchase contacts on the relevant settlement date may constitute indebtedness. Accordingly, <FONT STYLE="white-space:nowrap">pre-paid</FONT> purchase contracts will be issued under either the senior
indenture or the subordinated indenture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_11"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As specified in the applicable prospectus supplement, Teva may issue units consisting of one or more purchase contracts, debt securities,
ordinary shares, ADSs or any combination of such securities. The applicable prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the units and of the purchase contracts, debt securities, ordinary shares and/or ADSs comprising the
units, including whether and under what circumstances the securities comprising the units may be traded separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of the terms of any unit agreement governing the units; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a description of the provisions for the payment, settlement, transfer or exchange of the units.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_12"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The material Israeli, U.S. federal and, if applicable, Dutch income tax consequences relating to the purchase, ownership and disposition of
any of the securities offered by this prospectus will be set forth in the prospectus supplement offering those securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_13"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell our securities in any one or more of the following ways from time to time: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through agents; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers, including our affiliates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to any offering of our securities will set forth the terms of the offering, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of any underwriters, dealers or agents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities and the proceeds to us from the sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any underwriting discounts and commissions or agency fees and other items constituting underwriters&#146; or
agents&#146; compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delayed delivery arrangements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be
changed, at market prices prevailing at the time of sale, at prices related to the prevailing market prices or at negotiated prices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
securities are sold by means of an underwritten offering, we will execute an underwriting agreement with an underwriter or underwriters, and the names of the specific managing underwriter or underwriters, as well as any other underwriters, and the
terms of the transaction, including commissions, discounts and any other compensation of the underwriters and dealers, if any, will be set forth in the prospectus supplement which will be used by the underwriters to sell the securities. If
underwriters are utilized in the sale of the securities, the securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including negotiated transactions, at fixed public
offering prices or at varying prices determined by the underwriters at the time of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities to be sold by us may be offered
to the public either through underwriting syndicates represented by managing underwriters or directly by the managing underwriters. If any underwriter or underwriters are utilized in the sale of the securities, unless otherwise indicated in the
prospectus supplement, the underwriting agreement will provide that the obligations of the underwriters are subject to conditions precedent and that the underwriters with respect to a sale of securities will be obligated to purchase all of those
securities if they purchase any of those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may grant to the underwriters options to purchase additional securities to cover
over-allotments, if any, at the public offering price with additional underwriting discounts or commissions. If we grant any over-allotment option, the terms of any over-allotment option will be set forth in the prospectus supplement relating to
those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sales of securities in respect of which this prospectus is delivered, we will sell those
securities to the dealer as principal. The dealer may then resell those securities to the public at varying prices to be determined by the dealer at the time of resale. Any reselling dealer may be deemed to be an underwriter, as the term is defined
in the Securities Act, of the securities so offered and sold. The name of the dealer and the terms of the transaction will be set forth in the related prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited by agents designated by us from time to time.
Any agent involved in the offer or sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable by us to the agent will be set forth, in the applicable prospectus supplement. Unless otherwise
indicated in the prospectus supplement, any agent will be acting on a reasonable best efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the Securities Act, of the securities so
offered and sold. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us and the sale of those securities may be made by us
directly to institutional investors or others, who may be deemed to be underwriters within the meaning of the Securities Act with respect to any resale of those securities. The terms of any sales of this type will be described in the related
prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers, agents and remarketing firms may be entitled under relevant agreements entered into with us
to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, that may arise from any untrue statement or alleged untrue statement of a material fact or any omission or alleged omission to state a
material fact in this prospectus, any supplement or amendment hereto, or in the Registration Statement of which this prospectus forms a part, or to contribution with respect to payments which the agents, underwriters or dealers may be required to
make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the prospectus supplement, we will authorize underwriters or other persons acting as our agents to solicit
offers by institutions to purchase securities from us pursuant to contracts providing for payments and delivery on a future date. Institutions with which contracts of this type may be made include commercial and savings banks, insurance companies,
pension funds, investment companies, educational and charitable institutions and others, but in all cases those institutions must be approved by us. The obligations of any purchaser under any contract of this type will be subject to the condition
that the purchase of the securities shall not at the time of delivery be prohibited under the laws of the jurisdiction to which the purchaser is subject. The underwriters and other persons acting as our agents will not have any responsibility in
respect of the validity or performance of those contracts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One or more firms, referred to as &#147;remarketing firms,&#148; may also
offer or sell the securities, if the prospectus supplement so indicates, in connection with a remarketing arrangement upon their purchase. Remarketing firms will act as principals for their own accounts or as agents for Teva or any of its
subsidiaries. These remarketing firms will offer or sell the securities in accordance with a redemption or repayment pursuant to the terms of the securities. The prospectus supplement will identify any remarketing firm and the terms of its
agreement, if any, with Teva or any of its subsidiaries and will describe the remarketing firm&#146;s compensation. Remarketing firms may be deemed to be underwriters in connection with the securities they remarket. Remarketing firms may be entitled
under agreements that may be entered into with Teva or any of its subsidiaries to indemnification by Teva or any of its subsidiaries against certain civil liabilities, including liabilities under the Securities Act, and may engage in transactions
with or perform services for Teva or any of its subsidiaries in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disclosure in the prospectus supplement
of our use of delayed delivery contracts will include the commission that underwriters and agents soliciting purchases of the securities under delayed contracts will be entitled to receive in addition to the date when we will demand payment and
delivery of the securities under the delayed delivery contracts. These delayed delivery contracts will be subject only to the conditions that we describe in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any ADSs will be listed on the NYSE, but any other securities may or may not be listed on a national securities exchange. In connection with
the offering of securities, persons participating in the offering, such as any underwriters, may purchase and sell securities in the open market. These transactions may include over-allotment and stabilizing transactions and purchases to cover
syndicate short positions created in connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offering. Stabilizing transactions consist of bids or purchases for the purpose of preventing or retarding a decline in the market price of the securities, and syndicate short positions
involve the sale by underwriters of a greater number of securities than they are required to purchase from any issuer in the offering. Underwriters also may impose a penalty bid, whereby selling concessions allowed to syndicate members or other
broker-dealers in respect of the securities sold in the offering for their account may be reclaimed by the syndicate if the securities are repurchased by the syndicate in stabilizing or covering transactions. These activities may stabilize, maintain
or otherwise affect the market price of the securities, which may be higher than the price that might prevail in the open market, and these activities, if commenced, may be discontinued at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting (which is included
in the Report of Teva Management on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 have been
so incorporated in reliance on the report of Kesselman&nbsp;&amp; Kesselman, Certified Public Accountants (Isr.), a member of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of
said firm as experts in auditing and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_15"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters with respect to United States and New York law with respect to the validity of certain of the offered securities will be
passed upon for the issuers by Kirkland&nbsp;&amp; Ellis LLP, New York, New York. Certain legal matters with respect to Israeli law with respect to the validity of certain of the offered securities will be passed upon for the issuers by Agmon with
Tulchinsky Law Firm, Israel. Certain legal matters with respect to Dutch law will be passed upon for the issuers by Van Doorne N.V., Netherlands. Any underwriters will be advised about other issues relating to any offering by their own counsel. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_16"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Available Information </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus is part of a Registration Statement that we filed with the SEC. The Registration Statement, including the attached exhibits, contains additional relevant information about us. The rules and regulations of the SEC allow us to omit some of
the information included in the Registration Statement from this prospectus. In addition, we file annual and quarterly reports and other information with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC maintains an Internet website at <U>http://www.sec.gov</U> that contains reports, proxies, information statements and other material
that are filed through the SEC&#146;s Electronic Data Gathering, Analysis and Retrieval (EDGAR) system and filed electronically with the SEC. We began filing through the EDGAR system on October&nbsp;31, 2002. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information about us is also available on our website at <U>http://www.tevapharm.com</U>. Such information on our website is not part of this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Incorporation by Reference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules of the SEC allow us to incorporate by reference information into this prospectus. The information incorporated by reference is
considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following documents filed with the SEC are incorporated into this prospectus by reference: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/818686/000119312525020826/d865574d10k.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Those portions of our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/818686/000119312524097745/d11454ddef14a.htm">Schedule
 14A</A> filed with the SEC on April&nbsp;16, 2024 that are incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus all documents (other than current reports furnished under Items 2.02 or Item 7.01 of
Form <FONT STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items) that are filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus
until we sell all of the securities covered by this prospectus or the sale of securities by us pursuant to this prospectus is terminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement contained in a document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for
purposes of this Registration Statement to the extent that a statement contained in this prospectus or in any other subsequently filed document which is incorporated or deemed to be incorporated by reference modifies or supersedes such statement.
Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also obtain copies of these documents free of charge through our website at <U>http://www.tevapharm.com</U> or by contacting us at our
address or telephone number set forth below. Other than the documents incorporated by reference herein as specified above, the documents and other information on our website are not incorporated by reference herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Industries Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Investor Relations </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>124
Dvora Hanevi&#146;a Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tel Aviv, 6944020, Israel </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">+972-3-914-8213&#8201;</FONT>


<IMG SRC="g830217g84p82.jpg" ALT="LOGO" STYLE="width:0.141368in;height:0.141368in;">
 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx830217_17"></A>ENFORCEMENT OF CIVIL LIABILITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Pharmaceutical Industries Limited </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Teva is organized under the laws of Israel and certain of Teva&#146;s directors and officers reside outside of the United States. As a result,
service of process on them may be difficult to effect in the United States. Furthermore, a substantial portion of Teva&#146;s assets are located outside of the United States. Therefore, any judgment obtained in the United States against us or any of
our directors and officers may not be collectible within the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to various time limitations, an Israeli court may
declare a judgment rendered by a foreign court in a civil matter, including judgments awarding monetary or other damages in non civil matters, enforceable if it finds that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was rendered by a court which was, according to the foreign country&#146;s law, competent to
render it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment is no longer appealable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the obligation in the judgment is enforceable according to the rules relating to the enforceability of
judgments in Israel and the substance of the judgment is not contrary to public policy in Israel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment can be executed in the state in which it was given. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A foreign judgment will not be declared enforceable by Israeli courts if it was given in a state, the laws of which do not provide for the
enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty or security of Israel. An Israeli court also will not declare a foreign judgment enforceable if it is proven to
the Israeli court that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was obtained by fraud; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">there was no due process; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment was given by a court not competent to render it according to the laws of private international law
in Israel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the judgment conflicts with another judgment that was given in the same matter between the same parties and
which is still valid; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time the action was brought to the foreign court a claim in the same matter and between the same parties
was pending before a court or tribunal in Israel. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Teva Finance Netherlands II, Teva Finance Netherlands III and Teva Finance
Netherlands IV </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Netherlands BVs is organized under the laws of the Netherlands, and its managing directors and
supervisory directors reside outside the United States, and all or a significant portion of the assets of such person may be, and substantially all of the assets of each the Netherlands BVs are, located outside the United States. As a result, it may
not be possible to effect service of process within the United States upon any of the Netherlands BVs or any such person or to enforce against any of the Netherlands BVs or any such person judgments obtained in United States courts predicated upon
the civil liability provisions of the federal securities laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and the Netherlands do not
currently have a treaty providing for reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any federal or state court in the United States based on
civil liability, whether or not predicated solely upon the federal securities laws of the United States, would not be directly enforceable in the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the party in whose favor such a final judgment is rendered brings a new suit in a
competent court in the Netherlands, that party may submit to Dutch court the final judgment that has been rendered in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Dutch court will generally grant the same judgment without <FONT STYLE="white-space:nowrap">re-litigation</FONT> on the merits if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the jurisdiction of the court that rendered the judgment has been based on a ground of jurisdiction that is
generally acceptable according to international standards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that judgment results from judicial proceedings that meet the requirements of proper and sufficiently
safeguarded judicial procedure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the recognition of that judgment does not conflict with Dutch public policy; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the judgment is not inconsistent with a judgment rendered by a Dutch court between the same parties, or
with a previous judgment rendered by a foreign court between the same parties in a dispute concerning the same subject and relying on the same cause, provided that such previous judgment qualifies for recognition in the Netherlands.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recognition by the competent Dutch court may however be prevented on the ground that the relevant judgment is not, not
yet or no longer formally enforceable according to the law of origin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the foregoing and provided that service of process
occurs in accordance with applicable treaties, investors should be able to enforce in the Netherlands final judgments in civil and commercial matters obtained from U.S. federal or state courts. However, it is doubtful whether a Dutch court would
accept jurisdiction and impose civil liability in an original action commenced in the Netherlands and predicated solely upon U.S. securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>$2,000,000,000
(equivalent) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830217g41p95.jpg" ALT="LOGO" STYLE="width:1.61526in;height:0.569581in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>&#128;&#8195;&#8195;&nbsp;% Senior Notes due 2031 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;% Senior Notes due 2032 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands IV B.V. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>$&#8195;&#8195;% Senior Notes due 2030 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#8195;&#8195;&#8195;, 2025 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Active Joint Book-Running Managers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>BNP PARIBAS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>BofA
Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>HSBC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">IMI-Intesa</FONT> Sanpaolo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>J.P. Morgan </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Passive
Joint Book-Running Managers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Goldman Sachs Bank Europe SE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Mizuho </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>MUFG </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>PNC Capital Markets LLC </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g830217g04r34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830217g04r34.jpg
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M*"@H*"@H*"@H*"@H*"@H*"@H_\  $0@#8@=5 P$B  (1 0,1 ?_$ !T  0$
M P$! 0$!           '! 4& P(!" G_Q !D$  ! P,! @4." L%! D" @L!
M  (#! 41!A(A!Q,7,584%18B-T%15Y.4E;/1T@@R56%Q='6R(S8X4E1S=H&1
MDK$T-5-RM#-"HN(D8H*#H:2EQ-,E0\)$8\'P&"9%9(3A\:/_Q  6 0$! 0
M                 0+_Q  6$0$! 0                   1'_V@ , P$
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M\C3>?3^^G(;H'Y&F\^G]]4M$$4MNCK+H[ART[3:>I7TT-1;:F25KIWR;3A@
M]L3A6M334'=\TI]E57]0J6@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MT3L/I$^Q.O7"ET3L/I$^Q4I$$TT_K/579[;].:IL=NH>K*:6HCDIJDRG#/\
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M*7/9U/5,';R!F<1[4;G/P,8,1'?5$FIX9MCCHHY-AVTW;:#LGPCP%?9:"02
M2TY!(YD$DU%?V46HRVEO,\1H[W14DL=16%I;$YD8>T1YPZ,AVT9'Y)<3X 57
M%YNIX7/<]T,9>[&7%HR<<W\%Z("(B B(@(B()IJ#N^:4^RJK^H5+4TU!W?-*
M?955_4*EH"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("FFD>[EK[ZI
M0?<*I:FFD>[EK[ZI0?<*"EHB("(B B(@(B("(B B(@(B("(B B(@FFA.[-PF
M_P"6V^H<J6IIH3NS<)O^6V^H<J6@(B("(B B(@(B("(B B(@FGP<^Y90_6:G
MUSU2U-/@Y]RRA^LU/KGJEH"(B B(@(B("+6:GN[+!IVYW>6)TT=#3OJ'1M."
MX-:3@']RT&A.$K3.M8FBSU[6UF,NHZC\',W_ +.>V^EI(0:;@T[I?";]<I?4
ME4M33@T[I?";]<I?4E4M!I]8VZIN^E;O;:'B145E)+3L,SRUC2]A;DD G=GP
M+7SV>YR:-MUFV*,OXN&FK?\ I#VM,+0!(&$,R2YH(W@?&YUU"(.+K-*55'K.
MT7O3P@:V.&6EKVU55*730NP6AN0[>UPR-XYR.^LK0E@K+*;TZY1T1DK+E/6Q
M/@>7EK)"#LDEK<$8[V5U2(.7TS9;A;M5:HN-8*3J:Z30RPB*5SGMV(FQX<"T
M#?LYW$KQO%ANE3KF"\TK:(TD5KGH=F2=S7E\CV.!P&$8&QCG[ZZY$' Z?TE=
MJ!^CQ4NH3'9[5+;YW1S/)<YXB <P%@R/P7?(Y_F6NH]&7^W6S3#H8K)65EHI
M'VZ6FJ7O,,\)V,2-?L$L>#&#C9(P2,KINS:B$%VJ'4-Q%+:IWP5DPB:X1.:T
M.<=D.+B UP.0#N70LJXYJ!M929J89(Q+'Q1!XQI&1LY(&\?.@YJUV&Y4FK8K
MF]EN%*+7U&60N='B3C#)VK-G 9OQG.>_A::U:/OM'1:5BXRW,FM,U7))(V9[
MA^%;*UI:"P9P9 2#CF73VC55#==*/U!2QU H6,D>6R-:V3$9(=NSN(+3N)',
MMU1SFII8IS%+#QC0[BY0 ]N>\0"<%!.K5HV^]5F>Y.MS99K));*F9D\DKY)2
M01+O8-Q_-_W1N&>]L*+3%W,ND#6B@:RU4<U)4B*H>2=J-L8+,L&?BYWXQG&_
M&3W2(. LVD+E!;=,6VX.I'T^G9N-@GCD<'5(9&^.(.;L]IN>"[>[>W=G.[&M
M>CK]16[2D+)K='46B"JC?*V5[QM2,+6.:"P9P2"0<*D(@G%HTG?H:V>KJVVP
M35%EZWS%M5)(Z28.<>,+BS.#M?\ 9Q@ ][LM)4%1:M+VBW5G%&HHZ2*G>8G%
MS"6,#<@D X./ MJB IKP5?CKPD_:S/5JE*:\%7XZ\)/VLSU:"E(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("X_AB[ENJ?J$O]%V"X_AB[ENJ?J$O]$&VT1^)E@^SZ?U;5NEI=$?B98/L
M^G]6U;I 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$
M0$1$!$1 1$0$1$!$1 4TU9W=-!_4Z_[@5+4TU9W=-!_4Z_[@04M$1!QG#+(^
M'@RO\\,DD4T5/MQR1N+7,=M#>"-X*XW6E%<H;=K&HHF5]-IL6(XCJ)7#:K 2
M=N-KCM- ;N/,"<<_.J;JZPQ:FT]66>IJ)J>GJV[$CX=G;V<YW;0(_P#!?NH+
M(R^::J[-5U4S(JJ$P231AH?LD8)&00#^Y!I8M55T-1>:*HM#.JZ"CAK(6150
M(FCD+VC:<YH#"#&<\XQS$K$J-?R0VR\U#+=%42VVOIJ-S8JD[$K9N*V7L<6_
M_I1NQC=SK/O&B(+K-<9:BXUC9*VC@HW&,,&R(GE['#M>?:<<@Y!!QA>-5H**
MJCNPGO%Q>ZY5%-4SO+8LB2#8V2.TP,\6S(^;YT'A6:OOM)65U#+8*+JVDMYN
M+@+@2QS!(]NR'<5G)#,\V-_>PO:@UI55-4R-UG[2IM#KO1-BJ Z25K=@&-P+
M0&N/&-QVQ'/O"V=PTNRMNU;<'UU0R6JM_6YS6M9LM9EQVAD9VLN//N^9:VIX
M/Z2II8*>:X5W%16B2RC9V&DPOV<N)V?C=HW?S;N;>@\:;7S#+<*>HI(C4T[Z
M..'B*C;CF?4N+& /+1C#@02,C R,\RV-7J6MM^S#<K5Q57/6=24G%RF5E0.+
M,A>-EI>  UX(V<Y;X#E8-3P>4M:*\U]VN4\U9!3Q.E'%QNC? XNBE9LL&RX$
M_1X05EU^C>N%IA@KKU<I;E!.VIAN0XMDL4C00-EK6AFSAS@6[._:.>=!XVW5
MU;47.U4-;99*.:MDJHLRR.;@PC:#VAS 7,<",$@$;]VY8%OUC<[M=-+"EHZ:
M"FN+JT3L=,7.!@<6;CL<W^]S;S@;N_N:C2;IC:IW7FOZY4$KY>K2(R^3;9L/
M:6[.P 1C& ,8'SYQ[9H6FMS;-U/<J_;MDU1+&YQC)>V9VT]CNUYL]_G^=!B:
M>U)$2:*@MD=/7U=SKHN*-07,+H7GC92[9SO.-P'^\.\O2^:RN-GLIKJ^QMIY
M8J.:JFAEK&[S&=\<9:"7$M!=G  &,XWX^I= 0<4Q]-=:^FKX:^>XP5D8CVXG
MS$\8S!;LN8<G<0>]O7I=="0W$S&2[W)IJ+?);JEP,9,['ESBXY9VKLN/Q<#&
M!C "#67*ZBAUU47:*">=C--NJN(9DN?B4$ #?OQX!_%=5I6^,O\ ;Y*RGDHY
M:;C-F*6EGXUCQL@DG<"T@D@M(R,?.L#L1 K65<=VKV5#+=UN;(T1@ANT';?Q
M?C9 ^;YEL;#8:>SU%QJ8G!U3<)6S5#FL#&EP:&@AHW9P,D\Y/[L!MT1$$TU!
MW?-*?955_4*EJ::@[OFE/LJJ_J%2T!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!332/=RU]]4H/N%4M332/=RU]]4H/N%!2UH]66R"LM]153F;C*:
MEFXL,E<QH);G:(!&2-D8SS9/A6\6/<J7JVWU%+QCHA-&Z,O: 2T$8.,[D$_T
M;/367@\TYJ"<U4]=4T%+3N:9GOX^68Q@%PW[]H\X!."=QYEL:K6=PHJ6:HKK
M$^"G@KH:66>21[(^*D+0)F[48)#2[#@0,8SDA;#L,HG:'I],35-4^EIXHXX:
M@.#)HS&08WAP&-II:#G'>61#IMLM@KK9>;A57;JV)T,\U0&-<6$$8 8T-&,D
MYQG)SE!Y5^H:J!SC%10&G-8ZE;4R5.PP!K"2YW:Y^.#&&M!)/@69I*\LU)IF
MBNG4Y@%5&2Z%QVMD@EI&<#(R#W@L.ITG"^"Q,IJ^LI9;0XF*5A:]TF6%CB_;
M:0202<XSDGPK,TM8H].V**UTM5//%$7F-\^R7-#G%V-P .,H)E0U\\?!'JW%
M)<I98W738K!(#L;$DH80XOVALAHYANQN77674$[+;3VVT4;*VLHK33UE0)9S
M'M<8T[+0=EV7.V'$D_-X=V92Z+AI](W33PN-6ZEN!J.,E<&<8T3EQD [7'.]
MV,@X7U#HZ.EJ8*FAN573U3:%EOFE:UAXZ)F=@N!;@/;DX</"<@H.<IM3V^?5
M5/J=KY66Q^EY*]X=G+6"5CCVN<;0&1N7W-6UT_"#:JNIH8HQ-8*N9L+:IS@_
MMX#LN[7#2,\XSSGP;]\="VOC&,:910-M3K/U&,;!@=C._&UM;AORO*WZ(=2U
M5%42WVXU,E%1RT$)E;%_LG['QL,RXC8;O[^/I0:^QZIJ#0:5H+'9*=K;E9S6
MT\<M:YK80P1?@W'8)(Q(.VWG=S=]9MOUN;G1V!]#0 5-VH9:YK)YMAD8C#-I
MFT&G)R\#FY@3\QR;3HR&V26)]/<*HFST#[?!MM8=J-VQO=VN]WX-G-@;N;>N
M7O>EI[;#8+12NO,ELMU-(R.J@IJ>J)>X@;,D;VD##0<.#?\ >(R-^0VE-PAB
M>DLLDE%!1S7:D%53,JJDQME).Z)K]C!DP<X..<8SSC-X3[O56VV6FEHIG4TE
MVNE/;75+-SH62$ESFGO.PT@'O%P*^#I6JOFGS1:BK99(IX33RP.@B&6![BQ^
M&@ADH:0,MW;ANR 5T.H;%0W^T26VY1N?3N+7-<UQ:^-[3EKVNYPX$ @H-#>X
M+/8;A8&M@K(9ZBL$$+Z=Y(F>6.[6;+AM@M#CEV=XSS\_$::ND-5J"_:7KIJB
MDAK;S5M95/>X<8R,LQ30OSVKN<]X@'M=YRVBSZ8?6U5IENETJ*L6R?JF#\&Q
MA=(&N:'/(&_<X[@&A:^;@]H*BRWJVU574S1W.L?7F4A@DIYW8[>(AO:D8&#O
M(0=?3PQT\#(86[,;!AHSG 7HL*S4<UOM\5-4U]17OC&SQ]0&B1P_ZVR "?GP
MLU!--"=V;A-_RVWU#E2U#X-;6?1W#-P@F].JF]5"W\7Q%.^7XL!SG9!Q\8+I
M>6W1_P#BW/T?-[J"EHIIRVZ/_P 6Y^CYO=3EMT?_ (MS]'S>Z@I:*:<MNC_\
M6Y^CYO=3EMT?_BW/T?-[J"EHIIRVZ/\ \6Y^CYO=3EMT?_BW/T?-[J"EHIIR
MVZ/_ ,6Y^CYO=3EMT?\ XMS]'S>Z@I:*:<MNC_\ %N?H^;W4Y;='_P"+<_1\
MWNH*6BFG+;H__%N?H^;W4Y;='_XMS]'S>Z@?!S[EE#]9J?7/6PX=*^KMG!5?
MJRVU4U)5Q-BV)H7ECVYF8#@C>-Q(4VX%^%'3>G= TENN3ZX5+)YWD14<DC<.
ME<X;P,<Q7KPQ\*FFM0<&]ZM=N?7FKJ&QA@DHI&-W2L<<N(P-P**Z^GX+)Y:>
M*1VO];@N:''%R'?'^5>G)3-T_P!;^DA[B\Z7AKT@REA8Z2YY:P __3Y?!]"]
M>6W1_P#BW/T?-[J#\Y*9NG^M_20]Q.2F;I_K?TD/<7[RVZ/_ ,6Y^CYO=3EM
MT?\ XMS]'S>Z@_.2F;I_K?TD/<3DIFZ?ZW])#W%^\MNC_P#%N?H^;W5T.BM?
M6+6516P6.:H?+1ACIFS0.B+0[.S\8?,41/M?\&<]#HB_50UIK"L,-%+(*>>O
M#XY<,)V7-V=X/,0I!P=<!>J=02P5M?M6&A!#VRS B<_.R/<1])(_>O[*1%U)
M>!6W.M&LN$*@?655<ZGJ:1AJ:I^W+)^!.]Q[Y5:4TX-.Z7PF_7*7U)5+1!$1
M 1$0$1$$1DDI*NT\)$/9,Z@,USJ-BGB=$[CQQ$8P&[)D<'$%O:$$XW8*I6C;
MFP6'3U#<*>.VW2>WLE%O:".+:QK0X 'F VFC!.1^Y=)WTQOSWT$UI+=5V_6]
MTTW% \V2ZRMO#9 .TB /X>+_ +4@C./!(Y4".X4DERGM[)VNK(8V2R1#G:QQ
M(:?WEI_@LI!CG&$!$1 1$0$1$!0K3FCWZEU]P@2LU'?[1Q-S:S8ME4(6R98#
MEPP<E7537@J_'7A)^UF>K0?/)3-T_P!;^DA[B<E,W3_6_I(>XJ8B"9\E,W3_
M %OZ2'N)R4S=/];^DA[BIB()GR4S=/\ 6_I(>XG)3-T_UOZ2'N*F(@F?)3-T
M_P!;^DA[B<E,W3_6_I(>XJ8B"9\E,W3_ %OZ2'N)R4S=/];^DA[BIB()GR4S
M=/\ 6_I(>XG)3-T_UOZ2'N*F(@F?)3-T_P!;^DA[B<E,W3_6_I(>XJ8B"9\E
M,W3_ %OZ2'N)R4S=/];^DA[BIB()GR4S=/\ 6_I(>XG)3-T_UOZ2'N*F(@F?
M)3-T_P!;^DA[B<E,W3_6_I(>XJ8B",Q6:OTCPMZ,H8]4ZBNE'<F5IGAN-896
M?@X26[@ .<YWYY@K,IIK7NU\&_ZNX^H"I: B(@(B("(B B(@(B("(B B(@(B
M("(B B(@(B("X_AB[ENJ?J$O]%V"X_AB[ENJ?J$O]$&VT1^)E@^SZ?U;5NEI
M=$?B98/L^G]6U;I 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 4TU9W=-!_4Z_[@5+4TU9W=-!_4Z_[@04M$
M1 1$0<D^^7.775PL4,M!!3T]##6MEE@<]QVWO;LG\(!NV,Y^=;:WWF(LIZ>O
MJJ8W"2!U2&0@XDB:0-M@.3C!;NR<;07+UUDGEX1KC=:W3IN5NEML-)$3Q#^W
M;)(YQV7O&!AX7JZ@N\6H-.72"S8AIJ2JH'4K9V!U.Q[XC$YQ)P1B+?LY(SN!
MP@WE5K'3M+34]147FB9#40FHB<9!V\8P"\>$;QO69U^M?5S*0UL(G>\QM!.
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M;\<^-_A7NN(X2J]KM.0U5LE$E51W>C9&6'/X0SQM<T'OY:]S3])'A7;H"(B
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M7'Q?XL?\P6N=048NLU='+$'5,0AJ8S@MF:W.R2/"-HC/?!P>]CCN1'@^Z/\
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M_P#\Y4?_ "(*%Q\7^+'_ #!./B_Q8_Y@I[R(\'W1_P#\Y4?_ ")R(\'W1_\
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M^$/ZO;_5.5+4TT;W;^$/ZO;_ %3D%+1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M^:QIR>ZK\9EY\UC04U%,N3W5?C,O/FL:<GNJ_&9>?-8T'UK7NU\&_P"KN/J
MJ6OYZU-I#4%-PIZ*H9M<7*HJZJ.M,-8^GCVZ;9BRX-',=H;CE=UV :L\9=W\
MSB15+133L U9XR[OYG$G8!JSQEW?S.)$4M%-.P#5GC+N_F<2=@&K/&7=_,XD
M%+133L U9XR[OYG$G8!JSQEW?S.)!2T4T[ -6>,N[^9Q)V :L\9=W\SB04M%
M-.P#5GC+N_F<2=@&K/&7=_,XD%+133L U9XR[OYG$G8!JSQEW?S.)!2T4T[
M-6>,N[^9Q)V :L\9=W\SB04M%-.P#5GC+N_F<2=@&K/&7=_,XD%+133L U9X
MR[OYG$G8!JSQEW?S.)!2T4T[ -6>,N[^9Q+)X$+G<[GI>XF]7"6X55+=*BE$
M\H <YK" -PW>'^*"A(B("X_AB[ENJ?J$O]%V"X_AB[ENJ?J$O]$&VT1^)E@^
MSZ?U;5NEI=$?B98/L^G]6U;I 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&#?O[CN/U
M:3[I7(< W<CTU]7=]]RZ^_?W'<?JTGW2N0X!NY'IKZN[[[D'>HB("(B B(@(
MB("(B B(@FE%^45<?V;C_P!0J6II1?E%7']FX_\ 4*EH"(B"::0[N7"!]5M_
MJRJ6III#NY<('U6W^K*I: B(@(B("(B B(@(B("(B B(@(B("(B M-K2YS67
M2-ZN=*P25%'1RSQM(R"YK"1GYMRW*^9HF31/BF8U\;VEKFN&0X'<00@G51:H
MX^"E]WCJ']?&6OK@+IM?AC,(^,VB[\TG=L_%V=V,+TM&N;I6"GXRV4D<,=IH
M[M63R5+FED4H>9,,##VS=AQ S@^$+=MT;2BS"RFNK76,#8ZB+FXXK_"+]G;V
M,;L9SC=G&Y9@TS1]>ZZXODF>*RC902TIV.)XII=@ !NU_ON[_?0<D*ZKNFN=
M$7.2D@ABK*&KFA E)>&ED;FM?NQG!!R,X)(W\Y^]/:IJ>H-.4EGL=%3BZ&MV
M8S5.#(7Q2.S_ +F2"<G/A.,=];>T:&AMM3:)67BZ3,M+)(:..4Q$1QO &P3L
M9< &@ DYW#>O2UZ'I+:^SN@N-Q<;6ZH=!MF([7'$E^UB/?S[L8_>@P8];5=1
MIJW7.*WP1OJ(J@R-DGRULL+BTQM &T\N(=@@;@TD^!?L.L;G<:RS4]FM-*\W
M*U-NC75-66;#=J,%APP[P)-Q[Y\"]J;@_HJ6.A93W2Z,ZECJ8=K:BS)'.\/D
M8[M,#M@""W!'A678]'4UFJ[54P5]PF?;;>;=$R4QD/BRT]MA@.>T;O!'-]*#
MPLFJJJXM93R4,$-T9<9*&IIA,7")K 7&3.R,@LV'#</CM"PN$.*Y076W72*T
M&_V:GADCJ[:P@RM+BTMF8P[I' -<,<^\XYRO6VNHZ*ONNL[]1NL(E@BIGBMD
M8"UK7$%[MEQ:"XEC>?.&-^A=#76IU77QU]+<:JEE$7%8BV',>TG/;-<TY/@(
MQW_"4$[AJZ.KK=!5>EGFL8^IKQ%U5(]CF9CD)CD)!<-@DC!!.Y=%2ZRK*JP4
M%:RWT\4TSZF&8/GRQDL+G,V&@#;>7.:<8&X9)YL'/I-%4-)4VNH@JZULU!43
MU6UF/\/+,'"1\G:=_:.YN /W+'I=!4E*:!U/=+HQ](^J<'AT67MJ'[<C#VF,
M;0!! #AX4&);M:W*\5-EBM-HI2+E:H[KFHJRWBVE[ YAPPY(#]Q[^.\O:CUG
M65KJ:JHK)4U=KJ(YGMEA:_;9L EA.6AIV]G P3@D<_>S-.:*I+#56R>FN%PF
M-OH.ML3)C&6F+:!&<,!R-EN\$<WTKXM>B*>V.JHZ2ZW5EOE,KH:+C6\53.DS
MM.C[7:W;1(!) )SCFP&3HO4C-2TLM1!)221,# >(D)=&\YVHY&. <QS<#GY\
MYW<RT>B]C5-WU56WJ-M2**ZRVVFIY1M1P1Q!HV@T[MIQ)<7<^,#F"Z>S6""V
MW*MN''25%=61Q133/:QI>V/:V<AH )[<Y./!W@ L<Z7CAO57<[57U=NFK2TU
M4<(8Z.9P& \M>TX=C R,9P,Y0;*RVV.U41I89)9(A+)(TRO+W />7;.2<D#:
MP/F 6<O&DIQ30",/?(<DN?(<N<3SD_\ ^-PYA@+V0$1$!$1 1$0$1$!$1 1$
M0$1$$T^#GW+*'ZS4^N>O?X0O<>U'_DA]?&O#X.?<LH?K-3ZYZ]_A"]Q[4?\
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M0J6II5?E%T/[-O\ ]0J6@(B("(B B(@(B("(B B(@(B("(B IH_\HZ/]EO\
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MNO,<3I-N2(QO+9&![SDM(PX9)P0<>!;VGU/45L\= +1+%75,3ZB**2I:W-.
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M'VS_ /@*I:FG"S^-O!Q]L_\ X"J6@(B("(B B(@(B("(B B(@FGP;^XY8?\
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M<76WGJ;%?2'JG_8?AF_A?\N_MOW+T;6TKJMU*VI@-2W>81(-L?\ 9YU-;K9
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MHI=ICL,VV.=M-[;O;&,'PK(X2*"LNNA+[;K93NJ:RLI)((HP]K<N<T@$EQ
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M%EV^>:H@<^II)*1XD>P1O<UQ+0X@.RTD8< #CG&=Z#74M)<IKFVX7%E)%)!
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M^K2?=*Y#@&[D>FOJ[OON16#R;W_QD:D_X/8G)O?_ !D:D_X/8J6B(FG)O?\
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MFY7&VUD$$-%0RSB-\'&&21K2X9.1ANX?3GO8W^.G+C7LLM#=;Y<(9::LI()
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M$!33@#_%R_\ V]6_>"I:FG '^+E_^WJW[P0. ;^Y]4?M%6_>:C_RC8_V9/\
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M10W2C#FPU=.6[6P[XS'!P+7-.!N(YQD8*V%!1OIMI\]5-5S. !DEV1@#O -
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M&_N?5'[15OWFH_\ *-C_ &9/^I3@&_N?5'[15OWFH_\ *-C_ &9/^I04M$1
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MN^:4^RJK^H5+0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M=S6AS=^<;\\V5S&A;_>+W8:.]W*6UQ4+W3BH8R%\9B$;WM#]MTA&.TW@CO\
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M41$!$1 1$033@A_&/A%^WG_<:J6IIP0_C'PB_;S_ +C52T!$1 1$0$1$!$1
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M;&ZMKY(Z&VR6J-KG,&U"\-!VB& [6&,W@CF^E>NG]'P6:Y4]<VY7&JFAHFT
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M\HUW[,?^Y5+4T;^4:[]F/_<JEH"(B B(@(B("(B B(@(B("(B B(@(B("(B
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M>C/^9.52?Q?ZX]&?\R#VY$N#WHY'YS-[Z<B7![T<C\YF]]>/*I/XO]<>C/\
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MKF(1W%G_ +IHOU#/NA9:Q+/_ '31?J&?="RT!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!331O=OX0_J]O]4Y4M331O=OX0_J]O]4Y![\,UJO-PI=-5.GK8ZYU-
MLO$-<^G$S(MIC&O_ -YQP-Y [_.O#LTU_P"+&;TS![%2T033LTU_XL9O3,'L
M3LTU_P"+&;TS![%2T033LTU_XL9O3,'L3LTU_P"+&;TS![%2T033LTU_XL9O
M3,'L3LTU_P"+&;TS![%2T033LTU_XL9O3,'L3LTU_P"+&;TS![%2T033LTU_
MXL9O3,'L3LTU_P"+&;TS![%2T033LTU_XL9O3,'L3LTU_P"+&;TS![%2T033
MLTU_XL9O3,'L3LTU_P"+&;TS![%2T033LTU_XL9O3,'L3LTU_P"+&;TS![%2
MT0?P7IK76J=+:BJ76"JGA?+4N+Z$_A8WN+CVI9S$][(P?G7] :$O5\OW#/:J
MW4UC=9JXZ=D'$E^=MO'CM]D[V9.1LNW[E2=(<'VF]*32U%IMT?5TKG.?5S=O
M*23DX<?BCYA@+GZS\HNW_LW)_J$52U^/:'L<TYP1@X)!_B%^HB,"S6>ALM&:
M6UP=3TY<Y_%A[B-IQ))&2<9))/SE8D6EK/$VG;'1EK:>I=61#C7]I,[.T\;^
M<[3OYCX2MTB#1.TC8WANW;V.+:EU6TE[B1*X8<[.<]MDY',>_E?M#I.R4$E,
M^AH&T[J9LC83$]S>+$AR\#!W9('\!X MXB#GJC16GJB@H:*:UQ.IZ%Q=3-VG
M9BSSAKLY /?&<%>MQTC8+C6TE766JFDJ*1@BA?L[.RP;PP@;BT?FG(6\7 WN
M\STO"-+;JJ]U-#;#:!5M;''&=F3C7-)R6./,.9!VUPHJ:XT4U)7T\532S-V9
M(I6AS7#P$%8UMLE#;<=2QRDM;LMXZ=\NP/ W;<=D?,,+2\&5ZK+_ *6;75[V
M3;51-'!4-:&&>%KR&2%H^*2 "1N^@<RP[#>*NW:KU/:=0W&2:.")MQHI)&,:
M!2$$/':M&2Q[2"3G<6H.AMVG+5;3FAI!" U[&!KW8B:XY<(QG$8)QN;CF"^*
M72]GI!;A34?%BW[0I V5^(=H8=L[^^-R]=,1UK+- ZZ5$TU7+F5W&M:#&''(
MC[4 =J"!GOXRMH@XJNT8P7[3\MMAB@ME ^IEE:*F5DFW,!DL(W\^2>V&<GPE
M;FHTG8JD4PFME.X4\;X8]Q':/.7-/YP)WG.=^_G6\1!I(-*V:GV.(HA'L4O4
M3=B1XQ#^9S\V=_TK$%AG-=047$T$>G+:8Y:6,%[YN,8"&M.UN:UI(((.=P',
MNF1 1$031OY1KOV8_P#<JEJ:-_*-=^S'_N52T!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0%-. /\7+_]O5OW@J6IIP!_BY?_ +>K?O! X!?[@U%]OUOW
M@C_RC8_V9/\ J4X!?[@U%]OUOW@C_P HV/\ 9D_ZE!2UK[?9:"WUU964<!CJ
M:QP=42<8YQD(& 3D\X Q]"V"(--;-+62V76IN5OML$%;4.+I)& [W'XQ Y@3
MWR ,]]94EFMTD%QA?10.BN))JV%NZ8E@8=KP]JT#]RSUA7>Y16RF9--'-*9)
M60LCB;M.<][@UH\ WGG) "#%M&F[1:*IU3;J&.&I=$V!TH)<YS&DD DDDXR=
MYWKW99:!EZ?=FP$7%\7$NFXQV2P'(;C.,9)./"M*-<VTQT1;35[Y:JLFM[8F
M1!SFSQ!Y<QV#C_<.""1W\XWK(HM74%;04L\$55U145,M&RC<UHF$T9<)&D9V
M1L[#B3G&[GWC(9]78K=5ULU744Y=4S4YI9'\8X;41W[&X\V25KYM#Z<F862V
MJ%[3 RG(+G$&-GQ =_\ N]X\X&X%87!W=JFMLMXJ;G-4/-/<ZN(&H:T/9&QY
M :0W=N QN7CHFJN6K-,PWZ:Y5%$ZO#I:6G@:PL@CVB&9RT[;B "<G&3NP@Z!
MNG;6QU>YE+LFOC$53B1P$C0-D C.X ;MW>W+\ATW:H)J>6&F<R2GIC1Q.;,\
M%D)QE@W\VYO\!X N/.IJ[3NHKNV^25UPIJ*S4=5.VGB:6PNS,)I!\7=V@.,D
M^ ;MV_O6N;-:'/ZIE<Z*(Q<?+&6D0B3&R7 N#B,.:3L@X!!*#U?H?3;X(H'V
MF!T,=*:)K"7$<0<GBSOWM!)(!YL[L+V?I"P/N-+7NM=/U73,;''( 1VK=[01
MG#L'>,YP5KY]>VV"2I$E)<N)IJ]MMGF%/ED<KMC9SOR02]H& =YW@9&?*ZZM
MH9K'=7S"[6Z2@JH::H;'&SCXW/+"PC>YNRX.;O\  3S%!N>Q:R=?W7L6V 71
MV-J< @N(& XCF+@-V<9^=>46D+#%6LJV6R$5#*AU6QQ+CL2NSM.:,X&=HYQN
M).>=?5=J:DI*J6$05=0R">*FJ)8(]ML,DFSLAPSM<SV$X!P'#.%YLU51/O%/
M;C%5QNJ:B6DAG<P!CY8VESVC?GF:[!(P=DX/-D/4:4L@.6T#&'JKJWM'.;B?
M).WN//DN/TD^$H-)V(7>HN@M=/U=49XV3&YY+=DDM^+D@D$XR0<96%P<5M77
M:>GDKZF2IF9<*V 228R6LJ)&-&X ;FM YEU"#046C;!0EII+;%$YM.:4/#G;
M0B/^YG.<=X> ;AN6WMM#3VV@@HJ&/BJ6!@CBC!)#&C< ,]X#<LA$'\G?"G[I
M=-]EP^MF1/A3]TNF^RX?6S(C4?UBII>/R@=/?8M1ZP*EJ:7C\H'3WV+4>L",
MJ6B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B()E
MP;]U;A0^L4/J7*FJ9<&_=6X4/K%#ZERIJ B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B IIJSNZ:#^IU_W J6N4UIH"PZRJ:.HOD$\DU(US8G13OB+0
M[&?BD> (.K133D1T;_@7'TA-[R<B.C?\"X^D)O>04M%-.1'1O^!<?2$WO)R(
MZ-_P+CZ0F]Y!2T4TY$=&_P"!<?2$WO)R(Z-_P+CZ0F]Y!2T4TY$=&_X%Q](3
M>\G(CHW_  +CZ0F]Y!2T4TY$=&_X%Q](3>\G(CHW_ N/I";WD%+133D1T;_@
M7'TA-[R<B.C?\"X^D)O>04M%-.1'1O\ @7'TA-[R<B.C?\"X^D)O>04M%-.1
M'1O^!<?2$WO)R(Z-_P "X^D)O>04M%-.1'1O^!<?2$WO)R(Z-_P+CZ0F]Y U
M!W?-*?955_4*EKB-+<%^F=,7J.[6JGJFUL;'1M?+522 -=S[G$KMT!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0
M$1$!3SX0?<>U)^KB]<Q4-3SX0?<>U)^KB]<Q".XL_P#=-%^H9]T++6)9_P"Z
M:+]0S[H66@(B("(B B(@(B("(B B(@(B("(B B(@*::-[M_"']7M_JG*EJ::
M-[M_"']7M_JG(*6B(@(B("(B B(@(B("(B B(@(B("(B II6?E%V_P#9N3_4
M*EJ:5GY1=O\ V;D_U""EHB("(B B+73WBEAK:BG<]HZDAZHJI''#(&'.-H^$
M[+CCO 9.-V0V*Y6JLMU&N9+]1OH3$;>*$0RN>#ND+]O('SXQ_P"*](]5.ELI
MO$%HKI+68^-CD&P)'Q\XD$9.0TC?O[;'>73(.1TMIFOTY23MI:NDEJ+A=)+A
M7%T+FQALGQF1-#NU(PW!)/?)YUD:KTI'?KQ8[AQ[H)*"5PE#1_MX'#MHG?,7
M-8?H!\*Z9$&+5"N-91FE?3"D#G=4B1KB]PV3L[!!P#M8SG.Y929W9[R("+"J
M;C%2W&EI*@%G566P2'XKW@%Q9\QV02/" ? LU 1$0$1$$T;^4:[]F/\ W*I:
MFC?RC7?LQ_[E4M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!33@#_%R_
M_;U;]X*EJ:< ?XN7_P"WJW[P0:K@8U)8[5:=0T]TO-MHJCK[6NXJHJF1NP7C
M!PX@XW%9%NNMONWPA6SVJOI*Z%NFRQTE-,V5H=U1G!+21G!&[YUV-1P?Z0J)
MY)I],V>2:1Q>][J1A+G$Y))QSY7%6>R6RQ?"#%-9;?2T%._3AD='3QB-I=U0
M!G [^ /X(*XB(@+2:NME==;;##;:F*"1E1'+(R4'BYXVG+HW8WX/_P"K!R"5
MNSD X&3X%I=*Z@BU%2551!33T[*>JEI'"8MR7QN+7$;).[(0<O;-$7*BJZ!Y
MJK>Z&EO4]T#(XW1]K)&]FP!OQCC"?^R/#N0Z*NM+44MPI*NC%QI+I65S&/#C
M%)%4DE\;CC((R,.&>;FWJA9W96HTQ>VWZCJIVTTE,:>KGHW,D<"=J)Y83NW;
MR$&+HZQU5GI+G%<9Z>H=65T]7B)A:&B1Q=LG).>=8.EM/W;2U!UGML]%46B)
M[NI'S[8EIV.<3L$#=(!DX.6[L#YUUZ\!64YKC1"5IJA'QQC!WAF<!Q^;.?X'
MP(.0O6DZ^OJM2O94TY;=K.RUM=)G:86B4<8X 8.>-.X?F_/N^:'3%]MMWGGM
MMQH&4=?'#U9'-"Y[XI8XFQ%\)R!O:QNYPW$9W[PNOK)YXI*44]*ZH;)*&2N#
MVMXEF"=LYY]X P-^_P"99*#@JS1URGH;U3MGHP:^]075KB7=HV-T)V#NWD\0
M-_\ UOFW_MYT=<;@S5+63TC.O%32SQY+CQ0A$8(.[?GBQ]&>_A=XM)0:@CK-
M47.QMI9V34$44TDKBW8<V3:V<;\Y[1W. @U=+I^]6_4=SJ+;<*2.U729E341
M21.=+#*&-8[BW9 (<&-^,-QWX/,M>-'7@ZAH;E/7T,SJ.Z35K)7PN,KX9(Y&
M"(G.!L"3  W;L\^<]^M#V0ODO-ZM=-;YI:NW4L52P<8QHJ.,XS9:TY[7?&1D
MXYT#1=GJ+':IZ2KDAD>^LJ*D.BSC$LKI,;QWMO'SX6^7S$YSHF.>W8>X EI.
M<'P+Z0$1$'\G?"G[I=-]EP^MF1/A3]TNF^RX?6S(C4?UBII>/R@=/?8M1ZP*
MEJ:7C\H'3WV+4>L",J6B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B()EP;]U;A0^L4/J7*FJ9<&_=6X4/K%#ZERIJ B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("GGP@^X]J3]7%ZYBH:GGP@^X]J3]7%ZYB$=Q9_[IHOU
M#/NA9:Q+/_=-%^H9]T++0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%--&]V_A#
M^KV_U3E2U--&]V_A#^KV_P!4Y!2T1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%-*
MS\HNW_LW)_J%2U'M8ZBM.F.'JW5U^K8Z*D.GW1"1X)&T9R0-P/@*"PHN!Y8M
M ]):7R<GNIRQ:!Z2TODY/=0=\BX'EBT#TEI?)R>ZG+%H'I+2^3D]U!WRF$UF
MK+S0<*=G8[8N-;.1 YQP'1OI8Q&,_FY:X?Q6QY8M ]):7R<GNK&/"MP=FO%8
MW4=*VHV.+<YK)!MLWD!W:[\$DCP9..<Y#>:4U'236"@II(*B"YQ0,AEM[X7-
ME8\- +<$?%R/C?%QOSA<-?B:0:GH>I:KJKLCH:V!D5,]V(2ZEVGM+1C':R X
M[^0NFY8M ]):7R<GNIRQ:!Z2TODY/=0<_64%"'\(-QFMU75U$%5M4PA=(R38
M?31,D,9&_&=O:P#\4]\!81J:FBJ;X^GIJJ:S-N=#55,5-0R11OI3$!(YD>-[
M=H-+@,EP:[G!*ZWEBT#TEI?)R>ZG+%H'I+2^3D]U%8%:;1'#:!;J"LZU5ERE
MF:^:GE?3L<Z%V_B,9+220UI ;M9<.]G3Z-?)Q&F8=34\[[&VVU%+BL@=L,J1
M,,!X<-QXL8:3_P!8 Y*Z?EBT#TEI?)R>ZG+%H'I+2^3D]U$:>2END6A-'4M8
M9W7$7RG,'&D\:(6SN<W:SOR( <YW[CGOJK*<2<*W!W)6Q54FHZ5\L32V/+),
M,SSD#9YR-V?!N[YSD\L6@>DM+Y.3W4'?(N!Y8M ]):7R<GNIRQ:!Z2TODY/=
M0=\BX'EBT#TEI?)R>ZG+%H'I+2^3D]U!A-_*-=^S'_N52U'=+:DM&J.'Z6ML
M%='6TK-.&)TC 0 X5 )&\#O$?Q5B0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 4TX _Q<O\ ]O5OW@J6IIP!_BY?_MZM^\$%+4T?^4;'^S)_U*I:FC_R
MC8_V9/\ J4%+1$0?CB&M+G$  9)/>42ME-'445HBJ(9#G5]7)(TM<W\ _CR'
M.'YCLLWG<<A6Y$$9MLO6ZIHZ>III.Q6"^5[)8Q"YT432,TY+0/\ 9;1?@XV0
M=D]X+YM#([=3VBL925-/14>K*TO=U-(W8@D%0&;MG.P7.C'@SCP*S22,B;M2
M/:QO-EQP$CD9*W:B>U[>;+3E!'J2*::S3-@E902Q7VOE@BNE&_J29A>_99(#
MC9!:[M7#F(QS[E]TE/"Z\/JZVR24$E5I6%D;'0N<8Y&F4.9QF-S@TL&_!(('
MS*N2SQ1/B9++&Q\KMB-KG %[L$X'A. 3^XKT02*V6JDH;+P;U5-3/CK):FF=
M6OP[:R*1['&3/-AVRTYYC@+]L3(:JZ.-U=?(-3T%15.F$%,&A\;B_#N-V,/C
M+"TM!=N(: -RKB()_P &#*BEJZZCE9254+*6GXNYTL1AX]H+P&31GXLS>=V#
MS.&0.9<UK=AFN7"<UD<KW3V:ECI]AKOPDK!-EK"/C.!<W</"K'(]D;=J1S6-
M\+C@)'(R1NU&]KV^%IR$$=U#%/;;AJ,:;IY^(GMUOGG92M<738G?U06XWND,
M)&<=L01W\+YNC*"=W"')9*21M'5V" P&&E?&R24"< -[4#:R6;AOS\^59EYT
M\\51$)*>6.6,DC:8X.&0<$9'@((01K7$QFI*T4]+5BM@MM#+!-U/),7[,A<3
M"0,1[/\ OGG.X8&!FSQ/$D;7MV@UP!&TTM/[P=X7TB B(@_D[X4_=+IOLN'U
MLR)\*?NETWV7#ZV9$:C^L5-+Q^4#I[[%J/6!4M32\?E Z>^Q:CU@1E2T1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!,N#?NK<*
M'UBA]2Y4U3+@W[JW"A]8H?4N5-0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$
M!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 4\^$&,
M\#^I,?X<7KF+OZJ>*EII:BH>V.&)AD>]W,UH&23^Y:2UZB%;;ZVLK[3<+724
MS.,+ZYL8$C,$DM#'NY@._CG"#:6?^Z:+]0S[H66M3IZ[S7>*5\UGN-L#" T5
M@C!D![[=A[MWTXYUJ]1ZQ-DDK"=/WJLI:1H=+54[(N+YLD#;D:7$9[P._=SH
M.J1<[?=4"S5-,VJM5Q=1RS14\E8QK#'#)(X-8"-K:(RYH):" 3S\^/J+5=%)
M?^M;8YMHU+Z(3X&P9VQ"4LY\_$//C&01](= BQ:*M9625(A:XQPR<5QG^Z]P
M^,&^'!W'YP1WEE("(B B(@(B("(B B(@(B("+XJ)HZ>"2:=[8XHVE[WN. T
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M*5[*JYY&2RDVPQV/^MVQ</FC<NBK[O3TCJ:-HDJ:BI:YT$,&'.D:T N<,D#
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M R,MV]IT@ V<XSGP;Q_%?4]53P-C=//%&V0AK"]X <3S 9YT$Z[#^$/QF?\
MHL'M3L/X0_&9_P"BP>U41U93,<\.J86F/XX+P-GZ? O=!-.P_A#\9G_HL'M3
ML/X0_&9_Z+![52T033L/X0_&9_Z+![4[#^$/QF?^BP>U4M$$T[#^$/QF?^BP
M>U:RGEUEIOA,TC:;UJ[KU07<59DBZWQ0;/%1;0WMR>=P[XYE7E--==V;@R_R
MW+U#4'=:CK9+;IZZ5T 8Z:EI99V!XRTN:PD9QWLA3/35WX6-0V"@N]&-$LIJ
MV%LT;965(< 1NS@D9_>J'KC\2]0?9]1ZMRU/ YW+=+?4(OZ(-)CA?_.T)_+5
M>U,<+_YVA/Y:KVKJ-3:L@T]!5U%7;KA+1THCXVHA;&6 O<&AHVG@DY(S@;LK
M:VRX.K7U#):&KHY(2 6U 9VP(R"TL<X$<XY^\@X+'"_^=H3^6J]J8X7_ ,[0
MG\M5[52T033'"_\ G:$_EJO:F.%_\[0G\M5[5WE_NL-DLM;=*J.62GHX73RB
M( NV&@DD D9W ]]<_+KZWPQS]445?!4LM[KG'3R-9M3P-&7.80\M)'?:2#\R
M#1XX7_SM"?RU7M3'"_\ G:$_EJO:J);ZIM=04U7&TM9/$V5H=S@.&<'^*]T$
M9TSICA3T[->):&;1CW72NDKY^-ZI(;(_&0W &&[N_D_.MWCA?_.T)_+5>U4M
M$$TQPO\ YVA/Y:KVICA?_.T)_+5>U4M$$TQPO_G:$_EJO:F.%_\ .T)_+5>U
M4M>4]3#!) R:1K'SOXN,$[WNP78'SX:3^Y!.<<+_ .=H3^6J]J8X7_SM"?RU
M7M5"H:B6H$_'4DM-Q<KHV\86GC&CF>,$[CWLX/S+)033'"_^=H3^6J]JP[S7
M\+5IM%=<:@Z'=#1P25#VL;5%Q:QI<0,GGP%0I[W%#J:CLKX)N.J::6I9-VNQ
MB-S&N'/G/X1O>Q\ZQ>$+\0=3?9E3ZIR#TT/=I[[HZRW6L;&RIK:2*>1L0(:'
M.:"< DG'[UNURG!-W,M+?9L'W NK0%//A!]Q[4GZN+US%0U//A!]Q[4GZN+U
MS$([BS_W31?J&?="RUB6?^Z:+]0S[H66@(B("(B B(@(B("(B B(@(B("(B
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M&EV.M<._ ^E!4$7%\#%WKK]P:6.Y7>H=4UU0R0RRN !<1*\#< !S +M$!$1
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MWTSS%&YPL$C]K9!.T*A@S](&1E;EFDXH;M<[C2W2YT]3<7,=4&-\>'%C=EN
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M(9ZN>=@ZFVI-MQP '%V2XMP-QQG 703VF4WNV5=+53T]+1QOC=31RXBE:1@
MQXQD'!#L[L8QOW!MUP_#AW)]3_5#_4+N%P_#AW)]3_5#_4(1TVF/Q;M/U2+[
M@7#57Y1=#^S3_P#4+N=,?BW:?JD7W N&JORBZ']FG_ZA!2U@T-HH*"LJJJCI
MF15-40Z>1N<RD# +O"0-V2LY$&IM^F[-;KK4W.AM=)3W"IR9IXXP'/)WG?\
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M/F+X3,<NC9LM 9GOX(._GW[\G)085'I'3]%CJ2T4<)$)IPYD8!XL\[<\^/\
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M!$1 1$0$1$!$1 4TT;W;^$/ZO;_5.5+4TT;W;^$/ZO;_ %3D%+1$0$1$!$1
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MZ"H]0Z?T=;+++:&=50DL?/U2PQM:Z0DNP-YP'9QC>1C/?7OHBUW;1]J['V4
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M9'S[U^K\>7!CBP OQN!. 3]*#D^"NY5]XT=!<+K6/JJJ6>H87.8Q@ 9/)&W
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M#.-RT<3DUNG_ "L/M2"[Z;CND]P??;7)521B%KC51@1Q@D[+=_?)R3WSCO
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M ]S0X $C?CMCS86]1!@VVUT-GMK:.U4<%'2QM(;% P,:/W#^JX3X.7<=L/\
MFJ?]3*J/)_LW?05!N!/A/T?IW@UM-KO-ZCI:^!T_&1&&5Q;M3R.&\-(YB"@O
M:*><M/!_TCB\WF]Q.6G@_P"D<7F\WN(*&BGG+3P?](XO-YO<3EIX/^D<7F\W
MN(*&OR1C9&.9(UKF.&'-<,@CP%3WEIX/^D<7F\WN)RT\'_2.+S>;W$%# #0
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M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M]DBN5+37RK;7VNBHW@SUCF=L9';3FMSF4N .UM;F@ #G(%>BD9+&V2)S7QN
M<US3D$'F(0?2(B B(@(B()IPE]TC@S^NU/J52U-.$OND<&?UVI]2J6@(B()I
MP7]T#A+^T8/5*EJ:<%_= X2_M&#U2I: B(@(B("(OF61D43Y)'!K& N<X\P
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MN)BVIWD9(V6YV<;1RYSB  0!@D+(MFM:XT>D;O=C3PVB\V\OFXN,YBJN+$@
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MW%KF. W$$;P4'7HHUJNDN;+;JJHH>N5/IT:<D+Q4S/&U6 $M=$'':;AH.2,
MG'/SKL:?5E=3RW"AJ+.WJJDH(*V!L=4")8WN<SMR6@,+2PD_&&.8E!VB+A)=
M?O9;;E41VV.>6AN=/;GMBJ>TD$W%;,C'%HR/PS=Q YCOQO7Y7:RO='/<Z6;3
MU+U906X7*1HN)+',VY&[(=Q6=K$>1NQOWD80=M/2T\[@9X(I2-P+V!V/XK]F
MIX)S&9X8Y#&[:9MM!V3X1GF*Y*EUG52U<L3K,3QEJ-VHVQ5 =),P$#8<" &.
MRYO^\X;^?<O.GU[$>NL=12Q&>CEI(8NIZCC(YWU+MF,!Y:,=ON)P1@9^9!VI
M:TEI+02W>"1S+S=30.D=(Z"(O<6DN+!DD<V3\W>7-U>IJV@E%-<+28JN:JZF
MI.+E,L<XXHR%X+6%X #7 C8YP.\<CPM>KZRJN5KH:RR2T4];U4W\-(YNRZ'&
M\ L!<QP<"'8!^9!V"+@*/65RNM7I!U'14T-/=7U0G8^<EPXH.& =CFW;7-OP
M!NYU[V+4D(EFHZ*V,AKZJ[U=,(G5)<Q[XQM22EQ;D X':@<Y'SD!W"+B[QK"
MXVFS]65MB;3RLIIZB6*:L: 3$=T<9:TEY<W+AN&!SX6MJ[VVBUG6WF.&HFA&
MFHZSB&DDG\*X\PSC=C.!WN^@HR+4:7O++[;WUD+J.2G,FS%+25'',D;LM.<X
M&#DD%I&1A;= 4TN_Y05@^PZCUBI:FEW_ "@K!]AU'K$%+1$0$1$!37A6_'+@
MW^UW>K*I2FO"M^.7!O\ :[O5E"*4B(@(B("(B O.>GAJ !/#'*!S![0['\5,
M*0B36NMJ6>@N5=3MJZ2*/B*@L;3"2%FT1VX+1EQ<=D%;6XZB9IZIUA/%:S/4
MV>W4L\DKJLYJH\2X![4AI&R[F!SM(.XFI:>: 030120C&(WL!;NYMW,O5S&N
M #F@@$$ CFQS+D.RZMCJ[O25%G8*JCIH*R%D=6"V2*5[F9>XM 86ECB[XPQS
M$K$=KYXMM941VQDTE)=X;4]L=3VK^-XK9D8XM&1B5NX@<QWXWH.VEIH)7ETL
M$3W%NP2Y@)+?!]'S+U7&TNLY75-1;ZRWQ0W=ER;;60LJ2^)[G0\>'[98"!Q>
M2>USD8WY61/JBLINI:6KM#H;K423B.#C'2,='$0#*',8YVR=IF 6@]MOQA!U
M2+6Z<N,UVLM-6U5!46ZHD!VZ6<$/C()!YP,C=D' R"-RV2 B(@(B()IPE]TC
M@S^NU/J52U-.$OND<&?UVI]2J6@(B()IP7]T#A+^T8/5*EJ:<%_= X2_M&#U
M2I: B(@(B("_'L:]CF/:',<,$$9!'@7ZB#AF@'AMF! QV.LW?_W+UAVVZW2Z
MW*5])=*6ACH+Q)03TCGC?"UYC:P1[&0YPV7M=M=_P;AW(M5N%S-R%!2"XEG%
M]5<2WC=G\W;QG'S97EUBM/7GKOULHNNNSL=5\2WC<8QC;QGFW?0@Y+3=UN+[
MA5V.Y7"9U=::R6:JJ'-8.-I"-J$G#<#(>T;@/]D]8VB+_<*O4UMIZBX/K**O
MLQK@^1K&<:\2, D:P;V-<UYPTDG &<'*H3:>%M1).V*,32-:Q\@:-IS6YP">
M^!M._B5K[?IRRVV:*6WVBWTLL0<(WPT[&.8'8VL$#=G S]"#:HB("(B B(@*
M:<$OXU\(_P!M'[@5+4TX)?QKX1_MH_<""EHB("(B":?!O[CEA_[_ ->]4M33
MX-_<<L/_ '_KWJEH,*HML<]SI:YTLS9J=KF,:UV&X=C:R,;\[(^C&Y8E;IFT
M5U3<9ZJABDDN-,*2KS_]Z,9P'?.-H[^?^ 6X1!SD^CK94VZKHZQ]74MJ:844
MDLLQ,G$#_P"V'<X&_>><]\G 6;6:?HJRJM=34&=U1;MH02-E<TD. #@[&-H'
M9&0? MLM=J2IFH]/W*JI7AD]/3231ES=H;36DC([XW(,&UZ3MEL=3BD;,(:5
MSWTD+I-J.E<\$.,8/-N<X#.< D# .%\4.C[91-M+8'5(;:YI)Z4.ESLNDVMO
M/ASMNY^;.[O+WTC<:BOT=:;I<'"2HJJ**JD$49P"]@<0UHR3S[AO*Q;'K&WW
M6PT-S#:B!M:YS8(70/,C\9.YH&7=J,DC(&_?N0;"[V&ENEQMM;4OG$]ND,M/
MQ;]D->6EI)'?[4D;]V]8]7I6V5MWK;C6,DGEK*3J"=DC\QO@RX[&SX,N<<\^
M_G6+P<7FJONFW5M;*)9>K*J%KQ%Q>6,G>QO:\X.RT<^]9U]NQI+A:K738ZMN
M4CVL<1D1QL;M/?COX& /G<.]E!K(= V>.UMH3)<I61R1R0RRULCY8#&<L$;B
M<M />'/W\KV&B+0VFF@8:P1S5S+B_-2]QX]A#FNRXG_>:#\YY\KSTM=J^OU5
MJJ@JYHWTULGAA@V8]EQ#XFR$N/?.78W +3ZCU+=+38J>N-;3MV[X+>]\L0#&
M0&<Q%QWCM@!G.<?,@WU9HRU53;BU_5367"HCJYV,G<&F5A80X#F!S&PG'/L_
M2OVOT;:;@+L*YD\W7,QNJ"9"T[4>.+<PC&PYN!@C',O2RU5?=ZB2OBJ&QV22
M("E:8AQLIP?PN3N#3NV6D9[YW'"]M-7@W,7"FJ UM=;JDTM0&C )V0YKP.\'
M,<TX[V2,G&4&)V&6PMH2^6X/J:.5TK*IU9(9G%S=EP<_.2"W Q\PQA+9HRU6
MQ]J=1]5,ZV&7J9KIW.#1)\<'.<@[ACO=[?O72(@YZ@T?:J"]U%SI151OGE-0
M^F%2_J<S'GDXK.SM'GSCGW\^]="B(/"X?V"I_5._H5P?P>^X]IO]7+ZYZ[RX
M?V"I_5._H5P?P>^X]IO]7+ZYZ"AHB("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(
M"(B B(@(B("(B B(@(B("(B B(@GOP@>X_J3]5'ZUB[FV?W;2?J6?T"X;X0/
M<?U)^JC]:Q=S;/[MI/U+/Z!!DHB("X6U:CXO6>K+=>+[#!3T;X&TD<SH8RT/
MB#W') +L$[LY^?*[I<O8;-<K?JG4]SG%&Z"YOA? UDKMIICB#,.RS&_&=V<?
M.@UG!]JB6LT9;;A>*M];75]3400,CC8#)L2R- :&@#XD>T2=W/O7K>=3FJ.G
M9K+621QRWH6^LA=& X89(71O#AEI!:.;&X]\$+6V/1-XM=JTXX2T+KE9:RJF
M#!*_BIXIW2%[2=C+7 /&#@[V_/NRY-&UPJ*>KA?2=4R7X7FJ:Z1P:T"(Q!C#
ML[SLX.2!OR@]=2ZH>;CIUEGGJ!3SW@44\K8FF*8 /VV;1!.0YF,C W$9*RX-
M66RBAK9ZFNKZF,W7J !]([,,KM@"(!K0=G)&"=YSSG<M'0Z.O]'1V:ULEMLM
MOM-VZNAJ'RO$LD),AV'-V<!PXS&=K!QWED3:1N[X:MC74&9=0Q7AN9G_ .S8
MYAV#VGQNT^C?\R#H*?5]KGI))@:B.2.L%O-/+$62\>0"UFR?"'!V>;&_.XK-
ML-]H[V*OJ+CPZDF=3SMEA<S8D;\9N2,''S$C>/"IYJ^WU%HZNGK)[73ON=^A
MK:.:>=\;(3'"T=O)L88X\5@'#@=O9QWUU/!S*]]%7-=3T(+J@SOJJ&K-3%4R
M/R7.VRQO;# R , 8 \ #EJO5]10P:TDK=41TU5:JQ\5%3RQPGC0(F/:TL#0]
MV7.+>U(*H]HGJKA8**>LC=0UM13,?+&W!,+W-!(&01N/A"Y.FT[?:>+5D/4]
MGFCO=4^=IEGD+8VNB9'AS.+[;XF<9&<X^=;O2=GKM.VRSV=D\55;J*B$+YY"
MX3.E! ;@<VQC:[^1N"#0:9U!<WZ2OD%VJW2ZCME5)1/<V-C-J1SAQ!:W&,/#
MX\9!WDKN;?%-!101550ZIJ&L DF<T-+W=\X  'T+G)])[6OX]015&Q3/IPVJ
MI@-TTT9(AD/^5KW_ +PSP+H&&NZZ2A[:;K=Q3>+<"[C>,R=K(QC9QLX[^<H,
MI$1 4V^$;W'-0?\ <>OC5)4V^$;W'-0?]QZ^-"*0SXC?H7ZOQGQ&_0OU 1$0
M$1$!$1 1$0$1$!$1 1$032_]WS2OV55?U"I:FE_[OFE?LJJ_J%2T!:G5EDCU
M'IZNL\\\L$%9&8I'Q ;0:>?&01_X+5U&II:37%3:*UU'!;8+:VXOJI'%I:#(
MYFR23@ ;.<_NQWULAJ>QN@K98[K1RLHHN/J.+E#S&P@D.(&_?@H/V]61MWTO
M5V2IJ96QU5,ZFDF8T!^R1LD@8QG'S+37G0T5UFJ99[G5QRS4<%'M1M8-D0R\
M:QV"#D[6<@[B-V%MJ;4]HFLE)=9*^G@I*F(2M=+(UN!@$YW][._P+[FU-8H*
MGJ>:\VYD^0W8=4L!R6EP&,]\ GZ @T<^@XYVW(2WBO>ZOK::OE<61;I81'LD
M88-QXIF1\V["S[EI5E?<KI6OKIV/N%O%M>UK&X;&"\[3<CXV7NY\CFW+84&H
M;-<)S#0W6AJ)1"*C8BG:X\6<8?@'XN\;_G"QZS5=DI;1<+D;C3RTM#%QTYB>
M'EK2"6G \.-WA0:BMT#35L#89KC6!@M+K/V@:TF([)VLX^-EK?FY]V]?E1P?
MTU8RZBX76X5#[C#3LD>.+C,<D)+HY6;+1LN!P1WMV\%;NDO$5;=:..CKK>^"
M:E?.80_,[L.: YH!QL#+@3CGPLB*^VF5\S8[E1N="PRR8F;VK <%QW\V=V>9
M!HJ[1CZ^VT[*V^W*2[4T[:FGN8$;)(GM:6@!@:&;)#G @@YVCGO8]ZC2CII;
M35&\5W7*@?(XU9;&72B1H:\%NSL@8#<8 Q@?/G9T.H;/7ROCHKK0U$C(14.;
M'.UQ;&>9YP?B\V_YU@7[4U/#I:]W.R5-'65%NI7U!9M[3=S"\!V#D @;O"@P
M[;H6GM]-8HZ>YUVW:9II8I#Q9+VRYVV'M>;MN?G'A7E/H&%T9?3W6MIJ]EQE
MN<%7&UFU#)("'M +2US""1@@_2MQ=]14]ETD^^7('BHX&2N9&,E[G8 8T>$N
M( ^E>?5&HV4M/4R4MO>]\D8EI&.=M0L<X!Q$G,\M!)QLMSCG\(8%RT.ROD,D
MEYN0DEH9:"I?^#)G9(<N.]F&G/YH&[ [P7I!H[B*J.IAN]:VHCMT=N;(&QY#
M6.V@_P"+C:S^[&["VCM36-M0VG=>+>)W3&G#.J&9,H )9C/QMXW?.M/J36-/
M2V>GN%CJ[?70]<J:AJ'B7;;&))6L=O:=S@'9WH-OIZPT]EEN,T):9[A.*B<L
M8(V%X8UN0T<V0T$G>222MPN0U1K."ET?67W3E3;[HRFE9$X,EVV$ND:PC::=
MQ&T"LF_WRNMFHM,VR)E-(V[2RPR2.:X&,QQ.D) SOR&XQWO"4'3*:7?\H*P?
M8=1ZQ4M32[_E!6#[#J/6(*6B(@(B("FO"M^.7!O]KN]652E->%;\<N#?[7=Z
MLH12D1$!$7-:IU'UIO%EMC9*:GEN;I&LJ:K/%-+ #L8!&7NVMPR.8\_,0Z5%
MJ*&YS04$LVH6TU#)',Z(%LA+'@?%<"0.<;\=[FWXROFHU58*>".:>]VV.*2+
MCF/=4L ='D-VAOWC) SX2@^++IYMKOMZNC:N6:2ZOCDEC>UH:PL8&-V<#/,!
MG.5@WG1D-UDU$Z6NJ8VWNDCHYVL:W\&QFV 69'/^$=SY[RW,%\M512]4P7&D
MDI^.ZGXUDK2WC,XV,Y^-G=CGRO&VWB%]#4U57<;;) RI?$R6GD[0 .PUCB2>
MW[Q [_>0::\Z'BNM35U$USJXYJBFIJ?:C:P!G$2F5C@"#GMB<@Y!&["^9-!Q
MR-KQ)=ZYYK+A3W*0N;'_ +6(1XQAHW'BF9'S;L+H'WZTQV]E<^Y48HWYV9N-
M;L.QSX.>]@Y\&%]R7FVQR0,?7TH=/L&(<:.WVSAF/#M'</#WD'.W+0=/73W"
MI-RK(*VIKHKC#/$&!U--'&(VEH(((+!@AV<Y*]KGHYU=!;Y1>[C#>:*5TL=R
M8(^,)> U[2S9V"P@-&SL_P"Z#SY)R-?7VJT[81<*.*"9_5$$!9+D \9(V/.1
MX-K/SKXME\K:C7%TL<[*;B*&D@J>-8UP<_C"\8P20,;!\.<H-[;J4T5'' Z>
M6H>W)=-,07O<3DN. !O)Y@ !S  +)7,7J]W&FUC:K+1LI#'7TT]1QLH<2PQ&
M,$8!WYXP?1A:T:ON=5IS4M1;K;!)=K%/)!) )"^*H+&A_:. !R0>8C<=WSH.
MY1<WU^FK-/62NM#J6>:YNAXO;#@QS7-VG$8.1LL#G8_ZN.^ND'-O0$1$$TX2
M^Z1P9_7:GU*I:FG"7W2.#/Z[4^I5+0$1$$TX+^Z!PE_:,'JE2U-."_N@<)?V
MC!ZI4M 1$0<9PO3U%+HJ:HHZFIIIVU5*T24\SHW .J(VN&6D<[7$?O6WU!&>
MJ[!&R:HC::W8<(YWMVVB&1V'8/;#+0=^>99&J+)3ZBL57:JQTC(J@#\)&<.8
MYK@YKAGOAP!_<O&EM5?)5TD]WN,-5U(2^)L%-Q(+RTLVGY>[)V7.W# W\W-@
M)U9;Z^IU3J32\USKJ>>LN<T5/4RU$GX*%D<1,<#B<<9EY( YADG. #6:>F9!
M2,IV.F<QK=D.DE<]Y'SN)+B?GRN,J.#Z&KMVH*6MK&RFZ5AKXY6P%KZ2?9:U
MKXR'9RW9!'SY[QPNHLM)7T5KCIJ^XBOJ8V[(J70;!=NW%P!P3]&$$KIK]/'P
M-ZAF?57I]RB;<#'5_P#2'%CHY)1&1+S  -:.?&[?WUW-%?Y(::FMU!327&X0
M6V*MG;).0=EV0T;3LESW%K\ X&[>1N7C3Z*DBT'<=,&YAT5:*AKJCJ?#FMF<
MYS]VUC.7G!^CG61%I2>EN5/<:"Y-@KA0MM]0YU/M1S1L)+';.T"U[278.2-Y
MR.9!H8]5T,VJ:#4#*RH99)--U%<]KW.V6ALL.\LS@. +ANW]Y?E;J&:WZZBN
M5VBGH[>RP3U;H14&0'$L6.TW-$@!(W9YQVQ6SDX.[>Z."D$[Q;([1+9S!L]L
MZ.0M+G[>?C98#S=\KQEX/Y;CLMOUZDKHQ;9;6X,IVQ.?&\M.V3D]N"P'(P/F
M'?#;UFJ);9#627BUSTS81!Q+F/$C)WRNV&QM=NP\.P".8;0.2%E6J_=57VML
MM;3=2W&EB94;+9.,9+$\D!S78!W%I!! P?"#E:N71U3<-.SVR_WVJKY"(^(J
M6Q,A="Z-P>Q^!D.?M-:23N..89.=M:K(ZGN]1=J^H957*:".E,D<7%,;&PN<
M &[3CDN<23GP<V$&LOTU1#PA:5BBJIVT\\=6)8 _$;RUC2TD=\C)76+2W.R/
MK=26>ZBJ;&+<V5HAXK.WQ@ .79W;@,;END!$1 4TX)?QKX1_MH_<"I:FG!+^
M-?"/]M'[@04M$1 1$033X-_<<L/_ '_KWJEJ:?!O[CEA_P"_]>]4M 1$0%KM
M24T];I^Y4E(QKZBHIY(6!SMD9<T@9/>&];%$'):5IM06RPV&TST-%&VC@AIY
MZAM47]K&P EK=@9SLXWD8SGO8//V72NHK/3Z3FCBH9ZBR-J*22G%2X-GAEV?
MPC7%G:N!8#LD'<3O5-1!R&BK=>[+11TE7241CFN%943OCJ7.,;))'R,P"P;1
MRX C=@;_ )EZ:GHWQ:PTQ>__ ,K2]44M0>]&)FMV7GYMJ-K?^T.]E=6C@'-(
M< 0=Q![Z#D:>UW.RZLOMRH::*NI+OQ,I;QPC?#+&SBSG(P6D!IR#D'.XK!U/
MI>XW'3MLHHXJ2>=EW9<JIKY,1[/'F5T8RWMMSMD9 SC)PN\&X;D0</INQ7C2
MM[FH[4R&;2,K1)'!-.1+0R$DN;'N(,7-VI(P<XW<^;HFBD%UU/>'#$-TKFNI
MQ^=%'$R(/^AQ:X@]\8/?75.:'-+7 %I&"#WU^H"(B B(@\+A_8*G]4[^A7!_
M![[CVF_U<OKGKO+A_8*G]4[^A7!_![[CVF_U<OKGH*&B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B">_"![C^I/U4?K6+N;
M9_=M)^I9_0+AOA ]Q_4GZJ/UK%W-L_NVD_4L_H$&2B(@(B("(B#&N5=!;J4S
MU+B&[36-:!ESWN(:UK1WR20!]*U5'JFAFU/+IZ=LU)=60-J613;.)HR2"YA!
M(."-XW'YEK-=<9V0Z)+L]1BZNXWP;74\W%Y_[7_CA8.H['3:FU!=8::L;2WF
MBAIIZ*KC(+Z>8&;?COM.0'-[X/T(-S?-6T=KM5WK*^@K336Z9E/. V-Q)<&$
M%HV]X_",_C\Q6\J*KJ6WNJ74TP;&W:=$P O:._N!WX'>&?FR5(M3U]?6<%>K
MYKY1]07-]PACD@SD.>P4S2YGA:=@N'S%5&DU%:JZNBH[?6P5D[VN>1 \/#&C
MG<XCFWD#]_TH-E33Q55-%44TC98)6!\<C#D.:1D$'P$+T7'<$(E'!_;>-SL[
M<YAS_@\<_B_W;&SCYL+L4!$1 1$0%-OA&]QS4'_<>OC5)4V^$;W'-0?]QZ^-
M"*0SXC?H7ZOQGQ&_0OU 1$0$1$!$1 1$0$1$!$1 1$032_\ =\TK]E57]0J6
MII?^[YI7[*JOZA4M!.=4VFZ56K[]54ULGFI:G3;K?%('1@/GVY'!N"X$;G#>
M1A>,%@NCZFF:VVR0L[%GVUSG.8&MG);AAP[/>.\;OG5,1!*F6Z\TPL-15Z>N
M-91FSLME31P5;(Y89&X[8@2!KF.W@]MW@<+;:6L4ULOM^>ZS<12.H:.&DV'-
M>W,4;VEC23M;MH $XRN_1!([?IZ]TEETA%%8@^IMUAK*.>&9T?%\<^.,-8_#
MM[7.8<D9Y]Z^9=/7VNIM3M%IJXG7+34=%%U1)"W$[./_  >RQV&C\(W&-V.<
MY5>1!/KA:[M=;[03QT-30-?8:NB=.]\9-/-(8MC.RXG/:$[LXW+#I[)=*RDT
MMQULEHZFQT$]/4-VF$2N, B$<9#M[7$!V3@#9&<'FH_5,/51IN,!F#.,+1OV
M6YP"?!G!QGGP? 5K!JBS%@D%<WB"\1MGV'<2]Q.R&MDQLN).[ /.@GD.G[Y3
M6G3K(+"V6HH],5-OFAG='Q3IW-AV8WX=O:XQNR1NW\XRO1UEO<]/K,BT5^;K
M8H::GX^2$.=,ULS2PAKMEO\ M&XQNQ\ZH])>K?5U==2TT_&U%$0*B-K';41(
MR 1CG(W@=\+YME_MES@IIZ"L9-!4N<R&0 ALCFYR 2,$[CN^8^ H-#JW3=1J
M7@YZT1NZCK^)ADB,N\,FC+7M#L9W9;@XSSK UA#==3V"W48LM337-M;32S![
MF<7&QDC3+B0.PYI:'# WG.\!4!$$KN6GKG-:]30QV:5SZO45+70MS%V\#'4Y
M<[XV[=%)N._?S;U]:BT]=:VOU)-#:I9()KK;*V)I='^'C@,?&X!=SX8=SL95
M21!*=7Z9N-PMFL*JW6J5TEY=1,BH\QM<_B7@OD?EP R-V"<X:/"MO>]/<7K+
M1MPL]C$<%'//)5R0MC88VO@>QH(R">V<.;*[]$!32[_E!6#[#J/6*EJ:7?\
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M/^,!@;@<#*#GKI7R6^VU53!JET\%6RD%-^ 9+(USY0PEI&&_A-H!NU@-.3S
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M0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!/?A ]Q_4GZJ/UK%_#6V_\
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4TL#8@XXYR&@9*(@W2(B((B(/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g830217g10j07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830217g10j07.jpg
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MX=_.V***5Z)_PCX=_.V*.SH?H24_F1]4;/1$6>-:$1$ $1$ $1$ $1$ $1$
M$1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$
M$1$ $1$ $1$ $1$ $1$ $1$ $1$ $1$ >35XFL5'4/@J[U;()V')T<M4QKFG
MI!.87#]U^&_\0VC]<C_F6(Y9'RRODE<Y\CR7.<XYDD[R5\IIW?']0D[UE^DV
M]]U^&_\ $-H_7(_YEC['LT51C:_S4\C)89*Z9[)&.#FN!><B"-X7A(IZ,94M
MM/4JY.8\A)-::!$16BF%)M&-1#28_L,]5-'#!'5-<^21P:UHXDG8%&47,EO)
MHZA+=DI>1M[[K\-_XAM'ZY'_ #)]U^&_\0VC]<C_ )EB%%0[OC^H:=ZS_2;>
M^Z_#?^(;1^N1_P R?=?AO_$-H_7(_P"98A1'=\?U!WK/])N.EQ/8:NH9!2WN
MV33O.3(XZICG./  ':O76!XGNCE8]CBU[7 @@Y$'BMZTY)@C).9+02>Q5<G'
M5.FCUU+V'EO)UU6FA]HB*J70B*/8RQC9L(T/?%YJ@Q[@>2@9X4LOS6_6<ATK
MV,7)Z(YE)16LGHB0KRKYB*SV*/7O%SI*,99ALL@#CU-WGL"S=C335?[TZ2"S
MGV(H3L')'.9PZ7\WT<NLJKIYI:B9TM1*^65YS<][BYQ/22K]>!)\9O067;4C
M'A6M34UTTY81HW.;3.KJXCG@@U0>UY:H_/W0MO:3WO8*IXYB^=K?4"L[(K*P
MJESXE*6TKWR>GV-$0]T-0D^WX?J6#BRI:[UM"]ZUZ=<)U;@VK;7T).]TL.LT
M>82?0LLHO7A5/P".TKUS>OV-QV'$UEO[-:S72DJSEF61R#7'6W>.T+UU@B&6
M2"5LL,CXY&G-KV$@@]!"L_!.FF_V-\<%X<;O0C8>5=E,T=#^?Z6?6%5LP)+C
M!ZERG:D9<+%H:H11_!V,+-BZA[YLU4'N:!RD#_!DB/RF_6-G2I J#BXO1C2,
ME):Q>J"(B\.@O#Q!B2ELSVQ/8Z:=PUM1IRR'$E>XJIQP2<35F9W:G[H5#:&1
M/'JWH<V]".R3BM46!8+[2WJ)Y@#HY6>[C=O'2.(7K*EK57S6VNCJJ<Y/8=HY
MG#G!5O6JOAN5#'54YS8\;1SM/."N-GYOXF.[/J7N>5V;W!\SMHB)D2A$1 !$
M1 !$1 !$70O=SAM-!)4S;2-C&<[G<P7,I*$7*7)'C>G$ZN(,0TME#&RM=+.\
M9B-G#B3S+]P_B"EO37B$.CF8,W1NWY<0><*JZ^KFKJN6IJ7:TLAS/1T#H7O:
M/21B$9<\3DCJVG9;D**Z6]"!6MRT\"SD1$^+ 1$0 1>=?[Y;</VY]=>*N*EI
MF[-9YVN/!HWD] 5!8WT[5]8Z2FPI!WE3[N^IFATKND-VM;VYGJ4U5$[>E%>_
M)KH7QOCY&A+C<:*V4YGN593TD(\>>0,;Y25!;MIDP;;W.:RX2UKV[Q2PN</.
M.0/E65+I<ZZZU3JFYUE15SNWOFD+SZ5U%?A@174Q79M6;Z%H:3J>Z"L;7$4]
MHN4@XO+&?65Q1=T):2?;;)7-'R9&.^Q9Q12_@JO(@[QO\_8U/;=.F$:IP%3W
M_19\\T&L!YA<?0IS8<5V&_ >P]VHZIY&?)LD >.MI\(>18?7ZQSF/#F.+7 Y
M@@Y$%1RP(/I>A+#:EBZDF;Y19+P;I?Q+AYS(JJ<W6A&PPU3B7@?)DWCMS'0M
M#8#T@63&4'_A\W(UK1G)1S9"1O2/A#I';DJ-N-.KB^*&=&;7?P7!^1(:R[VV
MBEY*MN%'3R99ZDLS6'+J)7!]T=D_'-M_6F?:L<Z0II*C'6(7S/<]_?\ .W-Q
MSV"1P [  %'U:C@)I-R*,MJ-2:43<WW1V3\<VW]:9]J?='9/QS;?UIGVK#*+
MKN]?J.>]I?I-Y45=25T;GT-5!4L:<BZ&0/ /6"BPS;KK7VWE/8^LGIN4RU^2
M>6ZV6>6>7647#V>_"1(MK+3C$Z:(B:"4(B( (B( (B( (B( (B( _6^Z'6MZ
MTWWO%\P>I8*;[H=:WK3?>\7S!ZDMVA_C]QQLG_/[?R<B(H+I;QW%@JPYP%DE
MVJ@64L1VY<7N' >DY#BET(.<MV(VLLC7%RER1T-+6DZFP=3FAH-2IODC<VQG
M:V '<Y_U-Y^K?EJ\72MO-PFKKI4R5-5*<W22',]0X#H&Q<-;5SUU7-55DSYJ
MB9Q?)(\YESCO)7"G=%$:5PYF:R<J61+CR\@B(K!6"(B "(B "(B .]9;M762
MXPU]JJ9*:JB.;7L/H/$=!V+5.B?2528TH^]:O4IKW"W.2$'P91\-G1Q',LD+
MLVROJK77P5M!,^"J@>'QR,.1:0J]^/&Y?,M8N5+'EPY>1O%%#M%V-J?&N'FU
M(U8[A!E'5PCQ7<SA\D[QVCF4Q2247![K-+"<;(J4>3"JG''OGK/H?N!6LJJQ
MU[YZOJ9^X$GVQ^0O7^&1W=)X"]["5\=:*[5E)-)*<I!\'Y07@HL[5;*J:G#F
MBLFT]47FQS7L:]C@YKAF"-Q"_5 L"8@$>K;:V0!I.4#W'G)]Q]GD4]6PQLB.
M16IQ+L)*2U01$5@Z"(B "(B /B:5D$+Y97!D; 7.<=P"J;$]Y?>*\O&;:>/P
M8F'F'$])7L8YQ *N0T%%('4[#[:]IV/<.;J'K4/6<VIF=I+L8<ES^;*MMFO!
M!271[[XF_DG*-*3://?"/R3OJ5#"_P"Q#U(Z^I%G(B+9%X*':2<?6[!-M#ZC
M*HN,H/>](UV1=\IW!O3Y%VM(F,*/!F'I:^JRDJ'>!309Y&5_#J&\GZ\ECS$%
MYKK_ ':HN5TG=-53NS<X[@.8 <P',%<Q<;M7O2Y"_-S.P6Y#J_8[6+<477%5
MS=77FI=*_<R,;&1-^"UO,/2>=>*B)PDHK1&?E)R>KYA$1>G@1$0 1$0 7-1U
M4]%515-'-)!41.#F21N+7-/$$+A1>!R.:NJIJZMJ*NJ?RE1/(Z61^66LYQ))
MV=)7"B( (B+T B(@#GK:.HH:N:EJX7PU$+BR2-XR+2-X*X,CP*WN^&)[LWQL
M<>):"OGO>#XF/S0EBVA]/N.'LGZ_;^S!61X%%O7O>#XF/S0L5:0P&X\Q$
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MP)>L&U09=( ^E><HJJ+,QOZ,^8]!465V,E):Q%LX2@]V2T81$71R$1$ $1$
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M*")HUOEN^P+RDNPL'L9RMGU-O[+4<.>L5%!6KW/%.7XIN%1ELCHRW/I<]O\
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MUN-7=KC45UQG?/5SNUY)'G:3]G0K^)C.3WY\A7G9JA%UP?']CJ(B)L(@B(@
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*M\R18%"6FZ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g830217g41p95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830217g41p95.jpg
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MP='2%Q@S-#94<X*4)$-38Z*CPK/P%B4F1'6#X?_$ !H!  (# 0$
M       % P0& @'_Q  S$0 " @$# @,%"0 " P       0(#!!$2,04A$T%1
M%#(S<8$5(B-"4F&1H;$T\$/!T?_:  P# 0 "$0,1 #\ U2B(@#QWF5\%HKIH
MG:LD<#WM/ AI(*PO/55%1,^:>>625Y+G/>\DN/$E;EQ!ZPW+Y-+YI6%$SZ>N
MTA+U9]X_4^N<?[MWC3G'^[=XU\HF(H/KG'^[=XUJOD[5M36:.F=U323&&JDB
MC+SF6L :0.S:5E):EY-?L=O^72^:Q4\Y?A?48],?XWT+51$2<T 1$0 1$0 1
M$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1
M$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0 1$0!X,0>L-R^32^:5A1;KQ!ZP
MW+Y-+YI6%$SZ?Q(2]6YC]0B(F0H"U+R:_8[?\NE\UBRTM2\FOV.W_+I?-8J>
M=\+ZC#IGQOH6JB(DQH0B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B
M(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B(@ B
M(@"F:[3_ &2&KFBIK775$+'%K9=9K0\#I X+\/SA+5[R5WTK%G)$Z]BJ]#.?
M:-_K_1H2Y:?+75VZJIFV6M:Z:)\8)D;D,P1GY5GM$4U5,*M=I7NR)WZ;WP$1
M%*0A6[HKTKT.#,,.M=5;:FID-0^;7C>T#(AHRV]BJ)%'97&Q;9$E5TJ9;H<F
MC?SA+5[R5WTK$_.$M7O)7?2L6<D4'L57H6OM&_U_HT;^<):O>2N^E8@Y0EJS
MVV2N^D8LY(CV*KT#[1O]?Z-U8=N]-?[)1W2@U^YJJ,2,#QDX<0>L',+H*%Z%
M_8QL'\%WGN4T2>:VR:1H*I.4%)^:"(ORJZF&CII:BJECA@B:7ODD<&M:!O))
M7)V?JN'B;%ECPS#SE[N4%,2,VQDZTCNQ@VGQ*E=(^G":9\M!@[.&$=ZZO>WO
MW?PVG<.L[>H*D*NIGK*B2HJYI)YY#K/DD<7.<>))WJ_3@REWGV%>1U*,/NU]
MW_1H*_\ *"I(G.CL-GEJ.@354G-CYHS)\84(N&G'%]4X]SR4-&T[A#3AV7SR
MY5>BO1Q:H^0LGFWS_-_!.GZ6\;N<3Z.R#J$$0_XKU4>F;&M.X%]SBJ!PEIH_
ML *KM%WX-?Z5_!&LBU?F?\EXV3E!5\;FMO=FIIV=+Z5YC<.O)VL#XPK2PGI1
MPOB5S(::O%+5NV"GJQS;B> .>J3U YK'B*">%7+CL6:NHW0][NC?2+)VCW2W
M>L+NCIJY[[G:AD.9E=W\8^ X_4=G8M,X5Q);,4VIEPLU0)H3L<T['QN]RX=!
M_P"PEMV/.GG@<8^77>NW9^AV$1% 6@H?C7$=3;JEE'0$,DU0]\A )&>X#/L4
MP58Z0A_ZA/7$W[4OZG;.JC6#T>I':VH]CNX/Q1)73=QW)S>?=^CDRRUNH]:F
M*HUCG,>US"6N:<P1O!5J81OC;O1:LI K(@!(/=#W05;IF<[/PK'W\OW.*K->
MS.\B(G).$1$ $1$ $1$ %'\78@%GIQ'!JNK)/4@[0T>Z*Z5ZN<-IH)*F?;EL
M8SI<[H"J&X5DU?5RU-2[6DD.9ZNH=25]1S? CLA[S_HBMLVK1<DKPSBNNEND
M--7O$T4[@P'5 +2=VY6"J<P[Z_6[Y0SS@KC7G2;IVURWO71GE+;7<(B)J3!%
M_'O;&QSWN#6-&9<3D .*H_21INBHWRV_!^I43C-KZ]XSC:?@#VW:=G:I*ZI6
MO2*(;KX4QW39<%\OMKL-(:F\5]/1P]!E> 7=31O)Z@JJQ#I]LU(YT=DM]3<'
M#8))'<S&>L;"X^$!9WNUTKKQ6OJ[I5S5=2_?)*XN/8. Z@O&F5>#!>_W$]O4
M[)=JUHBV;CIYQ14.(I(+=1LZ-6(O=XW'+R+COTQXW<XD7=C>H4L67FJOD5E8
M]2_*BF\JY\R99-+IKQG X&2MIJ@#HEIF#S<E*;-R@ZYCFMO-EIIF]+Z60QD=
M>3M;/QA4:B\EC52YB=1S+X\29K_"NE?"N(7,BCKNXJIVP0U@$9)X!V>J?'FI
MV#F,QN6!5/< Z4;[A)\</.FOM8V&DG<3JCX#M[>S=U*G;@>=;+]'5/*U?5&A
M](6D>TX(FI8+A#4U%34-+VQP =ZT'+,DD=/U%0_\X*P^]-T_V_Q*L=-N*K;B
M^\6FXVE[S'W$&21R#)\;]=Q+3XQM&Q5RNZ<.#@G-=R._J%BL:K:T-*?G!6'W
MING^W^)/S@K#[TW3_;_$LUHI?8JO0A^T;_7^C4]GTXX5KF2FK[LH',(R$T8=
MKY\-4GRHLL(N7@U_N=KJ=R7D$1%=%P1$0 1$0 1$0 1$0 1$0!L;0O[&-@_@
MN\]RFBA>A?V,;!_!=Y[E-%GK??E\V:RCX4?DC\:VJ@H:2:JJY60T\+"^21YR
M#6C>2LHZ6])55C&N=24+GP6.%WI<6XS$>W?]@Z.U27E#8\=7U[L,VN7^QTSL
MZQ[3^DD'M.QO3U]BI1,</&VKQ)<BC/RW)NJ''F$1$P%01%]11OED#(F.>]VP
M-:,R? O /E%WH,&8FGCYR'#MW>SH<*.3(]FQ<NX6VNMTG-W"CJ:23W,\3HSX
MB%XI)]DSIPDEJT>5$1='(7?P5BNY80O++A:I<MPEA<>\F;[EP^WH7 1<N*DM
M&>QDXO='DV]@O$]!BVQ0W.V/[UW>R1./?1/Z6N_[VC:NXL=:)\;38,Q(R9[G
M.ME21'5Q#W/0\#BW?V9CI6PH)HZB".:![9(I&A['M.8<",P0DF31X,NW#-+A
MY*R(=^5R?:K'2'^T)_A-^U6<JRTA_M!_]+?M2/J__'^J)KO=(PO7:Z^:VUL=
M33NR>P[NAPZ05Y$69C)Q>Y<E1=BZ+3<(;G0QU5.>]<-K>EIZ05[%3-JQ6<+5
M4$LV;J">41SM&]H(/?#K&7B5QP31U$$<T#VR12-#F/:<PX'<0MAAWO(I5CY+
M=5JGJO-'VB(K1*$1$ %\3RQP0OEF<&1L!<YQW +[55XOQ@RZWBIL]N>'4E*/
M3I&G]))GN'4/K[%#D6^#5*S3@CLMC7IKYGGQ->7WBO,FUM.SO8F'H'$]97'1
M%C;+)62<Y<LJ-ZO5G1P[Z_6[Y0SS@KC5.X;]?K?_ !V?6KB3_HOPY?,L4<,+
MYFD9#$^69[61L:7.>XY!H&\D\%]+/W*&Q^Y\K\+6F;)C<C7R,/JCO$79TGP#
MH*?4U.V6U!D7QH@YLCVF+2G-B2>:TV.5T5D8=5\C=CJHCI/!G =.\\!4Z(GE
M=<:X[8F9MME;+=-A$12$81$0 1$0 1$0 1$0 1$0 1$0!IVNT"8:J*R::&MN
M5-&]Q<(HWL+69] S;GEVK\/S?L/>^EU^='^!7(B0^TV_J-/['1^DI*YZ!K!2
M6VKJ67.Z.?#"^0 NCR) )]SU+.2W7B#UAN7R:7S2L*)AA62L3W/45=1IA4X[
M%IR$1%>%H5RZ)-%=HQCA5USN-97PS"H?#JP.8&Y -/2T[=JII:EY-?L=O^72
M^:Q5<N<H5ZQ9=P*XV6[9K5:'C_-_PY[Y7;Y\?X$_-_PY[Y7;Y\?X%<*)7[3;
M^H=>Q4?I*>_-_P .>^5V^?'^!!R?\.9[;E=OGQ_@5PHCVFW]0>Q4?I/#8K52
MV.T4ELM["REIHQ&P$YG+B3Q)VK@Z4<4#"6#:VX,([K<.9I@>F5V>1\ !=X%+
M%FGE,7\UF)Z2RQ/])H(N<D _Q'[=O8W5^<5[CU^+8DPR[? I;C\D4[)(^61\
MDCB][R7.<XYDD[R5\HB>&8"(IYH:P8,88J:RK:3;*,":I^$,^]9_,?("N9S4
M(N3\CNNMV24(\LZVBK1+5XK8RY7=\E%9L^\R&4E1\7/<WX7B6C\-X6LN&Z<0
MV6W04PRR+VMS>[XSCM/C77BC9#$R*)C61L:&M:T9!H&X +Z22[(G:^_!I,?$
MKH79=_4+SU]%2W"F?3U]-#4P/V.CF8'M/@*]"*#@M-:E$Z3-"4#X)KC@UIBF
M:"Y] 79M?_#)W'X)V<,MRS[(Q\4CHY&N8]I+7-<,B"-X(6^%G7E(X.CHJJ#$
MM!&&1U3^9JVM&SG,LVO\(!!ZP.*98F2V_#F)L_"C&/BUK3U11Z(B9B<+3')O
MQ6ZZ8?GL57)K5-NR="2=KH2=W\IV=A:LSJ7Z)K\<.X]M56Y^K!))W//PU'[#
MGV'(^!5\FOQ*VO,M8=W@VI^3[,V6JETA7"/_ ,:NH7][)W,Q[#[K:[,=NQ6T
ML[:=Y'P8_BEB<6O;2QN:1T;7+-Y&,LFMUL?94ML-3JHN;8+HRZ40D&0F;LD;
MP/'L*Z2QUE<JI.$UW17336J.!C7UKB_C#S7*2Z&<;=RRLL%TE](D=E22./J'
M'VAZCT=?:HUC7UKB_C#S7*%@D$$'(CI6IZ0M<9?-BRZ^5&1OB;'10C1/BLXC
ML/-5;]:XT>4<I)VO;[5_AW'K'6INKYH*K(VP4X\,(BXN,+]#ANP5-QGR<Y@U
M8F$^KD/J1]_4"@ZE)03E+A$0TO8V%EHG6FVR97*H;W[VG;"P_P#(]' ;>"J7
M!'ZW5?$'UKAW&MJ+C73UE9(9*B9Y>]QZ25W,#_K55\0?6JW45IBS_P"^9G?:
M99&2I/CR)>B+\*^KBHJ22HG.3&#QG@%CHQ<FHQY8TX/7:[A'1XDLL)[Z6HJX
MV-;U:PS*O!96P?6RW'2+99YSM=619#H: [8 M4K7X>)[+4HOE\DN)/>FR,:2
M<3LPEA&MN>;34 <U3-/MI79ZOBVD]0*QA43RU-1+/4/=)-*XO>]QS+G$YDGP
MJX>4QB$UF):2R0O])H(^<E Z97[=O8W5^<532TF%5LKW>;%'4;O$MVKA!$17
M"@$16QH<T6/Q06W>^!\5E:[TN,=ZZI(WY'H;Q/3N'%1V61KCND2552NELAR0
M;"F#[YBJ<QV2@DG8TY/F/>QL[7'9X-ZMFR\GN9S&OO=\9&[ICI(B[_4[+ZE?
M5OHJ:W4<5)04\5/31#59%&T-:T=0"]"5V9TY/[O9#NGIM4%]_NRFCR?L/\WD
M+K==?CG'EXM51Z^<GRKCC<^QWJ*=PW1541C_ -3<_J"T,BC67:O,FE@426FT
MP]B?"]YPQ5BGO=!+3./J'D9L?\5PV%<9;NN]LHKQ02T5SIHJJEE&3HY&Y@]?
M4>L;5ES2]HRGP=4=WVXOGL<SLFN.UT#C[5W5P/@.W??Q\M6?=EV8JRL"5*WP
M[HK1$171>$1$ $1$ ;Z1$6:-B>#$'K#<ODTOFE846Z\0>L-R^32^:5A1,^G\
M2$O5N8_4(B)D* M2\FOV.W_+I?-8LM+4O)K]CM_RZ7S6*GG?"^HPZ9\;Z%JH
MB),:$(B( ;EA_&MT-ZQ;=[B7:PJ*E[F?$S(:/$ MF8JJS088O%8TY&GHYI0>
MMK''[%AE,NGQ]Z0GZK/W8A$1,Q,%<.AS2/A[!.'ZFFN%+7R5U1.9'OAC86ZH
M #1F7 [-I\*IY%'96K([9$M-LJ9;X\FGOR^X7_<KO]%'^-/R^X7_ '*[_11_
MC6845?V&HM?:5_[&GOR^X7_<KO\ 11_C3\ON%_W*[_11_C6841[#4'VE?^QI
M[\ON%_W*[_11_C4<TB:7,,XHP=<K3#27-L\[ 8G21,#6O:X.!)#SP5"(O8X=
M<6FCR74+I1<7IHPB(K91"#8<PB( W#@JYF\X2L]P<=9]12QO>?AZO?>7-4;I
M^_;F/Y''YSU8^@"J-3HPMK7',P/EB_W"1Y"% N4- 68LH9LMDE&&Y]8>_P"\
M)!*.VQHT5TM^-&7R*ZLUQDME:V>/,MW/;[IJLVEJ(ZJGCF@<'1O&8*J12+"-
MX[AJ.YJAW]FE.PGVCN/8E'5<'QX^+!?>7]HITV;7HSOXU]:XOXP\URA2FN-?
M6N+^,/-<H4N^C_\ &7S90SOBLDFCV_NPYBBDK'.(IGGFJ@<8W':?!L/@6I 0
MX M((.T$+&ZTSHHO!O."Z)\CM:>FSII#UMW'YI:F,EYE[I-W=U/YHEZH#3AB
M$W'$+;7 _.FH!DX ['2G?XAD/&KQOMQCM-FK:^7+4IHG29<2!L'A.062JJHD
MJJJ:HG<7S2O,CW'I<3F2O((EZK=M@JUYGY*2X'_6JKX@^M1I27 _ZU5?$'UJ
MKU+_ (L_^^8HQ/C1)>2 "20 -Y*KO%%X-RJN;A/]EB.3?A'W2Z^,KSJ-=;Z9
MW?']*X= ]RH8J'2,':O'L7=\?_1K=9K]U$BT=_MS8OED?G+61( ))R 65M%<
M!J-(%D8!GE-K_-:7?8M'XVK#;\'7RK:<G0T4SVGX6H<O+DG;6K2+6$]M<I&-
ML7W5U[Q1=;DXDBIJ7R-SZ&YG5'@&07(1%H$M%HC/-N3U81$7IX2O1CA1^,,6
MTMN.L*1OIU2\>UB;O\)S ':ME4E-#1TL--2Q-B@A8&1QL&0:T#( *G^3'96T
MN&*^[O;Z=6S\TT_Y;!^(N\05RI+F6N=FWR1HNG4JNK=YL(B*H7PB(@ O+=;?
M2W6VU-!7Q-FI:AACD8[I!^WK7J1">AXUKV9B/'6')\*8HKK3.2YL+LXI"/TD
M9VM=XM_7FN"M!\J*RM=2V>]QMR>Q[J25W$$%S/%D_P :SXG^/9XE:D9?*J\&
MUP7 1$4Q7"(B -](B+-&Q/!B#UAN7R:7S2L*+=>(/6&Y?)I?-*PHF?3^)"7J
MW,?J$1$R% 6I>37[';_ETOFL66EJ7DU^QV_Y=+YK%3SOA?48=,^-]"U41$F-
M"$1$ 1?2B\QZ.\1D=-%*WQM(^U8M6U])$)GT?XC8T9GN"9P\#"?L6*$UZ?[C
M$?5??C\@B(F J"(O?'9KI)&U\=MK7L< YKFP.((/2#DO&TCU)O@\"+H>@=V]
MZZ[^G?\ <GH'=O>NN_IW_<O-R]0VOT.>BZ'H'=O>NN_IW_<GH'=O>NN_IW_<
MC<O4-K]#GHNAZ!W;WKKOZ=_W)Z!W;WKKOZ=_W(W+U#:_0YZ+H>@=V]ZZ[^G?
M]R>@=V]ZZ[^G?]R-R]0VOT.>BZ'H'=O>NN_IW_<OZVPW=Q ;:J\D[ !3O^Y&
MY>I[MEZ&E>362='3P>BME \3%X>490%]!9[@T;(Y'P./Q@"/-*DVA&PUF'\
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M@,LOYAD.UH'2JF96YUZKR+W3K57;H^'V-*HB)*:,(B( (B( (B( (B( +^.
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M_1L/MSUGHZNW9 M!VCXXHNWHG=(L[+1O&;7#942#:&=@WGP#I6J0     !L
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M Z.INO\ YO7MV@RMRA8>IG3_ #9]@5I(J5N799VX0QIP*JN[[O\ < !H :
M-@ 1$54O!$1 !$1 !?,C&R1NCD:U[' M<UPS!!Z"OI$ 9,TT8 =A"]=U4$;C
M9:QQ,)W\R[>8S]8XCL*C.CJ-\N/<.MC:7.[O@.0X!X)\@6QL2VJAO-DJZ*Z4
MS*FE>PES'9[QM!!&T'K"JS05AJT0UURN$=$SNRGDYN*5SG.+&G//+,Y ]>],
MZ\O6I[N4+IXNEJV\,KOE'1O9I(D<YI#7TL3FD](VCZP5$]'^$ZS&.(H;;29L
MB]74399B*,':>WH XK26FZPVRYX6=6UU(R6KI2!%+F6N:"=HS!VCJ*Z&B2QV
MVSX2IY+;2,@DJASDSP27/(S S)).SANWKR.5LH6B[\ \;=<]7VY)-8[31V.T
MTUMML0BI:=@8QH\I/$D[2>)7N1$N;U[L8I:=D$1%X 1$0 1$0 7&Q1AFTXHH
M#27JCCJ(_:.W/C/%KAM"[*+U-IZH\E%26CX,UXST$W6@=)/AF=MQIMX@E(9,
MT< ?4N\G8JDNELKK54FGN='44DX]I-&6'RK=Z\]?0TEP@,%?2P5,)WQS1A[3
MX"KM>=./::U%MO3(2[P>A@U%JC'6C?"4=ODJH;+##-MVQ/?&/FM<!Y%F_$M%
M3T=6YE-'J-!RRS)^M,*<B-O JR,65'O,XZ*0X0MU+<*UD=9%SC"=HUB/J*TO
M@[1SA*"AAJA8Z628[=:<NE'B>2%Y=D1JY1[CXDK_ '69@PWA:]8DGYJRVZ>J
MVY.>UN3&]KCL'A*OG1]H/HK8^.MQ5)'7U0R<VE9GS+#\([W]FP=JN6&*.")L
M4,;(XVC)K&#( =0"^TNMS9S[1[(;T=.KK[R[LS9RGZ5\6)+-*V$LI>XN:8X-
MR;FU[B6CL!&SK5,+>T\$50S4GB9*S//5>T.'E7G]"[?^XTOT+?N7=6;X<%%K
M@COZ;XMCFI::_L811;N]"[?^XTOT+?N3T+M_[C2_0M^Y2?:"_3_9#]DO]?\
M1AZVVFX7/G/0ZBJ*KF\M?F8R[5SW9Y=A1;IIZ>&G:6T\4<32<R&-#1Y$7+Z@
*_*)VNDQT[R/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g830217g84p82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830217g84p82.jpg
M_]C_X  02D9)1@ ! 0$ :@!J  #_[0UH4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP"   "   < E  "TEN9'4@4V%X96YA #A"24T$)0
M    $.TLQ8 ?:(!>=F 5U^I=TZ8X0DE-!#H      4T    0     0
M"W!R:6YT3W5T<'5T    !P    !#;')396YU;0    !#;')3     %)'0D,
M    3FT@(%1%6%0    ( $, 20!% "  4@!' $(       !);G1E96YU;0
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M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$!:AM!         "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 &H;0P !  ( :AM#  $  CA"24T$)@      #@             _@
M.$))300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M301$       0     @   D    )      #A"24T$'@      !      X0DE-
M!!H      T$    &               /    #P    8 9 !S '  ,  T #
M   !                          $               \    /
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<    /     %)G
M:'1L;VYG    #P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    #P    !29VAT;&]N9P    \    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  (  R #  ,@ T     0 X0DE-!"(      4I-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   "    !^ 3(  @   !0   "> 3L  @    P
M  "RAVD !     $   #     [    &H    !    :@    %!9&]B92!0:&]T
M;W-H;W @,C4N,3(@*%=I;F1O=W,I #(P,C4Z,#(Z,#0@,3(Z,CDZ,C@ 26YD
M=2!387AE;F$      Z !  ,    !__\  * "  0    !    #Z #  0    !
M    #P         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
M $@    !    2     $X0DE- _T       @          /_A 5)%>&EF  !-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   "    !^ 3(  @   !0   "> 3L  @    P
M  "RAVD !     $   #     [    &H    !    :@    %!9&]B92!0:&]T
M;W-H;W @,C4N,3(@*%=I;F1O=W,I #(P,C4Z,#(Z,#0@,3(Z,CDZ,C@ 26YD
M=2!387AE;F$      Z !  ,    !__\  * "  0    !    #Z #  0    !
M    #P         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
M !$( "H *@,!(@ "$0$#$0'_Q  :   " P$!               &!P "!0,$
M_\0 +1   0(% @4# P4          0(#  0%!A$2(2(Q05%A!Q,R,W&!%2-2
MT?#_Q  8 0$  P$                #  ($ ?_$ !L1  (# 0$!
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JVB6.F4GTNZ  E6?@KS#)E&_8E&FP/BG$>F)$PFE D* )$7B1(B6'#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
